Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby

ABSTRACT

A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims the benefit of U.S. provisional application Ser. No. 60/410,303, filed Sep. 13, 2002.

FIELD OF THE INVENTION

[0002] The present invention relates to the fields of microbiology, molecular biology, and immunology and more particularly relates to surface-anchored proteins known as MSCRAMM®s, and to a bioinformatic method of identifying putative MSCRAMM® proteins, i.e., proteins that can bind to extracellular matrix molecules, from Gram positive bacteria having a recognizable cell wall sorting signal and the genes encoding those proteins through detecting structural features from potential proteins including immunoglobulin(Ig)-like fold regions. In addition, the invention relates to antibodies which recognize such proteins, including polyclonal and monoclonal antibodies as well as host cells transformed with nucleic acids encoding monoclonal antibodies, and the use of such antibodies in the diagnosis, treatment or prevention of Gram positive bacterial infections in humans and animals.

BACKGROUND OF THE INVENTION

[0003] There are numerous Gram positive bacteria which have been of interest in the fields of medicine and epidemiology because of their potential to cause a myriad of infectious diseases in humans and animals. One such Gram positive bacterium, Enterococcus faecalis, belongs to the commensal flora in mammalian intestines. It has also long been known as a major causative agent of bacterial endocarditis (Murray, 1990). During the last decades, E. faecalis has increasingly emerged as an opportunistic nosocomial pathogen, typically causing infections in hospitalized patients receiving antibiotic therapy. Clinical strains of this bacterium frequently harbor a multitude of acquired and intrinsically evolved resistance mechanisms toward the most commonly used antibiotics, which has complicated the treatment of enterococcal infections (Murray, 1990, 1999) (Tailor, 1993) (Huycke, 1998). Many of the antibiotic resistance genes are located in mobile genetic elements, e.g., small plasmids and transposons (Paulsen, 2003) This has raised fears for genetic transfer of resistance determinants from this organism to other bacterial species, e.g., the recently documented transfer of vancomycin resistance to Staphylococcus aureus (CDC, 2002). Still other Gram positive bacteria are known which commonly cause infections which are hard to control, including other bacteria from the Enterococcus genus, including Enterococcus faecium, as well as bacteria from species Streptococcus, such as Streptococcus mutans and pneumoniae, Staphylococcus, such as Staphylococcus aureus and epidermidis, and Bacillus, such as Bacillus anthracis.

[0004] The ability to adhere to mammalian tissue is a critical step in the colonization and onset of microbial infections. However, in light of the many unknown factors regarding microbial adherence, it remains a challenge to study and utilize information obtained regarding relatively little known adhesion mechanisms of Gram positive bacteria so as to provide a means for developing alternative antibacterial therapies. One such inroad into developing such therapies is the presence of the human extracellular matrix underneath epithelial and endothelial cells which is a complex, dynamic and multifunctional structure consisting mainly of collagens and other glycoproteins. As one of the outermost layers to external environment, it is a major adhesion target and entry point for pathogenic bacteria (Foster and Hook, 1998) (Westerlund and Korhonen, 1993). Numerous bacterial adhesins that specifically bind to ECM components have been characterized at the molecular level. A group of related cell surface proteins from Gram-positive bacteria, collectively designated MSCRAMM® proteins (microbial surface components recognizing adhesive matrix molecules) bind to major components of the ECM, such as collagens, fibronectin, laminin, fibrinogen, keratin, vitronectin and bone sialoprotein (Patti, 1994) (Foster and Hook, 1998) (Tung, 2000) (O'Brien, 2002). MSCRAMM® proteins are mosaic proteins that typically consist of an N-terminal signal sequence for Sec-dependent transport across the cytoplasmic membrane, followed by an N-terminal A domain which exhibits the binding activity in most cases and repetitive B domains that confer fibronectin binding in a group of fibronectin binding MSCRAMM® protein (Joh et al., 1994). Covalent attachment to the bacterial cell wall is mediated through a C-terminally located LPxTG motif preceded by a cell wall spanning domain and followed by a hydrophobic trans-membrane region and, finally, a cytosolic tail composed of a short sequence of positively charged amino acid residues (Schneewind et al., 1995) (Mazmanian et al., 2001).

[0005] In any event, it remains a distinct problem in the field of infectious diseases to develop new means of countering a wide range of bacterial infections in an efficient and effective manner without the potential of increasing the development of antibiotic-resistant bacterial strains. Moreover, in light of the potential problems that are caused by bacterial strains in general and antibiotic-resistant strains in general, particularly in hospitalized patients, it is increasingly important to develop methods to counteract such infections without utilizing antibiotics and without increasing the likelihood that antibiotic-resistant strains will develop. It is thus highly desirable to develop new means for identifying, treating and preventing infectious diseases caused by Gram positive bacteria, and to develop means for identifying and isolating new MSCRAMM® proteins from such bacteria which will allow the generation of antibodies thereto which will lead to new methods for treating and preventing the spread of infections from Gram-positive bacteria.

SUMMARY OF THE INVENTION

[0006] Accordingly, it is an object of the present invention to provide a bioinformatic method of identifying and isolating MSCRAMM® proteins from Gram-positive bacteria which can be utilized in methods of treating or preventing infectious diseases arising from Gram-positive bacteria.

[0007] It is another object of the present invention to identify and isolate proteins obtained using the bioinformatic method of the present invention, and to identify therein effective antigenic domains such as the A domain, and to utilize these antigenic domains in methods of treating or preventing infectious diseases arising from Gram-positive bacteria.

[0008] It is further an object of the present invention to utilize the proteins and antigenic domains isolated and identified using the bioinformatic method of the present invention to generate antibodies which can recognize these proteins and antigenic regions which can thus be useful in diagnosing, treating or preventing diseases and infections caused by Gram positive bacteria

[0009] It is still further an object of the present invention to provide vaccines, kits and other therapeutic methods which utilize the proteins and antigenic domains identified and isolated using the bioinformatic method of the present invention which can be used as an alternative to conventional antibiotic therapy and can thus provide safe and effective modes of treating or preventing infections caused by Gram-positive bacteria.

[0010] These and other objects are provided by virtue of the present invention which utilizes a bioinformatic approach to identify proteins with MSCRAMM®-like characteristics among Gram positive bacteria, such as bacteria from Enterococcus, Staphylococcus, Streptococcus and Bacillus, among many others, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. In particular, the method involves looking for proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. In particular, the present invention provides a method for identifying and isolating MSCRAMM® proteins, i.e., proteins that can bind to extracellular matrix molecules, such as by locating regions that adopt an immunoglobulin-like fold, and includes the recombinant production of these proteins from nucleic acids identified in the present process which code for those proteins. These Ig fold-containing regions consist of several consecutive and overlapping matches to solved crystal structures (˜150-500 aa) of the immunoglobulin superfamily (IgSF), which consist of one to four domains of equal size and Ig-type fold. The homologous Ig-fold regions are indicative of a “beads-in-a-string” arrangement of consecutive modules such like the ones found in fibronectin and other IgSF proteins (Leahy, 1996)(Sharma, 1999)(Hamburger, 1999)(Luo, 2000). For example, a tandem repeat of Ig folded subdomains (N2 and N3) is found in the crystal structure of the fibrinogen-binding domain of ClfA. The full-length A domains of ClfA and the similarly structured ClfB consist of an additional N-terminal subdomain, N1 (Deivanayagam, 2002)(Perkins, 2001). Based on sequence and secondary structure similarities, an analogous subdomain organization is also expected in other MSCRAMM® proteins including FnbpA, FnbpB, Ace and the Sdr proteins. The solved crystal structure of CNA minimum collagen-binding domain is made of a single Ig-type subdomain (N2) (Symersky, 1997) and the C-terminal repeat domains B1 and B2 each consist of a tandem repeat of Ig-folded subdomains (Deivanayagam, 2000). A similar modular structure is expected in the B3 and B4 repeats.

[0011] In accordance with the invention, novel MSCRAMM®-like protein surface-anchored proteins which can bind to major extracellular matrix proteins are obtained from Gram-positive bacteria such as those from the genera Enterococcus, Streptococcus, Staphylococcus and Bacillus, and such proteins are characterized in that they are (i) structurally homologous to the solved Ig-folded crystal structures of ClfA and CNA as well as to the predicted tertiary structures of other MSCRAMM® proteins, (ii) share a similar β-sheet rich secondary structure as is found in Ig-folded proteins and (iii) have a similar organization with a secretion signal, a non-repeated domain followed by repeats as well as a C-terminal cell wall anchor domain. Moreover, the binding of proteins identified by the present method has confirmed that they target and bind to various extracellular matrix (ECM) molecules including proteins and other components. For example, three of the isolated proteins bind to major ECM proteins; two to fibrinogen and at least one to collagen and laminin. The proteins of the present invention have also been shown to be present in most isolates and are expressed in vivo during infection.

[0012] Thus, in accordance with the present invention, a method is provided for identifying and isolating a module structure of multiple Ig-folded units which appears to be a general characteristic in the MSCRAMM® protein family. The length of the N-subdomains of MSCRAMM® proteins is typically ˜150 aa, and the proteins identified by the present invention including those set forth below may accommodate more than three Ig-folded subdomains in their A domains.

[0013] These embodiments and other alternatives and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the present specification and/or the references cited herein, all of which are incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

[0014]FIG. 1 is a schematic representation of MSCRAMM® proteins identified in accordance with the present invention illustrating the different regions of the proteins and their immunoglobulin-like fold regions

[0015]FIG. 2 illustrates a Coomassie stained SDS-PAGE of the E coli-expressed and purified A domains of the LPXTG-containing proteins of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] In accordance with the present invention, there is provided a bioinformatic method for identifying and isolating proteins from Gram-positive bacteria, for example bacteria from genera such as Enterococcus, Staphylococcus, Streptococcus and Bacillus, in particular proteins which have MSCRAMM®-like characteristics, and utilizing the identified and isolated proteins to generate antibodies and diagnose, treat or prevent infections caused by Gram-positive bacteria. In general, the method involves looking for proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and/or other structural similarities to MSCRAMM® proteins (Microbial Surface Components Recognizing Adhesive Matrix Molecules) having LPXTG-containing cell wall-anchored proteins. In the preferred embodiment, the present invention provides a method for identifying and isolating MSCRAMM® proteins, i.e., surface proteins that bind to extracellular matrix molecules, such as proteins, carbohydrates and other components, of host cells, wherein those located proteins contain regions that adopt an immunoglobulin-like fold. These Ig fold-containing regions consist of several consecutive and overlapping matches to solved crystal structures (˜150-500 aa) of the immunoglobulin superfamily (IgSF), which consist of one to four domains of equal size and Ig-type fold. The homologous Ig-fold regions are indicative of a “beads-in-a-string” arrangement of consecutive modules such like the ones found in fibronectin and other IgSF proteins (Leahy, 1996)(Sharma, 1 999)(Hamburger, 1999)(Luo, 2000). For example, a tandem repeat of Ig folded subdomains (N2 and N3) is found in the crystal structure of the fibrinogen-binding domain of ClfA. The full-length A domains of ClfA and the similarly structured ClfB consist of an additional N-terminal subdomain, N1 (Deivanayagam, 2002)(Perkins, 2001). Based on sequence and secondary structure similarities, an analogous subdomain organization is also expected in other MSCRAMM® proteins including FnbpA, FnbpB, Ace and the Sdr proteins. The solved crystal structure of CNA minimum collagen-binding domain is made of a single Ig-type subdomain (N2) (Symersky, 1997) and the C-terminal repeat domains B1 and B2 each consist of a tandem repeat of Ig-folded subdomains (Deivanayagam, 2000). A similar modular structure is expected in the B3 and B4 repeats.

[0017] In accordance with the invention novel MSCRAMM®-like protein surface-anchored proteins are obtained from Gram-positive bacteria such as those from the genera Enterococcus, Streptococcus, Staphylococcus and Bacillus, and such proteins are characterized in that they are (i) structurally homologous to the solved Ig-folded crystal structures of ClfA and CNA as well as to the predicted tertiary structures of other MSCRAMM® proteins, (ii) share a similar β-sheet rich secondary structure as is found in Ig-folded proteins and (iii) have a similar organization with a secretion signal, a non-repeated domain followed by repeats as well as a C-terminal cell wall anchor domain. Moreover, the binding of proteins identified by the present method has confirmed that they target and bind to various extracellular matrix molecules. For example, three of the isolated proteins bind to major ECM proteins; two to fibrinogen and at least one to collagen and laminin. The proteins of the present invention have also been shown to be present in most isolates and are expressed in vivo during infection.

[0018] In accordance with the present invention, a method is provided for identifying and isolating a module structure of multiple Ig-folded units which have the general characteristics of the MSCRAMM® protein family. The length of the N-subdomains of MSCRAMM® proteins is typically ˜150 aa, and the proteins identified by the present invention including those set forth below may accommodate more than three Ig-folded subdomains in their A domains. The isolation and use of the MSCRAMM® proteins of the present invention or their A domains in the generation of antibodies that can bind thereto or in methods of diagnosing, treating or preventing disease will be similar to that as described with other MSCRAMM® proteins such as in U.S. Pat. Nos. 6,288,214; 6,177,084; 6,008,241; 6,086,895; 5,980,908; 5,866,541; 5,851,794; 5,840,846; 5,789,549; 5,770,702, 5,652,217; 5,648,240; 5,571,514; 5,440,014; 5,416,021 and 5,320,951; and WO 00/68242; all of said references incorporated herein by reference.

[0019] In accordance with the present invention, a series of steps is undertaken in order to identify and isolate the characteristic module structure of one or more surface-anchored MSCRAMM® protein family of Gram positive bacteria, including the step of locating immunoglobulin-like (or Ig-like) folds in the putative LPXTG-containing proteins. This method can be used with any presently known database containing sequence information from Gram positive bacterial species, e.g., amino acid and/or nucleic acid sequences, and involves the steps of locating proteins with the LPXTG (SEQ ID NO:1) motif, and then reviewing and analyzing the sequence information so as to screen for proteins having particular structural similarities to MSCRAMM® as set forth below.

[0020] In the general process of the invention, the first part of the process is to search a database containing sequence information on one or more Gram positive bacteria so as to locate those proteins which contain the LPXTG (SEQ ID NO:1) motif contained in cell wall anchored proteins in annotated genomes of Gram-positive bacteria. This is done by initially obtaining the entire genome of amino acids sequences from one or more Gram positive bacteria of interest, such as from any of a number of web sites of sequencing centers, e.g., TIGR, NCBI, etc. In the preferred method, these sequences can be downloaded and stored in electronic memory before carrying out the identifying steps, such as in a local Silicon Graphics machine (SGI) or other suitable computer system. In the preferred method, this stored information is used to prepare a local searchable database, such as by using the program form “atdb” obtained from NCBI, and such a searchable database is installed locally on the SGI.

[0021] The LPXTG-motif is identified from the stored sequence information by any of a number of suitable programs. For example, these LPXTG-motif containing proteins can be identified using PHI-blast, which is obtained from NCBI and once again can be installed and stored locally on the SGI or other suitable computer system. The PHI-blast search uses a degenerate LPXTG pattern L-P-X-[TSA]-[GANS], X being any amino acid. The exact templates for PHI-blast can vary depending on the particular organism, but in any case, the present system includes methods of identifying the LPXTG motif. For each organism, it is preferred to use at least two known cell wall anchored proteins of S. aureus with no sequence homology as well as known cell wall anchored proteins from the target organism if available.

[0022] Once LPXTG-containing proteins are identified obtained using a suitable system such as PHI-blast, these proteins are further analyzed so as to select for those that contain typical features of LPXTG-motif containing cell wall anchored proteins which have the properties of MSCRAMM®S. In the preferred process, these features will generally include a signal peptide at the N-terminus, the LPXTG-motif being close to the C-terminus, followed by a hydrophobic transmembrane segment, and several positively charged residues at the C-terminus. These are done as described below:

[0023] The signal peptides may be identified using any suitable identification method such as that method described in “Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites”. Henrik Nielsen, Jacob Engelbrecht, Søren Brunak and Gunnar von Heijne, Protein Engineering 10, 1-6 (1997), incorporated herein by reference. In the present process, a preferred system is to us the SignalP prediction server at http://www.cbs.dtu.dk/services/SignalP/, but other similar methods for identifying the signal peptide may also be used. Location of LPXTG-motif and the determination of positively charged amino acids residues at the C terminus are accomplished using visual examination of the sequence, although databases may also be used to determine the presence of these features.

[0024] In the preferred embodiment, the hydrophobic transmembrane segment after the LPXTG-motif may also be located using a conventional program which can predict the presence of such regions. An example of one such system is the TMHMM server available on the Internet at http://www.cbs.dtu.dk/services/TMHMM-2.0/ which can be used for the prediction of transmembrane segments. However, a number of other suitable prediction servers are available either on the Internet or in stored computer programs, including the TMpred available at http://www.ch.embnet.org/software/TMPRED_form.html, the DAS system available at http://www.sbc.su.se/˜miklos/DAS/, and the HMMTOP at http://www.enzim.hu/hmmtop/.

[0025] By following the procedures set forth above, putative LPXTG-containing sequences that contain the above features can be selected as highly likely to be MSCRAMM® proteins, i.e., to have the ability to bind extracellular matrix components. Following these initial steps, it is contemplated that the LPXTG-containing proteins identified in this matter will turn out be MSCRAMM® proteins at least about 90% of the time, as confirmed by expressing the putative protein or its A domain and determining if that protein or it's a domain binds to extracellular matrix components. This can be done by simple binding assays which are routine in the art and which would be well within the abilities of one skilled in the art.

[0026] Additionally, the LPXTG-containing sequences as initially located, or as further selected using the signal peptide/C terminal/transmembrane identifying characteristics as described above, can be further analyzed as indicated below to confirm the presence of immunoglobulin-like folds characteristic of MSCRAMM® proteins from Gram positive bacteria.

[0027] Similarly, in such a method, LPXTG-containing cell wall proteins may also be located using an annotated genomic nucleotide database such as the one located at the TIGR website (comprehensive microbial resource) at http://www.tiqr.org/tiqr-scripts/CMR2/CMRHomePage.spl. With these databases, the term “LPXTG” or “cell wall” may be used to search for such proteins that are annotated as cell wall anchored proteins in the genome of interest.

[0028] Finally, LPXTG-motif containing cell wall anchored proteins may also be identified in un-annotated nucleotide genomes of Gram-positive bacteria. In this case, genome sequences are obtained from the web sites of sequencing centers, and the sequences may be stored as appropriate in computer memory such as a local Silicon Graphics machine (SGI). Gene prediction may be carried out using the program such as Glimmer 2.0 from TIGR, and this can be facilitated by UNIX C shell scripts which may be modified as desired to suit particular organisms or features. In the preferred process, the predicted genes are translated into amino acid sequences using a suitable translation program, preferably one that is capable of translating large batches of sequences. Finally, the translated amino acid sequences are formatted into a searchable database locally as described above, and subject to further analysis as described below.

[0029] In the preferred process of the present invention, steps are carried out by which the Immunoglobulin-like (Ig-like) fold in putative LPXTG-motif containing cell wall anchored proteins can be predicted and identified. In accordance with the invention, the amino acid sequences of putative LPXTG-motif containing cell wall anchored proteins are then analyzed to determine the presence of Ig-like folds which are characteristic of MSCRAMM® proteins. This can be done in a number of ways, such as by processing the putative MSCRAMM® using fold-recognition software, such as available using the web server 3D-PSSM available at (http://www.sbg.bio.ic.ac.uk/˜3dpssm/). Additional methods of fold prediction are discussed in Kelley L A, MacCallum R M & Sternberg M J E. Enhanced Genome Annotation using Structural Profiles in the Program 3D-PSSM. J Mol Biol. 2000 Jun. 2;299(2):499-520, incorporated herein by reference. Using this method, the output of 3D-PSSM gives a probability E value indicating the likelihood of the submitted sequence adopting a similar 3D structure as the known and published MSCRAMM®s. In accordance with the invention, proteins that have an E value <0.25 to a published Ig-like fold structure, are considered to contain the predicted Ig-like folds, and such proteins are identified as useful MSCRAMM proteins in accordance with the invention, i.e., proteins that recognize adhesin molecules on the extracellular matrix of host cells.

[0030] The present invention has thus been carried out so as to identify and produce proteins and A domains therefrom which have MSCRAMM®-like characteristics from such Gram positive bacteria, such as Enterococcus, Streptococcus, Staphylococcus and Bacillus. In the preferred process, proteins identified as set forth above or their antigenic A domains may be expressed, purified and characterized as set forth herein.

[0031] Accordingly, in accordance with the present invention, a bioinformatic approach was used to identify proteins with MSCRAMM®-like characteristics among Gram positive bacteria, and those predicted proteins have been shown to have MSCRAMM-like characteristics. In one such case using Enterococcus faecalis, forty-two proteins with a putative C-terminal LPxTG cell wall sorting signal were identified in the E. faecalis genome. In accordance with the present method, these proteins were analyzed to determine the presence of Ig-like folds in the manner set forth above. Based on the present method, nine proteins were found to contain regions that adopt an immunoglobulin-like fold. The Ig fold-containing regions for these nine proteins are shown in FIG. 1 and consist of several consecutive and overlapping matches to solved crystal structures (˜150-500 aa) of the immunoglobulin superfamily (IgSF), which consist of one to four domains of equal size and Ig-type fold. The homologous Ig-fold regions cover most of the enterococcal proteins and may indicate a similar “beads-in-a-string” arrangement of consecutive modules that are found in fibronectin and other IgSF proteins.

[0032] Further expression, purification and analysis of the A domains of these proteins was carried out. As shown in FIG. 2, the A regions of eight proteins expressed as N-terminal His₆-tag fusion proteins migrated as expected in SDS-PAGE gels, while EF1091 showed a band approx. 160 kDa in size; a larger-size molecule than the expected 113 kDa. Some degradation was observed in proteins EF1091, EF1824, EF0089 and EF3023, possibly due to their relatively large sizes. They were nevertheless estimated to be >95% pure. The putative glucosyl hydrolase domain of EF1824 (amino acids 42-819), which was cloned and expressed separately from the rest of the protein, (FIG. 1) was found in the insoluble fraction of E. coli cytoplasm. Hence, purification by metal affinity chromatography under native, non-denaturing conditions employed for the other expressed proteins was not feasible. The purified proteins were further characterized with Maldi-TOF mass spectrometry. All nine proteins, including EF1091 with aberrant migration in SDS-PAGE, gave peaks that were in good agreement with the molecular weights calculated from amino acid sequences (Table 1), and thus indicated that full-size proteins had been produced with no post-translational processing.

[0033] Secondary structure predictions and CD-measurements (Table 2) support finding of Ig-folded module-structures in the enterococcal proteins. Both methods show a similar high proportion of β-sheet (˜50%) and coil and a minor quantity of α-helix, an identical situation as seen in MSCRAMM® proteins and in IgSF in general. The higher amount of α-helix in EF1824 and EF3023 probably reflects their relatively short predicted regions with Ig-folds and suggests the remainder of the proteins is structurally more distant to MSCRAMM® proteins. Molecular size analysis Molecular mass (Da) Sequence Mass Protein prediction spectrometry EF1091 113,021 113,025 EF1824 111,893 111,901 EF0089 122,853 122,857 EF3023 113,338 113,323 EF1092 47,291 47,295 EF2224 82,194 82,199 EF1269 64,776 64,776 EF1099 39,281 39,293 EF1093 62,363 62,366

[0034] TABLE 2 Summary of secondary structure components Protein α-Helix β-Sheet Other Sequence prediction EF1091 0.10 ± 0.05 0.33 ± 0.08 0.53 ± 0.06 EF1824 0.45 ± 0.04 0.16 ± 0.04 0.39 ± 0.08 EF0089 0.07 ± 0.07 0.44 ± 0.14 0.49 ± 0.08 EF3023 0.24 ± 0.09 0.29 ± 0.10 0.47 ± 0.12 EF1092 0.15 ± 0.05 0.36 ± 0.06 0.49 ± 0.10 EF2224 0.15 ± 0.10 0.32 ± 0.05 0.54 ± 0.10 EF1269 0.09 ± 0.10 0.42 ± 0.12 0.49 ± 0.10 EF1099 0.04 ± 0.07 0.47 ± 0.07 0.49 ± 0.07 EF1093 0.09 ± 0.06 0.41 ± 0.11 0.51 ± 0.11 CD measurement EF1091 0.14 ± 0.05 0.41 ± 0.11 0.45 ± 0.10 EF1824 0.29 ± 0.04 0.29 ± 0.17 0.44 ± 0.17 EF0089 0.08 ± 0.04 0.49 ± 0.13 0.43 ± 0.12 EF3023 0.33 ± 0.05 0.16 ± 0.05 0.51 ± 0.03 EF1092 0.05 ± 0.04 0.50 ± 0.12 0.45 ± 0.14 EF2224 0.16 ± 0.03 0.36 ± 0.10 0.48 ± 0.09 EF1269 0.03 ± 0.04 0.55 ± 0.14 0.42 ± 0.12 EF1099 0.07 ± 0.03 0.49 ± 0.13 0.44 ± 0.14 EF1093 0.06 ± 0.05 0.57 ± 0.18 0.37 ± 0.17

[0035] In addition to EF1099 (Ace), the primary sequence of EF1269 is clearly related to the MSCRAMM® protein family. Similarly to Ace, it has homologous N2 and N3 subdomains including the conserved TYTDYVD-motif and a connecting tyrosine residue between the two subdomains. The absence of N1 further resembles Ace. However, the rest of their sequences share little homology. Although the A domain of EF1269 is made of similar N2 and N3 subdomains as the fibrinogen-binding ClfA, ClfB, SdrG, and to a lesser extent, FnbpA and FnbpB, it failed to bind fibrinogen. In this respect, EF1269 resembles SdrD and SdrE, which contain N2 and N3 subdomains, but for which the ligand is yet to be found. This is strengthened by our finding that the highest similarity of the EF1269 N2 and N3 domains is to the corresponding region in SdrE (identity 26%). Further, two putative repeats (95 and 109 aa) with lower conservation (identity 20%), which make up the rest of the C-terminal EF1269 sequence, show relatedness to the B repeats of SdrE (25% identity over 375 to 531 aa of EF1269). Proteins EF1091, EF0089, EF1092, EF2224 and EF1093 are not simply orthologs of previously described MSCRAMM® proteins, since they lack high sequence identity to streptococcal and staphylococcal adhesins. Yet, they share similar structural organization and an abundance of β-sheet rich secondary structures with similar predicted folding as MSCRAMM® proteins. The two remaining proteins, EF1824 and EF3023, have large regions related to known enzymes, glucosyl hydrolases and hyaluronan lyases, respectively, which sets these regions apart from MSCRAMM® proteins. Hyaluronidase activity could be significant for bacterial entry and spreading in hyaluronan-containing tissues during infection and/or potentially contribute to bacterial nutrition during commensal life in the human intestine. The large putative catalytic domains of EF1824 and EF3023 agree well with the above-discussed structural unrelatedness in these regions to MSCRAMM® proteins.

[0036] When screening binding to major ECM proteins, we found ligands for five of the MSCRAMM® proteins EF0089, EF1091, EF1092, EF1093, and EF2224. The presence of more than one fibrinogen-binding MSCRAMM® proteins in E. faecalis is consistent to findings in the related S. aureus in which four fibrinogen-binding MSCRAMM® proteins, ClfA, ClfB, FnbpA and FnbpB, have been described (McDevitt et al., 1994) (Ni Eidhin et al., 1998) (Wann et al., 2000) (Davis et al., 2001; Hartford et al., 2001). EF0089 and EF2224 have strong structural resemblance to MSCRAMM® proteins throughout their lengths: similar primary organization and homologous β-sheet rich secondary structure expected to form modular Ig-folded subdomains. Relatively low sequence identity to known fibrinogen binding adhesins may mean novel adaptations for ligand binding. Our initial results suggest EF2224 binds to the α- and β-chains of fibrinogen and thus resembles ClfB (Ni Eidhin et al., 1998). Mammalian tissue surfaces express a multitude of possible ligands for bacterial adherence. Here, we assessed binding to type I, III and IV collagens, laminin, fibronectin, fibrinogen and vitronectin.

[0037] In accordance with the invention, a PCR process may be used to amplify A domains from proteins identified and isolated using the present invention. Using PCR oligonucleotides such as those in Table 3, below, the A domains from EF0089, EF1091, EF1092, EF1093, EF1099, EF1269, EF1824, EF2224, and EF3023 were amplified from E. faecalis V583 or E. faecalis EF1 (EF1099) genomic DNA and subcloned into the E. coli expression vector PQE-30 (Qiagen). One liter culture of E. coli M15(pREP4) cultures harboring appropriate pQE-30 based constructs were grown to OD₆₀₀=0.6 with an initial 2% inoculation from overnight cultures. After 2-3 h induction with 0.4 mM isopropyl-beta-d-thiogalactoside (IPTG), cells were collected with centrifugation, resuspended in 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 and stored at −80 C.

[0038] To lyse the cells and release the expressed protein, cells were passed twice through French Press with a gauge pressure setting at 1200 PSI to give an estimated internal cell pressure of 20,000 PSI. The lysate was centrifuged at RCF_(max) of 165,000×g and the supernatant was filtered through a 0.45 □m filter. The volume was adjusted to 15 ml with 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 and 0.2 M imidazole in the same buffer was added to increase the imidazole concentration to 6.5 mM in order to minimize non-specific binding. The sample was loaded to a nickel affinity chromatography column (HiTrap chelating, Pharmacia) connected to an FPLC system (Pharmacia) and previously equilibrated with 10 mM Tris-Cl, 100 mM NaCl, pH 7.9. Bound protein was eluted with a linear gradient of 0-100 mM imidazole in 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 over 100-200 ml. Protein-containing fractions were analyzed in SDS-PAGE (FIG. 2) and dialyzed against 25 mM Tris-Cl, 1 mM EDTA, pH 6.5-9 (depending on pI of protein purified) before applying the samples to an ion-exchange column (HiTrap Q, Pharmacia) for further purification. Bound protein was eluted with a linear gradient of 0-0.5 M NaCl in 25 mM Tris-Cl, 1 mM EDTA, pH 6.5-9 over 100 ml. Finally, protein samples were dialyzed extensively against PBS and stored at +4° C.

[0039] Alternatively EF1091, EF1092, and EF1093 were expressed in shake flasks or in bioreactors, the cells were harvested by centrifugation and the cell paste frozen at −80° C. Cells were lysed in 1×PBS (10 mL of buffer/1 g of cell paste) using 2 passes through a microfluidizer at 10,000 psi. Lysed cells were spun down at 17,000 rpm for 30 minutes to remove cell debris. Supernatant was passed over a 5-mL HiTrap Chelating (Pharmacia) column charged with 0.1M NiCl₂. After loading, the column was washed with 5 column volumes of 10 mM Tris, pH 8.0, 100 mM NaCl (Buffer A). Protein was eluted using a 0-100% gradient of 10 mM Tris, pH 8.0, 100 mM NaCl, 500 mM imidazole (Buffer B). Protein containing fractions were dialyzed in 1×PBS.

[0040] The nine enterococcal genes encoding the MSCRAMM® are ubiquitous among E. faecalis strains as summarized in Table 3. Seven of the nine genes were 100% preserved in all strains. The two genes, EF1824 and EF3023, with predicted encoded protein catalytic domains and relatively low proportion of MSCRAMM®-like protein characteristics, were present in 16/30 and 23/30 strains, respectively. Nine enterococcal proteins encoded by their respective gene showed elevated titers in infected individuals suggesting expression in vivo during an E. faecalis infection. Although these proteins have a high distribution in strains, there were clear differences in induced antigenic responses; proteins EF1091, EF1092, EF1093 and EF2224 exhibited the highest titers. This may be due to different expression levels in physiological conditions or to highly immunogenic surface epitopes and, hence, a strong immune response. Interestingly, the three proteins (EF1091, EF1092 and EF1093) with the highest titers are organized as a putative operon in the E. faecalis genome. The operon is preceded by two promoter consensus regions and a ribosome binding site and thus, these proteins are likely co-transcribed. The next gene downstream, EF1094, codes for a putative LPxTG transpeptidase sortase and EF1099 (Ace) is closely linked. It remains to be seen what role this cluster of MCSRAMM®-like proteins and a putative sortase may have in the infection process. TABLE 3 Synthetic oligonucleotides used in this study Location Cloning Oligonucleotide (aa) site Oligonucleotide EF1091A   Fw 102 SphI 5′-CCGCATGCCAAGAGCAAACAGCAAAAGAAG-3′ Rev 1107 SalI 5′-CCGTCGAC ITAAGTACCAGAAGTGGTGGTTTTC-3′ EF1824AI  Fw 42 SphI 5′-CCGCATGCCAAGAGCAAACAGCAAAAGAAG-3′ Rev 819 SalI 5′-GGGTCGAC TTATTGTTTCAAGGTTACTTCTGTC EF1824AII Fw 819 BamHI 5′-CCGGATCCGCAGCTAATAAAGAAGAATTTTTAG Rev 1829 SalI 5′-CCGTCGAC TTAAGTACCAGAAGTGGTGGTTTTC-3′ EF0089A   Fw 35 SacI 5′-CCGAGCTCGAAGAGGTTAACAGCGATGG-3′ Rev 1143 PstI 5′-CCCTGCAG TTACCCACCAAATGTGATAACCC-3′ EF3023A   Fw 25 BamHI 5′-CCGGATCCGAAGAAATAACTGATTTATTTTTAC-3′ Rev 1024 SacI 5′-CCGAGCTC TTATTTGTTCCTGAATTTAATTTTTCTAAC-3′ EF1O92A   Fw 27 SphI 5′-CCGCATGCTCGCAAGCAAGCGTTCAAG-3′ Rev 438 PstI 5′-CCCTGCAG TTAGAAGCCTGACTCTTTTACTTTT-3′ EF2224A   Fw 30 BamHI 5′-CCGGATCCCAAGAAGTAACAAGTGATGCTG-3′ Rev 771 SacI 5′-CCGAGCTC TTAAGTTACTTGTTCGTCCGCAAT-3′ EF1269A   Fw 26 BamHI 5′-CCGGATCCGAAACAGGATATGCGCAAAC-3′ Rev 596 SacI 5′-CCGAGCTC TTATTCCTTATTTACGAATCGCCTG-3′ EF1093A   Fw 32 BamHI 5′-GCGGGATCCGAAGAAAATGGGGAGAGCGC-3′ Rev 590 SacI 5′-GCGGAGCTC TTAGGTACCTTTGTGTTTGTTTGG-3′

[0041] The presence of several MSCRAMM®-like proteins in E. faecalis including two that bind fibrinogen and the previously described collagen and laminin binding Ace, suggests that E. faecalis resembles S. aureus and other Gram-positive cocci by having an armory of ECM-binding adhesins. Since the introduction of antibiotic therapy, E. faecalis has shown an increasing tendency to emerge as an opportunistic pathogen capable of crossing the thin line from a harmless commensal to being able to invade host tissues and cause infections. A repertoire of adhesins may enhance its adaptability for colonizing and spreading in various human tissue types of susceptible human hosts.

[0042] Accordingly, the present invention allows for the identification and ultimate production of novel MSCRAMM®-like protein surface-anchored proteins from Gram positive bacteria which (i) are structurally homologous to the solved Ig-folded crystal structures of ClfA and CNA as well as to the predicted tertiary structures of other MSCRAMM® proteins, (ii) can share a similar β-sheet rich secondary structure as is found in Ig-folded proteins and (iii) have a similar organization with a secretion signal, a non-repeated domain followed by repeats as well as a C-terminal cell wall anchor domain. Further, these proteins may bind to major ECM proteins such as fibrinogen, collagen and laminin, and due to the similarities in proteins from different Gram positive bacterial species, these proteins may provide antibodies which are cross-reactive and can bind to similar proteins found in different Gram positive bacterial species. Such antibodies, as described further below, may thus be useful in diagnosing or fighting a variety of different infections at the same time.

[0043] In addition to proteins identified and isolated using the present method, particular, the present invention contemplates the generation of antibodies from the MSCRAMM®-like proteins obtained using the present method, or from antigenic regions such as the A domains from these proteins. By “antibody” is meant any intact antibody molecule or fragments thereof that recognize antigen (e.g. Fab or F(ab′)2 fragments) and can be of polyclonal or monoclonal type, and the antibodies in accordance with the invention will be capable of recognizing the MSCRAMM® proteins of the invention and/or the specific antigenic epitopes from said proteins including their A domains. These antibodies will thus be effective in methods of diagnosing, monitoring, treating or preventing infection from Gram positive bacteria. By “epitope” is meant any antigenic determinant responsible for immunochemical binding with an antibody molecule. Epitopes usually reside within chemically active surface groupings of protein molecules (including amino acids and often also sugar side-chains) and have specific three-dimensional structural characteristics and specific charge characteristics. With reference to the proteins of the invention, or epitopes and peptides as described herein, it is understood that such terms also include those proteins and peptides which differ from a naturally occurring or recombinant protein by the substitution, deletion and/or addition of one or more amino acids but which retains the ability to be recognized by an antibody raised against the entire protein. An example is a carrier/antigen fusion polypeptide of the whole antigen or an immunoreactive fragment thereof, where the antigen or fragment can be embedded within the carrier polypeptide or linked to the carrier polypeptide at either end.

[0044] Accordingly, in accordance with the present invention, isolated and/or purified antibodies can be generated from the Gram-positive MSCRAMM® proteins of the present invention, or from particular epitopes such as those epitopic peptide sequences from the A domains from those proteins as described herein. These antibodies may be monoclonal or polyclonal and may be generated using any suitable method to raise such antibodies such as would be well known in this art. The antibodies in accordance with the invention will be particularly useful in inhibiting the binding of Gram positive bacteria to extracellular matrix components of the host cells and in diagnosing, treating or preventing infections of Gram positive bacteria.

[0045] For example, with regard to polyclonal antibodies, these may be generated using a number of suitable methods generally involving the injection of the isolated and/or purified or recombinantly produced proteins (or their immunogenic active peptides or epitopes) into a suitable host in order to generate the polyclonal antibodies which can then be recovered from the host. For example, in accordance with the invention, an isolated and purified MSCRAMM® protein or its A domain may be injected into rabbits in order to generate polyclonal antisera recognizing this protein.

[0046] In addition, monoclonal antibodies in accordance with the invention may be generated using a suitable hybridoma as would be readily understood by those of ordinary skill in the art. In the preferred process, a protein in accordance with the invention is first identified and isolated using the bioinformatic method as described above. Next, the protein is isolated and/or purified in any of a number of suitable ways commonly known in the art, or after the protein is sequenced, the protein used in the monoclonal process may be produced by recombinant means as would be commonly used in the art and then purified for use. In one suitable purification process, the cell wall proteins of the invention are isolated and examined using polyacrylamide gel electrophoresis (PAGE) and Western-blot techniques, and other conventional techniques including those discussed herein. In one suitable process, monoclonal antibodies were generated from proteins isolated and purified as described above by mixing the protein with an adjuvant, and injecting the mixture into BALB/c mice.

[0047] Immunization protocols consisted of a first injection (using complete Freund's adjuvant), two subsequent booster injections (with incomplete Freund's adjuvant) at three-week intervals, and one final booster injection without adjuvant three days prior to fusion (all injections were subcutaneous). For hybridoma production, mice were sacrificed and their spleen removed aseptically. Antibody secreting cells isolated and mixed with myeloma cells (NS1) using drop-wise addition of polyethylene glycol. After the fusion, cells were diluted in selective medium (vitamin-supplemented DMEM/HAT) and plated at low densities in multiwell tissue culture dishes. Tissue supernatants from the resulting fusion were screened by both ELISA (using the total 2-ME extract to coat the wells of a microtiter plate) and immunoblot techniques. Cells from these positive wells were grown and single cell cloned by limiting dilution, and supernatants subjected to one more round of screening by both ELISA and immunoblot. Positive clones were identified, and monoclonal antibodies collected as hybridoma supernatants.

[0048] In accordance with the invention, antibodies are thus produced which are capable of recognizing and binding proteins obtained using the bioinformatic method of the present invention and/or its epitopes and active regions such as the A domain, and such antibodies can be utilized in many diagnostic and therapeutic applications such as the ones described in more detail below.

Vaccines, Humanized Antibodies and Adjuvants

[0049] The isolated antibodies of the present invention, or the isolated proteins or epitopes as described above, may also be utilized in the development of vaccines for active and passive immunization against bacterial infections, as described further below. In the case of active vaccines, said vaccines are prepared by providing an immunogenic amount of the proteins of the invention or their active regions or epitopes as set forth above, and the active vaccine in accordance with the invention will thus comprise an immunogenic amount of the protein or peptide and will be administered to a human or animal in need of such a vaccine. The vaccine may also comprise a suitable, pharmaceutically acceptable vehicle, excipient or carrier which will be those known and commonly used in the vaccine arts. As referred to above, an “immunogenic amount” of the antigen to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that an immunogenic response will be elicited in the host so that the desired prophylactic or therapeutic effect is produced. Accordingly, the exact amount of the antigen that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. Similarly, the “immunogenic amount” of any such antigenic vaccine composition will vary based on the particular circumstances, and an appropriate immunogenic amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual.

[0050] Further, when administered as pharmaceutical composition to a patient or used to coat medical devices or polymeric biomaterials in vitro and in vivo, the antibodies of the present invention may also be useful because these antibodies may be able to interfere with the ability of Gram positive bacteria to adhere to host cells and limit the extent and spread of the infection.

[0051] In addition, the antibody may be modified as necessary so that, in certain instances, it is less immunogenic in the patient to whom it is administered. For example, if the patient is a human, the antibody may be “humanized” by transplanting the complimentarity determining regions of the hybridoma-derived antibody into a human monoclonal antibody as described, e.g., by Jones et al., Nature 321:522-525 (1986) or Tempest et al. Biotechnology 9:266-273 (1991) or “veneered” by changing the surface exposed murine framework residues in the immunoglobulin variable regions to mimic a homologous human framework counterpart as described, e.g., by Padlan, Molecular Imm. 28:489-498 (1991), these references incorporated herein by reference. Even further, under certain circumstances, it may be desirable to combine the monoclonal antibodies of the present invention with a suitable antibiotic when administered so as to further enhance the ability of the present compositions to fight or prevent infections.

[0052] In a preferred embodiment, the antibodies may also be used as a passive vaccine which will be useful in providing suitable antibodies to treat or prevent a Gram-positive bacterial infection. As would be recognized by one skilled in this art, a vaccine may be packaged for administration in a number of suitable ways, such as by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration. One such mode is where the vaccine is injected intramuscularly, e.g., into the deltoid muscle, however, the particular mode of administration will depend on the nature of the bacterial infection to be dealt with and the condition of the patient. The vaccine is preferably combined with a pharmaceutically acceptable vehicle, carrier or excipient to facilitate administration, and the carrier is usually water or a buffered saline, with or without a preservative. The vaccine may be lyophilized for resuspension at the time of administration or in solution.

[0053] The preferred dose for administration of an antibody composition in accordance with the present invention is that amount will be effective in preventing of treating a bacterial infection, and one would readily recognize that this amount will vary greatly depending on the nature of the infection and the condition of a patient. An “effective amount” of antibody or pharmaceutical agent to be used in accordance with the invention is intended to mean a nontoxic but sufficient amount of the agent, such that the desired prophylactic or therapeutic effect is produced. Accordingly, the exact amount of the antibody or a particular agent that is required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. Accordingly, the “effective amount” of any particular antibody composition will vary based on the particular circumstances, and an appropriate effective amount may be determined in each case of application by one of ordinary skill in the art using only routine experimentation. The dose should be adjusted to suit the individual to whom the composition is administered and will vary with age, weight and metabolism of the individual. The compositions may additionally contain stabilizers or pharmaceutically acceptable preservatives, such as thimerosal (ethyl(2-mercaptobenzoate-S)mercury sodium salt) (Sigma Chemical Company, St. Louis, Mo.).

[0054] In addition, the antibody compositions of the present invention and the vaccines as described above may also be administered with a suitable adjuvant in an amount effective to enhance the immunogenic response against the conjugate. For example, suitable adjuvants may include alum (aluminum phosphate or aluminum hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, and other adjuvants used in research and veterinary applications. Still other chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol. 147:410-415 (1991) and incorporated by reference herein, encapsulation of the conjugate within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as Novasome™ lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be useful.

Pharmaceutical Compositions

[0055] As would be recognized by one skilled in the art, the identified and isolated proteins or the invention, and the antibodies thereto capable of recognizing and binding to said proteins may also be formed into suitable pharmaceutical compositions for administration to a human or animal patient in order to treat or prevent a Gram-positive bacterial infection, such as those caused by Enterococcus, Streptococcus, Staphylococcus, etc. Pharmaceutical compositions containing the proteins or antibodies of the present invention as defined and described above may be formulated in combination with any suitable pharmaceutical vehicle, excipient or carrier that would commonly be used in this art, including such as saline, dextrose, water, glycerol, ethanol, other therapeutic compounds, and combinations thereof. As one skilled in this art would recognize, the particular vehicle, excipient or carrier used will vary depending on the patient and the patient's condition, and a variety of modes of administration would be suitable for the compositions of the invention, as would be recognized by one of ordinary skill in this art. Suitable methods of administration of any pharmaceutical composition disclosed in this application include, but are not limited to, topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal and intradermal administration.

[0056] For topical administration, the composition may be formulated in the form of an ointment, cream, gel, lotion, drops (such as eye drops and ear drops), or solution (such as mouthwash). Wound or surgical dressings, sutures and aerosols may be impregnated with the composition. The composition may contain conventional additives, such as preservatives, solvents to promote penetration, and emollients. Topical formulations may also contain conventional carriers such as cream or ointment bases, ethanol, or oleyl alcohol.

[0057] Additional forms of compositions, and other information concerning compositions, methods and applications with regard to other microbial surface proteins and peptides of the present invention and antibodies thereto, will be found in other patent references relating to MSCRAMM®s, including, for example, in U.S. Pat. No. 6,288,214 (Hook et al.), incorporated herein by reference.

[0058] The compositions which are generated in accordance with the present invention may also be administered with a suitable adjuvant in an amount effective to enhance the immunogenic response in a patient. For example, suitable adjuvants may include alum (aluminum phosphate or aluminum hydroxide), which is used widely in humans, and other adjuvants such as saponin and its purified component Quil A, Freund's complete adjuvant, RIBI adjuvant, and other adjuvants used in research and veterinary applications. Still other chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol. 147:410-415 (1991) and incorporated by reference herein, encapsulation of the conjugate within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992) and incorporated by reference herein, and encapsulation of the protein in lipid vesicles such as Novasome™ lipid vesicles (Micro Vescular Systems, Inc., Nashua, N.H.) may also be useful.

[0059] In any event, the compositions of the present invention will thus be useful for interfering with, modulating, or inhibiting binding interactions by Gram positive bacteria. Accordingly, the present invention will have particular applicability in developing compositions and methods of preventing or treating Gram positive bacterial infections, and in inhibiting binding and spreading of bacteria to host cells.

Methods Detecting and Diagnosing Infections

[0060] In accordance with the present invention, methods are provided for identifying and diagnosing infection from Gram positive bacteria through the use of the proteins, epitopes and peptides obtained by the bioinformatic method of the invention as described above and antibodies that recognize such proteins, epitopes and/or peptides. In accordance with the present invention, the antibodies of the invention as set forth above may be used in kits to diagnose such infections, and such kits may be of the type generally known in the art and commonly used to detect an antigen or microorganism of interest which will bind to the antibodies of the invention. These diagnostic kits will generally include the antibodies of the invention along with suitable means for detecting binding by that antibody such as would be readily understood by one skilled in this art. For example, the means for detecting binding of the antibody may comprise a detectable label that is linked to said antibody. These kits can then be used in diagnostic methods to detect the presence of a Gram positive bacterial infection wherein one obtains a sample suspected of being infected by one or more Gram positive bacteria, such as a sample taken from an individual, for example, from one's blood, saliva, urine, cerebrospinal fluid, genitourinary tract, tissues, bone, muscle, cartilage, or skin, and introduces to the sample one or more of the antibodies as set forth herein. After introduction of the antibodies, it is then determined through conventional means whether there has been binding by the antigens or microorganisms in the sample, such as through suitable labeling, or assays wherein the antibodies are bound to solid supports, and this binding is reflective of the presence of the target antigens or microorganisms in the sample.

Methods for Monitoring Levels of Antibodies or Antigens

[0061] In accordance with the present invention, it is also contemplated that another use of the invention may be in monitoring the level of Gram positive bacterial antigens, or antibodies recognizing said antigens in a human or animal patients suspected of containing said antigens or antibodies. In the preferred process, this may be carried out by first obtaining a biological sample from the human or animal patient, and this would include any suitable sample routinely monitored for infection, such as for example, from one's blood, serum, saliva, tissues, bone, muscle, cartilage, or skin. Next, one would introduce into the sample either (1) when monitoring levels of one's antibodies to Gram positive bacteria, a determinable level of a protein or its A domain to which such antibodies will bind; or (2), when monitoring levels of bacterial infestation is desired, introducing into said sample a measurable level of an antibody to a protein as set forth above. The next step in the process is, after allowing sufficient time and conditions so that the antigens and antibodies in the sample can achieve binding, then determining the level of antigen-antibody binding which will be reflective of the amount or level of the Gram positive bacteria, or antibodies thereto, which are located in the sample. In the desired process, levels may be monitored at regular time periods (e.g., hourly, daily, etc.) so as to track the progression/remission of a Gram positive bacterial infection such as during the period of hospitalization or treatment.

Assays for Detecting and Diagnosing Infections

[0062] In accordance with the present invention, the detection of Gram positive bacteria present in a biological fluid (e.g. blood, serum, plasma, saliva, urine, cerebrospinal fluid, genitourinary tract) or other biological material (e.g., tissues, bone, muscle, cartilage, or skin) can constitute a method for the diagnosis of acute or chronic infections caused by Gram positive bacteria. Because the antibodies as set forth above can recognize the epitopes found in several Gram positive bacteria, these antibodies can be used in assays to allow the diagnosis of a wide variety of Gram positive bacteria and disease conditions. Either monoclonal antibodies or polyclonal antibodies could be used in the assay, and in the case of the monoclonals such as those referred to above. The detected antigens identified by use of the present assays can be detected by a number of conventional means, including Western immunoblot and other similar tests.

[0063] With regard to the assays of the present invention, these assays may use the antibodies of the invention in labeled form, and all well-known methods of labeling antibodies are contemplated, including without limitation enzymatic conjugates, direct labeling with dye, radioisotopes, fluorescence, or particulate labels, such as liposome, latex, polystyrene, and colloid metals or nonmetals. Multiple antibody assay systems, such as antigen capture sandwich assays, are also within the scope of this invention. Further, competitive immunoassays involving labeled protein or assays using the labeled protein to detect serum antibodies are also contemplated forms of the diagnostic assays of the present invention. Beyond diagnostic assays which occur in solution, assays which involve immobilized antibody or protein are also considered within the scope of the invention. (See, for example, Miles et al., Lancet 2:492, 1968; Berry et al., J. Virol. Met. 34:91-100, 1991; Engvall et al., G. Immunochemistry, 8:871, 1971, Tom, Liposomes and Immunology, Elsevier/North Holland, New York, N.Y., 1980; Gribnau et al., J. of Chromatogr. 376:175-89, 1986 and all references cited therein). Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds, particulates, and metal chelates. Those of ordinary skill in the art will know of other suitable labels for binding to the monoclonal or polyclonal antibody (or to an antigen) or will be able to ascertain the same by the use of routine experimentation. Furthermore, the binding of these labels to the monoclonal or polyclonal antibody (or antigen) can be accomplished using standard techniques commonly known to those of ordinary skill in the art.

[0064] One of the ways in which an assay reagent (generally, a monoclonal antibody, polyclonal antibody or antigen) of the present invention can be detectably labeled is by linking the monoclonal antibody, polyclonal antibody, or antigen to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric or fluorometric means. Examples of enzymes which can be used to detectably label the reagents of the present invention include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.

[0065] The presence of the detectably labeled reagent of the present invention can also be detected by labeling the reagent with a radioactive isotope which can then be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful for the purpose of the present invention are .sup.3 H, .sup.125 I, .sup.32 P, .sup.35 S, .sup.14 C, .sup.51 Cr, .sup.36 Cl, .sup.57 Co, .sup.58 Co, .sup.59 Fe and .sup.75 Se. It is also possible to detect the binding of the detectably labeled reagent of the present invention by labeling the monoclonal or polyclonal antibody with a fluorescent compound. When the fluorescently labeled reagent is exposed to light of the proper wave length, its presence can then be detected due to the fluorescence of the dye. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. The reagents of the present invention also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged reagent is then determined by detecting the presence of luminescence that arises during the course of the chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester. Likewise, a bioluminescent compound may be used to label the reagent of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent reagent is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

[0066] Another technique which may also result in greater sensitivity when used in conjunction with the present invention consists of coupling the monoclonal or polyclonal antibody of the present invention to low molecular weight haptens. The haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin (reacting with avidin) or dinitrophenol, pyridoxal and fluorescamine (reacting with specific antihapten antibodies) in this manner. Any biological sample containing the detectable yet unknown amount of a Gram positive antigen can be used in the assay. Normally, the sample is preferably a liquid, such as, for example, urine, saliva, cerebrospinal fluid, blood, serum and the like, or a solid or semi-solid, such as, for example, tissue, feces and the like.

[0067] The diagnostic assay of the present invention includes kit forms of such an assay. This kit would include antibodies as described above (raised against whole proteins or active immunoreactive fragments such as the A domain or immunogenic analogs thereof) which can be optionally immobilized, as well as any necessary reagents and equipment to prepare the biological sample for and to conduct analysis, e.g. preservatives, reaction media such as nontoxic buffers, microtiter plates, micropipettes, etc. The reagent (Abs and/or antigens) can be lyophilized or cryopreserved. As described above, depending on the assay format, the antibodies can be labeled, or the kit can further comprise labeled proteins, fragments or analogs thereof containing the relevant epitopes so as to enable the detection of antibodies to Gram positive bacteria in biological fluids and tissues. By analog is meant a protein or peptide which may differs from its naturally occurring or recombinant counterpart by the substitution, deletion and/or addition of one or more amino acids but which retains the ability to be recognized by an antibody raised against the entire protein. An example is a carrier/antigen fusion polypeptide of the whole antigen or an immunoreactive fragment thereof, where the antigen or fragment can be embedded within the carrier polypeptide or linked to the carrier polypeptide at either end. Accordingly, antibodies in accordance with the invention may also recognize such analogs. The types of immunoassays which can be incorporated in kit form are many. Typical examples of some of the immunoassays which can utilize the antibodies of the invention are radioimmunoassays (RIA) and immunometric, or sandwich, immunoassays.

[0068] By “immunometric assay” or “sandwich immunoassay”, in meant to include simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that the monoclonal antibodies, polyclonal antibodies and/or antigens of the present invention will be useful in other variations and forms of immunoassays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention. In a forward sandwich immunoassay, a sample is first incubated with a solid phase immunoadsorbent containing monoclonal or polyclonal antibody(ies) against the antigen. Incubation is continued for a period of time sufficient to allow the antigen in the sample to bind to the immobilized antibody in the solid phase. After the first incubation, the solid phase immunoadsorbent is separated from the incubation mixture and washed to remove excess antigen and other interfering substances, such as non-specific binding proteins, which also may be present in the sample. Solid phase immunoadsorbent containing antigen bound to the immobilized antibody is subsequently incubated for a second time with soluble labeled antibody or antibodies. After the second incubation, another wash is performed to remove unbound labeled antibody(ies) from the solid phase immunoadsorbent and removing non-specifically bound labeled antibody(ies). Labeled antibody(ies) bound to the solid phase immunoadsorbent is then detected and the amount of labeled antibody detected serves as a direct measure of the amount of antigen present in the original sample.

[0069] Alternatively, labeled antibody which is not associated with the immunoadsorbent complex can also be detected, in which case the measure is in inverse proportion to the amount of antigen present in the sample. Forward sandwich assays are described, for example, in U.S. Pat. Nos. 3,867,517; 4,012,294 and 4,376,110, incorporated herein by reference. In carrying out forward immunometric assays, the process may comprise, in more detail: (a) first forming a mixture of the sample with the solid phase bound antibody(ies) and incubating the mixture for a time and under conditions sufficient to allow antigen in the sample to bind to the solid phase bound antibody(ies), (b) adding to the mixture after said incubation of step (a) the detectably labeled antibody or antibodies and incubating the new resulting mixture for a time and under conditions sufficient to allow the labeled antibody to bind to the antigen-antibody complex on the solid phase immunoadsorbent; (c) separating the solid phase immunoadsorbent from the mixture after the incubation in step (b); and (d) detecting either the labeled antibody or antibodies bound to the antigen-antibody complex on the solid phase immunoadsorbent or detecting the antibody not associated therewith.

[0070] In a reverse sandwich assay, the sample is initially incubated with labeled antibody(ies), after which the solid phase immunoadsorbent containing multiple immobilized antibodies is added thereto, and a second incubation is carried out. The initial washing step of a forward sandwich assay is not required, although a wash is performed after the second incubation. Reverse sandwich assays have been described, for example, in U.S. Pat. Nos. 4,098,876 and 4,376,110. In carrying out reverse immunometric assays, the process may comprise, in more detail; (a) first forming a mixture of the sample with the soluble detectably labeled antibody for a time and under conditions sufficient to allow antigen in the sample to bind to the labeled antibody; (b) adding to the mixture after the incubation of step (a) the solid phase bound antibodies and incubating the new resulting mixture for a time and under conditions sufficient to allow antigen bound to the labeled antibody to bind to the solid phase antibodies; (c) separating the solid phase immunoadsorbent from the incubating mixture after the incubation in step (b); and (d) detecting either the labeled antibody bound to the solid phase immunoadsorbent or detecting the labeled antibody not associated therewith.

[0071] In a simultaneous sandwich assay, the sample, the immunoadsorbent having multiple immobilized antibodies thereon and labeled soluble antibody or antibodies are incubated simultaneously in one incubation step. The simultaneous assay requires only a single incubation and does not include washing steps. The use of a simultaneous assay is by far the preferred one. This type of assay brings about ease of handling, homogeneity, reproducibility, and linearity of the assays and high precision. The sample containing antigen, solid phase immunoadsorbent with immobilized antibodies and labeled soluble antibody or antibodies is incubated under conditions and for a period of time sufficient to allow antigen to bind to the immobilized antibodies and to the soluble antibody(ies). In general, it is desirable to provide incubation conditions sufficient to bind as much antigen as possible, since this maximizes the binding of labeled antibody to the solid phase, thereby increasing the signal. Typical conditions of time and temperature are two hours at 45 degrees C., or twelve hours at 37 degrees C. Antigen typically binds to labeled antibody more rapidly than to immobilized antibody, since the former is in solution whereas the latter is bound to the solid phase support. Because of this, labeled antibody may be employed in a lower concentration than immobilized antibody, and it is also preferable to employ a high specific activity for labeled antibody. For example, labeled antibody might be employed at a concentration of about 1-50 ng per assay, whereas immobilized antibody might have a concentration of 10-500 ng per assay per antibody. The labeled antibody might have a specific activity with, for instance, one radioiodine per molecule, or as high as two or more radioiodines per molecule of antibody.

[0072] Of course, the specific concentrations of labeled and immobilized antibodies, the temperature and time of incubation as well as other assay conditions can be varied, depending on various factors including the concentration of antigen in the sample, the nature of the sample and the like. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

[0073] In carrying out the simultaneous immunometric assay on a sample containing a multivalent antigen, the process may comprise, in more detail: (a) simultaneously forming a mixture comprising the sample, together with the solid phase bound antibody and the soluble labeled antibody or antibodies; (b) incubating the mixture formed in step (a) for a time and under conditions sufficient to allow antigen in the sample to bind to both immobilized and labeled antibodies;(c) separating the solid phase immunoadsorbent from the incubation mixture after the incubation; and(d) detecting either labeled antibody bound to the solid phase immunoadsorbent or detecting labeled antibody not associated therewith. Other such steps as washing, stirring, shaking filtering and the like may of course be added to the assays, as is the custom or necessity for any particular situation.

[0074] There are many solid phase immunoadsorbents which have been employed and which can be used in the present invention. Well-known immunoadsorbents include nitrocellulose, glass, polystyrene, polypropylene, dextran, nylon and other materials; tubes, beads, and microtiter plates formed from or coated with such materials, and the like. The immobilized antibodies can be either covalently or physically bound to the solid phase immunoadsorbent, by techniques such as covalent bonding via an amide or ester linkage, or by absorption. Those skilled in the art will know many other suitable solid phase immunoadsorbents and methods for immobilizing antibodies thereon, or will be able to ascertain such, using no more than routine experimentation.

Kits

[0075] As indicated above, in accordance with the present invention, the antibodies of the invention as set forth above may be used in kits to diagnose a Gram positive infection. Such diagnostic kits are well known in the art and will generally be prepared so as to be suitable for determining the presence of epitopes or proteins that will bind to the antibodies of the invention. These diagnostic kits will generally include the antibodies of the invention along with suitable means for detecting binding by that antibody such as would be readily understood by one skilled in this art. For example, the means for detecting binding of the antibody may comprise a detectable label that is linked to said antibody. These kits can then be used in diagnostic methods to detect the presence of a bacterial infection wherein one obtains a biological sample suspected of having such an infection, such as a sample taken from an individual, for example, from one's blood, saliva, urine, cerebrospinal fluid, genitourinary tract, tissues, bone, muscle, cartilage, or skin, introduces to the sample one or more of the antibodies as set forth herein, and then determines if the antibodies bind to the sample which would indicated the presence of such microorganisms in the sample.

[0076] In addition, as set forth above, these kits can also be useful in methods of monitoring the level of antibodies or bacterial antigens in the serum of a human or animal patient. If monitoring the level of antigen is desired, the kit will include an antibody in accordance with the present invention as described above along with a means of determining the level of binding to that antibody. When it is desired to measure the level of antibodies to Gram positive bacteria in a sample, the kit will preferably include an isolated protein or epitope (e.g., the A domain) such as described above, along with means for detecting binding of those antigens to antibodies present in the sample.

Treating or Protecting Against Infections

[0077] In accordance with the present invention, methods are provided for preventing or treating an infection caused by Gram positive bacteria which comprise administering an effective amount of the antibodies as described above to a human or animal patient in need of such treatment in amounts effective to treat or prevent the infection. Accordingly, in accordance with the invention, administration of an effective amount of the antibodies of the present invention in any of the conventional ways described above (e.g., topical, parenteral, intramuscular, etc.), and will thus provide an extremely useful method of treating or preventing bacterial infections in human or animal patients. As indicated above, by effective amount is meant that level of use, such as of an antibody titer, that will be sufficient to either prevent adherence of the bacteria, or to inhibit binding and colonization of such organisms to host cells and thus be useful in the treatment or prevention such infections. In addition, these antibodies also exhibit protective effects by a number of other mechanisms, including direct killing of the infectious microorganisms, increased opsonization, inhibition of morphological transition, etc., and thus an effective amount of antibodies will also include that amount by which any of the means to achieve a protective effect is obtained. As would be recognized by one of ordinary skill in this art, the level of antibody titer needed to be effective in treating or preventing infections will vary depending on the nature and condition of the patient, and/or the severity of the pre-existing infection.

Eliciting an Immune Response

[0078] In accordance with the present invention, a method is provided for eliciting an immunogenic reaction in a human or animal comprising administering to the human or animal an immunologically effective amount of a protein isolated using the bioinformatic method as described above, or a recombinantly produced version of such a protein, or an immunogenic fragment, region or epitope as described above so as to elicit an immunogenic response. As indicated above, an “immunogenic amount” of the antigen to be used in accordance with the invention to obtain an immunogenic reaction is intended to mean a nontoxic but sufficient amount of the agent, such that an immunogenic response will be elicited in the host so that the desired prophylactic or therapeutic effect is produced. Accordingly, the exact amount of the isolated protein that is required to elicit such a response will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular carrier or adjuvant being used and its mode of administration, and the like. The invention also contemplates methods of generating antibodies which recognize the proteins and epitopes as described above, and suitable methods of generating monoclonal and polyclonal antibodies are described in more detail above.

Coating Devices

[0079] In accordance with the invention, the antibodies and compositions as described above may also be utilized to treat or protect against outbreaks of bacterial infections on certain medical devices and other implanted materials such as prosthetic devices. Medical devices or polymeric biomaterials that may be advantageously coated with the antibodies and/or compositions described herein include, but are not limited to, staples, sutures, replacement heart valves, cardiac assist devices, hard and soft contact lenses, intraocular lens implants (anterior chamber or posterior chamber), other implants such as corneal inlays, kerato-prostheses, vascular stents, epikeratophalia devices, glaucoma shunts, retinal staples, scleral buckles, dental prostheses, thyroplastic devices, laryngoplastic devices, vascular grafts, soft and hard tissue prostheses including, but not limited to, pumps, electrical devices including stimulators and recorders, auditory prostheses, pacemakers, artificial larynx, dental implants, mammary implants, penile implants, cranio/facial tendons, artificial joints, tendons, ligaments, menisci, and disks, artificial bones, artificial organs including artificial pancreas, artificial hearts, artificial limbs, and heart valves; stents, wires, guide wires, intravenous and central venous catheters, laser and balloon angioplasty devices, vascular and heart devices (tubes, catheters, balloons), ventricular assists, blood dialysis components, blood oxygenators, urethral/ureteral/urinary devices (Foley catheters, stents, tubes and balloons), airway catheters (endotracheal and tracheostomy tubes and cuffs), enteral feeding tubes (including nasogastric, intragastric and jejunal tubes), wound drainage tubes, tubes used to drain the body cavities such as the pleural, peritoneal, cranial, and pericardial cavities, blood bags, test tubes, blood collection tubes, vacutainers, syringes, needles, pipettes, pipette tips, and blood tubing.

[0080] It will be understood by those skilled in the art that the term “coated” or “coating”, as used herein, means to apply the antibody or composition as defined above to a surface of the device, preferably an outer surface that would be exposed to an infection such as those caused by Gram positive bacteria. The surface of the device need not be entirely covered by the protein, antibody or active fragment.

[0081] As indicated above, the antibodies of the present invention, or active portions or fragments thereof, may also be useful for interfering with the physical interaction between bacteria responsible for infection and a mammalian host, and may also be useful in interfering with the ability of the bacteria to adhere to extracellular matrix proteins such as fibrinogen, collagen, laminin, etc. Accordingly, the antibodies of the invention may be useful both in treating patients and in preventing or reducing bacterial infections, or for reducing or eliminating infection and infestation of such organisms in-dwelling medical devices and prosthetics to make them safer for use.

[0082] In short, the antibodies of the present invention as described above can be extremely useful in detecting, treating or preventing infections by Gram positive bacteria in human and animal patients, or in preventing or reducing infection of medical devices and prosthesis that can be caused by such organisms. In particular, the present invention will be of importance in the treatment or prevention of such infections in highly susceptible groups such as premature newborns, AIDS and debilitated cancer patients, and are particularly frequent and severe after bone marrow transplantation.

EXAMPLES

[0083] The following examples are provided which exemplify aspects of the preferred embodiments of the present invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES Example 1 Method to Identify MSCRAMM® Proteins from Gram Positive Bacteria and Expression and Purification of Their A Domains

[0084] A. Searching for LPXTG-motif containing cell wall anchored proteins in annotated genomes of Gram-positive bacteria.

[0085] 1. Obtain the amino acid sequences of the entire genome of interest from web sites of sequencing centers. These sequences are stored in a local Silicon Graphics machine (SGI).

[0086] 2. A local searchable database is established using the program format db obtained from NCBI and installed locally on the SGI.

[0087] 3. LPXTG-motif containing proteins are identified using PHI-blast, which is obtained from NCBI and installed locally on the SGI. The PHI-blast search uses a degenerate LPXTG pattern L-P-X-[TSA]-[GANS], X being any amino acid. The templates for PHI-blast vary depend on the particular organism. For each organism, two known cell wall anchored proteins of S. aureus with no sequence homology were used as well as known cell wall anchored proteins from that particular organism if available.

[0088] 4. The LPXTG-containing proteins obtained from PHI-blast were analyzed to select for those that contain typical features of LPXTG-motif containing cell wall anchored proteins: a signal peptide at the N-terminus, the LPXTG-motif being close to the C-terminus followed by a hydrophobic transmembrane segment, and several positively charged residues at the C-terminus. These are done as described below:

[0089] Signal peptide: we use the SignalP prediction server at http://www.cbs.dtu.dk/services/SignalP/. The method has been described in “Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites”. Henrik Nielsen, Jacob Engelbrecht, Søren Brunak and Gunnar von Heijne, Protein Engineering 10, 1-6 (1997).

[0090] Location of LPXTG-motif: visual examination of the sequence.

[0091] A hydrophobic transmembrane segment after the LPXTG-motif: we use the TMHMM server at http://www.cbs.dtu.dk/services/TMHMM-2.0/ for the prediction of transmembrane segments. Several other prediction web servers can also be used, among which are TMpred at http://www.ch.embnet.org/software/TMPRED form.html, DAS at http://www.sbc.su.se/˜miklos/DAS/, and HMMTOP at http://www.enzim.hu/hmmtop/.

[0092] Positively charged residues at C-terminus: visual examination.

[0093] 5. Sequences that contain the above features are putative LPXTG-motif containing cell wall anchored proteins.

[0094] 6. The term “LPXTG” or “cell wall” are used to search for proteins that are annotated as cell wall anchored proteins in the genome of interest at TIGR website (comprehensive microbial resource, http://www.tigr.org/tigrscripts/CMR2/CMRHomePage.spl).

[0095] B. Searching for LPXTG-motif containing cell wall anchored proteins in unannotated genomes of Gram-positive bacteria.

[0096] 1. Obtain genome sequences from the web sites of sequencing centers. These sequences are stored in a local Silicon Graphics machine (SGI).

[0097] 2. Gene prediction using the program Glimmer 2.0 from TIGR. This is facilitated by UNIX C shell scripts written in house.

[0098] 3. The predicted genes are translated into amino acid sequences using a translation program written in house. This program is capable of translating large batch of sequences.

[0099] 4. The translated amino acid sequences are formatted into a searchable database locally as in Section A.2. Subsequent analysis is as described in Section A.3-5.

[0100] C. Prediction of Immunoglobulin-like (Ig-like) fold in putative LPXTG-motif containing cell wall anchored proteins.

[0101] The amino acid sequences of putative LPXTG-motif containing cell wall anchored proteins are submitted to a Fold recognition web server 3D-PSSM (http://www.sbq.bio.ic.ac.uk/˜3dpssm/). The method of prediction is described in Kelley L A, MacCallum R M & Sternberg M J E. Enhanced Genome Annotation using Structural Profiles in the Program 3D-PSSM. J Mol Biol. 2000 Jun. 2;299(2):499-520

[0102] The output of 3D-PSSM gives a probability E value indicating the likelihood of the submitted sequence adopting a similar 3D structure as a published structure.

[0103] Proteins that have E value <0.25 to a published Ig-like fold structure, are considered containing predicted Ig-like folds. These should be considered MSCRAMM® proteins.

[0104] Accordingly, in accordance with the present invention, a bioinformatic approach was used to identify proteins with MSCRAMM®-like characteristics among Gram positive bacteria, particularly Enterococcus faecalis. Forty-two proteins with a putative C-terminal LPxTG cell wall sorting signal were identified in the E. faecalis genome. We then looked for structural similarities to MSCRAMM® proteins among LPxTG-anchored enterococcal proteins. Nine proteins were predicted to contain regions that adopt an immunoglobulin-like fold. The Ig fold-containing regions in FIG. 1 consist of several consecutive and overlapping matches to solved crystal structures (˜150-500 aa) of the immunoglobulin superfamily (IgSF), which consist of one to four domains of equal size and Ig-type fold. The homologous Ig-fold regions cover most of the enterococcal proteins and may indicate a similar “beads-in-a-string” arrangement of consecutive modules that are found in fibronectin and other IgSF proteins (Leahy, 1996)(Sharma, 1999)(Hamburger, 1999)(Luo, 2000). A tandem repeat of Ig folded subdomains (N2 and N3) is found in the crystal structure of the fibrinogen-binding domain of ClfA. The full-length A domains of ClfA and the similarly structured ClfB consist of an additional N-terminal subdomain, N1 (Deivanayagam, 2002)(Perkins, 2001). Based on sequence and secondary structure similarities, an analogous subdomain organization is also expected in other MSCRAMM® proteins including FnbpA, FnbpB, Ace and the Sdr proteins. The solved crystal structure of CNA minimum collagen-binding domain is made of a single Ig-type subdomain (N2) (Symersky, 1997) and the C-terminal repeat domains B1 and B2 each consist of a tandem repeat of Ig-folded subdomains (Deivanayagam, 2000). A similar modular structure is expected in the B3 and B4 repeats. Thus, a module structure of multiple Ig-folded units seems a general characteristic in the MSCRAMM® protein family. The length of the N-subdomains of MSCRAMM® proteins is typically ˜150 aa suggesting that the large size of the A domains of EF1091 and EF0089 could accommodate more than three Ig-folded subdomains in their A domains.

Example 3 Expression and Purification of Recombinant Enterococcal MSCRAMM® Protein Fragments

[0105] To further characterize the utility of this invention, the A-domains of EF1091, EF1092 and EF1093 proteins from E. faecalis as well as Efae 2926, Efae 2925 and Efae 2924 proteins from E. faecium were cloned, expressed and purified. In addition, EF1824 was cloned in two segments, EF1824AI (aa 43-819) and EF1824AII (aa 820-1829) because of the large size of the protein. EF1824AI was insoluble in E. coli cytoplasm and excluded from the assays. Bolded and underlined sequence represents the putative A-domains that were cloned. EF1824A1: amino acid residues 43-819 QEQTAKEDVADSATSVGAIVSIEKAEKNFVITYASGKKAQISILNDHLFRYHLDP (SEQ ID NO:2) TGKFEEYPTPNDPKHVAKITAKTMADYGTQAFEQTNVTDSGNQFILENNGLKI MFEKESALMKVLDKKKNQVILEETAPLSFKNDKATQTLKQSSQENYFGGGTQ NGRFTHKGTAIQIVNTNNWVDGGVASPNPFYWSTAGYGVVRNTWKPGNYDF GSHDPQKTTTTHEGTDFDAFYFFNDSSAGILKDYYELTGKPALMPEYGFYEAH LNAYNRDYWVKVAEGTAGAVKFEDGNFYKEYQPGDLGNLNGTLESLNGEKE NYQFSARAVIDRYKKNDMPLGWFLPNDGYGAGYGQTDSLDGDVQNLKEFTEY AQANGVEVGLWTQSNLHPADPKNPKKGERDIAKEVSVAGVKALKTDVAWVG YGYSFGLNGVEDAANVFVKETDGAVRPMIVSLDGWAGTQRHAGIWTGDQTG GQWEYIRFHIPTYIGTSLSGQPNVGSDMDGIFGGKNKEINIRDFQWKTFTPVQL NMDGWGSNPKTPFAFDQEATDLNRAYLKLKSMMMPYNYSIAKESVDGLPMV RAMALEFPNEGTAYTKDSQYQYMWGPNLLVAPIYNGNQDEAGNSIRDGIYLPD EKQVWVDLFTGEKYQGGRVLNGVKTPLWKVPVFVKDGSIIPMTNPNNNPKEI QRDQRSFLIYPNGTTSFNMYEDDGISTSYEAGQSATTKINSQGPKSNEKGDLT VTIEPTKGSYKDFVDERSTTLDLLASEAPESVTAMVGGTEVTLKQ EF1824A1: amino acid residues 820-1829 AANKEEFLAGTNLYYFDKEFQVNQYLSEASGEKLNQSALSVKLAKQSVTAKDVQITVK (SEQ ID NO:3) GFINKGTVDGGNTTVDDQLTIPANVAINEEKTFPSSLTLQWDQVTEATSYEVERDGTVF GNIQTNTATFDGFSFLSEHTFRVRAVGKNGVSEWSEPIKGKTQDDPYKETINQVKATS NLPEQPGAELKKLTDKDLSTGWHTNWSTGIANPSDGNFLSLKFDLGAEYQMDKIEYL PRDNAGNGNILQLQYRTSKDGANWTEFSEPINWKQDALTKTIETKDQAYRFVEMKVL KSVGNFGSGREMLFYKQPGTEGILHGDITNDGTIDENDAMSYRNYTGLESVDSDFNGY VEKGDLNKNGVIDAYDISYVLRQLDGGIEIPDVEEIAGGLSLAWNENGKDTYLPGDTLT FILKGQDLKNINALSTKMSFDSSKFELVGQPAUNNTQQMENYSKYRKHSNDVENLYL VLSNQGNKQLLNGSMDLVTFKVKVKETTRVKRATUVEQPLQFDMSQGLLVGQGFQQ ATLSDFSVTVKPTELVDKELLQALITLNQARVEKEYTPETWAIFKPILDEAVAVLANEQA TQTDVSAAAENLEKAASQLEKMPDVANKADLEKAIQEGLAKKPSDGQEFTEETKKVL EESLAAAQKVFAQEKVTQEEIDQATKTLREAIAQLKEQPVAVDKETLKEQIAQARGRK PEEGYQFTKETEKQLQEAIQAAEAIVAKETATKEEVSEALNALETAMAQLKEVPLVNK DQLQEWKRAQQVTPSEGHQFTASSLQELQKALLAAKNTLKNPAANQKMIDEAVAEL TSAIDGLQEEVLVTDKKALEAMIAKAKAIKPSAGKEFTSESKARLTEAIDQAEGILADKN ARQEQIDIAEKNVKTALDSLEEQVLQTDKTKLKELLQKAETLKPKAGKQFTKASQEAL AEAIKQAKALVEDPNATQEAVDKCLSILSQAIEAMAEEPISSNSTGNNGNHSTVSGTGG VTSQGKGTATGGTTTKTTTSGT EF0089A: amino acid residues 36-1143 EEVNSDGQLTLGEVKQTSQQEMTLALQGKAQPVTQEWVHYSANVSIKAAHWAAPN (SEQ ID NO:4) NTRKIQVDDQKKQIQIELNQQALADTLVLTLNPTATEDVTFSYGQQQRALTLKTGTDPT ESTAITSSPAASANEGSTEEASTNSSVPRSSEEVASTTKAIESKTTESTTVKPRVAGPT DISDYFTGDETTIIDNFEDPIYLNPDGTPATPPYKEDVTIHWNFNWSIPEDVREQMKAGD YFEFQLPGNLKPNKPGSGDLVDAEGNVYGTYTISEDGTVRFTFNERITSESDIHGDFSL DTHLNDSDGRGPGDWVIDIPTQEDLPPVVIPIVPDTEQQIDKQGHFDRTPNPSAITWTV DINQAMKDQTNPVTETWPTGNTFKSVKVYELVMNLDGTIKEVGRELSPDEYTVDKNG NVTIKGDTNKAYRLEYQTTTDEAVIPDGGGDVPFKNHATLTSDNNPNGLDAEATVTATY GKMLDKRNIDYDEANQEFTWEINYNYGEQTIPKDQAVITDTMGDNLTFEPDSLHLYSVT FDDKGNEVVGAELVEGKDYKVVINGDGSFAIDFLHDVTGAVKIDYKTKVDGIVEGDVAV NNRVDVGTGQHSEDDGTASQQNIIKNTGAVDYQNSTIGWTLAVNQNNYLMENAVITDT YEPVPGLTMVPNSLWKDTTUGAQLTLGKDFMVEITRNADGETGFKVSFIGAYAKTSD AFHITTYTFFDVTELDANNPALDHYRNTAAIDWTDEAGNNHHSEDSKPFKPLPAFDLNA QKSGVYNAVTKEITWTIAVNLSNNRLVDAFLTDPILTNQTYLAGSLKVYEGNTKPDGSV EKVKPTQPLTDITMEEPSEKNQNTWRVDFPNDSRTYVIEFKTSVDEKVIEGSASYDNTA SYTNQGSSRDVTGKVSIQHGGESVKKGGEYHKDDPDHVYWHVMINGAQSVLDDWIT DTPSPNQVLDPESLVIYGTNVTEDGTITPDKSVILEEGKDYTLEVTTDNETGQQKIWKM AHIEAPYYMEYRSLVTSSAAGSTDTVSNQVSITGNGSEWHGDDNGDWVDIDHSGGH ATGTKGKIQLKKTAMDETTILAGAHFQIWDQAKTQVLREGTVDATGVITFGG EF3023A: amino acid residues 26-1024 EEITDLFLQKEVTYSGVEGGKIGENWKYPQFVGEKAVDGDETRWSADKQDEQWLIV (SEQ ID NO:5) DLGEVKNIGELVLQLHAESPVYEILVSTDGESYQSIFKEENGKGGQPTKKYIDGNNVQA RFVKYQQMKMWQHTNKQFYSSSIISFEAYEKKRLPEAIKLLTENLTISEKRKQQLAFEV SPAGVDITEDQIEWSSSDPTIVVDQTGNLTAVKSGEAKVVKIKGTEISDTIPVTWAEN KQYAEMRAKWKMRLLG1TQYDNDADVQQYRAQIATESLALWQTLNQAADREYLWER KPSDTVSADYTTQFTNIKKLALGYYEPSSELFEKPEVYDAIVKGIEFMIDTKKYNGTYYT GNWWDWQIGSAQPLTDTLILLHDDLLNTDAEKLNKFTAPLMLYAKDPNIQWPIYRATG ANLTDISITVLGTGLLLEDNQRLVQVQEAVPSVLKSVSSGOGLYPDGSLIQHGYFPYNG SYGNELLKGFGRIQTILQGSDWEMNDPNISNLFNWDKGYLQLMVNGKMPSMVSGRS ISRAPETNPFTTEFESGKETIANLTLIAKFAPENLRNDIYTSIQTWLQQSGSYYHFFKKP RDFEALIDLKNWNSASPAQATPMQSLNVYGSMDRVLQKNNEYAVGISMYSQRVGNY EFGNTENKKGWHTADGMLYLYNQDFAQFDEGYWATIDPYRLPG1TVDTRELANGAYT GKRSPQSWVGGSNNGQVASIGMFLDKSNEGMNLVAKKSWFLLDGQIINLGSGITGTT DASIETILDNRMIHPQEVKLNQGSDKDNSWISLSAANPLNNIGYVFPNSMNTLDVQIEE RSGRYGDINEYFVNDKTYTNTFAKISKNYGK1VENGTVEYLTVVGKTNEEIAALSKNKG YTVLENTANLQAIEAGNYVMMNTWNNDQEIAGLYAYDPMSVISEKIDNGVYRLTLANPL QNNASVSIEFDKGILEWAADPEISVDQNIITLNSAGLNGSSRSIIVKTTPEVTKEALEKLI QEQ EF2224A: amino acid residues 31-771 QEVTSDAEKTVEKDGLKVIGKIEDTSSQEDIKTVTYEVTNTRDVPIKDLILKQKNTNDSPI (SEQ ID NO:6) KFVLDTLSEERGPTSLEEQAKVETNEKDQTTDIKLLNLQPNSTRKITINGQITTKASNKL LVSVLIEDNEKGTLVIDLPSKDILADKESVSKEKQETSETKVENQANETASSTNEMTARR SNETKPEAGKAIESIQETALTQATESPEQPPLKAQPTGPLVPPTPGRGFNTPIYQSVHK GELFSTGNTNLKIANENTAAAQTFLNTRGASSGYAINNFPLEFADVDNDPNTYNSSRAY IDLNGAKEIAWAGLFWSASRYKGPAYGTNLSDEEISAPVQFTTPNGTVQRVSPQRYHR IDQDATNPGQRFGYNNTGFSNYADVTSILQGDKSATGSYTLADIPMTSSLNGQYQYYN FSGWSLFVVTKDQASKSRAFSIYVGARGNAAGTNNEFTMSNFLTAKQGNLDPIVTWFT VQGDKYWTGDNAQIKNSAGTWVNISNTLNPVNNAMNATVTDNDEHMVDKYPGKFAP DHPNFLDIDIDRMAIPEGVLNAGQNQINFRTTSSGDDYSTNAIGFAVNAETPEFEIKKEIV EPKETYKVGETITYRVSLKNTKADSEAINSVSKDALDGRLNYLPGSLKIISGPNSGEKTD ASGDDQAEYDETNKQIIVRVGNGATATQGGSYKADTAETIYEFKARINERAKANELVPN SATVEAVDILTSAKVNETSNIVEAKIADEQVT EF1269A: amino acid residues 27-596 ETGYAQTEPTSTSETNQISATPNWPRKQVGNIVTAIQLTDKEGNPLGTINQYTDIYLRIE (SEQ ID NO:7) FNLPDNTVNSGDTSVITLPEELRLEKNMTFNWDDTGTWAIAQTDVANKTVTLTYTDY VENHANISGSLYFTSLIDFENVENESKIPIYVTVEGEKIFAGDLDYQGEGDDVNEKFSKY SWFIEDDPTEIYNVLRINPTGQTYTDLEVEDVLKTESLSYMKDTMKIERGQWTLDGNAI WQFTPEEDITDQLAVQYGPDDRNFSVHFGNIGTNEYRITYKTKIDHLPEKGETFTNYAK LTENQTVVEEVEVSRVSQTGGGEANGEQYVVEIHKEDEAGQRLAGAEFELIRNSTNQT VAKITTDQNGTAIVKGLLKDNYTLVETKAPTGYQLSQNKIPITPEDFGKNLVALKTVVNH KISYQPVAASFLAGKVLLGKPLKDAEFQFELLDEKGTVLETVSNDTLGKIQFSPLTFET PGNYQYTIREVNTQQTGVSYDTHNLQVQVTVEALLGNLVA1TQYDGGQVFTNHYTPE KPIESTTPPTSGTUDTTUNSTTETTSITIEKQAIRNKE EF109I: Nucleotide Sequence    0   ATGATAACAG ATGAGAATGA TAAAACGAAT ATTAATATCG AGTTAAATCT (SEQ ID NO:8)   50   TCTCAACCAA ACAGAGCAGC CATTACAACG AGAAATTCAA TTGAAAAATG  100   CACAGTTCAT GGATACTGCT GTAATTGAAA AAGACGGATA TTCTTACCAA  150   GTGACTAATG GTACGCTTTA TCTGACTTTG GACGCAC AAG TAAAAAAGCC  200   GGTACAGCTT TCGTTAGCTG TTGAGCAAAG TTCGCTTCAA ACAGCTCAGC  250   CACCTAAGTT ATTGTATGAA AACAACGAAT ATGATGTTTC AGTTACTTCT  300   GAAAAAATAA CAGTAGAGGA TTCTGCTAAA GAATCAACTG AACCAGAAAA  350   AATAACTGTA CCAGAAAATA CGAAAGAAAC TAACAAAAAT GATTCGGCTC  400   CAGAAAAAAC AGAACAGCCG ACCGCAACAG AAGAGGTAAC CAATCCATTT  450   GCAGAAGCAA GAATGGCGCC AGCTACTTTG AGAGCGAATC TGGCACTGCC  500   TTTAATTGCA CCACAATACA CGACGGATAA TTCTGGGACT TATCCGACAG  550   CTAATUGGCA GCCCACAGGC AATCAAAATG TGTTAAACCA TCAAGGGAAT  600   AAAGACGGTA GTGCACAATG GGACGGCCAA ACGAGTTGGA ATGGGGACCC  650   TACTAATCGC ACAAATTCTT ATATTGAGTA TGGCGGTACA GGAGACCAAG  700   CCGATTATGC CATCCGAAAA TATGCTAGAG AAACAACAAC ACCAGGGCTT  750   TTTGATGTAT ATCTTAATGT GCGTGGGAAT GTTCAGAAAG AAATCACGCC  800   ATTGGATTTG GTCTTAGTCG TTGACTGGTC CGGTAGTATG AATGAAAACA  850   ATCGGATTGG TGAAGTTCAA AAAGGAGTGA ACCGTTTTGT TGATACATTG  900   GCAGATAGCG GTATTACCAA TAACATCAAC ATGGGCTATG TTGGCTACTC  950   AAGTGACGGT TATAATAACA ACGCCATTCA AATGGGGCCG TTTGATACAG 1000   TCAAAAATCC AATTAAAAAT ATTACGCCAA GTAGCACTAG AGGAGGAACT 1050   TTCACTCAAA AAGCATUAAG AGATGCTGGT GATATGTUAG CAACGCCAAA 1100   TGGACATAAG AAAGTCATTG TACTTTTAAC GGATGGCGTC CCAACCTTCT 1150   CTTATAAAGT GAGTCGAGTT CAAACAGAGG CGGATGGTCG CTTTTACGGG 1200   ACACAATTTA CGAATCGACA AGATCAACCA GGTAGCACTT CTTATATCTC 1250   TGGTAGCTAT AATGCGCCAG ATCAAAACAA TATCAATAAA CGGATTAACA 1300   GTACGTTTAT CGCCACGATA GGTGAGGCAA TGGTCTTAAA ACAACGTGGG 1350   ATTGAAATAC ATGGATTGGG CATTCAATTG CAAAGCGATC CACGAGCTAA 1400   TTTATCTAAA CAACAAGTUG AAGATAAAAT GCGTGAGATG GTGTCAGCCG 1450   ATGAAAATGG AGACCTTTAT TATGAATCCG CGGATTATGC ACCAGACATT 1500   TCTGATTATT TAGCGAAAAA AGCCGTTCAG ATTTCAGGAA CGGTTGTAAA 1550   CGGAAAAGTA GTTGATCCAA TTGCTGAACC TTTTAAATAC GAGCCAAATA 1600   CATTATCAAT GAAAAGTGTG GGTCCTGTTC AGGTTCAAAC ATTACCAGAA 1650   GTGTCGCTAA CAGGCGCTAC AATTAATAGT AATGAGATTT ATTTGGGTAA 1700   AGGGCAAGAA ATTCAAATTC ATTATCAAGT ACGTATTCAA ACAGAGTCAG 1750   AAAACTTCAA ACCTGATTTT TGGTATCAAA TGAATGGTCG GACAACGTTU 1800   CAGCCATTAG CCACGGCCCC TGAAAAAGTT GATTTTGGGG TTCCTTCGGG 1850   AAAAGCACCT GGCGTGAAGT TAAACGTGAA AAAAATCTGG GAAGAGTATG 1900   ATCAAGACCC GACAAGTCGG CCAGATAATG TGATTTATGA AATTAGTAGA 1950   AAGCAAGTAA CTGACACAGC CAACTGGCAA ACTGGGTATA TTAAATTATC 2000   AAAACCAGAA AATGATACCA GCAATAGTTG GGAGCGCAAA AATGTAACCC 2050   AACTTTCCAA AACCGCGGAT GAAAGCTATC AAGAAGTTCT TGGGCTTCCC 2100   CAATACAACA ATCAAGGACA AGCTTTCAAT TATCAAACAA CCCGTGAATT 2150   AGCAGTTCCT GGTTACAGTC AAGAAAAAAT CGACGATACT ACTTGGAAAA 2200   ACACGAAGCA GTTCAAGCCA TTAGATTTAA AAGTAATCAA AAATTCTTCC 2250   TCAGGTGAGA AAAACTTAGT GGGAGCCGTC TTTGAATTGA GTGGTAAAAA 2300   TGTTCAAACA ACATTAGTGG ACAATAAAGA TGGTAGCTAT TCCTTGCCAA 2350   AAGATGTGCG CCTACAAAAA GGGGAACGCT ATACATTAAC TGAAGTAAAA 2400   GCACCTGCAG GACATGAGTT AGGCAAGAAA ACGACTTGGC AAATTGAGGT 2450   GAGTGAGCAA GGCAAAGTAA GCATCGATGG ACAAGAAGTG ACCACCACAA 2500   ATCAAGTTAT TCCATTGGAA ATTGAAAATA AATTTTCTTC TTTGCCAATC 2550   AGAATTAGAA AATACACCAT GCAAAATGGC AAACAAGTGA ACTTAGCAGA 2600   GGCGACTTTT GCGTTGCAAA GAAAAAATGC TCAAGGAAGT TACCAAACTG 2650   TGGCAACTCA AAAAACAGAT ACTACAGGAT TGAGCTATTT TAAAATTAGT 2700   GAACCTGGTG AGTATCGAAT GGTGGAACAA TCAGGACCAT TAGGCTACGA 2750   CACTCTTGCT GGAAATTATG AATTTACTGT TGATAAATAT GGGAAAATUC 2800   ACTATGCAGG CAAAAATATT GAAGAAAATG CGCCAGAATG GACACTGACA 2850   CATCAAAATA ATTTGAAACC TTTTGACTTA ACAGTTAATA AAAAAGCCGA 2900   TAATCAGACG CCACTTAAAG GAGCGAAATT CCGTTTAACA GGACCAGATA 2950   CGGATATTGA ATTACCAAAA GATGGCAAAG AAACGGATAC TTTTGTTTTT 3000   GAAAACTTAA AACCAGGGAA ATATGTTCTA ACAGAAACCT TTACGCCAGA 3050   AGGATATCAG GGGTTAAAAG AACCAATCGA ATTAATAATT CGTGAAGATG 3100   GTTCAGTCAC GATAGATGGG GAAAAAGTAG CAGATGTTTT AATTTCTGGA 3150   GAGAAGAATA ATCAAATTAC TTTAGACGTT ACGAACCAAG CAAAGGTTCC 3200   T TTACCTGAA ACTGGTGGCA TAGGACGCTT GTGGTTTTAC TTGATAGCGA 3250   TTAGTACATT CGTGATAGCG GGTGTTTATC TCTTTATTAG ACGACCAGAA 3300   GGGAGTGTG EF1091 amino acid residues 63-1067    0   MITDENDKTN INIELNLLNQ TEQPLQREIQ LKNAQFMDTA VIEKDGYSYQ (SEQ ID NO:9)   50   VTNGTLYLTL DA QVKKPVQL SLAVEQSSLQ TAQPPKLLYE NNEYDVSVTS  100   EKITVEDSAK ESTEPEKITV PENTKETNKN DSAPEKTEQP TATEEVTNPF  150   AEARMAPATL RANLALPLIA PQYTTDNSGT YPTANWQPTG NQNVLNHQGN  200   KDGSAQWDGQ TSWNGDPTNR TNSYIEYGGT GDQADYAIRK YARETTTPGL  250   FDVYLNVRGN VQKEITPLDL VLVVDWSGSM NENNRIGEVQ KGVNRFVDTL  300   ADSGITNNIN MGYVGYSSDG YNNNAIQMGP FDTVKNPIKN ITPSSTRGGT  350   FTQKALRDAG DMLATPNGHK KVIVLLTDGV PTFSYKVSRV QTEADGRFYG  400   TQFTNRQDQP GSTSYISGSY NAPDQNNINK RINSTFIATI GEAMVLKQRG  450   IEIHGLGIQL QSDPRANLSK QQVEDKMREM VSADENGDLY YESADYAPDI  500   SDYLAKKAVQ ISG7VVNGKV VDPIAEPFKY EPNTLSMKSV GPVQVQTLPE  550   VSLTGATINS NEIYLGKGQE IQIHYQVRIQ TESENFKPDF WYQMNGRTTF  600   QPLATAPEKV DFGVPSGKAP GVKLNVKKIW EEYDQDPTSR PDNVIYEISR  650   KQVTDTANWQ TGYIKLSKPE NDTSNSWERK NVTQLSKTAD ESYQEVLGLP  700   QYNNQGQAFN YQTTRELAVP GYSQEKIDDT TWKNTKQFKP LDLKVIKNSS  750   SGEKNLVGAV FELSGKNVQT TLVDNKDGSY SLPKDVRLQK GERYTLTEVK  800   APAGHELGKK TTWQIEVSEQ GKVSIDGQEV TTTNQVIPLE IENKFSSLPI  850   RIRKYTMQNG KQVNLAEATF ALQRKNAQGS YQTVATQKTD TTGLSYFKIS  900   EPGEYRMVEQ SGPLGYDTLA GNYEFTVDKY GKIHYAGKNI EENAPEWTLT  950   HQNNLKPFDL TVNKKADNQT PLKGAKFRLT GPDTDIELPK DGKETDTFVF 1000   ENLKPGKYVL TETFTPEGYQ GLKEPIELII REDGSVTIDG EKVADVLISG 1050   EKNNQITLDV TNQAKVP LPE TGGIGRLWFY LIAISTFVIA GVYLFIRRPE 1100   GSV EF1092: Nucleotide Sequence    0   ATGAAAAACG CACGTTGGTT AAGTATTTGC GTCATGCTAC TCGCTCTTTT (SEQ ID NO:10)   50   CGGGTTTTCA CAGCAAGCAT TAGCAGAGGC ATCGCAAGCA AGCGTTCAAG  100   TTACGT TGCA CAAATTATTG TTCCCTGATG GTCAATTACC AGAACAGCAG  150   CAAAACACAG GGGAAGAGGG AACGCTGCTT CAAAATTATC GGGGCTTAAA  200   TGACGTCACT TATCAAGTCT ATGATGTGAC GGATCCGTTT TATCAGCTTC  250   GTTCTGAAGG AAAAACGGTC CAAGAGGCAC AGCGTCAATT AGCAGAAACC  300   GGTGCAACAA ATAGAAAACC GATCGCAGAA GATAAAACAC AGACAATAAA  350   TGGAGAAGAT GGAGTGGTTT CTTTTTCATT AGCTAGCAAA GATTCGCAGC  400   AACGAGATAA AGCCTATTTA TTTGTTGAAG CGGAAGCACC AGAAGTGGTA  450   AAGGAAAAAG CTAGCAACCT AGTAGTGATT TTGCCTGTTC AAGATCCACA  500   AGGGCAATCG TTAACGCATA TTCATTTATA TCCAAAAAAT GAAGAAAATG  550   CCTATGACTT ACCACCACTT GAAAAAACGG TACTCGATAA GCAACAAGGC  600   TTTAATCAAG GAGAGCACAT TAACTATCAG TTAACGACTC AGATTCCAGC  650   GAATATTTTA GGATATCAGG AATTCCGTTT GTCAGATAAG GCGGATACAA  700   CGTTGACACT TTTACCAGAA TCAATTGAGG TAAAAGTGGC TGGAAAAACA  750   GTTACTACAG GTTACACACT GACGACGCAA AAGCATGGAT TTACGCTTGA  800   TTTTTCAATT AAAGACTTAC AAAACTTTGC AAATCAAACA ATGACTGTGT  850   CGTATCAAAT GCGTTTAGAA AAGACCGCTG AACCTGACAC TGCGATTAAC  900   AACGAAGGAC AATTAGTCAC GGACAAACAT ACCTTGACTA AAAGAGCCAC  950   AGTTCGTACA GGCGGCAAGT CTTTTGTCAA AGTTGATAGT GAAAATGCGA 1000   AAATCACCTT GCCAGAGGCT GTTTTTATCG TCAAAAATCA AGCGGGGGAA 1050   TACCTCAATG AAACAGCAAA CGGGTATCGT TGGCAAAAAG AAAAAGCATT 1100   AGCTAAAAAA TTCACGTCTA ATCAAGCCGG TGAATTTTCA GTTAAAGGCT 1150   TAAAAGATGG CCAGTACTTC TTGGAAGAAA TCTCTGCACC AAAAGGTTAT 1200   CTTCTGAATC AAACAGAAAT TCCTTTTACG GTGGGAAAAA ATTCTTATGC 1250   AACGAACGGA CAACGAACAG CACCGTTACA TGTAATCAAT AAAAAAGTAA 1300   AAGAGTCAGG CTTCTT ACCA AAAACAAATG AAGAACGTTC TATTTGGTTG 1350   ACGATTGCAG GCCTGCTAAT CATTGGGATG GTAGTCATTT GGCTATTTTA 1400   TCAAAAACAA AAAAGAGGAG AGAGAAAA EF1092 amino acid residues 28-438    0   MKNARWLSIC VMLLALFGFS QQALAEA SQA SVQVTLHKLL FPDGQLPEQQ (SEQ ID NO:11)   50   QNTGEEGTLL QNYRGLNDVT YQVYDVTDPF YQLRSEGKTV QEAQRQLAET  100   GATNRKPIAE DKTQTINGED GVVSFSLASK DSQQRDKAYL FVEAEAPEVV  150   KEKASNLVVI LPVQDPQGQS LTHIHLYPKN EENAYDLPPL EKTVLDKQQG  200   FNQGEHINYQ LTTQIPANIL GYQEFRLSDK ADTTLTLLPE SIEVKVAGKT  250   VTTGYTLTTQ KHGFTLDFSI KDLQNFANQT MTVSYQMRLE KTAEPDTAIN  300   NEGQLVTDKH TLTKRATVRT GGKSFVKVDS ENAKITLPEA VFIVKNQAGE  350   YLNETANGYR WQKEKALAKK FTSNQAGEFS VKGLKDGQYF LEEISAPKGY  400   LLNQTEIPFT VGKNSYATNG QRTAPLHVIN KKVKESGF LP KTNEERSIWL  450   TIAGLLIIGM VVIWLFYQKQ KRGERK EF1093 (V583): Nucleotide Sequence    0   ATGAAGCAAT TAAAAAAAGT TTGGTACACC GTTAGTACCT TGTTACTAAT (SEQ ID NO:12)   50   TTVGCCACTT TTCACAAGTG TATTAGOGAC AACAACTGCA TTTGCA GAAG  100   AAAATGGGGA GAGCGCACAG CTCGTGATTC ACAAAAAGAA AATGACGGAT  150   TTACCAGATC CGCTTATTCA AAATAGCGGG AAAGAAATGA GCGAGTTTGA  200   TAAATATCAA GGACTGGCAG ATGTGACGTT TAGTATTTAT AACGTGACGA  250   ACGAATTTTA CGAGCAACGA GCGGCAGGCG CAAGCGTTGA TGCAGCTAAA  300   CAAGCTGTCC AAAGTTTAAC TCCTGGGAAA CCTGTTGCTC AAGGAACCAC  350   CGATGCAAAT GGGAATGTCA CTGTTCAGTT ACCTAAAAAA CAAAATGGTA  400   AAGATGCAGT GTATACCATT AAAGAAGAAC CAAAAGAGGG TGTAGTTGCT  450   GCTACGAATA TGGTGGTGGC GTTCCCAGTT TACGAAATGA TCAAGCAAAC  500   AGATGGTTCC TATAAATATG GAACAGAAGA ATTAGOGGTT GTTCATATTT  550   ATCCTAAAAA TGTGGTAGCC AATGATGGTA GTTTACATGT GAAAAAAGTA  600   GGAACTGCTG AAAATGAAGG ATTAAATGGC GCAGAATTTG TTATTTCTAA  650   AAGCGAAGGC TCACCAGGCA CAGTAAAATA TATCCAAGGA GTCAAAGATG  700   GATTATATAC ATGGACAACG GATAAAGAAC AAGCAAAACG CTTTATTACT  750   GGGAAAAGTT ATGAAATTGG CGAAAATGAT TTCACAGAAG CAGAGAATGG  800   AACGGGAGAA TTAACAGTTA AAAATCTTGA GGTTGGTTCG TATATTTTAG  850   AAGAAGTAAA AGCTCCAAAT AATGCAGAAT TAATTGAAAA TCAAACAAAA  900   ACACCATTTA CAATTGAAGC AAACAATCAA ACACCTGTTG AAAAAACAGT  950   CAAAAATGAT ACCTCTAAAG TTGATAAAAC AACACCAAGC TTAGATGGTA 1000   AAGATGTGGC AATTGGCGAA AAAATTAAAT ATCAAATTTC TGTAAATATT 1050   CCATTGGGGA TTGCAGACAA AGAAGGCGAC GCTAATAAAT ACGTCAAATT 1100   CAATTTAGTT GATAAACATG ATGCAGCCTT AACTTTTGAT AACGTGACTT 1150   CTGGAGAGTA TGCTTATGCG TTATATGATG GGGATACAGT GATTGCTCCT 1200   GAAAATTATC AAGTGACTGA ACAAGCAAAT GGCTTCACTG TCGCCGTTAA 1250   TCCAGCGTAT ATTCCTACGC TAACACCAGG CGGCACACTA AAATTCGTTT 1300   ACTTTATGCA TTTAAATGAA AAAGCAGATC CTACGAAAGG CTTTAAAAAT 1350   GAGGCGAATG TTGATAACGG TCATACCGAC GACCAAACAC CACCAACTGT 1400   TGAAGTTGTG ACAGGTGGGA AACGTTTCAT TAAAGTCGAT GGCGATGTGA 1450   CAGCGACACA AGCCTTGGCG GGAGCTTCCT TTGTCGTCCG TGATCAAAAC 1500   AGCGACACAG CAAATTATTT GAAAATCGAT GAAACAACGA AAGCAGCAAC 1550   TTGGGTGAAA ACAAAAGCTG AAGCAACTAC TTTTACAACA ACGGCTGATG 1600   GATTAGTTGA TATCACAGGG CTTAAATACG GTACCTATTA TTTAGAAGAA 1650   ACTGTAGCTC CTGATGATTA TGTCTTGTTA ACAAATCGGA TTGAATTTGT 1700   GGTCAATGAA CAATCATATG GCACAACAGA AAACCTAGTT TCACCAGAAA 1750   AAGTACCAAA CAAACACAAA GGTACC TTAC CTTCAACAGG TGGCAAAGGA 1800   ATCTACGTTT ACTTAGGAAG TGGCGCAGTC TTGCTACTTA TTGCAGGAGT 1850   CTACTTTGCT AGACGTAGAA AAGAAAATGC T EF1093 amino acid residues 33-590    0   MKQLKKVWYT VSTLLLILPL FTSVLGTTTA FA EENGESAQ LVIHKKKMTD (SEQ ID NO:13)   50   LPDPLIQNSG KEMSEFDKYQ GLADVTFSIY NVTNEFYEQR AAGASVDAAK  100   QAVQSLTPGK PVAQGTUDAN GNVTVQLPKK QNGKDAVYTI KEEPKEGVVA  150   ATNMVVAFPV YEMIKQTDGS YKYGTEELAV VHIYPKNVVA NDGSLHVKKV  200   GTAENEGLNG AEFVISKSEG SPGTVKYIQG VKDGLYTWTT DKEQAKRFIT  250   GKSYEIGEND FTEAENGTGE LTVKNLEVGS YILEEVKAPN NAELIENQTK  300   TPFTIEANNQ TPVEKTVKND TSKVDK1TPS LDGKDVAIGE KIKYQISVNI  350   PLGIADKEGD ANKYVKFNLV DKHDAALTFD NVTSGEYAYA LYDGDTVIAP  400   ENYQVTEQAN GFTVAVNPAY IPTLTPGGTL KFVYFMHLNE KADPTKGFKN  450   EANVDNGHTD DQTPPTVEVV TGGKRFIKVD GDVTATQALA GASFVVRDQN  500   SDTANYLKID ETTKAATWVK TKAEATTFTT TADGLVDITG LKYGTYYLEE  550   TVAPDDYVLL TNRIEFVVNE QSYGTTENLV SPEKVPNKHK GT LPSTGGKG  600   IYVYLGSGAV LLLIAGVYFA RRRKENA Efae2926: Nucteotide Sequence    0   ATGACGACCA CAGGGAAGAA ACTGAAAGTT ATTTTCATGC TGATAATATT (SEQ ID NO:14)   50   GAGTTTATCA AACTTTGTGC CATTATCTGC AATAGCAGAC ACTACAGATG  100   ATCCAACAGT TTTAGAAACA ATTTCAGCTG AAGTCATTTC GGATCAGTCT  150   GGAAAA AAAG CACTGAACAT CAAGCTAAAT GCGAATAACA CCAGTGCTGA  200   AAAGATAGAA AAAGAAATTG GTCTAGTCGA AAATTACTTA AGTGATGTGG  250   AAAGAAAAGA AGGAGATGGC TATGCTTATC AGGTAAATAG CGGGAAAATT  300   ACGTTGGAAA TCTCATCAAA CACTAAACAA ACTATCGATC TGAGTTTTCC  350   AATCGATCCA GCACTTTACC ACAGCCAGGC AAACAAGCTG ATCGTCGATA  400   ATAAAGAATA TGACATTATT GATGAGACAG AAAATAAGAA AGATACAGAT  450   GTGTCAGTAC CAAAGCCAGA CGAAATAGAA GAAGAATCAT CAAAAGAAAA  500   CGAAAATTCT GTCAGCCCAT TTACATTGCC TACATTATCC TTGCCAGCTG  550   TGAGTGTGCC ATCTAATCAA ACGATTCCTA CAGAATATAC AACAGATGAT  600   CAGGGCACTT ATCCTAAAGC CAGTTGGCAA CCTACAGGAA ATACAAATGT  650   TCTTGATCAT CAAGGCAATA AAAACGGAAC AAATCAATGG GATGGTATAA  700   ATTCTTGGAA TGGAGATCCT AATGATCGGA CCCATTCGTA TATCGAATAT  750   GGAGGAACCG GTAATCAAGC AGACTATGCG ATACGAAAGT ATGCAAAGGA  800   AACAAGTACA CCCGGATTGT TTGATGTTTA TTTGAATGCT CGTGGAAATG  850   TACAAAAAGA TATCACGCCT CTTGATCTCG TATTGGTCGT AGACTGGTCA  900   GGAAGTATGA ACGACAATAA TCGGATCGGT GAAGTAAAGA TTGGTGTCGA  950   TCGTTTTGTC GATACTTTAG CAGATAGCGG TATCACAGAC AAAATCAATA 1000   TGGGATATGT CGGCTACTCA AGCGAAGGAT ATAGCTACAG TAACGGTGCA 1050   GTACAGATGG GTTCATTTGA TTCAGTGAAA AATCAAGTAA AATCCATTAC 1100   ACCTTCACGG ACAAATGGTG GTACTTTTAC ACAAAAAGCA CTAAGAGATG 1150   CAGGAAGCAT GCTATCCGTT CCAAATGGAC ATAAAAAAGT GATCGTTTTG 1200   CTGACGGATG GTGTACCAAC ATTTTCCTAT AAAGTACAGC GGGTACACGC 1250   ACAATCAAGC AGCAATTATT ACGGAACTCA GTTTTCTAAT ACGCAAGATC 1300   GGCCGGGAAA TACTTCTCTA ATCTCAAGAA TCTATGATGC ACCTGACCAA 1350   AACAATCTAT CCAGAAGAAT CGACAGTACG TTTATCGCAA CCATCGGAGA 1400   AGCGATGGCA CTCAAAGAAC GAGGAATCGA AATACATGGT CTTGGCATCC 1450   AACTTCAAAG CGATCCGGCA GCTGGTCTCT CAAAAGCAGA AGTAGAGTCT 1500   CGTATGCGAC AAATGGTTTC ATCAGATGAA AAAGGCGATC TTTACTATGA 1550   ATCAGCTGAT CATGCAACAG ATATCTCTGA ATACCTAGCC AAAAAAGCTG 1600   TACAGATCTC AGCAACTGTA AGCAATGGAC AAATAAATGA TCCAATCGCA 1650   GAACCATTCA TTTATCAGCC TGGTACACTT TCAGTCAAGA GTGTGGGGAC 1700   AAGTCCTACA ACGGTCACTC CATCTATTTC CATAGAAGGA AATACCATCA 1750   AGAGCAATCA GATCTATTTA GGAAAAGACC AAGAAATCCA AATCCATTAC 1800   CAAGTGAGAA TCCAAACAGA AAATGAGGAC TTCCATCCAA ATTTCTGGTA 1850   TCAAATGAAC GGCAGGACAA CTTTCCAGCC AAACATTGAT ACCAATGAAT 1900   TAGCTGAATT CGGTATACCA TCTGCTAAAG CTCCCGGAGT CAGTCTTCAC 1950   ATCAAAAAGT TATGGGAAGA ATTTGACAAC AATCTAGCTG ATCGTCCAGA 2000   TCAAGTTACT TTTGAGATTC AACGGGAACA TACGACAAAT GCTGCAGCTT 2050   GGAAAAACGG ATATATTCGA ATCATTAAAC CAGCTAAAGA TACAACAAAT 2100   ACGTGGGAAC GTGCAGACAT TGACAAATTA TCTGCAAATA GCGGAGAAAG 2150   TTATCAAGAG ATATTATCAC TACCTCAATA CAATAATCAA GGTCAAGCAT 2200   TC AGTTACCA AACAATCAAA GAATTACCTG TACCAGGATA CGATTCTCAA 2250   CAAATAGATG CAATGACATG GAAAAATACT AAACAATTCA CACCGTTAAA 2300   CTTGAAAATA ACGAAAAATT CCTCTACAGG TGAAAAGGAT CTTATTGGCG 2350   CTGTTTTCAA ATTAACAGGA GATTCTATTG ATACTTTACT AACAGATCAT 2400   GGCGACGGAA CCTATTCTCT TCCAGAAAAT GTCAAATTGC AAAAAGAAAT 2450   GACCTATACG CTGACAGAAA CAAAAGCTCC AGAAGGGCAT GGATTAAGCA 2500   AAAAGACTAC TTGGGAAATC AAGATCGCTT CTGATGGTAC GGTAACCATT 2550   GATGGAAAAA CAGTCACTAC TTCCGATGAT ACGATCCAGT TGACTATTGA 2600   AAATCCTTTT GTTGAAGTTC CTGTAGCAGT ACGTAAGTAT GCGATGCAAG 2650   GGACGGACAA AGAGATAAAT CTTAAAGGAG CAGCATTTTC CCTACAGAAA 2700   AAAGAAGCAA ATGGTACTTA TCAGCCAATT GACAGCCAAA CAACGAATGA 2750   AAAAGGTCTT GCCAGTTTTG ATTCACTCAC ACCTGGTAAA TATCGAGTCG 2800   TTGAAACAGC TGGTCCTGCC GGATATGATA CTTCGCCGGG AAATTATGAA 2850   TTCCAAATCG ATAAATATGG AAAAATCATT TACACGGGAA AAAATACCGA 2900   GATGACAAAT AATGTATGGA CGCTCACTCA TCAAAATCGA CTAAAAGCGT 2950   TTGATCTAAC GGTACACAAA AAAGAAGACA ACGGACAGAC ATTAAAAGGA 3000   GCAAAATTCA GACTGCAGGG ACCAGAAATG GACTTAGAAT CGCCAAAAGA 3050   TGGACAAGAA ACAGATACCT TTCTATTCGA AAATTTAAAA CCTGGAACTT 3100   ATACGCTGAC CGAAACTTTT ACACCAGAAG GATACCAAGG TCTAAAAGAG 3T50   CCAGTTACTA TAGTTATACA CGAAGATGGG TCAATTCAAG TGGATGGACA 3200   AGATCATGAA TCTGTTCTGT CACCAGGAGC CAAAAACAAC CAGATTTCTT 3250   TAGACATOAC GAATCAGGCA AAAGTACCAT TACCTGAAAC GGGAGGAATT 3300   GGCCGTTTAG GAATCTATCT AGTAGGGATG ATTGGTTGTG CGTTTTCTAT 3350   TTGGTATCTT TTTTTGAAAA AAGAAAGAGG GGGCAGC Efae2926: amino acid residues 53-734    0   MTTTGKKLKV IFMLIILSLS NFVPLSAIAD TTDDPTVLET ISAEVISDQS (SEQ ID NO:15)   50   GK KALNIKLN ANNTSAEKIE KEIGLVENYL SDVERKEGDG YAYQVNSGKI  100   TLEISSNTKQ TIDLSFPIDP ALYHSQANKL IVDNKEYDII DETENKKDTD  150   VSVPKPDEIE EESSKENENS VSPFTLPTLS LPAVSVPSNQ TIPTEYTTDD  200   QGTYPKASWQ PTGNTNVLDH QGNKNGTNQW DGINSWNGDP NDRTHSYIEY  250   GGTGNQADYA IRKYAKETST PGLFDVYLNA RGNVQKDITP LDLVLVVDWS  300   GSMNDNNRIG EVKIGVDRFV DTLADSGITD KINMGYVGYS SEGYSYSNGA  350   VQMGSFDSVK NQVKSITPSR TNGGTFTQKA LRDAGSMLSV PNGHKKVIVL  400   LTDGVPTFSY KVQRVHAQSS SNYYGTQFSN TQDRPGNTSL ISRIYDAPDQ  450   NNLSRRIDST FIATIGEAMA LKERGIEIHG LGIQLQSDPA AGLSKAEVES  500   RMRQMVSSDE KGDLYYESAD HATDISEYLA KKAVQISATV SNGQINDPIA  550   EPFIYQPGTL SVKSVGTSPT TVTPSISIEG NTIKSNQIYL GKDQEIQIHY  600   QVRIQTENED FHPNFWYQMN GRTTFQPNID TNELAEFGIP SAKAPGVSLH  650   IKKLWEEFDN NLADRPDQVT FEIQREHTTN AAAWKNGYIR IIKPAKDTTN  700   TWERADIDKL SANSGESYQE ILSLPQYNNQ GQAF SYQTIK ELPVPGYDSQ  750   QIDAMWIKNT KQFTPLNLKI TKNSSTGEKD LIGAVFKLTG DSIDTLLTDH  800   GDGTYSLPEN VKLQKEMTYT LTETKAPEGH GLSKKTTWEI KIASDGTVTI  850   DGKTVTTSDD TIQLTIENPF VEVPVAVRKY AMQGTDKEIN LKGAAFSLQK  900   KEANGTYQPI DSQTTNEKGL ASFDSLTPGK YRVVETAGPA GYDTSPGNYE  950   FQIDKYGKII YTGKNTEMTN NWJTLTHQNR LKAFDLTVHK KEDNGQTLKG 1000   AKFRLQGPEM DLESPKDGQE TDTFLFENLK PGTYTLTETF TPEGYQGLKE 1050   PVTIVIHEDG SIQVDGQDHE SVLSPGAKNN QISLDITNQA KVPLPETGGI 1100   GRLGIYLVGM IGCAFSIWYL FLKKERGGS Efae2925: Nucleotide Sequence    0   ATGAAAAAAC TTGGTTGGCT TAGTATGTGT CTCTTCTTGT TACTATTTAA (SEQ ID NO:16)   50   ACCAGCTTTT ACTCAGGTAG CAACAGAAAC AGAAACA GAA ATGGTTCAGA  100   TTACTTTACA CAAATTGCTT TTCCCAAACG GGCAACTGCC GAAAAATCAT  150   CCAAATGACG GACAAGAAAA AGCTTTATTA CAAACGTATC GAGGATTAAA  200   TGGTGTCACA TTCCAAGTTT ATGATGTCAC AGATTCTTTT TACCATCTAC  250   GGGAAAAGGG CAAAACGGTA GAAGAAGCAC AAGCAGAGAT CGCAAAAAAC  300   GGTGCGTCTT CCGGTATGTT TACCGCAGAA GCAACAACTA CAACTCTTAA  350   CAACGAAGAT GGTATCGCTT CTTTTTCTCT GGCCGCTAAA GATCAAGAAA  400   AAAGAGATAA AGCGTATCTT TTCATTGAAT CCAAAGTACC AGAAGTCGTC  450   AAAGAAAAGG CAGAGAATAT GGTAGTTGTT CTTCCTGTAC ATGGACAAAA  500   CAATCAAAAA CTTTCAACTA TCCATTTGTA TCCTAAAAAT GAAGAAAACG  550   ACTACCCTGA TCCACCTTTT GAGAAGGTAT TAGAAGAGCC TAGAAATGAT  600   TTTACGATTG GTGAAAAAAT CACTTATTCC TTGCATACGA CAATTCCTGT  650   AAATATCCTT GACTATCAAA AGTTCGAATT GTCAGATAGT GCGGATGAAG  700   CATTAACGTT TTTACCTAAT AGTTTAACGA TTTCATCGAA TGGAGAAAAG  750   CTGACAGAAG GCTTTGTCAT ACACAAGAAA CCTCACGGAT TTGATGTTTT  800   ATTTTCGATC CCTTCGTTGG AAAAATATGC TGGAAAAAAA CTGACCATTT  850   CTTATCAGAT GCAGCTAAGC AGTACAGCAC AGGCGAACAA GGAAATCAAC  900   AACAACGGAA CACTGGATTT TGGTTTTGGT GTCAGTACAA AGAAAGTCTC  950   TGTATATACA GGGAGTAAGC AATTTGTCAA AATCGAGACA AATAAACCAG 1000   ATAAACGATT AGCTGGCGCA GTATTCCTTA TTAAAAACAA AGCAGGAAAT 1050   TACCTCCAGC AAACAGCCAA CGGATACAAG TGGACAAAGA ACGAATCAGA 1100   TGCGCTTCAC CTGATTTCCG ATAAAAATGG CGCTTTTTCA ATTTCCGGGT 1150   TGAAAACAGG AAGTTATCGA TTAAAAGAGA TCGAAGCACC TTCTGGTTAT 1200   ATTTTAAGTG AAACAGAAAT TCCGTTTACC ATTTCAACTT TTCTTTCTGA 1250   GGATAAAGAG GCGGACAGTA TATTGAAAGT AGTCAAT AAA AAAGAAAATA 1300   GCCGTCCATT TCTTCCAAAA ACAAACGAAA CGAAAAATAC ACTTTTAGGC 1350   GTTGTTGGTA TGGTATTCGC AAGCTTTGCA ATCTGGTTGT TTATGAAAAA 1400   AAGAACAGGA GTGAAAAAAT GA Efae 2925: amino acid residues 30-429    0   MKKLGWLSMC LFLLLFKPAF TQVATETET E MVQITLHKLL FPNGQLPKNH (SEQ ID NO:17)   50   PNDGQEKALL QTYRGLNGVT FQVYDVTDSF YHLREKGKTV EEAQAEIAKN  100   GASSGMFTAE ATTTTLNNED GIASFSLAAK DQEKRDKAYL FIESKVPEVV  150   KEKAENMVVV LPVHGQNNQK LSTIHLYPKN EENDYPDPPF EKVLEEPRND  200   FTIGEKITYS LHTTIPVNIL DYQKFELSDS ADEALTFLPN SLTISSNGEK  250   LTEGFVIHKK PHGFDVLFSI PSLEKYAGKK LTISYQMQLS STAQANKEIN  300   NNGTLDFGFG VSTKKVSVYT GSKQFVKIET NKPDKRLAGA VFLIKNKAGN  350   YLQQTANGYK WTKNESDALH LISDKNGAFS ISGLKTGSYR LKEIEAPSGY  400   ILSETEIPFT ISTFLSEDKE ADSILKVVN K KENSRPFLPK TNETKNTLLG  450   VVGMVFASFA IWLFIKKRTG VKK Efae 2924: Nucleotide sequence    0   ATGAAAAATC ATAAAAAAAT AAACGTTATG TTAGGAGTCC TTTTCCTTAT (SEQ ID NO:18)   50   TTTACCATTA CTCACAAACA GCTTCGGCGC AAAAAAAGTG TTTGCAGAGG  100   AGACAGCAGC TCAAGTCATC CTTCATAAAA AGAAAATGAC TGATTTACCC  150   GATCCTTTAA TC CAAAACAG CGGGAAAGAA ATGAGCGAAT TCGATCAATA  200   CCAAGGATTA GCCGATATTT CATTTTCAGT TTATAACGTC ACTCAAGAAT  250   TTTATGCGCA ACGAGATAAA GGAGCGTCCG TGGATGCAGC AAAACAAGCA  300   GTCCAGTCTT TGACTCCTGG TACACCAGTT GCTTCAGGAA CGACAGATGC  350   TGATGGAAAT GTCACTTTAT CTTTACCTAA AAAACAAAAT GGGAAAGATG  400   CAGTCTACAC GATCAAAGAA GAACCAAAAG ACGGAGTGTC AGCTGCCGCA  450   AACATGGTTT TAGCTTTCCC TGTATATGAG ATGATCAAAC AAGCAGATGG  500   CTCTTATAAA TACGGGACAG AAGAACTAGA TACTATCCAT CTCTACCCTA  550   AAAATACAGT CGGTAATGAT GGAACGTTGA AAGTTACAAA AATCGGTACT  600   GCCGAAAACG AAGCACTAAA TGGAGCAGAA TTTATTATTT CTAAAGAAGA  650   AGGAACACCA AGCGTCAAAA AATACATCCA AAGTGTCACA GATGGATTGT  700   ACACTTGGAC AACTGATCAA ACCAAAGCCA AACATTTCAT TACTGGTCAT  750   TCTTATGACA TCGGCAACAA TGACTTTGCC GAGGCATCTA TTGAAAAAGG  800   CCAGTTGATC GTTAATCATT TAGAAGTTGG AAAATATAAT TTAGAAGAAG  850   TAAAAGCTCC TGATAATGCG GAAATGATTG AAAAGCAAAC AATCACGCCT  900   TTTGAGATCC TGGCAAATAG CCAAACACCA GTAGAAAAGA CCATCAAAAA  950   TGATACGTCT AAAGTTGATA AAACAACACC TCAATTGAAT GGAAAAGATG 1000   TCGCAATCGG TGAAAAAATT CAATATGAGA TTTCTGTCAA TATCCCATTA 1050   GGTATCGCTG ATAAAGAAGG AACGCAAAAC AAGTACACAA CATTCAAACT 1100   TATCGATACT CATGACGCTG CTTTAACATT TGATAATGAT TCTTCAGGAA 1150   CGTATGCTTA TGCCITATAT GATGGAAATA AAGAAATCGA CCCAGTAAAT 1200   TATTCTGTCA CTGAGCAAAC AGACGGATTC ACGGTTTCAG TTGATCCGAA 1250   TTATATTCCT TCATTAACTC CTGGCGGTAC ATTGAAATTC GTTTACTATA 1300   TGCATTTGAA CGAAAAAGCA GATCCAACCA AAGGATTTTC TAACCAAGCA 1350   AATGTCGATA ACGGGCATAC AAATGATCAA ACACCACCGT CAGTCGATGT 1400   CGTTACTGGG GGCAAACGAT TTGTTAAAGT AGATGGTGAC GTTACATCAG 1450   ACCAAACACT TGCTGGAGCA GAATTCGTCG TTCGTGATCA AGATAGTGAC 1500   ACAGCGAAAT ATTTATCGAT CGACCCATCC ACAAAAGCCG TCAGCTGGGT 1550   ATCGGCGAAA GAATCAGCAA CGGTTTTTAC AACCACAAGT AACGGTTTAA 1600   TCGATGTGAC AGGTCTAAAA TATGGCACGT ACTATCTGGA AGAAACGAAA 1650   GCGCCAGAAA AATATGTTCC ATTAACAAAC CGTGTAGCAT TTACTATCGA 1700   TGAACAATCT TATGTAACAG CAGGACAGTT GATTTCTCCT GAAAAAATAC 1750   CAAATAAACA CAAAGGTACA  CTTCCTTCAA CAGGCGGTAA GGGAATCTAT 1800   GTGTATATCG GTGCAGGAGT AGTCCTTCTA CTGATTGCTG GACTGTACTT 1850   TGCTAGACGC AAGCACAGTC AGATTTAG Efae 2924: amino acid residues 55-588    0   MKNHKKINVM LGVLFLILPL LTNSFGAKKV FAEETAAQVI LHKKKMTDLP (SEQ ID NO:19)   50   DPLI QNSGKE MSEFDQYQGL ADISFSVYNV TQEFYAQRDK GASVDAAKQA  100   VQSLTPGTPV ASGTTDADGN VTLSLPKKQN GKDAVYTIKE EPKDGVSAAA  150   NMVLAFPVYE MIKQADGSYK YGTEELDTIH LYPKNTVGND GTLKVTKIGT  200   AENEALNGAE FIISKEEGTP SVKKYIQSVT DGLYTWTTDQ TKAKHFITGH  250   SYDIGNNDFA EASIEKGQLI VNHLEVGKYN LEEVKAPDNA EMIEKQTITP  300   FEILANSQTP VEKTIKNDTS KVDKTTPQLN GKDVAIGEKI QYEISVNIPL  350   GIADKEGTQN KYTTFKLIDT HDAALTFDND SSGTYAYALY DGNKEIDPVN  400   YSVTEQTDGF TVSVDPNYIP SLTPGGTLKF VYYMHLNEKA DPTKGFSNQA  450   NVDNGHTNDQ TPPSVDVVTG GKRFVKVDGD VTSDQTLAGA EFVVRDQDSD  500   TAKYLSIDPS TKAVSWVSAK ESATVFTTUS NGLIDVTGLK YGTYYLEETK  550   APEKYVPLTN RVAFTIDEQS YVTAGQLISP EKIPNKHKGT  LPSTGGKGIY  600   VYIGAGVVLL LIAGLYFARR KHSQI

Protein Expression and Purification

[0106] Using PCR (the oligonucleotides used in the PCR reaction are shown in Table 3), the A domains from EF0089, EF1091, EF1092, EF1093, EF1099, EF1269, EF1824, EF2224, and EF3023 were amplified from E. faecalis V583 or E. faecalis EF1 (EF1099) genomic DNA and subcloned into the E. coli expression vector PQE-30 (Qiagen). One liter culture of E. coli M15(pREP4) cultures harboring appropriate pQE-30 based constructs were grown to OD₆₀₀=0.6 with an initial 2% inoculation from overnight cultures. After 2-3 h induction with 0.4 mM isopropyl-beta-d-thiogalactoside (IPTG), cells were collected with centrifugation, resuspended in 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 and stored at −80 C.

[0107] To lyse the cells and release the expressed protein, cells were passed twice through French Press with a gauge pressure setting at 1200 PSI to give an estimated internal cell pressure of 20,000 PSI. The lysate was centrifuged at RCF_(max) of 165,000×g and the supernatant was filtered through a 0.45 □m filter. The volume was adjusted to 15 ml with 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 and 0.2 M imidazole in the same buffer was added to increase the imidazole concentration to 6.5 mM in order to minimize non-specific binding. The sample was loaded to a nickel affinity chromatography column (HiTrap chelating, Pharmacia) connected to an FPLC system (Pharmacia) and previously equilibrated with 10 mM Tris-Cl, 100 mM NaCl, pH 7.9. Bound protein was eluted with a linear gradient of 0-100 mM imidazole in 10 mM Tris-Cl, 100 mM NaCl, pH 7.9 over 100-200 ml. Protein-containing fractions were analyzed in SDS-PAGE (FIG. 2) and dialyzed against 25 mM Tris-Cl, 1 mM EDTA, pH 6.5-9 (depending on pI of protein purified) before applying the samples to an ion-exchange column (HiTrap Q, Pharmacia) for further purification. Bound protein was eluted with a linear gradient of 0-0.5 M NaCl in 25 mM Tris-Cl, 1 mM EDTA, pH 6.5-9 over 100 ml. Finally, protein samples were dialyzed extensively against PBS and stored at +4° C. Alternatively EF1091, EF1092, and EF1093 were expressed in shake flasks or in bioreactors, the cells were harvested by centrifugation and the cell paste frozen at −80° C. Cells were lysed in 1×PBS (10 mL of buffer/1 g of cell paste) using 2 passes through a microfluidizer at 10,000 psi. Lysed cells were spun down at 17,000 rpm for 30 minutes to remove cell debris. Supernatant was passed over a 5-mL HiTrap Chelating (Pharmacia) column charged with 0.1M NiCl₂. After loading, the column was washed with 5 column volumes of 10 mM Tris, pH 8.0, 100 mM NaCl (Buffer A). Protein was eluted using a 0-100% gradient of 10 mM Tris, pH 8.0, 100 mM NaCl, 500 mM imidazole (Buffer B). Protein containing fractions were dialyzed in 1×PBS.

Example 3 MSCRAMM® Genes Common to E. faecalis and E. faecium PCR Analysis

[0108] Primers for flanking regions of sequences above were used to amplify 1 μg genomic DNA from each E. faecalis strain. PCR products from 5 E. faecalis strains in Table 1 were sequenced and compared to the TIGR database sequence. Primers used to amplify the enterococcal MSCRAMM® A-domain gene products are shown below. Protein 5′ Primer 3′ Primer ACE40 GAATTGAGCAAAAGTTCAATC GTCTGTCTTTTCACTTGTTTC G TGTTG EF1091 CAAGTAAAAAAGCCGGTACAG AAAGGAACCTTTGCTTGGTTC C EF1092 TCGCAAGCAAGCGTTCAAG AAGCCTGACTCTTTTACTTTT TTATTG EF1093 GAGAGCGCACAGCTCGTG GGTACCTTTGTGTTTGTTTGG TAC Efae2924 CGGGATCCCAAAACAGCGGGA CCCAAGCTTTCATGTACCTTT AAGAAATGAGCGA GTGTTTATTTGG Efae2925 CGGGATCCGAAATGGTTCAGA TCTGCAGTTCAATTGACTACT TTACTTTACAC TTCAATATACTGTC Efae2926 CGGGATCCAAAGCACTGAACA CCCAAGCTTTCAGAATGCTTG TCAAGCTAAATGCG ACCTTGATTATTGTA

Homology Among Enterococcal MSCRAMM® Proteins

[0109] A blastp search was performed using the AA sequence listed above with the NCBI search engine. The accession number is given for each putative homologue found. Both percent identity and similarity refer to the percentage of AA that match the query sequence exactly while similarity includes conservative AA changes in the matching calculation. TABLE 4 Comparison of E. faecium homologues of E. faecalis MSCRAMM ® protein E. faecalis E. faecium Protein Protein Accession % Similarity Homologue Name Number Identity % EF1091 Efae2926 00038011 60 75 EF1092 Efae2925 00038010 48 63 EF1093 Efae2924 00038009 74 83

[0110] The “A” domain amino acid sequence from each E. faecalis MSCRAMM® protein was used as a query in a blastp (http://www.ncbi.nlm.nih.gov/BLAST/) search. Results shown were scored by NCBI computers. Identity is calculated as exact matches between the subject and query sequences while similarity also includes conservative changes in sequence at the same position.

Example 4 Additional Gram Positive Amino Acid Sequences Predicted to be MSCRAMM® Proteins

[0111] List of LPXTG-motif containing cell wall anchored proteins that contain predicted immunoglobulin-like fold. The sequencing center for each genome is indicated in the parenthesis. All the sequence except for those of CNA from S. aureus and Staphylococcus epidermidis can be obtained from TIGR website (www.tir.org), comprehensive microbial resource section. The S. epidermidis RP64A genome is not annotated. However, the nucleotide coordinates of the genes encoding the listed S. epidermidis proteins can be obtained through TIGR website.

Streptococcus pneumoniae TIGR4 (TIGR)

[0112] SP0368

[0113] SP0462

[0114] SP0463

[0115] SP0464

Enterococcus faecalis V583 (TIGR)

[0116] EF2224

[0117] EF1099

[0118] EF1092

[0119] EF3023

[0120] EF1269

[0121] EF0089

[0122] EF1824

[0123] EF1091

[0124] EF1093

[0125] EF1075

[0126] EF1074

[0127] EF1651

Streptococcus mutans UA159 (University of Oklahoma)

[0128] SMU.610

[0129] SMU.987

[0130] SMU.63c

Staphylococcus aureus N315 (Juntendo University, Japan)

[0131] SA2447

[0132] SA2290

[0133] SA2291

[0134] SA2423

[0135] SA0742

[0136] SA0519

[0137] SA0520

[0138] SA0521

Bacillus anthracis Ames (TIGR)

[0139] BA0871

[0140] BA5258 Staphylococcus epidermidis strain RP62A (TIGR) (SEQ ID NO:20) >SERP_GSE_14_6.AA 2402 residues mknkqgflpnhlnkygirklsagtaslligatlvfgingqvkaaetdnivsqngdnktndsessdkelvkseddkts ststdtnlesefdqnnnpssieestnrndedtlnqrtstetekdthvksadtqttnettnknddnattnhtesisdes tyqsddskttqhdnsntnqdtqstlnptskessnkdeatsptpkestsiektnlsndanhqttdevnhsdsdnmt nstpndteneldttqltshdespspqsdnftgftnlmatplnlrndnprinllaatedtkpktykkpnnseysyllndl gydattvkensdlrhagisqsqdntgsviklnltkwlslqsdfvnggkvnlsfaqsdfytqiesitlndvkmdttnng qnwsapingstvrsgligsvtnhdivitlknsqtlsslgysnnkpvylthtwttndgaiaeesiqvasitptldskapnt iqksdftagrmtnkikydssqnsiksvhtfkpnenflqtdyravlyikeqvnkelipyidpnsvklyvsdpdgnpisq dryvngsidndglfdsskineisiknnntsgqlsnartsldrnvffgtlgqsrsytisyklkdgytlesvaskvsaretfd swmevdyldsydsgapnkrllgsyassyidmidrippvapkansittedtsikgtaevdtninltfndgrtlngkvd sngnfsiaipsyyvltgketikitsidkgdnvspaitisvidktppavkaisnktqkvnteiepikieatdnsgqavtnk veglpagmtfdeatntisgtpsevgsyditvtttdengnsetttftidvedttkptvesvadqtqevnteiepikieatd nsgravtnkvdglpdgvtfdeatntisgtpsevgsyditvtttdesgnvtetiftidvedttkptvesiagqtqevntet epikieakdnsgqtvtnkvdglpdgvtfdeatntisgtpsevgsydvtvtttdesgnsetttftievkdttkptvesva dqtqevnteiepikieardnsgqavtnkvdglpdgvtfdeatntisgtpsevgsyditvtttdesgnvtettftievedt tkptvenvadqtqevnteitpitiesednsgqMnkvdglpdgvtfdettntisgtpskvgsyditvtttdesgnatet tftievedttkptvenvagqtqeinteiepikieatdnsgqavtnkveglpagvtfdeatntisgtpsevgsytvtvtt mdesgnatettftidvedttkptvesvadqtqevnteitpitiesednsdqavtnkvdglpdgvtfdeatntisgtps evgsyMvtttdesgnatettftidvedttkptvksvsdqtqevnteitpikieatdnsgqtvtnkvdglpdgitfdeat ntisgtpsevgsyditvtttdesgnatettftinvedttkptvediadqtqevnteiepikieatdnggqavtnkvdglp dgvtfdeatntisgtpsevgsydiivtttdengnsetttftidvedttkptveswdqtqevnteitpikieatdnsgqa vankvdglpngvtfdettntisgtpsevgsydiivtttdesgnvtetiftidvedttkptvesiagqtqevnteiepikie atd nsgqavtnkvdgipngvtfdeatntisgtpsevgiytvtvtttdesgnatettftidvedttkptvesvadqtqev nteitpitiesednsgqavtnkveglpagmtfdettntisgtpsevgsytvtvtttdesgnetettftidvedttkptves ianqtqevnteitpikieatdnsgqavtnkvdglpngvtfdettntisgtpsevgsydikvtttdesg natettftinve dttkptvesvadqtqeinteiepikieardnsgqavtnkvdglpdgvtfdeatntisgtpsevgsyditvtttdesgn atettftidvedttkptveditdqtqeintemtpikieatdnsgqavtnkveglpdgvtfdeatntisgtpsevgkylitit tidkdgntatttltinvidtttpeqptinkvtenstevngrgepgtwevtfpdgnkvegkvdsdgnyhiqipsettikg gqpiqviaidkagnkseatttnvidttapeqptinkvtenstevsgrgepgtvvevtfpdgnkvegkvdsdgnyhi qipsderfkvgqqlivkwdeegnvsepsitmvqkedknseklstvtgtvtknnskslkhkaseqqsyhnkseki knvnkptkivekdmstydysryskdisnknnksatfeqqnvsdinnnqysrnkvnqpvkksrkneinkdlpqtg eenfnkstlfgtlvaslgalllffkrrkkderideke >SERP_GSE_2_50.AA 892 residues (SEQ ID NO:21) lfglghneakaeentvqdvkdsnmddelsdsndqssneekndvinnsqsintdddnqikkeetnsndaienr skditqsttnvdeneatflqktpqdntqlkeevvkepssvessnssmdtaqqpshttinseasiqtsdneensrv sdfanskiiesntesnkeentieqpnkvredsitsqpssyknidekisnqdellnlpineyenkvrplsttsaqpss krvtvnqlaaeqgsnvnhlikvtdqsitegyddsdgiikahdaenliydvtfevddkvksgdtmtvnidkntvpsdl tdsfaipkikdnsgeiiatgtydntnkqitytftdyvdkyenikahlkltsyidkskvpnnntkldveyktalssvnktitv eyqkpnenrtanlqsmftnidtknhtveqtiyinplrysaketnvnisgngdegstiiddstiikvykvgdnqnlpds nriydyseyedvtnddyaqlgnnndvninfgnidspyiikviskydpnkddyttiqqtvtmqttineytgefrtasyd ntiafstssgqgqgdlppektykigdyvwedvdkdgiqntndnekplsnvlvtltypdgtsksvrtdeegkyqfdgl kngltykitfetpegytptlkhsgtnpaldsegnsvwvtingqddmtidsgfyqtpkyslgnyvwydtnkdgiqgd dekgisgvkvtlkdengniisttttdengkyqfdnlnsgnyivhfdkpsgmtqtttdsgdddeqdadgeevhvtit dhddfsidngyydddsdsdsdsdsdsddsdsdsdsdsdsdsdsdsdsdsdsdsdsdsdsdsdsdsdsd sdsgldnssdkntkdklpdtganedhdskgtllgalfaglgalllgkrrknrknkn >SERP_GSE_9_28.AA 1973 residues (SEQ ID NO:22) mkenkrknnldknntrfsirkyqgygatsvaiigfiuiscfseakadsdkheikshqqsmtnhlttlpsdnqentsn nefnnrnhdishlslnksiqmdelkklikqykainlndkteesiklfqsdlvqaeslinnpqsqqhvdafyhkflnsa gklrkketvsikhersesntyrlgdevrsqtfshirhkrnavsfrnadqsnlstdplkaneinpeiqngnfsqvsggp lptsskrltvvtnvdnwhsystdpnpeypmfytttavnypnfmsngnapygvilgrttdgwnrnvidskvagiyq didwpgselnvnfistspvfsdgaagaklkisnveqnrvtfdsrlngmgpyptgkfsamvnipndinrvrisflpvs stgrvsvqrssrehgfgdnssyyhggsvsdvrinsgsywskvtqreyttrpnssndtfaratinlsvenkghnqs kdtyyevilpqnsrlistrggsgnynnatnklsirldnlnpgdrrdisytvdfessspklinlnahllyktnatfrgndgqr tgdnivdlqsiallmnkdvletelneidkfirdlneadftidswsalqekmteggnhlneqqnqvalenqasqetinn vtqsleilknnlkyktpsqpiiksnnqipnitispadkadkltityqntdnesasiignklnnqwslnnnipgieidmqt glvtidykavypeswgandktgnsdasaesritmprkeatplspiveaneervnwiapngeatqiaikyrtpd gqeatlvaskngsswtlnkqidyvnieensgkvtigyqavqpeseviatetkgnsdesaesrvtmprkeatphs piveaneehvnvtiapngeatqiaikyrtpdgqettliaskngsswtlnkqidyvnieensgkvtigyqavqiesev iatetkgnsdasaesritmlrkeatphspiveaneehvnvtiapngeatqiaikyrtpdgqeatlvasknesswtl nkqidhvnidensgkvtigyqavqpeseiiatetkgnsdasaesritmprkeatpipptleasvqeasvtvtpne natkvfikyldindeistiiaskinqqwtlnkdnfgikinpltgkviisyvavqpesdviaiesqgnsdlseesriimptk eeppeppilesdsieakvnifpndeatrivimytslegqeatlvasknesswtlnkqidhvnidensgkvtigyqa vqpeseviatetkgnsdasaesrvtmprkeatphspivetneervnwiapngeatqiaikyrtpdgqettliask ngsswtlnkqidhvnidensgkvtigyqavqpeseiiatetkgnsdasaesritmprkeaiphspiveaneehv nvtiapngettqiavkyrtpdgqeatliasknesswtlnkqidhvnidensgkvtigyqavqpeseviatetkgns dasaesritmpvkektpappisiinesnasveiipqvnvtqlslqyidakgqqqnhiatlnqnqwtlnknvshitvd kntgkvlinyqavypeseviareskgnsdssnvsmvimprktatpkppiikvdemnaslaiipyknntainihyi dkkgiksmvtaiknndqwqldekikyvkidaktgtviinyqivqenseiiataingnsdkseevkvlmpikeftpla plletnykkatvsilpqsnatkldfkyrdkkgdskiiivkrfkniwkaneqisgvtinpefgqwinyqavypesdila aqyvgnsdasewakvkmpkkelaphspsliydnrnnkiliapnsnatemelsyvdknnqslkvkalkinnrwk fdssvsnisinpntgkivlqpqflltnskiivfakkgnsdasisvsfrvpavkkiefepmfnvpvtvslnkkriqfddcs gvknclnkqisktqlpdtgysdkasksnhlsvlllgfgflsysrkrkekq >|cl|SEPN_5_124.AA 10203 residues (SEQ ID NO:23) MKSKPKLNGRNICSFLLSKCMSYSLSKLSTLKTYNFQITSNNKEKTSRIGVAIALN NRDKLQKFSIRKYAIGTFSTVIAT LVFMGINTNHASADELNQNQKLIKQLNQTDDDDSNTHSQEIENNKQNSSGKTE SLRSSTSQNQANARLSDQFKDTNETSQ QLPTNVSDDSINQSHSEANMNNEPLKVDNSTMQAHSKIVSDSDGNASENKHHK LTENVLAESRASKNDKEKENLQEKDKS QQVHPPLDKNALQAFFDASYHNYRMIDRDRADATEYQKVKSTFDYVNDLLGNN QNIPSEQLVSAYQQLEKALELARTLPQ QSTTEKRGRRSTRSWENRSSRSDYLDARTEYYVSKDDDDSGFPPGTFFHAS NRRWPYNLPRSRNILRASDVQGNAYITT KRLKDGYQWDILFNSNHKGHEYMYYWFGLPSDQTPTGPVTFTIINRDGSSTST GGVGFGSGAPLPQFWRSAGAINSSVAN DFKHGSATNYAFYDGVNNFSDFARGGELYFDREGATQTNKYYGDENFALLNSE KPDQIRGLDTIYSFKGSGDVSYRISFK TQGAPTARLYYAAGARSGEYKQATNYNQLYVEPYKNYRNRVQSNVQVKNRTL HLKRTIRQFDPTLQRTTDVPILDSDGSG SIDSVYDPLSYVKNVTGTVLGIYPSYLPYNQERWQGANAMNAYQIEELFSQENL QNAARSGRPIQFLVGFDVEDSHHNPE TLLPVNLYVKPELKHTIELYHDNEKQNRKEFSVSKRAGHGVFQIMSGTLHNTVG SGILPYQQEIRIKLTSNEPIKDSEWS ITGYPNTLTLQNAVGRTNNATEKNLALVGHIDPGNYFITVKFGDKVEQFEIRSKP TPPRIITTANELRGNSNHKPEIRVT DIPNDTTAKIKLVMGGTDGDHDPEINPYTVPENYTWAEAYHDNDPSKNGVLTF RSSDYLKDLPLSGELKAIVYYNQYVQ SNFSNSVPFSSDTTPPTINEPAGLVHKYYRGDHVEITLPVTDNTGGSGLRDVNV NLPQGWTKTFTINPNNNTEGTLKLIG NIPSNEAYNTTYHFNITATDNSGNTTNPAKTFILNVGKLADDLNPVGLSRDQLQL VTDPSSLSNSEREEVKRKISEANAN IRSYLLQNNPILAGVNGDVTFYYRDGSVDVIDAENVITYEPERKSIFSENGNTNK KEAVITIARGQNYTIGPNLRKYFSL SNGSDLPNRDFTSISAIGSLPSSSEISRLNVGNYNYRVNAKNAYHKTQQELNLKL KIVEVNAPTGNNRVYRVSTYNLTND EINKIKQAFKAANSGLNLNDNDITVSNNFDHRNVSSVTVTIRKGDLIKEFSSNLNN MNFLRWVNIRDDYTISWTSSKIQG RNTDGGLEWSPDHKSLIYKYDATLGRQINTNDVLTLLQATAKNSNLRSNINSNE KQLAERGSNGYSKSIIRDDGEKSYLL NSNPIQVLDLVEPDNGYGGRQVSHSNVIYNEKNSSIVNGQVPEANGASAFNIDK WKANAANNGIMGVIYKAQLYLAPYS PKGYIEKLGQNLSNTNNVINVYFVPSDKVNPSITVGNYDHHTVYSGETFKNTINV NDNYGLNTVASTSDSAITMTRNNNE LVGQAPNVTNSTNKIVKVKATDKSGNESIVSFTVNIKPLNEKYRITTSSSNQTPV RISNIQNNANLSIEDQNRVKSSLSM TKILGTRNYVNESNNDVRSQWSKVNRSGNNATVNVTTTFSDGTTNTITVPVKH VLLEWPTTRTTVRGQQFPTGKGTSP NDFFSLRTGGPVDARIVWVNNQGPDINSNQIGRDLTLHAEIFFDGETTPIRKDTT YKLSQSIPKQIYETTINGRFNSSGD AYPGNFVQAVNQYWPEHMDFRWAQGSGTPSSRNAGSFTKTVTWYQNGQTE NVNVLFKVKPNKPVIDSNSVISKGQLNGQ QILVRNVPQNAQVTLYQSNGTVIPNTNTTIDSNGIATVTIQGTLPTGNITAKTSMT NNVTYTKQNSSGIASNTTEDISVF SENSDQVNVTAGMQAKNDGIKIIKGTNYNFNDFNSFISNIPAHSTLTWNEEPNS WKNNIGTTTKTVTVTLPNHQGTRTVD IPITIYPTVTAKNPVRDQKGRNLTNGTDVYNYIIFENNNRLGGTASWKDNRQPDK NIAGVQNLIALVNYPGISTPLEVPV KVWVYNFDFTQPIYKIQVGDTFPKGTWAGYYKHLENGEGLPIDGWKFYWNQQ STGTTSDQWQSLAYTRTPFVKTGTYDW NPSNWGVWQTSQSAKFIVTNAKPNQPTITQSKTGDVTVTPGAVRNILISGTNDY IQASADKIVINKNGNKLTTFVKNNDG RWTVETGSPDINGIGPTNNGTAISLSRLAVRPGDSIEAIATEGSGETISTSATSEI YIVKAPQPEQVATHTYDNGTFDIL PDNSRNSLNPTERVEINYTEKLNGNETQKSFTITKNNNGKWTINNKPNYVEFNQ DNGKWFSANTIKPNSQITITPKAGQ GNTENTNPTVIQAPAQHTLTINEIVKEQGQNVTNDDINNAVQVPNKNRVAIKQG NALPTNLAGGSTSHIPWIYYSDGSS EEATETVRTKVNKTELINARRRLDEEISKENKTPSSIRNFDQAMNRAQSQINTAK SDADQVIGTEFATPQQVNSALSKVQ AAQNKINEAKALLQNKADNSQLVRAKEQLQQSIQPAASTDGMTQDSTRNYKNK RQAAEQAIQHANSVINNGDATSQQIND AKNTVEQAQRDYVEAKSNLRADKSQLQSAYDTLNRDVLTNDKKPASVRRYNEA ISNIRKELDTAKADASSTLRNTN PSVE QVRDALNKINTVQPKVNQAIALLQPKENNSELVQAKKRLQDAVNDIPQTQGMTQ QTINNYNDKQREAERALTSAQRVIDN GDATTQEITSEKSKVEQAMQALTNAKSNLRADKNELQTAYNKLIENVSTNGKKP ASIRQYETAKARIQNQINDAKNEAER ILGNDNPQVSQVTQALNKIKAIQPKLTEAINMLQNKENNTELVNAKNRLENAVND TDPTHGMTQETINNYNAKKREAQNE IQKANMIINNGDATAQDISSEKSKVEQVLQALQNAKNDLRADKRELQTAYNKLIQ NVNTNGKKPSSIQNYKSARRNIENQ YNTAKNEAHNVLENTNPTVNAVEDALRKINAIQPEVTKAINILQDKEDNSELVRA KEKLDQAINSQPSLNGMTQESINNY TTKRREAQNIASSADTIINNGDASIEQITENKIRVEEATNALNEAKQHLTADTTSL KTEVRKLSRRGDTNNKKPSSVSAY NNTIHSLQSEITQTENRANTIINKPIRSVEEVNNALHEVNQLNQRLTDTINLLQPL ANKESLKEARNRLESKINETVQTD GMTQQSVENYKQAKIKAQNESSIAQTLINNGDASDQEVSTEIEKLNQKLSELTN SINHLTVNKEPLETAKNQLQANIDQK PSTDGMTQQSVQSYERKLQEAKDKINSINNVLANNPDVNAIRTNKVETEQINNE LTQAKQGLTVDKQPLI NAKTALQQSL DNQPSTTGMTEATIQNYNAKRQKAEQVIQNANKIIENAQPSVQQVSDEKSKVEQ ALSELNNAKSALRADKQELQQAYNQL IQPTDLNNKKPASITAYNQRYQQFSNELNSTKTNTDRILKEQNPSVADVNNALN KVREVQQKLNEARALLQNKEDNSALV RAKEQLQQAVDQVPSTEGMTQQTKDDYNSKQQAAQQEISKAQQVIDNGDATT QQISNAKTNVERALEALNNAKTGLRADK EELQNAYNQLTQNIDTSGKTPASIRKYNEAKSRIQTQIDSAKNEANSILTNDNPQ VSQVTAALNKIKAVQPELDKAIAML KNKENNNALVQAKQQLQQIVNEVDPTQGMTTDTANNYKSKKREAEDEIQKAQQ IINNGDATEQQITNETNRVNQAINAIN KAKNDLRADKSQLENAYNQLIQNVDTNGKKPASIQQYQAARQAIETQYNNAKS EAHQILENSNPSVNEVAQALQKVEAVQ LKVNDAIHILQNKENNSALVTAKNQLQQSVNDQPLTTGMTQDSINNYEAKRNEA QSAIRNAEAVINNGDATAKQISDEKS KVEQALAHLNDAKQQLTADTTELQTAVQQLNRRGDTNNKKPRSINAYNKAIQSL ETQITSAKDNANAVIQKPIRTVQEVN NALQQVNQLNQQLTEAINQLQPLSNNDALKAARLNLENKINQTVQTDGMTQQSI EAYQNAKRVAQNESNTALALINNGDA DEQQITTETDRVNQQTTNLTQAINGLTVNKEPLETAKTALQNNIDQVPSTDGMT QQSVANYNQKLQIAKNEINTINNVLA NNPDVNAIKTNKAEAERISNDLTQAKNNLQVDTQPLEKIKRQLQDEIDQGTNTD GMTQDSVDNYNDSLSAAIIEKGKVNK LLKRNPTVEQVKESVANAQQVIQDLQNARTSLVPDKTQLQEAKNRLENSINQQT DTDGMTQDSLNNYNDKLAKARQNLEK ISKVLGGQPTVAEIRQNTDEANAHKQALDTARSQLTLNREPYINHINNESHLNNA QKDNFKAQVNSAPNHNTLETIKNKA DTLNQSMTALSESIADYENQKQQENYLDASNNKRQDYDNAVNAAKGILNQTQS PTMSADVIDQKAEDVKRTKTALDGNQR LEVAKQQALNHLNTLNDLNDAQRQTLTDTINHSPNINSVNQAKEKANTVNTAMT QLKQTIANYDDELHDGNYINADKDKK DAYNNAVNNAKQLINQSDANQAQLDPAEINKVTQRVNTTKNDLNGNDKLAEAK RDANTTIDGLTYLNEAQRNKAKENVGK ASTKTNITSQLQDYNQLNIAMQALRNSVNDVNNVKANSNYINEDNGPKEAYNQA VTHAQTLINAQSNPEMSRDWNQKTQ AVNTAHQNLHGQQKLEQAQSSANTEIGNLPNLTNTQKAKEKELVNSKQTRTEV QEQLNQAKSLDSSMGTLKSLVAKQPTV QKTSVYINEDQPEQSAYNDSITMGQTIINKTADPVLDKTLVDNAISNISTKENALH GEQKLTTAKTEAINALNTLADLNT PQKEAIKTAINTAHTRTDVTAEQSKANQINSAMHTLRQNISDNESVTNESNYINA EPEKQHAFTEALNNAKEIVNEQQAT LOANSINQKAQAILTTKNALDGEEQLRRAKENADQEINTLNQLTDAQRNSEKGL VNSSQTRTEVASQLAKAKELNKVMEQ LNHLINGKNQMINSSKFINEDANQQQAYSNAIASAEALKNKSQNPELDKVTIEQA INNINSAINNLNGEAKLTKAKEDAV ASINNLSGLTNEQKPKENQAVNGAQTRDQVANKLRDAEALDQSMQTLRDLVNN QNAIHSTSNYFNEDSTQKNTYDNAIDN GSTYITGQHNPELNKSTIDQTISRINTAKNDLHGVEKLQRDKGTANQEIGQLGYL NDPQKSGEESLVNGSNTRSEVEEHL NEAKSLNNAMKQLRDKVAEKTNVKQSSDYINDSTEHQRGYDQALQEAENIINEI GNPTLNKSEIEQKLQQLTDAQNALQG SHLLEEAKNNAITGINKLTALNDAQRQKAIENVQAQQTIPAVNQQLTLDREINTA MQALRDKVGQQNNVHQQSNYFNEDE QPKHNYDNSVQAGQTIIDKLQDPIMNKNEIEQAINQINTTQTALSGENKLHTDQE STNRQIEGLSSLNTAQINAEKDLVN QAKTRTDVAQKLAAAKEINSAMSNLRDGIQNKEDIKRSSAYINADPTKVTAYDQ ALQNAENIINATPNVELNKATIEQAL SRVQQAQQDLDGVQQLANAKQQATQTVNGLNSLNDGQKRELNLLINSANTRT KVQEELNKATELNHAMEALRNSVQNVDQ VKQSSNYVNEDQPEQHNYDNAVNEAQATINNNAQPVLDKLAIERLTQTVNTTK DALHGAQKLTQDQQAAETGIRGLTSLN EPQKNAEVAKVTAATTRDEVRNIRQEATTLDTAMLGLRKSIKDKNDTKNSSKYI NEDHDQQQAYDNAVNNAQQVIDETQA TLSSDTINQLANAVTQAKSNLHGDTKLQHDKDSAKQTIAQLQNLNSAQKHMED SLIDNESTRTQVQHDLTEAQALDGLMG ALKESIKDYTNIVSNGNYINAEPSKKQAYDAAVQNAQNIINGTNQPTINKGNVTT ATQTVKNTKDALDGDHRLEEAKNNA NQTIRNLSNLNNAQKDAEKNLVNSASTLEQVQQNLQTAQQLDNAMGELRQSIA KKDQVKADSKYLNEDPQIKQNYDDAVQ RVETIINETQNPELLKANIDQATQSVQNAEQALHGAEKLNQDKQTSSTELDGLT DLTDAQREKLREQINTSNSRDDIKQK IEQAKALNDAMKKLKEQVAQKDGVHANSDYTNEDSAQKDAYNNALKQAEDIIN NSSNPNLNAQDITNALNNIKQAQDNLH GAQKLQQDKNTTNQAIGNLNHLNQPQKDALIQAINGATSRDQVAEKLKEAEALD EAMKQLEDQVNQDDQISNSSPFINED SDKQKTYNDKIQAAKEIINQTSNPTLDKQKIADTLQNIKDAVNNLHGDQKLAQSK QDANNQLNHLDDLTEEQKNHFKPLI NNADTRDEVNKQLEIAKQLNGDMSTLHKVINDKDQIQHLSNYINADNDKKQNYD NAIKEAEDLIHNHPDTLDHKALQDLL NKIDQAHNELNGESRFKQALDNALNDIDSLNSLNVPQRQTVKDNINHVTTLESL AQELQKAKELNDAMKAMRDSIMNQEQ IRKNSNYTNEDLAQQNAYNHAVDKINNIIGEDNATMDPQIIKQATQDINTAINGLN GDQKLQDAKTDAKQQITNFTGLTE PQKQALENIINQQTSRANVAKQLSHAKFLNGKMEELKVAVAKASLVRQNSNYIN EDVSEKEAYEQAIAKGQEIINSENNP TISSTDINRTIQEINDAEQNLHGDNKLRQAQEIAKNEIQNLDGLNSAQITKLIQDIG RTTTKPAVTQKLEEAKAINQAMQ QLKQSIADKDATLNSSNYLNEDSEKKLAYDNAVSQAEQLINQLNDPTMDISNIQA ITQKVIQAKDSLHGANKLAQNQADS NLIINQSTNLNDKQKQALNDLINHAQTKQQVAEIIAQANKLNNEMGTLKTLVEEQ SNVHQQSKYINEDPQVQNIYNDSIQ KGREILNGTTDDVLNNNKIADAIQNIHLTKNDLHGDQKLQKAQQDATNELNYLTN LNNSQRQSEHDEINSAPSRTEVSND LNHAKALNEAMRQLENEVALENSVKKLSDFINEDEAAQNEYSNALQKAKDIING VPSSTLDKATIEDALLELQNARESLH GEQKLQEAKNQAVAEIDNLQALNPGQVLAEKTLVNQASTKPEVQEALQKAKEL NEAMKALKTEINKKEQIKADSRYVNAD SGLQANYNSALNYGSQIIATTQPPELNKDVINRATQTIKTAENNLNGQSKLAEAK SDGNQSIEHLQGLTQSQKDKQHDLI NQAQTKQQVDDIVNNSKQLDNSMNQLQQIVNNDNTVKQNSDFINEDSSQQDA YNHAIQAAKDLITAHPTIMDKNQIDQAI ENIKQALNDLHGSNKLSEDKKEASEQLQNLNSLTNGQKDTILNHIFSAPTRSQV GEKIASAKQLNNTMKALRDSIADNNE ILQSSKYFNEDSEQQNAYNQAVNKAKNIINDQPTPVMANDEIQSVLNEVKQTKD NLHGDQKLANDKTDAQATLNALNYLN QAQRGNLETKVQNSNSRPEVQKWQLANQLNDAMKKLDDALTGNDAIKQTSN YINEDTSQQVNFDEYTDRGKNIVAEQTN PNMSPTNINTIADKITEAKNDLHGVQKLKQAQQQSINTINQMTGLNQAQKEQLN QEIQQTQTRSEVHQVINKAQALNDSM NTLRQSITDEHEVKQTSNYINETVGNQTAYNNAVDRVKQIINQTSNPTMNPLEV ERATSNVKISKDALHGERELNDNKNS KTFAVNHLDNLNQAQKEALTHEIEQATIVSQVNNIYNKAKALNNDMKKLKDIVAQ QDNVRQSNNYINEDSTPQNMYNDTI NHAQSIIDQVANPTMSHDEIENAINNIKHAINALDGEHKLQQAKENANLLINSLND LNAPQRDAINRLVNEAQTREKVAE QLQSAQALNDAMKHLRNSIQNQSSVRQESKYINASDAKKEQYNHAVREVENIIN EQHPTLDKEIIKQLTDGVNQANNDLN GVELLDADKQNAHQSIPTLMHLNQAQQNALNEKINNAVTRTEVAAIIGQAKLLDH AMENLEESIKDKEQVKQSSNYINED SDVQETYDNAVDHVTEILNQTVNPTLSIEDIEHAINEVNQAKKQLRGKQKLYQTI DLADKELSKLDDLTSQQSSSISNQI YTAKTRTEVAQAIEKAKSLNHAMKALNKVYKNADKVLDSSRFINEDQPEKKAYQ QAINHVDSIIHRQTNPEMDPTVINSI THELETAQNNLHGDQKLAHAQQDAANVINGLIHLNVAQREVMINTNTNATTREK VAKNLDNAQALDKAMETLQQWAHKN NILNDSKYLNEDSKYQQQYDRVIADAEQLLNQTTNPTLEPYKVDIVKDNVLANEK ILFGAEKLSYDKSNANDEIKHMNYL NNAQKQSIKDMISHAALRTEVKQLLQQAKILDEAMKSLEDKTQWITDTTLPNYT EASEDKKEKVDQTVSHAQAIIDKIN GSNVSLDQVRQALEQLTQASENLDGDQRVEEAKVHANQTIDQLTHLNSLQQQT AKESVKNATKLEEIATVSNNAQALNKV MGKLEQFINHADSVENSDNYRQADDDKIIAYDEALEHGQDIQKTNATQNETKQA LQQLIYAETSLNGFERLNHARPRALE YIKSLEKINNAQKSALEDKVTQSHDLLELEHIVNEGTNLNDIMGELANAIVNNYAP TKASINYINADNLRKDNFTQAINN ARDALNKTQGQNLDFNAIDTFKDDIFKTKDALNGIERLTAAKSKAEKLIDSLKFIN KAQFTHANDEIINTNSIAQLSRIV NQAFDLNDAMKSLRDELNNQAFPVQASSNYINSDEDLKQQFDHALSNARKVLA KENGKNLDEKQIQGLKQVIEDTKDALN GIQRLSKAKAKAIQYVQSLSYINDAQRHIAENNIHNSDDLSSLANTLSKASDLDN AMKDLRDTIESNSTSVPNSVNYINA DKNLQIEFDEALQQASATSSKTSENPATIEEVLGLSQAIYDTKNALNGEQRLATE KSKDLKLIKGLKDLNKAQLEDVTNK VNSANTLTELSQLTQSTLELNDKMKLLRDKLKTLVNPVKASLNYRNADYNLKRQ FNKALKEAKGVLNKNSGTNVNINDIQ HLLTQIDNAKDQLNGERRLKEHQQKSEVFIIKELDILNNAQKAAIINQIRASKDIKII NQIVDNAIELNDAMQGLKEHVA QLTATTKDNIEYLNADEDHKLQYDYAINLANNVLDKENGTNKDANIIIGMIQNMD DARALLNGIERLKDAQTKAHNDIKD TLKRQLDEIEHANATSNSKAQAKQMVNEEARKALSNINDATSNDLVNQAKDEG QSAIEHIHADELPKAKLDANQMIDQKV EDINHLISQNPNLSNEEKNKLISQINKLVNGIKNEIQQAINKQQIENATTKLDEVIET TKKLIIAKAEAKQMIKELSQKK ROAINNNTDLTPSQKAHALADIDKTEKDALQHIENSNSIDDINNNKEHAFNTLAHII IWDTDQQPLVFELPELSLQNALV TSEVVVHRDETISLESIIGAMTLTDELKVNIVSLPNTDKVADHLTAKVKVILADGS YVTVNVPVKWEKELQIAKKDAIK TIDVLVKQKIKDIDSNNELTSTQREDAKAEIERLKKQAIDKVNHSKSIKDIETVKRT DFEEIDQFDPKRFTLNKAKKDII TDVNTQIQNGFKEIETIKGLTSNEKTQFDKQLTALQKEFLEKVEHAHNLVELNQL QQEFNNRYKHILNQAHLLGEKHIAE HKLGYVVVNKTQQILNNQSASYFIKQWALDRIKQIQLETMNSIRGAHTVQDVHK ALLQGIEQILKVNVSIINQSFNDSLH NFNYLHSKFDARLREKDVANHIVQTETFKEVLKGTGVEPGKINKETQQPKLHKN DNDSLFKHLVDNFGKTVGVITLTGLL SSFWLVLAKRRKKEEEEKQSIKNHHKDIRLSDTDKIDPIVITKRKIDKEEQIQNDD KHSIPVAKHKKSKEKQLSEEDIHS IPWKRKQNSDNKDTKQKKVTSKKKKTPQSTKKWKTKKRSKK >|cl|SEPN_8_63.AA 1973 residues (SEQ ID NO:24) MKENKRKNNLDKNNTRFSIRKYQGYGATSVAIIGFIIISCFSEAKADSDKHEIKSH QQSMTNHLTTLPSDNQENTSNNEF NNRNHDISHLSLNKSIQMDELKKLIKQYKAINLNDKTEESIKLFQSDLVQAESLIN NPQSQQHVDAFYHKFLNSAGKLRK KETVSIKHERSESNTYRLGDEVRSQTFSHIRHKRNAVSFRNADQSNLSTDPLKA NEINPEIQNGNFSQVSGGPLPTSSKR LTVVTNVDNWHSYSTDPNPEYPMFYTTTAVNYPNFMSNGNAPYGVILGRTTDG WNRNVIDSKVAGIYQDIDWPGSELNV NFISTSPVFSDGAAGAKLKISNVEQNRVLFDSRLNGMGPYPTGKLSAMVNIPNDI NRVRISFLPVSSTGRVSVQRSSREH GFGDNSSYYHGGSVSDVRINSGSYWSKVTQREYTTRPNSSNDTFARATINLS VENKGHNQSKDTYYEVILPQNSRLIST RGGSGNYNNATNKLSIRLDNLNPGDRRDISYTVDFESSSPKLINLNA HLLYKTNATFRGNDGQRTGDNIVDLQSIALLMN KDVLETELNEIDKFIRDLNEADFTIDSWSALQEKMTEGGNILNEQ QNQVALENQASQETINNVTQSLEILKNNLKYKTPS QPIIKSNNQIPNITISPADKADKLTITYQNTDNESASIIGNKLNNQWSLNNNIPGIEI DMQTGLVTIDYKAVYPESWGA NDKTGNSDASAESRITMPRKEATPLSPIVEANEERVNWIAPNGEATQIAIKYRT PDGQEATLVASKNGSSWTLNKQIDY VNIEENSGKVTIGYQAVQPESEVIATETKGNSDESAESRVTMPRKEATPHSPIVE ANEEHVNVTIAPNGEATQIAIKYRT PDGQETTLIASKNGSSWTLNKQIDYVNIEENSGKVTIGYQAVQLESEVIATETKG NSDASAESRITMLRKEATPHSPIVE ANEEHVNVTIAPNGEATQIAIKYRTPDGQEATLVASKNESSWTLNKQIDHVNIDE NSGKVTIGYQAVQPESEIIATETKG NSDASAESRITMPRKEATPIPPTLEASVQEASVTVTPNENATKVFIKYLDINDEIS TIIASKINQQWTLNKDNFGIKINP LTGKVIISYVAVQPESDVIAIESQGNSDLSEESRIIMPTKEEPPEPPILESDSIEAK VNIFPNDEATRIVIMYTSLEGQE ATLVASKNESSWTLNKQIDHVNIDENSGKVTIGYQAVQPESEVIATETKGNSDA SAESRVTMPRKEATPHSPIVETNEER VNWIAPNGEATQIAIKYRTPDGQETTLIASKNGSSWTLNKQIDHVNIDENSGKV TIGYQAVQPESEIIATETKGNSDAS AESRITMPRKEAIPHSPIVEANEEHVNVTIAPNGETTQIAVKYRTPDGQEATLIAS KNESSWTLNKQIDHVNIDENSGKV TIGYQAVQPESEVIATETKGNSDASAESRITMPVKEKTPAPPISIINESNASVEIIP QVNVTQLSLQYIDAKGQQQNLIA TLNQNQWTLNKNVSHITVDKNTGKVLINYQAVYPESEVIARESKGNSDSSNVSM VIMPRKTATPKPPIIKVDEMNASLAI IPYKNNTAINIHYIDKKGIKSMVTAIKNNDQWQLDEKIKYVKIDAKTGTVIINYQIVQ ENSEIIATAINGNSDKSEEVKV LMPIKEFTPLAPLLETNYKKATVSILPQSNATKLDFKYRDKKGDSKIIIVKRFKNIW KANEQISGVTINPEFGQWINYQ AVYPESDILAAQYVGNSDASEWAKVKMPKKELAPHSPSLIYDNRNNKILIAPNSN ATEMELSYVDKNNQSLKVKALKINN RWKFDSSVSNISINPNTGKIVLQPQFLLTNSKIIVFAKKGNSDASISVSLRVPAVK KIELEPMFNVPVLVSLNKKRIQFD DCSGVKNCLNKQISKTQLPDTGYSDKASKSNILSVLLLGFGFLSYSRKRKEKQ

Example 5 Immunization Strategies for Antibody Production Using Three Representative Enterococcal MSCRAMM® Proteins

[0141] Purified EF1091, EF1092, and EF1093 proteins were used to generate a panel of murine antibodies. Briefly, a group of Balb/C mice received a series of subcutaneous immunizations of 1-10 mg of protein in solution or mixed with adjuvant as described below in Table 5:

Table 5. Immunization Scheme

[0142] Conventional Injection Day Amount (μg) Route Adjuvant Primary 0 5 Subcutaneous FCA Boost #1 14 1 Intraperitoneal RIBI Boost #2 28 1 Intraperitoneal RIBI Boost #3 42 1 Intraperitoneal RIBI

[0143] At the time of sacrifice serum was collected and titered in ELISA assays against MSCRAMM® proteins ACE, EF1091, EF1092 and EF1093 (Table 6).

Serum ELISA

[0144] Immulon 2-HB high protein binding 96 well plates were coated with 100 ng/well of the purified A-domains of EF1091, EF1092 or EF1093 and incubated overnight at 2-8° C. Plates were washed four times (350 μl/well) with PBS/0.5% Tween 20 using the Skatron Skanwasher plate washer and then blocked with 1% bovine serum albumin (BSA) solution, 200 μl/well for 1-2 hour at room temperature. Following incubation, the plates were washed as before and 100 μl of 1×PBS, 0.05% Tween 20, 0.1% BSA buffer was added to each well of rows B-H of the 96-well plate. The negative control serum (preimmune Balb/C serum) and hyperimmune samples were then diluted 1:100 in 1×PBS, 0.05% Tween 20, 0.1% BSA buffer. 200 μl of negative control serum was added in duplicate to wells Al and A2 of the 96-well plate and 200 μl of each diluted hyperimmune test serum were added in duplicate to wells A3 toA12. Two-fold serial dilutions were performed down the plate ending with Row H with the remaining 100 μl being discarded. The plates were incubated for 1 hour at room temperature. The plates were again washed as before followed by the addition of 1:5000 dilution of a secondary antibody solution, Goat anti-mouse IgG (whole molecule)-AP conjugate (Sigma Cat. A-5153), to each well (100 μl/well) and incubated for 1 hour at room temperature. Following incubation, the plates were washed 4 times (350 μl/well) with PBS/0.5% Tween 20. The developing solution, 1 mg/ml 4-nitrophenyl phosphate (pNPP) in 1M Diethanolamine, pH9.8, 0.5mM MgCl₂, was added to each well (100 μl/well) and the plates incubated at 37° C. for 30 minutes. After incubation, the absorbance (A405_(nm)) of each well was measured using the Spectra MAX 190 plate reader (Molecular Devices Corp., Sunnyvale, Calif.). The data was analyzed using SOFTmax Pro v.3.1.2. software (Molecular Devices Corp.) The dilution of the hyperimmune sera where the absorbance was 2-fold above the negative control serum absorbance was used as the titre for that hyperimmune serum sample. TABLE 6 Antibody Titer at Sacrifice Antigen Polyclonal Antibody Titre EF1091 >12,800 EF1092 >12,800 EF1093 >12,800

Example 6 Antibody Reactivity Against E. faecalis MSCRAMM® Proteins

[0145] Antisera derived from Balb/c mice (as described in Example 3) was used to identify EF1091, EF1092 or EF1093 natively expressed on the surface of E. faecalis strains.

Flow Cytometry Analysis—Whole Cell Staining

[0146] Bacterial samples (Table 7) were collected, washed and incubated with polyclonal antisera or pre-immune sera (control) at a dilution of 1:2000 after blocking with rabbit IgG (50 mg/ml). Following incubation with sera, bacterial cells were incubated with Goat-F_((ab′)2)-Anti-Mouse-F_((ab′)2)-FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow cytometer to analyze fluorescence emission (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. TABLE 7 Whole Cell Staining of E. faecalis and E. faecium EF1091 EF1092 EF1093 E. faecalis ATCC700802 −− −− Not done (NA) 687097 −− −− ND V583 −− −− ND OG110 −− −− ND OG1RF + + + TX2708 −− −− ND TX0020 ND ND ND TX0045 −− −− ND TX0002 −− −− ND TX0039 −− −− ND TX0052 ND ND ND TX0012 −− −− ND TX0017 ND ND ND TX0008 ND ND ND TX0024 ND ND ND E. faecium 935/01 −− −− ND TX0016 ND ND ND TX0054 +/− +/− ND TX0074 + + ND TX0078 −− −− ND TX0080 +/− +/− ND TX0081 +/− +/− ND TX2535 ND ND ND TX2555 +/− + + TX0110 −− −− −− TX0111 ND ND ND

[0147] Polyclonal antisera raised in mice against EF1091, EF1092 and EF1093 were shown to recognize the native protein expressed on the surface of E. faecalis strains as well as E. faecium strains in flow cytometry studies (Table 7).

Example 7 Immunization Strategies for Monoclonal Antibody Production

[0148] With the goal of generating and characterizing monoclonal antibodies (mAbs), strategies were formulated to generate mAbs against EF1091, EF 1092 and EF 1093 that were of high affinity, able to interrupt or restrict the binding of extracellular matrix proteins (ECM) and demonstrate therapeutic efficacy in vivo. E. coli expressed and purified EF1091, EF1092, and EF1093 proteins were used to generate a panel of murine monoclonal antibodies. Briefly, a group of Balb/C or SJL mice received a series of subcutaneous immunizations of 1-10 □g of protein in solution or mixed with adjuvant as described below in Table 8: TABLE 8 Immunization Schemes Day Amount (μg) Route Adjuvant RIMMS Injection #1 0 5 Subcutaneous FCA/RIBI #2 2 1 Subcutaneous FCA/RIBI #3 4 1 Subcutaneous FCA/RIBI #4 7 1 Subcutaneous FCA/RIBI #5 9 1 Subcutaneous FCA/RIBI Conventional Injection Primary 0 5 Subcutaneous FCA Boost #1 14 1 Intraperitoneal RIBI Boost #2 28 1 Intraperitoneal RIBI Boost #3 42 1 Intraperitoneal RIBI

[0149] At the time of sacrifice (RIMMS) or seven days after a boost (conventional) serum was collected and titered in ELISA assays against in immunizing MSCRAMM or on whole cells (E. faecalis and/or E. faecium). Three days after the final boost, the spleens or lymph nodes were removed, teased into a single cell suspension and the lymphocytes harvested. The lymphocytes were then fused to a P3X63Ag8.653 myeloma cell line (ATCC #CRL-1580). Cell fusion, subsequent plating and feeding were performed according to the Production of Monoclonal Antibodies protocol from Current Protocols in Immunology (Chapter 2, Unit 2.).

Example 8 Screening and Selection of Anti-EF1091 Monoclonal Antibodies

[0150] Any clones that were generated from the EF1091 fusion were then screened for specific anti-EF1091 antibody production using a standard ELISA assay. Positive clones were expanded and tested further for activity in a whole bacterial cell binding assay by flow cytometry and EF1091 binding by Biacore analysis (Table 9).

ELISA Analysis

[0151] Immulon 2-HB high-binding 96-well microtiter plates (Dynex) were coated with 1 pg/well of rEF1091 in 1×PBS, pH 7.4 and incubated for 2 hours at room temperature. All washing steps in ELISAs were performed three times with 1×PBS, 0.05% Tween-20 wash buffer. Plates were washed and blocked with a 1% BSA solution at room temperature for 1 hour before hybridoma supernatant samples were added to wells. Plates were incubated with samples and relevant controls such as media alone for one hour at room temperature, washed, and goat anti-mouse IgG-AP (Sigma) diluted 1:5000 in 1×PBS, 0.05% Tween-20, 0.1% BSA was used as a secondary reagent. Plates were developed by addition of 1 mg/ml solution of 4-nitrophenyl phosphate (pNPP) (Sigma), followed by incubation at 37° C. for 30 minutes. Absorbance was read at 405 nm using a SpectraMax 190 Plate Reader (Molecular Devices Corp.). Antibody supernatants that had an OD₄₀₅≧3 times above background (media alone, ˜0.1 OD) were considered positive.

Biacore Analysis

[0152] Throughout the analysis, the flow rate remained constant at 10 ml/min. Prior to the EF1091 injection, test antibody was adsorbed to the chip via RAM-Fc binding. At time 0, EF1091 at a concentration of 30 mg/ml was injected over the chip for 3 min followed by 2 minutes of dissociation. This phase of the analysis measured the relative association and disassociation kinetics of the mAb/EF1091 interaction.

Flow Cytometric Analysis

[0153] Bacterial samples were collected, washed and incubated with mAb or PBS alone (control) at a concentration of 2 mg/ml after blocking with rabbit IgG (50 mg/ml). Following incubation with antibody, bacterial cells were incubated with Goat-F_((ab′)2)-Anti-Mouse-F_((ab′)2)-FITC which served as the detection antibody. After antibody labeling, bacterial cells were aspirated through the FACScaliber flow 10 cytometer to analyze fluorescence emission (excitation: 488, emission: 570). For each bacterial strain, 10,000 events were collected and measured. TABLE 9 Representative Examples of Hybridoma Supernatants Flow Cytometric Fusion- Immunization ELISA Data Biacore E. faecalis Clone Antigen (EF1091) Analysis Staining 85-8 EF 1091 0.70 + + 85-25 EF 1091 0.75 + + 85-58 EF 1091 0.76 + −− 85-78 EF 1091 0.83 + + 85-81 EF 1091 0.84 + + 85-162 EF 1091 0.78 + + 85-310 EF 1091 0.30 −− −− 85-341 EF 1091 0.31 −− −− 85-359 EF 1091 0.48 −− −− 85-374 EF 1091 0.39 −− −− 85-380 EF 1091 0.32 −− −− 85-399 EF 1091 0.98 + −− 85-473 EF 1091 0.55 + −− 85-511 EF 1091 0.85 + −− 85-581 EF 1091 0.88 + + 85-586 EF 1091 0.88 + + 85-641 EF 1091 0.45 + + 85-661 EF 1091 0.32 −− −− 85-712 EF 1091 0.30 −− −−

Example 9 Binding of Enterococcal MSCRAMM Proteins to Extracellular Matrix (ECM) Proteins

[0154] Understanding the potential extracellular matrix proteins that these MSCRAMMs expressed from Enterococcus bind to is of great biological importance with therapeutic implications.

ELISA Based Extracellular Matrix Ligand Screening

[0155] To determine the binding activity of the recombinant proteins EF1091, EF1092 and EF1093 (Table 10) with extracellular matrix molecules, duplicate wells of a 96-well Costar micro-titer plate (Corning) were coated overnight at 4° C. with 2 μg of either human collagen type I, III, IV, V or VI (Rockland Immunochemicals), fibrinogen, fibronectin, plasminogen, vitronectin (Sigma) or elastin (CalBiochem) in 100 μL of 1×PBS, pH 7.4 (Gibco). Wells were washed 4 times with 1×PBS, pH 7.4 containing 0.05% Tween 20 (1×PBST). Wells were then blocked with a 1% (w/v) solution of BSA in 1×PBS, pH 7.4 for 1 hour followed by 4 washes with 1×PBST. Next, 5 μg of recombinant protein in 100μL of 1×PBST containing 0.1%BSA (1×PBST-BSA) was added to each well. After incubation with the protein for 1 hour at room temperature, wells were washed 4 times with 1×PBST and 100 □L of mouse polyclonal antisera raised against the respective recombinant protein was added to each well at a dilution of 1:2000 in 1×PBST-BSA. Following the 1 hour incubation at room temperature with antisera, the wells were washed 4 times with 1×PBST. Finally, goat anti-mouse IgG-alkaline phsophatase conjugate (Sigma) was diluted 1:2000 with 1×PBST-BSA and 100 μL was added to each well. This incubation proceeded for 1 hour at room temperature and the wells were then washed 4 times with 1×PBST. The alkaline phosphatase was developed by adding 100 μL of a 1 mg/mL pNP solution (Sigma 104 tablets) to each well and incubating for 30 minutes at room temperature. Development was stopped by addition of 50 μL of 2M NaOH to each well. The absorbance at 405 nm (A₄₀₅) was measured using a SpectraMax 190 (Molecular Devices). Reactivity was noted as positive if the signal was 2.5× greater than background.

[0156] Alternatively, EF0089 and EF2224 binding to components of the ECM (Table 10) was tested by immobilizing 1 □g of each ECM protein (human laminin, fibronectin, fibrinogen, type I, III and IV collagens) in 100 □l PBS, or 3% acetic acid in the case of collagens, on microplate wells (96-well, 4HBX, Thermo Labsystems, Franklin, Mass.) overnight at 4° C. Plates were washed once with PBS and blocked with 1% BSA in PBS for 1 h. Fifty □l of 5 and 10 □M concentrations of purified His-tag proteins in the blocking buffer were added and incubated at ambient temperature for 2 h. Plates were washed three times with 0.05% Tween20 in PBS and incubated 2 h with 1:3000 dilution of His₆-tag monoclonal antibody (Amersham Biosciences Corp., Piscataway, N.J.) in blocking buffer. After three washes, 1:3000 dilution of alkaline phosphatase-conjugated anti-mouse antibody in blocking buffer was added to the wells and incubated 2 h. Finally, signal was detected with nitrobluetetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) in 0.1 M NaHCO₃, 1 mM MgCl₂, pH 9.8. Absorbance at 405 nm was measured with an ELISA reader TABLE 10 MSCRAMM ® Protein Recognition of ECM Proteins ECM Proteins EF0089 EF2224 EF 1091 EF 1092 EF 1093 Fibrinogen + + — — + Fibronectin — — — — — Collagen I — — — — — Collagen III — — — — — Collagen IV — — — — — Collagen V Not ND — — — determine d (ND) Collagen VI — — — + — Vitronectin — — — — — Elastin ND ND— — — — Plasminogen ND ND + + +

Example 10 Serum From Patients Infected With E. faecalis Contain Elevated Levels of Antibodies Against MSCRAMM® Proteins

[0157] The presence of antibodies against enterococcal proteins in human sera collected from hospitalized patients with and without a previous E. faecalis infection was tested by an ELISA assay described in (Arduino et al., 1994) (Nallapareddy et al., 2000b) with some modifications (Table 11). Briefly, 20 ng of each purified enterococcal protein in 100 μl PBS was coated on microplates (96 well, 4HBX, Thermo Labsystems, Franklin, Mass.) overnight at 4 □C. The plates were blocked with 1% BSA, 0.01% Tween20 in PBS at ambient temperature for 1 h and 100 μl of the sera in blocking buffer were added. Each serum was tested in triplicate with serial dilutions from 1:100 to 1:6400. Plates were incubated for 2 h at ambient temperature and washed three times with 0.01% Tween20 in PBS. 100 μl of 1:3000 dilution of horseradish peroxidase-conjugated anti human IgG was added and incubated 2 h. After three washes, signal was detected with 3,3′,5,5′-tetramethylbenzidine (TMB) in the presence of H₂O₂ in 0.1 M citrate-acetate buffer, pH 6.0 at ambient temperature for 15 min. The reaction was stopped with 2 M H₂SO₄ and absorbance at 450 nm was recorded. Titers were determined after subtracting A_(450nm) values from appropriate controls. To determine a cut-off level for serum titers, four additional control sera from healthy individuals without a prior E. faecalis infection were assayed. The sum of average A_(450nm) values and two times the standard deviations for each dilution of the control sera were set as cut-off levels for positive titers. TABLE 11 Infection ≧1:6400 • • • • • • • • • • • • • • • • • • • • • • • • • • •   1:3200 • • •   1:1600   1:800   1:400 •   1:200 • • • • • • • • ≧1:100 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • EF1091 EF1824 EF0089 EF3023 EF1092 EF2224 EF1269 EF1093 No infection ≧1:6400 •   1:3200   1:1600   1:800   1:400   1:200 • • • • • ≧1:100 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • EF1091 EF1824 EF0089 EF3023 EF1092 EF2224 EF1269 EF1093

[0158] The following references referred to in the above description are incorporated as is set forth in their entirety herein:

[0159] CDC. 2002. Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. 51:902.

[0160] Deivanayagam, C. C., R. L. Rich, M. Carson, R. T. Owens, S. Danthuluri, T. Bice, M. Hook, and S. V. Narayana. 2000. Novel fold and assembly of the repetitive B region of the Staphylococcus aureus collagen-binding surface protein. Structure Fold Des 8:67-78.

[0161] Deivanayagam, C. C., E. R. Wann, W. Chen, M. Carson, K. R. Rajashankar, M. Hook, and S. V. Narayana. 2002. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. Embo J 21:6660-72.

[0162] Hamburger, Z. A., M. S. Brown, R. R. Isberg, and P. J. Bjorkman. 1999. Crystal structure of invasin: a bacterial integrin-binding protein. Science 286:291-5.

[0163] Huycke, M. M., D. F. Sahm, and M. S. Gilmore. 1998. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 4:239-49.

[0164] Leahy, D. J., I. Aukhil, and H. P. Erickson. 1996. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84:155-64.

[0165] Luo, Y., E. A. Frey, R. A. Pfuetzner, A. L. Creagh, D. G. Knoechel, C. A. Haynes, B. B. Finlay, and N. C. Strynadka. 2000. Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature 405:1073-7.

[0166] O'Brien, L. M., E. J. Walsh, R. C. Massey, S. J. Peacock, and T. J. Foster. 2002. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 4:759-70.

[0167] Patti, J. M., and M. Hook. 1994. Microbial adhesins recognizing extracellular matrix macromolecules. Curr. Biol. 6:752-758.

[0168] Paulsen, I. T., L. Banerjei, G. S. Myers, K. E. Nelson, R. Seshadri, T. D. Read, D. E. Fouts, J. A. Eisen, S. R. Gill, J. F. Heidelberg, H. Tettelin, R. J. Dodson, L. Umayam, L. Brinkac, M. Beanan, S. Daugherty, R. T. DeBoy, S. Durkin, J. Kolonay, R. Madupu, W. Nelson, J. Vamathevan, B. Tran, J. Upton, T. Hansen, J. Shetty, H. Khouri, T. Utterback, D. Radune, K. A. Ketchum, B. A. Dougherty, and C. M. Fraser. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:20714.

[0169] Perkins, S., E. J. Walsh, C. C. Deivanayagam, S. V. Narayana, T. J. Foster, and M. Hook. 2001. Structural organization of the fibrinogen-binding region of the clumping factor B MSCRAMM of Staphylococcus aureus. J Biol Chem 276:44721-8.

[0170] Sharma, A., J. A. Askari, M. J. Humphries, E. Y. Jones, and D. I. Stuart. 1999. Crystal structure of a heparin- and integrin-binding segment of human fibronectin. Embo J 18:1468-79.

[0171] Symersky, J., J. M. Patti, M. Carson, K. House-Pompeo, M. Teale, D. Moore, L. Jin, A. Schneider, L. J. DeLucas, M. Hook, and S. V. Narayana. 1997. Structure of the collagen-binding domain from a Staphylococcus aureus adhesin. Nat Struct Biol 4:833-8.

[0172] Tailor, S. A., E. M. Bailey, and M. J. Rybak. 1993. Enterococcus, an emerging pathogen. Ann Pharmacother 27:1231-42.

[0173] Tung, H., B. Guss, U. Hellman, L. Persson, K. Rubin, and C. Ryden. 2000. A bone sialoprotein-binding protein from Staphylococcus aureus: a member of the staphylococcal Sdr family. Biochem J 345 Pt 3:611-9.

[0174] Arduino, R. C., Murray, B. E., and Rakita, R. M. (1994) Roles of antibodies and complement in phagocytic killing of enterococci. Infection and Immunity 62: 987-993.

[0175] Davis, S. L., Gurusiddappa, S., McCrea, K. W., Perkins, S., and Hook, M. (2001) SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from Staphylococcus epidermidis, targets the thrombin cleavage site in the Bbeta chain. J Biol Chem 276: 27799-27805.

[0176] Deivanayagam, C. C., Perkins, S., Danthuluri, S., Owens, R. T., Bice, T., Nanavathy, T., Foster, T. J., Hook, M., and Narayana, S. V. (1999) Crystallization of ClfA and ClfB fragments: the fibrinogen-binding surface proteins of Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr 55 ( Pt 2): 554-556.

[0177] Deivanayagam, C. C., Wann, E. R., Chen, W., Carson, M., Rajashankar, K. R., Hook, M., and Narayana, S. V. (2002) A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. Embo J 21: 6660-6672.

[0178] Foster, T. J., and Hook, M. (1998) Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6: 484488.

[0179] Hartford, O., O'Brien, L., Schofield, K., Wells, J., and Foster, T. J. (2001) The Fbe (SdrG) protein of Staphylococcus epidermidis HB promotes bacterial adherence to fibrinogen. Microbiology 147: 2545-2552.

[0180] Joh, H. J., House-Pompeo, K., Patti, J. M., Gurusiddappa, S., and Hook, M. (1994) Fibronectin receptors from Gram-positive bacteria: comparison of active sites. Biochemistry 33: 6086-6092.

[0181] Lee, J. O., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Crystal structure of the A-domain from the a subunit of integrin CR3 (CDllb/CD18). Cell 80: 631-638.

[0182] Mazmanian, S. K., Ton-That, H., and Schneewind, O. (2001) Sortase-catalyzed anchoring of surface proteins to the cell wall of Staphylococcus aureus. Molecular Microbiology 40: 1049-1057.

[0183] McDevitt, D., Francois, P., Vaudaux, P., and Foster, T. J. (1994) Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11: 237-248.

[0184] Murray, B. E. (1990) The life and times of the enterococcus. Clin. Microbiol. Rev 3: 46-65.

[0185] Murray, B. E., and Weinstock, G. M. (1999) Enterococci: new aspects of an old organism. Proc. Assoc. Am. Physicians 111: 328-334.

[0186] Nallapareddy, S. R., Qin, X., Weinstock, G. M., Hook, M., and Murray, B. E. (2000a) Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect Immun 68: 5218-5224.

[0187] Nallapareddy, S. R., Singh, K. V., Duh, R. W., Weinstock, G. M., and Murray, B. E. (2000b) Diversity of ace, a gene encoding a microbial surface component recognizing adhesive matrix molecules, from different strains of Enterococcus faecalis and evidence for production of ace during human infections. Infect Immun 68: 5210-5217.

[0188] Ni Eidhin, D., Perkins, S., Francois, P., Vaudaux, P., Hook, M., and Foster, T. J. (1998) Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol Microbiol 30: 245-257.

[0189] Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Science 4: 2411-2423.

[0190] Perkins, S., Walsh, E. J., Deivanayagam, C. C., Narayana, S. V., Foster, T. J., and Hook, M. (2001) Structural organization of the fibrinogen-binding region of the clumping factor B MSCRAMM of Staphylococcus aureus. J Biol Chem 276: 44721-44728.

[0191] Ponnuraj, K., Xu, Y., Moore, D., Deivanayagam, C. C., Boque, L., Hook, M., and Narayana, S. V. (2002) Crystallization and preliminary X-ray crystallographic analysis of Ace: a collagen-binding MSCRAMM from Enterococcus faecalis. Biochim Biophys Acta 1596: 173-176.

[0192] Rich, R. L., Kreikemeyer, B., Owens, R. T., LaBrenz, S., Narayana, S. V., Weinstock, G. M., Murray, B. E., and Hook, M. (1999) Ace is a collagen-binding MSCRAMM from Enterococcus faecalis. J Biol Chem 274: 26939-26945.

[0193] Sahm, D. F., Kissinger, J., Gilmore, M. S., Murray, P. R., Mulder, R., Solliday, J., and Clarke, B. (1989) In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 33: 1588-1591.

[0194] Schneewind, O., Fowler, A., and Faull, K. F. (1995) Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 268: 103-106.

[0195] Symersky, J., Patti, J. M., Carson, M., House-Pompeo, K., Teale, M., Moore, D., Jin, L., Schneider, A., DeLucas, L. J., Hook, M., and Narayana, S. V. (1997) Structure of the collagen-binding domain from a Staphylococcus aureus adhesin. Nature Structural Biology 4: 833-838.

[0196] Wann, E. R., Gurusiddappa, S., and Hook, M. (2000) The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J Biol Chem 275: 13863-13871.

[0197] Westerlund, B., and Korhonen, T. K. (1993) Bacterial proteins binding to the mammalian extracellular matrix. Mol. Microbiol. 9: 687-694.

1 24 1 5 PRT Staphylococcus epidermidis MISC_FEATURE (3)..(3) X = any amino acid 1 Leu Pro Xaa Thr Gly 1 5 2 777 PRT Staphylococcus epidermidis 2 Gln Glu Gln Thr Ala Lys Glu Asp Val Ala Asp Ser Ala Thr Ser Val 1 5 10 15 Gly Ala Ile Val Ser Ile Glu Lys Ala Glu Lys Asn Phe Val Ile Thr 20 25 30 Tyr Ala Ser Gly Lys Lys Ala Gln Ile Ser Ile Leu Asn Asp His Leu 35 40 45 Phe Arg Tyr His Leu Asp Pro Thr Gly Lys Phe Glu Glu Tyr Pro Thr 50 55 60 Pro Asn Asp Pro Lys His Val Ala Lys Ile Thr Ala Lys Thr Met Ala 65 70 75 80 Asp Tyr Gly Thr Gln Ala Phe Glu Gln Thr Asn Val Thr Asp Ser Gly 85 90 95 Asn Gln Phe Ile Leu Glu Asn Asn Gly Leu Lys Ile Met Phe Glu Lys 100 105 110 Glu Ser Ala Leu Met Lys Val Leu Asp Lys Lys Lys Asn Gln Val Ile 115 120 125 Leu Glu Glu Thr Ala Pro Leu Ser Phe Lys Asn Asp Lys Ala Thr Gln 130 135 140 Thr Leu Lys Gln Ser Ser Gln Glu Asn Tyr Phe Gly Gly Gly Thr Gln 145 150 155 160 Asn Gly Arg Phe Thr His Lys Gly Thr Ala Ile Gln Ile Val Asn Thr 165 170 175 Asn Asn Trp Val Asp Gly Gly Val Ala Ser Pro Asn Pro Phe Tyr Trp 180 185 190 Ser Thr Ala Gly Tyr Gly Val Val Arg Asn Thr Trp Lys Pro Gly Asn 195 200 205 Tyr Asp Phe Gly Ser His Asp Pro Gln Lys Thr Thr Thr Thr His Glu 210 215 220 Gly Thr Asp Phe Asp Ala Phe Tyr Phe Phe Asn Asp Ser Ser Ala Gly 225 230 235 240 Ile Leu Lys Asp Tyr Tyr Glu Leu Thr Gly Lys Pro Ala Leu Met Pro 245 250 255 Glu Tyr Gly Phe Tyr Glu Ala His Leu Asn Ala Tyr Asn Arg Asp Tyr 260 265 270 Trp Val Lys Val Ala Glu Gly Thr Ala Gly Ala Val Lys Phe Glu Asp 275 280 285 Gly Asn Phe Tyr Lys Glu Tyr Gln Pro Gly Asp Leu Gly Asn Leu Asn 290 295 300 Gly Thr Leu Glu Ser Leu Asn Gly Glu Lys Glu Asn Tyr Gln Phe Ser 305 310 315 320 Ala Arg Ala Val Ile Asp Arg Tyr Lys Lys Asn Asp Met Pro Leu Gly 325 330 335 Trp Phe Leu Pro Asn Asp Gly Tyr Gly Ala Gly Tyr Gly Gln Thr Asp 340 345 350 Ser Leu Asp Gly Asp Val Gln Asn Leu Lys Glu Phe Thr Glu Tyr Ala 355 360 365 Gln Ala Asn Gly Val Glu Val Gly Leu Trp Thr Gln Ser Asn Leu His 370 375 380 Pro Ala Asp Pro Lys Asn Pro Lys Lys Gly Glu Arg Asp Ile Ala Lys 385 390 395 400 Glu Val Ser Val Ala Gly Val Lys Ala Leu Lys Thr Asp Val Ala Trp 405 410 415 Val Gly Tyr Gly Tyr Ser Phe Gly Leu Asn Gly Val Glu Asp Ala Ala 420 425 430 Asn Val Phe Val Lys Glu Thr Asp Gly Ala Val Arg Pro Met Ile Val 435 440 445 Ser Leu Asp Gly Trp Ala Gly Thr Gln Arg His Ala Gly Ile Trp Thr 450 455 460 Gly Asp Gln Thr Gly Gly Gln Trp Glu Tyr Ile Arg Phe His Ile Pro 465 470 475 480 Thr Tyr Ile Gly Thr Ser Leu Ser Gly Gln Pro Asn Val Gly Ser Asp 485 490 495 Met Asp Gly Ile Phe Gly Gly Lys Asn Lys Glu Ile Asn Ile Arg Asp 500 505 510 Phe Gln Trp Lys Thr Phe Thr Pro Val Gln Leu Asn Met Asp Gly Trp 515 520 525 Gly Ser Asn Pro Lys Thr Pro Phe Ala Phe Asp Gln Glu Ala Thr Asp 530 535 540 Leu Asn Arg Ala Tyr Leu Lys Leu Lys Ser Met Met Met Pro Tyr Asn 545 550 555 560 Tyr Ser Ile Ala Lys Glu Ser Val Asp Gly Leu Pro Met Val Arg Ala 565 570 575 Met Ala Leu Glu Phe Pro Asn Glu Gly Thr Ala Tyr Thr Lys Asp Ser 580 585 590 Gln Tyr Gln Tyr Met Trp Gly Pro Asn Leu Leu Val Ala Pro Ile Tyr 595 600 605 Asn Gly Asn Gln Asp Glu Ala Gly Asn Ser Ile Arg Asp Gly Ile Tyr 610 615 620 Leu Pro Asp Glu Lys Gln Val Trp Val Asp Leu Phe Thr Gly Glu Lys 625 630 635 640 Tyr Gln Gly Gly Arg Val Leu Asn Gly Val Lys Thr Pro Leu Trp Lys 645 650 655 Val Pro Val Phe Val Lys Asp Gly Ser Ile Ile Pro Met Thr Asn Pro 660 665 670 Asn Asn Asn Pro Lys Glu Ile Gln Arg Asp Gln Arg Ser Phe Leu Ile 675 680 685 Tyr Pro Asn Gly Thr Thr Ser Phe Asn Met Tyr Glu Asp Asp Gly Ile 690 695 700 Ser Thr Ser Tyr Glu Ala Gly Gln Ser Ala Thr Thr Lys Ile Asn Ser 705 710 715 720 Gln Gly Pro Lys Ser Asn Glu Lys Gly Asp Leu Thr Val Thr Ile Glu 725 730 735 Pro Thr Lys Gly Ser Tyr Lys Asp Phe Val Asp Glu Arg Ser Thr Thr 740 745 750 Leu Asp Leu Leu Ala Ser Glu Ala Pro Glu Ser Val Thr Ala Met Val 755 760 765 Gly Gly Thr Glu Val Thr Leu Lys Gln 770 775 3 1010 PRT Staphylococcus epidermidis 3 Ala Ala Asn Lys Glu Glu Phe Leu Ala Gly Thr Asn Leu Tyr Tyr Phe 1 5 10 15 Asp Lys Glu Phe Gln Val Asn Gln Tyr Leu Ser Glu Ala Ser Gly Glu 20 25 30 Lys Leu Asn Gln Ser Ala Leu Ser Val Lys Leu Ala Lys Gln Ser Val 35 40 45 Thr Ala Lys Asp Val Gln Ile Thr Val Lys Gly Phe Ile Asn Lys Gly 50 55 60 Thr Val Asp Gly Gly Asn Thr Thr Val Asp Asp Gln Leu Thr Ile Pro 65 70 75 80 Ala Asn Val Ala Ile Asn Glu Glu Lys Thr Thr Pro Ser Ser Leu Thr 85 90 95 Leu Gln Trp Asp Gln Val Thr Glu Ala Thr Ser Tyr Glu Val Glu Arg 100 105 110 Asp Gly Thr Val Phe Gly Asn Ile Gln Thr Asn Thr Ala Thr Phe Asp 115 120 125 Gly Phe Ser Phe Leu Ser Glu His Thr Phe Arg Val Arg Ala Val Gly 130 135 140 Lys Asn Gly Val Ser Glu Trp Ser Glu Pro Ile Lys Gly Lys Thr Gln 145 150 155 160 Asp Asp Pro Tyr Lys Glu Thr Ile Asn Gln Val Lys Ala Thr Ser Asn 165 170 175 Leu Pro Glu Gln Pro Gly Ala Glu Leu Lys Lys Leu Thr Asp Lys Asp 180 185 190 Leu Ser Thr Gly Trp His Thr Asn Trp Ser Thr Gly Ile Ala Asn Pro 195 200 205 Ser Asp Gly Asn Phe Leu Ser Leu Lys Phe Asp Leu Gly Ala Glu Tyr 210 215 220 Gln Met Asp Lys Ile Glu Tyr Leu Pro Arg Asp Asn Ala Gly Asn Gly 225 230 235 240 Asn Ile Leu Gln Leu Gln Tyr Arg Thr Ser Lys Asp Gly Ala Asn Trp 245 250 255 Thr Glu Phe Ser Glu Pro Ile Asn Trp Lys Gln Asp Ala Leu Thr Lys 260 265 270 Thr Ile Glu Thr Lys Asp Gln Ala Tyr Arg Phe Val Glu Met Lys Val 275 280 285 Leu Lys Ser Val Gly Asn Phe Gly Ser Gly Arg Glu Met Leu Phe Tyr 290 295 300 Lys Gln Pro Gly Thr Glu Gly Ile Leu His Gly Asp Ile Thr Asn Asp 305 310 315 320 Gly Thr Ile Asp Glu Asn Asp Ala Met Ser Tyr Arg Asn Tyr Thr Gly 325 330 335 Leu Glu Ser Val Asp Ser Asp Phe Asn Gly Tyr Val Glu Lys Gly Asp 340 345 350 Leu Asn Lys Asn Gly Val Ile Asp Ala Tyr Asp Ile Ser Tyr Val Leu 355 360 365 Arg Gln Leu Asp Gly Gly Ile Glu Ile Pro Asp Val Glu Glu Ile Ala 370 375 380 Gly Gly Leu Ser Leu Ala Val Val Asn Glu Asn Gly Lys Asp Thr Tyr 385 390 395 400 Leu Pro Gly Asp Thr Leu Thr Phe Ile Leu Lys Gly Gln Asp Leu Lys 405 410 415 Asn Ile Asn Ala Leu Ser Thr Lys Met Ser Phe Asp Ser Ser Lys Phe 420 425 430 Glu Leu Val Gly Gln Pro Ala Thr Thr Asn Asn Thr Gln Gln Met Glu 435 440 445 Asn Tyr Ser Lys Tyr Arg Lys His Ser Asn Asp Val Glu Asn Leu Tyr 450 455 460 Leu Val Leu Ser Asn Gln Gly Asn Lys Gln Leu Leu Asn Gly Ser Met 465 470 475 480 Asp Leu Val Thr Phe Lys Val Lys Val Lys Glu Thr Thr Arg Val Lys 485 490 495 Arg Ala Thr Thr Val Glu Gln Pro Leu Gln Phe Asp Met Ser Gln Gly 500 505 510 Leu Leu Val Gly Gln Gly Phe Gln Gln Ala Thr Leu Ser Asp Phe Ser 515 520 525 Val Thr Val Lys Pro Thr Glu Leu Val Asp Lys Glu Leu Leu Gln Ala 530 535 540 Leu Ile Thr Leu Asn Gln Ala Arg Val Glu Lys Glu Tyr Thr Pro Glu 545 550 555 560 Thr Trp Ala Ile Phe Lys Pro Ile Leu Asp Glu Ala Val Ala Val Leu 565 570 575 Ala Asn Glu Gln Ala Thr Gln Thr Asp Val Ser Ala Ala Ala Glu Asn 580 585 590 Leu Glu Lys Ala Ala Ser Gln Leu Glu Lys Met Pro Asp Val Ala Asn 595 600 605 Lys Ala Asp Leu Glu Lys Ala Ile Gln Glu Gly Leu Ala Lys Lys Pro 610 615 620 Ser Asp Gly Gln Glu Phe Thr Glu Glu Thr Lys Lys Val Leu Glu Glu 625 630 635 640 Ser Leu Ala Ala Ala Gln Lys Val Phe Ala Gln Glu Lys Val Thr Gln 645 650 655 Glu Glu Ile Asp Gln Ala Thr Lys Thr Leu Arg Glu Ala Ile Ala Gln 660 665 670 Leu Lys Glu Gln Pro Val Ala Val Asp Lys Glu Thr Leu Lys Glu Gln 675 680 685 Ile Ala Gln Ala Arg Gly Arg Lys Pro Glu Glu Gly Tyr Gln Phe Thr 690 695 700 Lys Glu Thr Glu Lys Gln Leu Gln Glu Ala Ile Gln Ala Ala Glu Ala 705 710 715 720 Ile Val Ala Lys Glu Thr Ala Thr Lys Glu Glu Val Ser Glu Ala Leu 725 730 735 Asn Ala Leu Glu Thr Ala Met Ala Gln Leu Lys Glu Val Pro Leu Val 740 745 750 Asn Lys Asp Gln Leu Gln Glu Val Val Lys Arg Ala Gln Gln Val Thr 755 760 765 Pro Ser Glu Gly His Gln Phe Thr Ala Ser Ser Leu Gln Glu Leu Gln 770 775 780 Lys Ala Leu Leu Ala Ala Lys Asn Thr Leu Lys Asn Pro Ala Ala Asn 785 790 795 800 Gln Lys Met Ile Asp Glu Ala Val Ala Glu Leu Thr Ser Ala Ile Asp 805 810 815 Gly Leu Gln Glu Glu Val Leu Val Thr Asp Lys Lys Ala Leu Glu Ala 820 825 830 Met Ile Ala Lys Ala Lys Ala Ile Lys Pro Ser Ala Gly Lys Glu Phe 835 840 845 Thr Ser Glu Ser Lys Ala Arg Leu Thr Glu Ala Ile Asp Gln Ala Glu 850 855 860 Gly Ile Leu Ala Asp Lys Asn Ala Arg Gln Glu Gln Ile Asp Ile Ala 865 870 875 880 Glu Lys Asn Val Lys Thr Ala Leu Asp Ser Leu Glu Glu Gln Val Leu 885 890 895 Gln Thr Asp Lys Thr Lys Leu Lys Glu Leu Leu Gln Lys Ala Glu Thr 900 905 910 Leu Lys Pro Lys Ala Gly Lys Gln Phe Thr Lys Ala Ser Gln Glu Ala 915 920 925 Leu Ala Glu Ala Ile Lys Gln Ala Lys Ala Leu Val Glu Asp Pro Asn 930 935 940 Ala Thr Gln Glu Ala Val Asp Lys Cys Leu Ser Ile Leu Ser Gln Ala 945 950 955 960 Ile Glu Ala Met Ala Glu Glu Pro Ile Ser Ser Asn Ser Thr Gly Asn 965 970 975 Asn Gly Asn His Ser Thr Val Ser Gly Thr Gly Gly Val Thr Ser Gln 980 985 990 Gly Lys Gly Thr Ala Thr Gly Gly Thr Thr Thr Lys Thr Thr Thr Ser 995 1000 1005 Gly Thr 1010 4 1108 PRT Staphylococcus epidermidis 4 Glu Glu Val Asn Ser Asp Gly Gln Leu Thr Leu Gly Glu Val Lys Gln 1 5 10 15 Thr Ser Gln Gln Glu Met Thr Leu Ala Leu Gln Gly Lys Ala Gln Pro 20 25 30 Val Thr Gln Glu Val Val Val His Tyr Ser Ala Asn Val Ser Ile Lys 35 40 45 Ala Ala His Trp Ala Ala Pro Asn Asn Thr Arg Lys Ile Gln Val Asp 50 55 60 Asp Gln Lys Lys Gln Ile Gln Ile Glu Leu Asn Gln Gln Ala Leu Ala 65 70 75 80 Asp Thr Leu Val Leu Thr Leu Asn Pro Thr Ala Thr Glu Asp Val Thr 85 90 95 Phe Ser Tyr Gly Gln Gln Gln Arg Ala Leu Thr Leu Lys Thr Gly Thr 100 105 110 Asp Pro Thr Glu Ser Thr Ala Ile Thr Ser Ser Pro Ala Ala Ser Ala 115 120 125 Asn Glu Gly Ser Thr Glu Glu Ala Ser Thr Asn Ser Ser Val Pro Arg 130 135 140 Ser Ser Glu Glu Thr Val Ala Ser Thr Thr Lys Ala Ile Glu Ser Lys 145 150 155 160 Thr Thr Glu Ser Thr Thr Val Lys Pro Arg Val Ala Gly Pro Thr Asp 165 170 175 Ile Ser Asp Tyr Phe Thr Gly Asp Glu Thr Thr Ile Ile Asp Asn Phe 180 185 190 Glu Asp Pro Ile Tyr Leu Asn Pro Asp Gly Thr Pro Ala Thr Pro Pro 195 200 205 Tyr Lys Glu Asp Val Thr Ile His Trp Asn Phe Asn Trp Ser Ile Pro 210 215 220 Glu Asp Val Arg Glu Gln Met Lys Ala Gly Asp Tyr Phe Glu Phe Gln 225 230 235 240 Leu Pro Gly Asn Leu Lys Pro Asn Lys Pro Gly Ser Gly Asp Leu Val 245 250 255 Asp Ala Glu Gly Asn Val Tyr Gly Thr Tyr Thr Ile Ser Glu Asp Gly 260 265 270 Thr Val Arg Phe Thr Phe Asn Glu Arg Ile Thr Ser Glu Ser Asp Ile 275 280 285 His Gly Asp Phe Ser Leu Asp Thr His Leu Asn Asp Ser Asp Gly Arg 290 295 300 Gly Pro Gly Asp Trp Val Ile Asp Ile Pro Thr Gln Glu Asp Leu Pro 305 310 315 320 Pro Val Val Ile Pro Ile Val Pro Asp Thr Glu Gln Gln Ile Asp Lys 325 330 335 Gln Gly His Phe Asp Arg Thr Pro Asn Pro Ser Ala Ile Thr Trp Thr 340 345 350 Val Asp Ile Asn Gln Ala Met Lys Asp Gln Thr Asn Pro Thr Val Thr 355 360 365 Glu Thr Trp Pro Thr Gly Asn Thr Phe Lys Ser Val Lys Val Tyr Glu 370 375 380 Leu Val Met Asn Leu Asp Gly Thr Ile Lys Glu Val Gly Arg Glu Leu 385 390 395 400 Ser Pro Asp Glu Tyr Thr Val Asp Lys Asn Gly Asn Val Thr Ile Lys 405 410 415 Gly Asp Thr Asn Lys Ala Tyr Arg Leu Glu Tyr Gln Thr Thr Ile Asp 420 425 430 Glu Ala Val Ile Pro Asp Gly Gly Gly Asp Val Pro Phe Lys Asn His 435 440 445 Ala Thr Leu Thr Ser Asp Asn Asn Pro Asn Gly Leu Asp Ala Glu Ala 450 455 460 Thr Val Thr Ala Thr Tyr Gly Lys Met Leu Asp Lys Arg Asn Ile Asp 465 470 475 480 Tyr Asp Glu Ala Asn Gln Glu Phe Thr Trp Glu Ile Asn Tyr Asn Tyr 485 490 495 Gly Glu Gln Thr Ile Pro Lys Asp Gln Ala Val Ile Thr Asp Thr Met 500 505 510 Gly Asp Asn Leu Thr Phe Glu Pro Asp Ser Leu His Leu Tyr Ser Val 515 520 525 Thr Phe Asp Asp Lys Gly Asn Glu Val Val Gly Ala Glu Leu Val Glu 530 535 540 Gly Lys Asp Tyr Lys Val Val Ile Asn Gly Asp Gly Ser Phe Ala Ile 545 550 555 560 Asp Phe Leu His Asp Val Thr Gly Ala Val Lys Ile Asp Tyr Lys Thr 565 570 575 Lys Val Asp Gly Ile Val Glu Gly Asp Val Ala Val Asn Asn Arg Val 580 585 590 Asp Val Gly Thr Gly Gln His Ser Glu Asp Asp Gly Thr Ala Ser Gln 595 600 605 Gln Asn Ile Ile Lys Asn Thr Gly Ala Val Asp Tyr Gln Asn Ser Thr 610 615 620 Ile Gly Trp Thr Leu Ala Val Asn Gln Asn Asn Tyr Leu Met Glu Asn 625 630 635 640 Ala Val Ile Thr Asp Thr Tyr Glu Pro Val Pro Gly Leu Thr Met Val 645 650 655 Pro Asn Ser Leu Val Val Lys Asp Thr Thr Thr Gly Ala Gln Leu Thr 660 665 670 Leu Gly Lys Asp Phe Met Val Glu Ile Thr Arg Asn Ala Asp Gly Glu 675 680 685 Thr Gly Phe Lys Val Ser Phe Ile Gly Ala Tyr Ala Lys Thr Ser Asp 690 695 700 Ala Phe His Ile Thr Tyr Thr Thr Phe Phe Asp Val Thr Glu Leu Asp 705 710 715 720 Ala Asn Asn Pro Ala Leu Asp His Tyr Arg Asn Thr Ala Ala Ile Asp 725 730 735 Trp Thr Asp Glu Ala Gly Asn Asn His His Ser Glu Asp Ser Lys Pro 740 745 750 Phe Lys Pro Leu Pro Ala Phe Asp Leu Asn Ala Gln Lys Ser Gly Val 755 760 765 Tyr Asn Ala Val Thr Lys Glu Ile Thr Trp Thr Ile Ala Val Asn Leu 770 775 780 Ser Asn Asn Arg Leu Val Asp Ala Phe Leu Thr Asp Pro Ile Leu Thr 785 790 795 800 Asn Gln Thr Tyr Leu Ala Gly Ser Leu Lys Val Tyr Glu Gly Asn Thr 805 810 815 Lys Pro Asp Gly Ser Val Glu Lys Val Lys Pro Thr Gln Pro Leu Thr 820 825 830 Asp Ile Thr Met Glu Glu Pro Ser Glu Lys Asn Gln Asn Thr Trp Arg 835 840 845 Val Asp Phe Pro Asn Asp Ser Arg Thr Tyr Val Ile Glu Phe Lys Thr 850 855 860 Ser Val Asp Glu Lys Val Ile Glu Gly Ser Ala Ser Tyr Asp Asn Thr 865 870 875 880 Ala Ser Tyr Thr Asn Gln Gly Ser Ser Arg Asp Val Thr Gly Lys Val 885 890 895 Ser Ile Gln His Gly Gly Glu Ser Val Lys Lys Gly Gly Glu Tyr His 900 905 910 Lys Asp Asp Pro Asp His Val Tyr Trp His Val Met Ile Asn Gly Ala 915 920 925 Gln Ser Val Leu Asp Asp Val Val Ile Thr Asp Thr Pro Ser Pro Asn 930 935 940 Gln Val Leu Asp Pro Glu Ser Leu Val Ile Tyr Gly Thr Asn Val Thr 945 950 955 960 Glu Asp Gly Thr Ile Thr Pro Asp Lys Ser Val Ile Leu Glu Glu Gly 965 970 975 Lys Asp Tyr Thr Leu Glu Val Thr Thr Asp Asn Glu Thr Gly Gln Gln 980 985 990 Lys Ile Val Val Lys Met Ala His Ile Glu Ala Pro Tyr Tyr Met Glu 995 1000 1005 Tyr Arg Ser Leu Val Thr Ser Ser Ala Ala Gly Ser Thr Asp Thr 1010 1015 1020 Val Ser Asn Gln Val Ser Ile Thr Gly Asn Gly Ser Glu Val Val 1025 1030 1035 His Gly Asp Asp Asn Gly Asp Val Val Val Asp Ile Asp His Ser 1040 1045 1050 Gly Gly His Ala Thr Gly Thr Lys Gly Lys Ile Gln Leu Lys Lys 1055 1060 1065 Thr Ala Met Asp Glu Thr Thr Ile Leu Ala Gly Ala His Phe Gln 1070 1075 1080 Ile Trp Asp Gln Ala Lys Thr Gln Val Leu Arg Glu Gly Thr Val 1085 1090 1095 Asp Ala Thr Gly Val Ile Thr Phe Gly Gly 1100 1105 5 999 PRT Staphylococcus epidermidis 5 Glu Glu Ile Thr Asp Leu Phe Leu Gln Lys Glu Val Thr Tyr Ser Gly 1 5 10 15 Val Glu Gly Gly Lys Ile Gly Glu Asn Trp Lys Tyr Pro Gln Phe Val 20 25 30 Gly Glu Lys Ala Val Asp Gly Asp Glu Thr Thr Arg Trp Ser Ala Asp 35 40 45 Lys Gln Asp Glu Gln Trp Leu Ile Val Asp Leu Gly Glu Val Lys Asn 50 55 60 Ile Gly Glu Leu Val Leu Gln Leu His Ala Glu Ser Pro Val Tyr Glu 65 70 75 80 Ile Leu Val Ser Thr Asp Gly Glu Ser Tyr Gln Ser Ile Phe Lys Glu 85 90 95 Glu Asn Gly Lys Gly Gly Gln Pro Thr Lys Lys Tyr Ile Asp Gly Asn 100 105 110 Asn Val Gln Ala Arg Phe Val Lys Tyr Gln Gln Met Lys Met Trp Gln 115 120 125 His Thr Asn Lys Gln Phe Tyr Ser Ser Ser Ile Ile Ser Phe Glu Ala 130 135 140 Tyr Glu Lys Lys Arg Leu Pro Glu Ala Ile Lys Leu Leu Thr Glu Asn 145 150 155 160 Leu Thr Ile Ser Glu Lys Arg Lys Gln Gln Leu Ala Phe Glu Val Ser 165 170 175 Pro Ala Gly Val Asp Ile Thr Glu Asp Gln Ile Glu Trp Ser Ser Ser 180 185 190 Asp Pro Thr Ile Val Thr Val Asp Gln Thr Gly Asn Leu Thr Ala Val 195 200 205 Lys Ser Gly Glu Ala Lys Val Thr Val Lys Ile Lys Gly Thr Glu Ile 210 215 220 Ser Asp Thr Ile Pro Val Thr Val Val Ala Glu Asn Lys Gln Tyr Ala 225 230 235 240 Glu Met Arg Ala Lys Trp Lys Met Arg Leu Leu Gly Thr Thr Gln Tyr 245 250 255 Asp Asn Asp Ala Asp Val Gln Gln Tyr Arg Ala Gln Ile Ala Thr Glu 260 265 270 Ser Leu Ala Leu Trp Gln Thr Leu Asn Gln Ala Ala Asp Arg Glu Tyr 275 280 285 Leu Trp Glu Arg Lys Pro Ser Asp Thr Val Ser Ala Asp Tyr Thr Thr 290 295 300 Gln Phe Thr Asn Ile Lys Lys Leu Ala Leu Gly Tyr Tyr Glu Pro Ser 305 310 315 320 Ser Glu Leu Phe Glu Lys Pro Glu Val Tyr Asp Ala Ile Val Lys Gly 325 330 335 Ile Glu Phe Met Ile Asp Thr Lys Lys Tyr Asn Gly Thr Tyr Tyr Thr 340 345 350 Gly Asn Trp Trp Asp Trp Gln Ile Gly Ser Ala Gln Pro Leu Thr Asp 355 360 365 Thr Leu Ile Leu Leu His Asp Asp Leu Leu Asn Thr Asp Ala Glu Lys 370 375 380 Leu Asn Lys Phe Thr Ala Pro Leu Met Leu Tyr Ala Lys Asp Pro Asn 385 390 395 400 Ile Gln Trp Pro Ile Tyr Arg Ala Thr Gly Ala Asn Leu Thr Asp Ile 405 410 415 Ser Ile Thr Val Leu Gly Thr Gly Leu Leu Leu Glu Asp Asn Gln Arg 420 425 430 Leu Val Gln Val Gln Glu Ala Val Pro Ser Val Leu Lys Ser Val Ser 435 440 445 Ser Gly Asp Gly Leu Tyr Pro Asp Gly Ser Leu Ile Gln His Gly Tyr 450 455 460 Phe Pro Tyr Asn Gly Ser Tyr Gly Asn Glu Leu Leu Lys Gly Phe Gly 465 470 475 480 Arg Ile Gln Thr Ile Leu Gln Gly Ser Asp Trp Glu Met Asn Asp Pro 485 490 495 Asn Ile Ser Asn Leu Phe Asn Val Val Asp Lys Gly Tyr Leu Gln Leu 500 505 510 Met Val Asn Gly Lys Met Pro Ser Met Val Ser Gly Arg Ser Ile Ser 515 520 525 Arg Ala Pro Glu Thr Asn Pro Phe Thr Thr Glu Phe Glu Ser Gly Lys 530 535 540 Glu Thr Ile Ala Asn Leu Thr Leu Ile Ala Lys Phe Ala Pro Glu Asn 545 550 555 560 Leu Arg Asn Asp Ile Tyr Thr Ser Ile Gln Thr Trp Leu Gln Gln Ser 565 570 575 Gly Ser Tyr Tyr His Phe Phe Lys Lys Pro Arg Asp Phe Glu Ala Leu 580 585 590 Ile Asp Leu Lys Asn Val Val Asn Ser Ala Ser Pro Ala Gln Ala Thr 595 600 605 Pro Met Gln Ser Leu Asn Val Tyr Gly Ser Met Asp Arg Val Leu Gln 610 615 620 Lys Asn Asn Glu Tyr Ala Val Gly Ile Ser Met Tyr Ser Gln Arg Val 625 630 635 640 Gly Asn Tyr Glu Phe Gly Asn Thr Glu Asn Lys Lys Gly Trp His Thr 645 650 655 Ala Asp Gly Met Leu Tyr Leu Tyr Asn Gln Asp Phe Ala Gln Phe Asp 660 665 670 Glu Gly Tyr Trp Ala Thr Ile Asp Pro Tyr Arg Leu Pro Gly Thr Thr 675 680 685 Val Asp Thr Arg Glu Leu Ala Asn Gly Ala Tyr Thr Gly Lys Arg Ser 690 695 700 Pro Gln Ser Trp Val Gly Gly Ser Asn Asn Gly Gln Val Ala Ser Ile 705 710 715 720 Gly Met Phe Leu Asp Lys Ser Asn Glu Gly Met Asn Leu Val Ala Lys 725 730 735 Lys Ser Trp Phe Leu Leu Asp Gly Gln Ile Ile Asn Leu Gly Ser Gly 740 745 750 Ile Thr Gly Thr Thr Asp Ala Ser Ile Glu Thr Ile Leu Asp Asn Arg 755 760 765 Met Ile His Pro Gln Glu Val Lys Leu Asn Gln Gly Ser Asp Lys Asp 770 775 780 Asn Ser Trp Ile Ser Leu Ser Ala Ala Asn Pro Leu Asn Asn Ile Gly 785 790 795 800 Tyr Val Phe Pro Asn Ser Met Asn Thr Leu Asp Val Gln Ile Glu Glu 805 810 815 Arg Ser Gly Arg Tyr Gly Asp Ile Asn Glu Tyr Phe Val Asn Asp Lys 820 825 830 Thr Tyr Thr Asn Thr Phe Ala Lys Ile Ser Lys Asn Tyr Gly Lys Thr 835 840 845 Val Glu Asn Gly Thr Tyr Glu Tyr Leu Thr Val Val Gly Lys Thr Asn 850 855 860 Glu Glu Ile Ala Ala Leu Ser Lys Asn Lys Gly Tyr Thr Val Leu Glu 865 870 875 880 Asn Thr Ala Asn Leu Gln Ala Ile Glu Ala Gly Asn Tyr Val Met Met 885 890 895 Asn Thr Trp Asn Asn Asp Gln Glu Ile Ala Gly Leu Tyr Ala Tyr Asp 900 905 910 Pro Met Ser Val Ile Ser Glu Lys Ile Asp Asn Gly Val Tyr Arg Leu 915 920 925 Thr Leu Ala Asn Pro Leu Gln Asn Asn Ala Ser Val Ser Ile Glu Phe 930 935 940 Asp Lys Gly Ile Leu Glu Val Val Ala Ala Asp Pro Glu Ile Ser Val 945 950 955 960 Asp Gln Asn Ile Ile Thr Leu Asn Ser Ala Gly Leu Asn Gly Ser Ser 965 970 975 Arg Ser Ile Ile Val Lys Thr Thr Pro Glu Val Thr Lys Glu Ala Leu 980 985 990 Glu Lys Leu Ile Gln Glu Gln 995 6 741 PRT Staphylococcus epidermidis 6 Gln Glu Val Thr Ser Asp Ala Glu Lys Thr Val Glu Lys Asp Gly Leu 1 5 10 15 Lys Val Ile Gly Lys Ile Glu Asp Thr Ser Ser Gln Glu Asp Ile Lys 20 25 30 Thr Val Thr Tyr Glu Val Thr Asn Thr Arg Asp Val Pro Ile Lys Asp 35 40 45 Leu Ile Leu Lys Gln Lys Asn Thr Asn Asp Ser Pro Ile Lys Phe Val 50 55 60 Leu Asp Thr Leu Ser Glu Glu Arg Gly Pro Thr Ser Leu Glu Glu Gln 65 70 75 80 Ala Lys Val Glu Thr Asn Glu Lys Asp Gln Thr Thr Asp Ile Lys Leu 85 90 95 Leu Asn Leu Gln Pro Asn Ser Thr Arg Lys Ile Thr Ile Asn Gly Gln 100 105 110 Ile Thr Thr Lys Ala Ser Asn Lys Leu Leu Val Ser Val Leu Ile Glu 115 120 125 Asp Asn Glu Lys Gly Thr Leu Val Ile Asp Leu Pro Ser Lys Asp Ile 130 135 140 Leu Ala Asp Lys Glu Ser Val Ser Lys Glu Lys Gln Glu Thr Ser Glu 145 150 155 160 Thr Lys Val Glu Asn Gln Ala Asn Glu Thr Ala Ser Ser Thr Asn Glu 165 170 175 Met Thr Ala Thr Thr Ser Asn Glu Thr Lys Pro Glu Ala Gly Lys Ala 180 185 190 Ile Glu Ser Ile Gln Glu Thr Ala Leu Thr Gln Ala Thr Glu Ser Pro 195 200 205 Glu Gln Pro Pro Leu Lys Ala Gln Pro Thr Gly Pro Leu Val Pro Pro 210 215 220 Thr Pro Gly Arg Gly Phe Asn Thr Pro Ile Tyr Gln Ser Val His Lys 225 230 235 240 Gly Glu Leu Phe Ser Thr Gly Asn Thr Asn Leu Lys Ile Ala Asn Glu 245 250 255 Asn Thr Ala Ala Ala Gln Thr Phe Leu Asn Thr Arg Gly Ala Ser Ser 260 265 270 Gly Tyr Ala Ile Asn Asn Phe Pro Leu Glu Phe Ala Asp Val Asp Asn 275 280 285 Asp Pro Asn Thr Tyr Asn Ser Ser Arg Ala Tyr Ile Asp Leu Asn Gly 290 295 300 Ala Lys Glu Ile Ala Trp Ala Gly Leu Phe Trp Ser Ala Ser Arg Tyr 305 310 315 320 Lys Gly Pro Ala Tyr Gly Thr Asn Leu Ser Asp Glu Glu Ile Ser Ala 325 330 335 Pro Val Gln Phe Thr Thr Pro Asn Gly Thr Val Gln Arg Val Ser Pro 340 345 350 Gln Arg Tyr His Arg Ile Asp Gln Asp Ala Thr Asn Pro Gly Gln Arg 355 360 365 Phe Gly Tyr Asn Asn Thr Gly Phe Ser Asn Tyr Ala Asp Val Thr Ser 370 375 380 Ile Leu Gln Gly Asp Lys Ser Ala Thr Gly Ser Tyr Thr Leu Ala Asp 385 390 395 400 Ile Pro Met Thr Ser Ser Leu Asn Gly Gln Tyr Gln Tyr Tyr Asn Phe 405 410 415 Ser Gly Trp Ser Leu Phe Val Val Thr Lys Asp Gln Ala Ser Lys Ser 420 425 430 Arg Ala Phe Ser Ile Tyr Tyr Gly Ala Arg Gly Asn Ala Ala Gly Thr 435 440 445 Asn Asn Glu Phe Thr Met Ser Asn Phe Leu Thr Ala Lys Gln Gly Asn 450 455 460 Leu Asp Pro Ile Val Thr Trp Phe Thr Val Gln Gly Asp Lys Tyr Trp 465 470 475 480 Thr Gly Asp Asn Ala Gln Ile Lys Asn Ser Ala Gly Thr Trp Val Asn 485 490 495 Ile Ser Asn Thr Leu Asn Pro Val Asn Asn Ala Met Asn Ala Thr Val 500 505 510 Thr Asp Asn Asp Glu His Met Val Asp Lys Tyr Pro Gly Lys Phe Ala 515 520 525 Pro Asp His Pro Asn Phe Leu Asp Ile Asp Ile Asp Arg Met Ala Ile 530 535 540 Pro Glu Gly Val Leu Asn Ala Gly Gln Asn Gln Ile Asn Phe Arg Thr 545 550 555 560 Thr Ser Ser Gly Asp Asp Tyr Ser Thr Asn Ala Ile Gly Phe Ala Val 565 570 575 Asn Ala Glu Thr Pro Glu Phe Glu Ile Lys Lys Glu Ile Val Glu Pro 580 585 590 Lys Glu Thr Tyr Lys Val Gly Glu Thr Ile Thr Tyr Arg Val Ser Leu 595 600 605 Lys Asn Thr Lys Ala Asp Ser Glu Ala Ile Asn Ser Val Ser Lys Asp 610 615 620 Ala Leu Asp Gly Arg Leu Asn Tyr Leu Pro Gly Ser Leu Lys Ile Ile 625 630 635 640 Ser Gly Pro Asn Ser Gly Glu Lys Thr Asp Ala Ser Gly Asp Asp Gln 645 650 655 Ala Glu Tyr Asp Glu Thr Asn Lys Gln Ile Ile Val Arg Val Gly Asn 660 665 670 Gly Ala Thr Ala Thr Gln Gly Gly Ser Tyr Lys Ala Asp Thr Ala Glu 675 680 685 Thr Ile Tyr Glu Phe Lys Ala Arg Ile Asn Glu Arg Ala Lys Ala Asn 690 695 700 Glu Leu Val Pro Asn Ser Ala Thr Val Glu Ala Val Asp Ile Leu Thr 705 710 715 720 Ser Ala Lys Val Asn Glu Thr Ser Asn Ile Val Glu Ala Lys Ile Ala 725 730 735 Asp Glu Gln Val Thr 740 7 570 PRT Staphylococcus epidermidis 7 Glu Thr Gly Tyr Ala Gln Thr Glu Pro Thr Ser Thr Ser Glu Thr Asn 1 5 10 15 Gln Ile Ser Ala Thr Pro Asn Val Val Pro Arg Lys Gln Val Gly Asn 20 25 30 Ile Val Thr Ala Ile Gln Leu Thr Asp Lys Glu Gly Asn Pro Leu Gly 35 40 45 Thr Ile Asn Gln Tyr Thr Asp Ile Tyr Leu Arg Ile Glu Phe Asn Leu 50 55 60 Pro Asp Asn Thr Val Asn Ser Gly Asp Thr Ser Val Ile Thr Leu Pro 65 70 75 80 Glu Glu Leu Arg Leu Glu Lys Asn Met Thr Phe Asn Val Val Asp Asp 85 90 95 Thr Gly Thr Val Val Ala Ile Ala Gln Thr Asp Val Ala Asn Lys Thr 100 105 110 Val Thr Leu Thr Tyr Thr Asp Tyr Val Glu Asn His Ala Asn Ile Ser 115 120 125 Gly Ser Leu Tyr Phe Thr Ser Leu Ile Asp Phe Glu Asn Val Glu Asn 130 135 140 Glu Ser Lys Ile Pro Ile Tyr Val Thr Val Glu Gly Glu Lys Ile Phe 145 150 155 160 Ala Gly Asp Leu Asp Tyr Gln Gly Glu Gly Asp Asp Val Asn Glu Lys 165 170 175 Phe Ser Lys Tyr Ser Trp Phe Ile Glu Asp Asp Pro Thr Glu Ile Tyr 180 185 190 Asn Val Leu Arg Ile Asn Pro Thr Gly Gln Thr Tyr Thr Asp Leu Glu 195 200 205 Val Glu Asp Val Leu Lys Thr Glu Ser Leu Ser Tyr Met Lys Asp Thr 210 215 220 Met Lys Ile Glu Arg Gly Gln Trp Thr Leu Asp Gly Asn Ala Ile Trp 225 230 235 240 Gln Phe Thr Pro Glu Glu Asp Ile Thr Asp Gln Leu Ala Val Gln Tyr 245 250 255 Gly Pro Asp Asp Arg Asn Phe Ser Val His Phe Gly Asn Ile Gly Thr 260 265 270 Asn Glu Tyr Arg Ile Thr Tyr Lys Thr Lys Ile Asp His Leu Pro Glu 275 280 285 Lys Gly Glu Thr Phe Thr Asn Tyr Ala Lys Leu Thr Glu Asn Gln Thr 290 295 300 Val Val Glu Glu Val Glu Val Ser Arg Val Ser Gln Thr Gly Gly Gly 305 310 315 320 Glu Ala Asn Gly Glu Gln Tyr Val Val Glu Ile His Lys Glu Asp Glu 325 330 335 Ala Gly Gln Arg Leu Ala Gly Ala Glu Phe Glu Leu Ile Arg Asn Ser 340 345 350 Thr Asn Gln Thr Val Ala Lys Ile Thr Thr Asp Gln Asn Gly Thr Ala 355 360 365 Ile Val Lys Gly Leu Leu Lys Asp Asn Tyr Thr Leu Val Glu Thr Lys 370 375 380 Ala Pro Thr Gly Tyr Gln Leu Ser Gln Asn Lys Ile Pro Ile Thr Pro 385 390 395 400 Glu Asp Phe Gly Lys Asn Leu Val Ala Leu Lys Thr Val Val Asn His 405 410 415 Lys Ile Ser Tyr Gln Pro Val Ala Ala Ser Phe Leu Ala Gly Lys Val 420 425 430 Leu Leu Gly Lys Pro Leu Lys Asp Ala Glu Phe Gln Phe Glu Leu Leu 435 440 445 Asp Glu Lys Gly Thr Val Leu Glu Thr Val Ser Asn Asp Thr Leu Gly 450 455 460 Lys Ile Gln Phe Ser Pro Leu Thr Phe Glu Thr Pro Gly Asn Tyr Gln 465 470 475 480 Tyr Thr Ile Arg Glu Val Asn Thr Gln Gln Thr Gly Val Ser Tyr Asp 485 490 495 Thr His Asn Leu Gln Val Gln Val Thr Val Glu Ala Leu Leu Gly Asn 500 505 510 Leu Val Ala Thr Thr Gln Tyr Asp Gly Gly Gln Val Phe Thr Asn His 515 520 525 Tyr Thr Pro Glu Lys Pro Ile Glu Ser Thr Thr Pro Pro Thr Ser Gly 530 535 540 Thr Thr Asp Thr Thr Thr Asn Ser Thr Thr Glu Thr Thr Ser Ile Thr 545 550 555 560 Ile Glu Lys Gln Ala Ile Arg Asn Lys Glu 565 570 8 3309 DNA Staphylococcus epidermidis 8 atgataacag atgagaatga taaaacgaat attaatatcg agttaaatct tctcaaccaa 60 acagagcagc cattacaacg agaaattcaa ttgaaaaatg cacagttcat ggatactgct 120 gtaattgaaa aagacggata ttcttaccaa gtgactaatg gtacgcttta tctgactttg 180 gacgcacaag taaaaaagcc ggtacagctt tcgttagctg ttgagcaaag ttcgcttcaa 240 acagctcagc cacctaagtt attgtatgaa aacaacgaat atgatgtttc agttacttct 300 gaaaaaataa cagtagagga ttctgctaaa gaatcaactg aaccagaaaa aataactgta 360 ccagaaaata cgaaagaaac taacaaaaat gattcggctc cagaaaaaac agaacagccg 420 accgcaacag aagaggtaac caatccattt gcagaagcaa gaatggcgcc agctactttg 480 agagcgaatc tggcactgcc tttaattgca ccacaataca cgacggataa ttctgggact 540 tatccgacag ctaattggca gcccacaggc aatcaaaatg tgttaaacca tcaagggaat 600 aaagacggta gtgcacaatg ggacggccaa acgagttgga atggggaccc tactaatcgc 660 acaaattctt atattgagta tggcggtaca ggagaccaag ccgattatgc catccgaaaa 720 tatgctagag aaacaacaac accagggctt tttgatgtat atcttaatgt gcgtgggaat 780 gttcagaaag aaatcacgcc attggatttg gtcttagtcg ttgactggtc cggtagtatg 840 aatgaaaaca atcggattgg tgaagttcaa aaaggagtga accgttttgt tgatacattg 900 gcagatagcg gtattaccaa taacatcaac atgggctatg ttggctactc aagtgacggt 960 tataataaca acgccattca aatggggccg tttgatacag tcaaaaatcc aattaaaaat 1020 attacgccaa gtagcactag aggaggaact ttcactcaaa aagcattaag agatgctggt 1080 gatatgttag caacgccaaa tggacataag aaagtcattg tacttttaac ggatggcgtc 1140 ccaaccttct cttataaagt gagtcgagtt caaacagagg cggatggtcg cttttacggg 1200 acacaattta cgaatcgaca agatcaacca ggtagcactt cttatatctc tggtagctat 1260 aatgcgccag atcaaaacaa tatcaataaa cggattaaca gtacgtttat cgccacgata 1320 ggtgaggcaa tggtcttaaa acaacgtggg attgaaatac atggattggg cattcaattg 1380 caaagcgatc cacgagctaa tttatctaaa caacaagttg aagataaaat gcgtgagatg 1440 gtgtcagccg atgaaaatgg agacctttat tatgaatccg cggattatgc accagacatt 1500 tctgattatt tagcgaaaaa agccgttcag atttcaggaa cggttgtaaa cggaaaagta 1560 gttgatccaa ttgctgaacc ttttaaatac gagccaaata cattatcaat gaaaagtgtg 1620 ggtcctgttc aggttcaaac attaccagaa gtgtcgctaa caggcgctac aattaatagt 1680 aatgagattt atttgggtaa agggcaagaa attcaaattc attatcaagt acgtattcaa 1740 acagagtcag aaaacttcaa acctgatttt tggtatcaaa tgaatggtcg gacaacgttt 1800 cagccattag ccacggcccc tgaaaaagtt gattttgggg ttccttcggg aaaagcacct 1860 ggcgtgaagt taaacgtgaa aaaaatctgg gaagagtatg atcaagaccc gacaagtcgg 1920 ccagataatg tgatttatga aattagtaga aagcaagtaa ctgacacagc caactggcaa 1980 actgggtata ttaaattatc aaaaccagaa aatgatacca gcaatagttg ggagcgcaaa 2040 aatgtaaccc aactttccaa aaccgcggat gaaagctatc aagaagttct tgggcttccc 2100 caatacaaca atcaaggaca agctttcaat tatcaaacaa cccgtgaatt agcagttcct 2160 ggttacagtc aagaaaaaat cgacgatact acttggaaaa acacgaagca gttcaagcca 2220 ttagatttaa aagtaatcaa aaattcttcc tcaggtgaga aaaacttagt gggagccgtc 2280 tttgaattga gtggtaaaaa tgttcaaaca acattagtgg acaataaaga tggtagctat 2340 tccttgccaa aagatgtgcg cctacaaaaa ggggaacgct atacattaac tgaagtaaaa 2400 gcacctgcag gacatgagtt aggcaagaaa acgacttggc aaattgaggt gagtgagcaa 2460 ggcaaagtaa gcatcgatgg acaagaagtg accaccacaa atcaagttat tccattggaa 2520 attgaaaata aattttcttc tttgccaatc agaattagaa aatacaccat gcaaaatggc 2580 aaacaagtga acttagcaga ggcgactttt gcgttgcaaa gaaaaaatgc tcaaggaagt 2640 taccaaactg tggcaactca aaaaacagat actacaggat tgagctattt taaaattagt 2700 gaacctggtg agtatcgaat ggtggaacaa tcaggaccat taggctacga cactcttgct 2760 ggaaattatg aatttactgt tgataaatat gggaaaattc actatgcagg caaaaatatt 2820 gaagaaaatg cgccagaatg gacactgaca catcaaaata atttgaaacc ttttgactta 2880 acagttaata aaaaagccga taatcagacg ccacttaaag gagcgaaatt ccgtttaaca 2940 ggaccagata cggatattga attaccaaaa gatggcaaag aaacggatac ttttgttttt 3000 gaaaacttaa aaccagggaa atatgttcta acagaaacct ttacgccaga aggatatcag 3060 gggttaaaag aaccaatcga attaataatt cgtgaagatg gttcagtcac gatagatggg 3120 gaaaaagtag cagatgtttt aatttctgga gagaagaata atcaaattac tttagacgtt 3180 acgaaccaag caaaggttcc tttacctgaa actggtggca taggacgctt gtggttttac 3240 ttgatagcga ttagtacatt cgtgatagcg ggtgtttatc tctttattag acgaccagaa 3300 gggagtgtg 3309 9 1103 PRT Staphylococcus epidermidis 9 Met Ile Thr Asp Glu Asn Asp Lys Thr Asn Ile Asn Ile Glu Leu Asn 1 5 10 15 Leu Leu Asn Gln Thr Glu Gln Pro Leu Gln Arg Glu Ile Gln Leu Lys 20 25 30 Asn Ala Gln Phe Met Asp Thr Ala Val Ile Glu Lys Asp Gly Tyr Ser 35 40 45 Tyr Gln Val Thr Asn Gly Thr Leu Tyr Leu Thr Leu Asp Ala Gln Val 50 55 60 Lys Lys Pro Val Gln Leu Ser Leu Ala Val Glu Gln Ser Ser Leu Gln 65 70 75 80 Thr Ala Gln Pro Pro Lys Leu Leu Tyr Glu Asn Asn Glu Tyr Asp Val 85 90 95 Ser Val Thr Ser Glu Lys Ile Thr Val Glu Asp Ser Ala Lys Glu Ser 100 105 110 Thr Glu Pro Glu Lys Ile Thr Val Pro Glu Asn Thr Lys Glu Thr Asn 115 120 125 Lys Asn Asp Ser Ala Pro Glu Lys Thr Glu Gln Pro Thr Ala Thr Glu 130 135 140 Glu Val Thr Asn Pro Phe Ala Glu Ala Arg Met Ala Pro Ala Thr Leu 145 150 155 160 Arg Ala Asn Leu Ala Leu Pro Leu Ile Ala Pro Gln Tyr Thr Thr Asp 165 170 175 Asn Ser Gly Thr Tyr Pro Thr Ala Asn Trp Gln Pro Thr Gly Asn Gln 180 185 190 Asn Val Leu Asn His Gln Gly Asn Lys Asp Gly Ser Ala Gln Trp Asp 195 200 205 Gly Gln Thr Ser Trp Asn Gly Asp Pro Thr Asn Arg Thr Asn Ser Tyr 210 215 220 Ile Glu Tyr Gly Gly Thr Gly Asp Gln Ala Asp Tyr Ala Ile Arg Lys 225 230 235 240 Tyr Ala Arg Glu Thr Thr Thr Pro Gly Leu Phe Asp Val Tyr Leu Asn 245 250 255 Val Arg Gly Asn Val Gln Lys Glu Ile Thr Pro Leu Asp Leu Val Leu 260 265 270 Val Val Asp Trp Ser Gly Ser Met Asn Glu Asn Asn Arg Ile Gly Glu 275 280 285 Val Gln Lys Gly Val Asn Arg Phe Val Asp Thr Leu Ala Asp Ser Gly 290 295 300 Ile Thr Asn Asn Ile Asn Met Gly Tyr Val Gly Tyr Ser Ser Asp Gly 305 310 315 320 Tyr Asn Asn Asn Ala Ile Gln Met Gly Pro Phe Asp Thr Val Lys Asn 325 330 335 Pro Ile Lys Asn Ile Thr Pro Ser Ser Thr Arg Gly Gly Thr Phe Thr 340 345 350 Gln Lys Ala Leu Arg Asp Ala Gly Asp Met Leu Ala Thr Pro Asn Gly 355 360 365 His Lys Lys Val Ile Val Leu Leu Thr Asp Gly Val Pro Thr Phe Ser 370 375 380 Tyr Lys Val Ser Arg Val Gln Thr Glu Ala Asp Gly Arg Phe Tyr Gly 385 390 395 400 Thr Gln Phe Thr Asn Arg Gln Asp Gln Pro Gly Ser Thr Ser Tyr Ile 405 410 415 Ser Gly Ser Tyr Asn Ala Pro Asp Gln Asn Asn Ile Asn Lys Arg Ile 420 425 430 Asn Ser Thr Phe Ile Ala Thr Ile Gly Glu Ala Met Val Leu Lys Gln 435 440 445 Arg Gly Ile Glu Ile His Gly Leu Gly Ile Gln Leu Gln Ser Asp Pro 450 455 460 Arg Ala Asn Leu Ser Lys Gln Gln Val Glu Asp Lys Met Arg Glu Met 465 470 475 480 Val Ser Ala Asp Glu Asn Gly Asp Leu Tyr Tyr Glu Ser Ala Asp Tyr 485 490 495 Ala Pro Asp Ile Ser Asp Tyr Leu Ala Lys Lys Ala Val Gln Ile Ser 500 505 510 Gly Thr Val Val Asn Gly Lys Val Val Asp Pro Ile Ala Glu Pro Phe 515 520 525 Lys Tyr Glu Pro Asn Thr Leu Ser Met Lys Ser Val Gly Pro Val Gln 530 535 540 Val Gln Thr Leu Pro Glu Val Ser Leu Thr Gly Ala Thr Ile Asn Ser 545 550 555 560 Asn Glu Ile Tyr Leu Gly Lys Gly Gln Glu Ile Gln Ile His Tyr Gln 565 570 575 Val Arg Ile Gln Thr Glu Ser Glu Asn Phe Lys Pro Asp Phe Trp Tyr 580 585 590 Gln Met Asn Gly Arg Thr Thr Phe Gln Pro Leu Ala Thr Ala Pro Glu 595 600 605 Lys Val Asp Phe Gly Val Pro Ser Gly Lys Ala Pro Gly Val Lys Leu 610 615 620 Asn Val Lys Lys Ile Trp Glu Glu Tyr Asp Gln Asp Pro Thr Ser Arg 625 630 635 640 Pro Asp Asn Val Ile Tyr Glu Ile Ser Arg Lys Gln Val Thr Asp Thr 645 650 655 Ala Asn Trp Gln Thr Gly Tyr Ile Lys Leu Ser Lys Pro Glu Asn Asp 660 665 670 Thr Ser Asn Ser Trp Glu Arg Lys Asn Val Thr Gln Leu Ser Lys Thr 675 680 685 Ala Asp Glu Ser Tyr Gln Glu Val Leu Gly Leu Pro Gln Tyr Asn Asn 690 695 700 Gln Gly Gln Ala Phe Asn Tyr Gln Thr Thr Arg Glu Leu Ala Val Pro 705 710 715 720 Gly Tyr Ser Gln Glu Lys Ile Asp Asp Thr Thr Trp Lys Asn Thr Lys 725 730 735 Gln Phe Lys Pro Leu Asp Leu Lys Val Ile Lys Asn Ser Ser Ser Gly 740 745 750 Glu Lys Asn Leu Val Gly Ala Val Phe Glu Leu Ser Gly Lys Asn Val 755 760 765 Gln Thr Thr Leu Val Asp Asn Lys Asp Gly Ser Tyr Ser Leu Pro Lys 770 775 780 Asp Val Arg Leu Gln Lys Gly Glu Arg Tyr Thr Leu Thr Glu Val Lys 785 790 795 800 Ala Pro Ala Gly His Glu Leu Gly Lys Lys Thr Thr Trp Gln Ile Glu 805 810 815 Val Ser Glu Gln Gly Lys Val Ser Ile Asp Gly Gln Glu Val Thr Thr 820 825 830 Thr Asn Gln Val Ile Pro Leu Glu Ile Glu Asn Lys Phe Ser Ser Leu 835 840 845 Pro Ile Arg Ile Arg Lys Tyr Thr Met Gln Asn Gly Lys Gln Val Asn 850 855 860 Leu Ala Glu Ala Thr Phe Ala Leu Gln Arg Lys Asn Ala Gln Gly Ser 865 870 875 880 Tyr Gln Thr Val Ala Thr Gln Lys Thr Asp Thr Thr Gly Leu Ser Tyr 885 890 895 Phe Lys Ile Ser Glu Pro Gly Glu Tyr Arg Met Val Glu Gln Ser Gly 900 905 910 Pro Leu Gly Tyr Asp Thr Leu Ala Gly Asn Tyr Glu Phe Thr Val Asp 915 920 925 Lys Tyr Gly Lys Ile His Tyr Ala Gly Lys Asn Ile Glu Glu Asn Ala 930 935 940 Pro Glu Trp Thr Leu Thr His Gln Asn Asn Leu Lys Pro Phe Asp Leu 945 950 955 960 Thr Val Asn Lys Lys Ala Asp Asn Gln Thr Pro Leu Lys Gly Ala Lys 965 970 975 Phe Arg Leu Thr Gly Pro Asp Thr Asp Ile Glu Leu Pro Lys Asp Gly 980 985 990 Lys Glu Thr Asp Thr Phe Val Phe Glu Asn Leu Lys Pro Gly Lys Tyr 995 1000 1005 Val Leu Thr Glu Thr Phe Thr Pro Glu Gly Tyr Gln Gly Leu Lys 1010 1015 1020 Glu Pro Ile Glu Leu Ile Ile Arg Glu Asp Gly Ser Val Thr Ile 1025 1030 1035 Asp Gly Glu Lys Val Ala Asp Val Leu Ile Ser Gly Glu Lys Asn 1040 1045 1050 Asn Gln Ile Thr Leu Asp Val Thr Asn Gln Ala Lys Val Pro Leu 1055 1060 1065 Pro Glu Thr Gly Gly Ile Gly Arg Leu Trp Phe Tyr Leu Ile Ala 1070 1075 1080 Ile Ser Thr Phe Val Ile Ala Gly Val Tyr Leu Phe Ile Arg Arg 1085 1090 1095 Pro Glu Gly Ser Val 1100 10 1428 DNA Staphylococcus epidermidis 10 atgaaaaacg cacgttggtt aagtatttgc gtcatgctac tcgctctttt cgggttttca 60 cagcaagcat tagcagaggc atcgcaagca agcgttcaag ttacgttgca caaattattg 120 ttccctgatg gtcaattacc agaacagcag caaaacacag gggaagaggg aacgctgctt 180 caaaattatc ggggcttaaa tgacgtcact tatcaagtct atgatgtgac ggatccgttt 240 tatcagcttc gttctgaagg aaaaacggtc caagaggcac agcgtcaatt agcagaaacc 300 ggtgcaacaa atagaaaacc gatcgcagaa gataaaacac agacaataaa tggagaagat 360 ggagtggttt ctttttcatt agctagcaaa gattcgcagc aacgagataa agcctattta 420 tttgttgaag cggaagcacc agaagtggta aaggaaaaag ctagcaacct agtagtgatt 480 ttgcctgttc aagatccaca agggcaatcg ttaacgcata ttcatttata tccaaaaaat 540 gaagaaaatg cctatgactt accaccactt gaaaaaacgg tactcgataa gcaacaaggc 600 tttaatcaag gagagcacat taactatcag ttaacgactc agattccagc gaatatttta 660 ggatatcagg aattccgttt gtcagataag gcggatacaa cgttgacact tttaccagaa 720 tcaattgagg taaaagtggc tggaaaaaca gttactacag gttacacact gacgacgcaa 780 aagcatggat ttacgcttga tttttcaatt aaagacttac aaaactttgc aaatcaaaca 840 atgactgtgt cgtatcaaat gcgtttagaa aagaccgctg aacctgacac tgcgattaac 900 aacgaaggac aattagtcac ggacaaacat accttgacta aaagagccac agttcgtaca 960 ggcggcaagt cttttgtcaa agttgatagt gaaaatgcga aaatcacctt gccagaggct 1020 gtttttatcg tcaaaaatca agcgggggaa tacctcaatg aaacagcaaa cgggtatcgt 1080 tggcaaaaag aaaaagcatt agctaaaaaa ttcacgtcta atcaagccgg tgaattttca 1140 gttaaaggct taaaagatgg ccagtacttc ttggaagaaa tctctgcacc aaaaggttat 1200 cttctgaatc aaacagaaat tccttttacg gtgggaaaaa attcttatgc aacgaacgga 1260 caacgaacag caccgttaca tgtaatcaat aaaaaagtaa aagagtcagg cttcttacca 1320 aaaacaaatg aagaacgttc tatttggttg acgattgcag gcctgctaat cattgggatg 1380 gtagtcattt ggctatttta tcaaaaacaa aaaagaggag agagaaaa 1428 11 476 PRT Staphylococcus epidermidis 11 Met Lys Asn Ala Arg Trp Leu Ser Ile Cys Val Met Leu Leu Ala Leu 1 5 10 15 Phe Gly Phe Ser Gln Gln Ala Leu Ala Glu Ala Ser Gln Ala Ser Val 20 25 30 Gln Val Thr Leu His Lys Leu Leu Phe Pro Asp Gly Gln Leu Pro Glu 35 40 45 Gln Gln Gln Asn Thr Gly Glu Glu Gly Thr Leu Leu Gln Asn Tyr Arg 50 55 60 Gly Leu Asn Asp Val Thr Tyr Gln Val Tyr Asp Val Thr Asp Pro Phe 65 70 75 80 Tyr Gln Leu Arg Ser Glu Gly Lys Thr Val Gln Glu Ala Gln Arg Gln 85 90 95 Leu Ala Glu Thr Gly Ala Thr Asn Arg Lys Pro Ile Ala Glu Asp Lys 100 105 110 Thr Gln Thr Ile Asn Gly Glu Asp Gly Val Val Ser Phe Ser Leu Ala 115 120 125 Ser Lys Asp Ser Gln Gln Arg Asp Lys Ala Tyr Leu Phe Val Glu Ala 130 135 140 Glu Ala Pro Glu Val Val Lys Glu Lys Ala Ser Asn Leu Val Val Ile 145 150 155 160 Leu Pro Val Gln Asp Pro Gln Gly Gln Ser Leu Thr His Ile His Leu 165 170 175 Tyr Pro Lys Asn Glu Glu Asn Ala Tyr Asp Leu Pro Pro Leu Glu Lys 180 185 190 Thr Val Leu Asp Lys Gln Gln Gly Phe Asn Gln Gly Glu His Ile Asn 195 200 205 Tyr Gln Leu Thr Thr Gln Ile Pro Ala Asn Ile Leu Gly Tyr Gln Glu 210 215 220 Phe Arg Leu Ser Asp Lys Ala Asp Thr Thr Leu Thr Leu Leu Pro Glu 225 230 235 240 Ser Ile Glu Val Lys Val Ala Gly Lys Thr Val Thr Thr Gly Tyr Thr 245 250 255 Leu Thr Thr Gln Lys His Gly Phe Thr Leu Asp Phe Ser Ile Lys Asp 260 265 270 Leu Gln Asn Phe Ala Asn Gln Thr Met Thr Val Ser Tyr Gln Met Arg 275 280 285 Leu Glu Lys Thr Ala Glu Pro Asp Thr Ala Ile Asn Asn Glu Gly Gln 290 295 300 Leu Val Thr Asp Lys His Thr Leu Thr Lys Arg Ala Thr Val Arg Thr 305 310 315 320 Gly Gly Lys Ser Phe Val Lys Val Asp Ser Glu Asn Ala Lys Ile Thr 325 330 335 Leu Pro Glu Ala Val Phe Ile Val Lys Asn Gln Ala Gly Glu Tyr Leu 340 345 350 Asn Glu Thr Ala Asn Gly Tyr Arg Trp Gln Lys Glu Lys Ala Leu Ala 355 360 365 Lys Lys Phe Thr Ser Asn Gln Ala Gly Glu Phe Ser Val Lys Gly Leu 370 375 380 Lys Asp Gly Gln Tyr Phe Leu Glu Glu Ile Ser Ala Pro Lys Gly Tyr 385 390 395 400 Leu Leu Asn Gln Thr Glu Ile Pro Phe Thr Val Gly Lys Asn Ser Tyr 405 410 415 Ala Thr Asn Gly Gln Arg Thr Ala Pro Leu His Val Ile Asn Lys Lys 420 425 430 Val Lys Glu Ser Gly Phe Leu Pro Lys Thr Asn Glu Glu Arg Ser Ile 435 440 445 Trp Leu Thr Ile Ala Gly Leu Leu Ile Ile Gly Met Val Val Ile Trp 450 455 460 Leu Phe Tyr Gln Lys Gln Lys Arg Gly Glu Arg Lys 465 470 475 12 1881 DNA Staphylococcus epidermidis 12 atgaagcaat taaaaaaagt ttggtacacc gttagtacct tgttactaat tttgccactt 60 ttcacaagtg tattagggac aacaactgca tttgcagaag aaaatgggga gagcgcacag 120 ctcgtgattc acaaaaagaa aatgacggat ttaccagatc cgcttattca aaatagcggg 180 aaagaaatga gcgagtttga taaatatcaa ggactggcag atgtgacgtt tagtatttat 240 aacgtgacga acgaatttta cgagcaacga gcggcaggcg caagcgttga tgcagctaaa 300 caagctgtcc aaagtttaac tcctgggaaa cctgttgctc aaggaaccac cgatgcaaat 360 gggaatgtca ctgttcagtt acctaaaaaa caaaatggta aagatgcagt gtataccatt 420 aaagaagaac caaaagaggg tgtagttgct gctacgaata tggtggtggc gttcccagtt 480 tacgaaatga tcaagcaaac agatggttcc tataaatatg gaacagaaga attagcggtt 540 gttcatattt atcctaaaaa tgtggtagcc aatgatggta gtttacatgt gaaaaaagta 600 ggaactgctg aaaatgaagg attaaatggc gcagaatttg ttatttctaa aagcgaaggc 660 tcaccaggca cagtaaaata tatccaagga gtcaaagatg gattatatac atggacaacg 720 gataaagaac aagcaaaacg ctttattact gggaaaagtt atgaaattgg cgaaaatgat 780 ttcacagaag cagagaatgg aacgggagaa ttaacagtta aaaatcttga ggttggttcg 840 tatattttag aagaagtaaa agctccaaat aatgcagaat taattgaaaa tcaaacaaaa 900 acaccattta caattgaagc aaacaatcaa acacctgttg aaaaaacagt caaaaatgat 960 acctctaaag ttgataaaac aacaccaagc ttagatggta aagatgtggc aattggcgaa 1020 aaaattaaat atcaaatttc tgtaaatatt ccattgggga ttgcagacaa agaaggcgac 1080 gctaataaat acgtcaaatt caatttagtt gataaacatg atgcagcctt aacttttgat 1140 aacgtgactt ctggagagta tgcttatgcg ttatatgatg gggatacagt gattgctcct 1200 gaaaattatc aagtgactga acaagcaaat ggcttcactg tcgccgttaa tccagcgtat 1260 attcctacgc taacaccagg cggcacacta aaattcgttt actttatgca tttaaatgaa 1320 aaagcagatc ctacgaaagg ctttaaaaat gaggcgaatg ttgataacgg tcataccgac 1380 gaccaaacac caccaactgt tgaagttgtg acaggtggga aacgtttcat taaagtcgat 1440 ggcgatgtga cagcgacaca agccttggcg ggagcttcct ttgtcgtccg tgatcaaaac 1500 agcgacacag caaattattt gaaaatcgat gaaacaacga aagcagcaac ttgggtgaaa 1560 acaaaagctg aagcaactac ttttacaaca acggctgatg gattagttga tatcacaggg 1620 cttaaatacg gtacctatta tttagaagaa actgtagctc ctgatgatta tgtcttgtta 1680 acaaatcgga ttgaatttgt ggtcaatgaa caatcatatg gcacaacaga aaacctagtt 1740 tcaccagaaa aagtaccaaa caaacacaaa ggtaccttac cttcaacagg tggcaaagga 1800 atctacgttt acttaggaag tggcgcagtc ttgctactta ttgcaggagt ctactttgct 1860 agacgtagaa aagaaaatgc t 1881 13 627 PRT Staphylococcus epidermidis 13 Met Lys Gln Leu Lys Lys Val Trp Tyr Thr Val Ser Thr Leu Leu Leu 1 5 10 15 Ile Leu Pro Leu Phe Thr Ser Val Leu Gly Thr Thr Thr Ala Phe Ala 20 25 30 Glu Glu Asn Gly Glu Ser Ala Gln Leu Val Ile His Lys Lys Lys Met 35 40 45 Thr Asp Leu Pro Asp Pro Leu Ile Gln Asn Ser Gly Lys Glu Met Ser 50 55 60 Glu Phe Asp Lys Tyr Gln Gly Leu Ala Asp Val Thr Phe Ser Ile Tyr 65 70 75 80 Asn Val Thr Asn Glu Phe Tyr Glu Gln Arg Ala Ala Gly Ala Ser Val 85 90 95 Asp Ala Ala Lys Gln Ala Val Gln Ser Leu Thr Pro Gly Lys Pro Val 100 105 110 Ala Gln Gly Thr Thr Asp Ala Asn Gly Asn Val Thr Val Gln Leu Pro 115 120 125 Lys Lys Gln Asn Gly Lys Asp Ala Val Tyr Thr Ile Lys Glu Glu Pro 130 135 140 Lys Glu Gly Val Val Ala Ala Thr Asn Met Val Val Ala Phe Pro Val 145 150 155 160 Tyr Glu Met Ile Lys Gln Thr Asp Gly Ser Tyr Lys Tyr Gly Thr Glu 165 170 175 Glu Leu Ala Val Val His Ile Tyr Pro Lys Asn Val Val Ala Asn Asp 180 185 190 Gly Ser Leu His Val Lys Lys Val Gly Thr Ala Glu Asn Glu Gly Leu 195 200 205 Asn Gly Ala Glu Phe Val Ile Ser Lys Ser Glu Gly Ser Pro Gly Thr 210 215 220 Val Lys Tyr Ile Gln Gly Val Lys Asp Gly Leu Tyr Thr Trp Thr Thr 225 230 235 240 Asp Lys Glu Gln Ala Lys Arg Phe Ile Thr Gly Lys Ser Tyr Glu Ile 245 250 255 Gly Glu Asn Asp Phe Thr Glu Ala Glu Asn Gly Thr Gly Glu Leu Thr 260 265 270 Val Lys Asn Leu Glu Val Gly Ser Tyr Ile Leu Glu Glu Val Lys Ala 275 280 285 Pro Asn Asn Ala Glu Leu Ile Glu Asn Gln Thr Lys Thr Pro Phe Thr 290 295 300 Ile Glu Ala Asn Asn Gln Thr Pro Val Glu Lys Thr Val Lys Asn Asp 305 310 315 320 Thr Ser Lys Val Asp Lys Thr Thr Pro Ser Leu Asp Gly Lys Asp Val 325 330 335 Ala Ile Gly Glu Lys Ile Lys Tyr Gln Ile Ser Val Asn Ile Pro Leu 340 345 350 Gly Ile Ala Asp Lys Glu Gly Asp Ala Asn Lys Tyr Val Lys Phe Asn 355 360 365 Leu Val Asp Lys His Asp Ala Ala Leu Thr Phe Asp Asn Val Thr Ser 370 375 380 Gly Glu Tyr Ala Tyr Ala Leu Tyr Asp Gly Asp Thr Val Ile Ala Pro 385 390 395 400 Glu Asn Tyr Gln Val Thr Glu Gln Ala Asn Gly Phe Thr Val Ala Val 405 410 415 Asn Pro Ala Tyr Ile Pro Thr Leu Thr Pro Gly Gly Thr Leu Lys Phe 420 425 430 Val Tyr Phe Met His Leu Asn Glu Lys Ala Asp Pro Thr Lys Gly Phe 435 440 445 Lys Asn Glu Ala Asn Val Asp Asn Gly His Thr Asp Asp Gln Thr Pro 450 455 460 Pro Thr Val Glu Val Val Thr Gly Gly Lys Arg Phe Ile Lys Val Asp 465 470 475 480 Gly Asp Val Thr Ala Thr Gln Ala Leu Ala Gly Ala Ser Phe Val Val 485 490 495 Arg Asp Gln Asn Ser Asp Thr Ala Asn Tyr Leu Lys Ile Asp Glu Thr 500 505 510 Thr Lys Ala Ala Thr Trp Val Lys Thr Lys Ala Glu Ala Thr Thr Phe 515 520 525 Thr Thr Thr Ala Asp Gly Leu Val Asp Ile Thr Gly Leu Lys Tyr Gly 530 535 540 Thr Tyr Tyr Leu Glu Glu Thr Val Ala Pro Asp Asp Tyr Val Leu Leu 545 550 555 560 Thr Asn Arg Ile Glu Phe Val Val Asn Glu Gln Ser Tyr Gly Thr Thr 565 570 575 Glu Asn Leu Val Ser Pro Glu Lys Val Pro Asn Lys His Lys Gly Thr 580 585 590 Leu Pro Ser Thr Gly Gly Lys Gly Ile Tyr Val Tyr Leu Gly Ser Gly 595 600 605 Ala Val Leu Leu Leu Ile Ala Gly Val Tyr Phe Ala Arg Arg Arg Lys 610 615 620 Glu Asn Ala 625 14 3387 DNA Staphylococcus epidermidis 14 atgacgacca cagggaagaa actgaaagtt attttcatgc tgataatatt gagtttatca 60 aactttgtgc cattatctgc aatagcagac actacagatg atccaacagt tttagaaaca 120 atttcagctg aagtcatttc ggatcagtct ggaaaaaaag cactgaacat caagctaaat 180 gcgaataaca ccagtgctga aaagatagaa aaagaaattg gtctagtcga aaattactta 240 agtgatgtgg aaagaaaaga aggagatggc tatgcttatc aggtaaatag cgggaaaatt 300 acgttggaaa tctcatcaaa cactaaacaa actatcgatc tgagttttcc aatcgatcca 360 gcactttacc acagccaggc aaacaagctg atcgtcgata ataaagaata tgacattatt 420 gatgagacag aaaataagaa agatacagat gtgtcagtac caaagccaga cgaaatagaa 480 gaagaatcat caaaagaaaa cgaaaattct gtcagcccat ttacattgcc tacattatcc 540 ttgccagctg tgagtgtgcc atctaatcaa acgattccta cagaatatac aacagatgat 600 cagggcactt atcctaaagc cagttggcaa cctacaggaa atacaaatgt tcttgatcat 660 caaggcaata aaaacggaac aaatcaatgg gatggtataa attcttggaa tggagatcct 720 aatgatcgga cccattcgta tatcgaatat ggaggaaccg gtaatcaagc agactatgcg 780 atacgaaagt atgcaaagga aacaagtaca cccggattgt ttgatgttta tttgaatgct 840 cgtggaaatg tacaaaaaga tatcacgcct cttgatctcg tattggtcgt agactggtca 900 ggaagtatga acgacaataa tcggatcggt gaagtaaaga ttggtgtcga tcgttttgtc 960 gatactttag cagatagcgg tatcacagac aaaatcaata tgggatatgt cggctactca 1020 agcgaaggat atagctacag taacggtgca gtacagatgg gttcatttga ttcagtgaaa 1080 aatcaagtaa aatccattac accttcacgg acaaatggtg gtacttttac acaaaaagca 1140 ctaagagatg caggaagcat gctatccgtt ccaaatggac ataaaaaagt gatcgttttg 1200 ctgacggatg gtgtaccaac attttcctat aaagtacagc gggtacacgc acaatcaagc 1260 agcaattatt acggaactca gttttctaat acgcaagatc ggccgggaaa tacttctcta 1320 atctcaagaa tctatgatgc acctgaccaa aacaatctat ccagaagaat cgacagtacg 1380 tttatcgcaa ccatcggaga agcgatggca ctcaaagaac gaggaatcga aatacatggt 1440 cttggcatcc aacttcaaag cgatccggca gctggtctct caaaagcaga agtagagtct 1500 cgtatgcgac aaatggtttc atcagatgaa aaaggcgatc tttactatga atcagctgat 1560 catgcaacag atatctctga atacctagcc aaaaaagctg tacagatctc agcaactgta 1620 agcaatggac aaataaatga tccaatcgca gaaccattca tttatcagcc tggtacactt 1680 tcagtcaaga gtgtggggac aagtcctaca acggtcactc catctatttc catagaagga 1740 aataccatca agagcaatca gatctattta ggaaaagacc aagaaatcca aatccattac 1800 caagtgagaa tccaaacaga aaatgaggac ttccatccaa atttctggta tcaaatgaac 1860 ggcaggacaa ctttccagcc aaacattgat accaatgaat tagctgaatt cggtatacca 1920 tctgctaaag ctcccggagt cagtcttcac atcaaaaagt tatgggaaga atttgacaac 1980 aatctagctg atcgtccaga tcaagttact tttgagattc aacgggaaca tacgacaaat 2040 gctgcagctt ggaaaaacgg atatattcga atcattaaac cagctaaaga tacaacaaat 2100 acgtgggaac gtgcagacat tgacaaatta tctgcaaata gcggagaaag ttatcaagag 2160 atattatcac tacctcaata caataatcaa ggtcaagcat tcagttacca aacaatcaaa 2220 gaattacctg taccaggata cgattctcaa caaatagatg caatgacatg gaaaaatact 2280 aaacaattca caccgttaaa cttgaaaata acgaaaaatt cctctacagg tgaaaaggat 2340 cttattggcg ctgttttcaa attaacagga gattctattg atactttact aacagatcat 2400 ggcgacggaa cctattctct tccagaaaat gtcaaattgc aaaaagaaat gacctatacg 2460 ctgacagaaa caaaagctcc agaagggcat ggattaagca aaaagactac ttgggaaatc 2520 aagatcgctt ctgatggtac ggtaaccatt gatggaaaaa cagtcactac ttccgatgat 2580 acgatccagt tgactattga aaatcctttt gttgaagttc ctgtagcagt acgtaagtat 2640 gcgatgcaag ggacggacaa agagataaat cttaaaggag cagcattttc cctacagaaa 2700 aaagaagcaa atggtactta tcagccaatt gacagccaaa caacgaatga aaaaggtctt 2760 gccagttttg attcactcac acctggtaaa tatcgagtcg ttgaaacagc tggtcctgcc 2820 ggatatgata cttcgccggg aaattatgaa ttccaaatcg ataaatatgg aaaaatcatt 2880 tacacgggaa aaaataccga gatgacaaat aatgtatgga cgctcactca tcaaaatcga 2940 ctaaaagcgt ttgatctaac ggtacacaaa aaagaagaca acggacagac attaaaagga 3000 gcaaaattca gactgcaggg accagaaatg gacttagaat cgccaaaaga tggacaagaa 3060 acagatacct ttctattcga aaatttaaaa cctggaactt atacgctgac cgaaactttt 3120 acaccagaag gataccaagg tctaaaagag ccagttacta tagttataca cgaagatggg 3180 tcaattcaag tggatggaca agatcatgaa tctgttctgt caccaggagc caaaaacaac 3240 cagatttctt tagacatcac gaatcaggca aaagtaccat tacctgaaac gggaggaatt 3300 ggccgtttag gaatctatct agtagggatg attggttgtg cgttttctat ttggtatctt 3360 tttttgaaaa aagaaagagg gggcagc 3387 15 1129 PRT Staphylococcus epidermidis 15 Met Thr Thr Thr Gly Lys Lys Leu Lys Val Ile Phe Met Leu Ile Ile 1 5 10 15 Leu Ser Leu Ser Asn Phe Val Pro Leu Ser Ala Ile Ala Asp Thr Thr 20 25 30 Asp Asp Pro Thr Val Leu Glu Thr Ile Ser Ala Glu Val Ile Ser Asp 35 40 45 Gln Ser Gly Lys Lys Ala Leu Asn Ile Lys Leu Asn Ala Asn Asn Thr 50 55 60 Ser Ala Glu Lys Ile Glu Lys Glu Ile Gly Leu Val Glu Asn Tyr Leu 65 70 75 80 Ser Asp Val Glu Arg Lys Glu Gly Asp Gly Tyr Ala Tyr Gln Val Asn 85 90 95 Ser Gly Lys Ile Thr Leu Glu Ile Ser Ser Asn Thr Lys Gln Thr Ile 100 105 110 Asp Leu Ser Phe Pro Ile Asp Pro Ala Leu Tyr His Ser Gln Ala Asn 115 120 125 Lys Leu Ile Val Asp Asn Lys Glu Tyr Asp Ile Ile Asp Glu Thr Glu 130 135 140 Asn Lys Lys Asp Thr Asp Val Ser Val Pro Lys Pro Asp Glu Ile Glu 145 150 155 160 Glu Glu Ser Ser Lys Glu Asn Glu Asn Ser Val Ser Pro Phe Thr Leu 165 170 175 Pro Thr Leu Ser Leu Pro Ala Val Ser Val Pro Ser Asn Gln Thr Ile 180 185 190 Pro Thr Glu Tyr Thr Thr Asp Asp Gln Gly Thr Tyr Pro Lys Ala Ser 195 200 205 Trp Gln Pro Thr Gly Asn Thr Asn Val Leu Asp His Gln Gly Asn Lys 210 215 220 Asn Gly Thr Asn Gln Trp Asp Gly Ile Asn Ser Trp Asn Gly Asp Pro 225 230 235 240 Asn Asp Arg Thr His Ser Tyr Ile Glu Tyr Gly Gly Thr Gly Asn Gln 245 250 255 Ala Asp Tyr Ala Ile Arg Lys Tyr Ala Lys Glu Thr Ser Thr Pro Gly 260 265 270 Leu Phe Asp Val Tyr Leu Asn Ala Arg Gly Asn Val Gln Lys Asp Ile 275 280 285 Thr Pro Leu Asp Leu Val Leu Val Val Asp Trp Ser Gly Ser Met Asn 290 295 300 Asp Asn Asn Arg Ile Gly Glu Val Lys Ile Gly Val Asp Arg Phe Val 305 310 315 320 Asp Thr Leu Ala Asp Ser Gly Ile Thr Asp Lys Ile Asn Met Gly Tyr 325 330 335 Val Gly Tyr Ser Ser Glu Gly Tyr Ser Tyr Ser Asn Gly Ala Val Gln 340 345 350 Met Gly Ser Phe Asp Ser Val Lys Asn Gln Val Lys Ser Ile Thr Pro 355 360 365 Ser Arg Thr Asn Gly Gly Thr Phe Thr Gln Lys Ala Leu Arg Asp Ala 370 375 380 Gly Ser Met Leu Ser Val Pro Asn Gly His Lys Lys Val Ile Val Leu 385 390 395 400 Leu Thr Asp Gly Val Pro Thr Phe Ser Tyr Lys Val Gln Arg Val His 405 410 415 Ala Gln Ser Ser Ser Asn Tyr Tyr Gly Thr Gln Phe Ser Asn Thr Gln 420 425 430 Asp Arg Pro Gly Asn Thr Ser Leu Ile Ser Arg Ile Tyr Asp Ala Pro 435 440 445 Asp Gln Asn Asn Leu Ser Arg Arg Ile Asp Ser Thr Phe Ile Ala Thr 450 455 460 Ile Gly Glu Ala Met Ala Leu Lys Glu Arg Gly Ile Glu Ile His Gly 465 470 475 480 Leu Gly Ile Gln Leu Gln Ser Asp Pro Ala Ala Gly Leu Ser Lys Ala 485 490 495 Glu Val Glu Ser Arg Met Arg Gln Met Val Ser Ser Asp Glu Lys Gly 500 505 510 Asp Leu Tyr Tyr Glu Ser Ala Asp His Ala Thr Asp Ile Ser Glu Tyr 515 520 525 Leu Ala Lys Lys Ala Val Gln Ile Ser Ala Thr Val Ser Asn Gly Gln 530 535 540 Ile Asn Asp Pro Ile Ala Glu Pro Phe Ile Tyr Gln Pro Gly Thr Leu 545 550 555 560 Ser Val Lys Ser Val Gly Thr Ser Pro Thr Thr Val Thr Pro Ser Ile 565 570 575 Ser Ile Glu Gly Asn Thr Ile Lys Ser Asn Gln Ile Tyr Leu Gly Lys 580 585 590 Asp Gln Glu Ile Gln Ile His Tyr Gln Val Arg Ile Gln Thr Glu Asn 595 600 605 Glu Asp Phe His Pro Asn Phe Trp Tyr Gln Met Asn Gly Arg Thr Thr 610 615 620 Phe Gln Pro Asn Ile Asp Thr Asn Glu Leu Ala Glu Phe Gly Ile Pro 625 630 635 640 Ser Ala Lys Ala Pro Gly Val Ser Leu His Ile Lys Lys Leu Trp Glu 645 650 655 Glu Phe Asp Asn Asn Leu Ala Asp Arg Pro Asp Gln Val Thr Phe Glu 660 665 670 Ile Gln Arg Glu His Thr Thr Asn Ala Ala Ala Trp Lys Asn Gly Tyr 675 680 685 Ile Arg Ile Ile Lys Pro Ala Lys Asp Thr Thr Asn Thr Trp Glu Arg 690 695 700 Ala Asp Ile Asp Lys Leu Ser Ala Asn Ser Gly Glu Ser Tyr Gln Glu 705 710 715 720 Ile Leu Ser Leu Pro Gln Tyr Asn Asn Gln Gly Gln Ala Phe Ser Tyr 725 730 735 Gln Thr Ile Lys Glu Leu Pro Val Pro Gly Tyr Asp Ser Gln Gln Ile 740 745 750 Asp Ala Met Thr Trp Lys Asn Thr Lys Gln Phe Thr Pro Leu Asn Leu 755 760 765 Lys Ile Thr Lys Asn Ser Ser Thr Gly Glu Lys Asp Leu Ile Gly Ala 770 775 780 Val Phe Lys Leu Thr Gly Asp Ser Ile Asp Thr Leu Leu Thr Asp His 785 790 795 800 Gly Asp Gly Thr Tyr Ser Leu Pro Glu Asn Val Lys Leu Gln Lys Glu 805 810 815 Met Thr Tyr Thr Leu Thr Glu Thr Lys Ala Pro Glu Gly His Gly Leu 820 825 830 Ser Lys Lys Thr Thr Trp Glu Ile Lys Ile Ala Ser Asp Gly Thr Val 835 840 845 Thr Ile Asp Gly Lys Thr Val Thr Thr Ser Asp Asp Thr Ile Gln Leu 850 855 860 Thr Ile Glu Asn Pro Phe Val Glu Val Pro Val Ala Val Arg Lys Tyr 865 870 875 880 Ala Met Gln Gly Thr Asp Lys Glu Ile Asn Leu Lys Gly Ala Ala Phe 885 890 895 Ser Leu Gln Lys Lys Glu Ala Asn Gly Thr Tyr Gln Pro Ile Asp Ser 900 905 910 Gln Thr Thr Asn Glu Lys Gly Leu Ala Ser Phe Asp Ser Leu Thr Pro 915 920 925 Gly Lys Tyr Arg Val Val Glu Thr Ala Gly Pro Ala Gly Tyr Asp Thr 930 935 940 Ser Pro Gly Asn Tyr Glu Phe Gln Ile Asp Lys Tyr Gly Lys Ile Ile 945 950 955 960 Tyr Thr Gly Lys Asn Thr Glu Met Thr Asn Asn Val Trp Thr Leu Thr 965 970 975 His Gln Asn Arg Leu Lys Ala Phe Asp Leu Thr Val His Lys Lys Glu 980 985 990 Asp Asn Gly Gln Thr Leu Lys Gly Ala Lys Phe Arg Leu Gln Gly Pro 995 1000 1005 Glu Met Asp Leu Glu Ser Pro Lys Asp Gly Gln Glu Thr Asp Thr 1010 1015 1020 Phe Leu Phe Glu Asn Leu Lys Pro Gly Thr Tyr Thr Leu Thr Glu 1025 1030 1035 Thr Phe Thr Pro Glu Gly Tyr Gln Gly Leu Lys Glu Pro Val Thr 1040 1045 1050 Ile Val Ile His Glu Asp Gly Ser Ile Gln Val Asp Gly Gln Asp 1055 1060 1065 His Glu Ser Val Leu Ser Pro Gly Ala Lys Asn Asn Gln Ile Ser 1070 1075 1080 Leu Asp Ile Thr Asn Gln Ala Lys Val Pro Leu Pro Glu Thr Gly 1085 1090 1095 Gly Ile Gly Arg Leu Gly Ile Tyr Leu Val Gly Met Ile Gly Cys 1100 1105 1110 Ala Phe Ser Ile Trp Tyr Leu Phe Leu Lys Lys Glu Arg Gly Gly 1115 1120 1125 Ser 16 1422 DNA Staphylococcus epidermidis 16 atgaaaaaac ttggttggct tagtatgtgt ctcttcttgt tactatttaa accagctttt 60 actcaggtag caacagaaac agaaacagaa atggttcaga ttactttaca caaattgctt 120 ttcccaaacg ggcaactgcc gaaaaatcat ccaaatgacg gacaagaaaa agctttatta 180 caaacgtatc gaggattaaa tggtgtcaca ttccaagttt atgatgtcac agattctttt 240 taccatctac gggaaaaggg caaaacggta gaagaagcac aagcagagat cgcaaaaaac 300 ggtgcgtctt ccggtatgtt taccgcagaa gcaacaacta caactcttaa caacgaagat 360 ggtatcgctt ctttttctct ggccgctaaa gatcaagaaa aaagagataa agcgtatctt 420 ttcattgaat ccaaagtacc agaagtcgtc aaagaaaagg cagagaatat ggtagttgtt 480 cttcctgtac atggacaaaa caatcaaaaa ctttcaacta tccatttgta tcctaaaaat 540 gaagaaaacg actaccctga tccacctttt gagaaggtat tagaagagcc tagaaatgat 600 tttacgattg gtgaaaaaat cacttattcc ttgcatacga caattcctgt aaatatcctt 660 gactatcaaa agttcgaatt gtcagatagt gcggatgaag cattaacgtt tttacctaat 720 agtttaacga tttcatcgaa tggagaaaag ctgacagaag gctttgtcat acacaagaaa 780 cctcacggat ttgatgtttt attttcgatc ccttcgttgg aaaaatatgc tggaaaaaaa 840 ctgaccattt cttatcagat gcagctaagc agtacagcac aggcgaacaa ggaaatcaac 900 aacaacggaa cactggattt tggttttggt gtcagtacaa agaaagtctc tgtatataca 960 gggagtaagc aatttgtcaa aatcgagaca aataaaccag ataaacgatt agctggcgca 1020 gtattcctta ttaaaaacaa agcaggaaat tacctccagc aaacagccaa cggatacaag 1080 tggacaaaga acgaatcaga tgcgcttcac ctgatttccg ataaaaatgg cgctttttca 1140 atttccgggt tgaaaacagg aagttatcga ttaaaagaga tcgaagcacc ttctggttat 1200 attttaagtg aaacagaaat tccgtttacc atttcaactt ttctttctga ggataaagag 1260 gcggacagta tattgaaagt agtcaataaa aaagaaaata gccgtccatt tcttccaaaa 1320 acaaacgaaa cgaaaaatac acttttaggc gttgttggta tggtattcgc aagctttgca 1380 atctggttgt ttatcaaaaa aagaacagga gtgaaaaaat ga 1422 17 473 PRT Staphylococcus epidermidis 17 Met Lys Lys Leu Gly Trp Leu Ser Met Cys Leu Phe Leu Leu Leu Phe 1 5 10 15 Lys Pro Ala Phe Thr Gln Val Ala Thr Glu Thr Glu Thr Glu Met Val 20 25 30 Gln Ile Thr Leu His Lys Leu Leu Phe Pro Asn Gly Gln Leu Pro Lys 35 40 45 Asn His Pro Asn Asp Gly Gln Glu Lys Ala Leu Leu Gln Thr Tyr Arg 50 55 60 Gly Leu Asn Gly Val Thr Phe Gln Val Tyr Asp Val Thr Asp Ser Phe 65 70 75 80 Tyr His Leu Arg Glu Lys Gly Lys Thr Val Glu Glu Ala Gln Ala Glu 85 90 95 Ile Ala Lys Asn Gly Ala Ser Ser Gly Met Phe Thr Ala Glu Ala Thr 100 105 110 Thr Thr Thr Leu Asn Asn Glu Asp Gly Ile Ala Ser Phe Ser Leu Ala 115 120 125 Ala Lys Asp Gln Glu Lys Arg Asp Lys Ala Tyr Leu Phe Ile Glu Ser 130 135 140 Lys Val Pro Glu Val Val Lys Glu Lys Ala Glu Asn Met Val Val Val 145 150 155 160 Leu Pro Val His Gly Gln Asn Asn Gln Lys Leu Ser Thr Ile His Leu 165 170 175 Tyr Pro Lys Asn Glu Glu Asn Asp Tyr Pro Asp Pro Pro Phe Glu Lys 180 185 190 Val Leu Glu Glu Pro Arg Asn Asp Phe Thr Ile Gly Glu Lys Ile Thr 195 200 205 Tyr Ser Leu His Thr Thr Ile Pro Val Asn Ile Leu Asp Tyr Gln Lys 210 215 220 Phe Glu Leu Ser Asp Ser Ala Asp Glu Ala Leu Thr Phe Leu Pro Asn 225 230 235 240 Ser Leu Thr Ile Ser Ser Asn Gly Glu Lys Leu Thr Glu Gly Phe Val 245 250 255 Ile His Lys Lys Pro His Gly Phe Asp Val Leu Phe Ser Ile Pro Ser 260 265 270 Leu Glu Lys Tyr Ala Gly Lys Lys Leu Thr Ile Ser Tyr Gln Met Gln 275 280 285 Leu Ser Ser Thr Ala Gln Ala Asn Lys Glu Ile Asn Asn Asn Gly Thr 290 295 300 Leu Asp Phe Gly Phe Gly Val Ser Thr Lys Lys Val Ser Val Tyr Thr 305 310 315 320 Gly Ser Lys Gln Phe Val Lys Ile Glu Thr Asn Lys Pro Asp Lys Arg 325 330 335 Leu Ala Gly Ala Val Phe Leu Ile Lys Asn Lys Ala Gly Asn Tyr Leu 340 345 350 Gln Gln Thr Ala Asn Gly Tyr Lys Trp Thr Lys Asn Glu Ser Asp Ala 355 360 365 Leu His Leu Ile Ser Asp Lys Asn Gly Ala Phe Ser Ile Ser Gly Leu 370 375 380 Lys Thr Gly Ser Tyr Arg Leu Lys Glu Ile Glu Ala Pro Ser Gly Tyr 385 390 395 400 Ile Leu Ser Glu Thr Glu Ile Pro Phe Thr Ile Ser Thr Phe Leu Ser 405 410 415 Glu Asp Lys Glu Ala Asp Ser Ile Leu Lys Val Val Asn Lys Lys Glu 420 425 430 Asn Ser Arg Pro Phe Leu Pro Lys Thr Asn Glu Thr Lys Asn Thr Leu 435 440 445 Leu Gly Val Val Gly Met Val Phe Ala Ser Phe Ala Ile Trp Leu Phe 450 455 460 Ile Lys Lys Arg Thr Gly Val Lys Lys 465 470 18 1878 DNA Staphylococcus epidermidis 18 atgaaaaatc ataaaaaaat aaacgttatg ttaggagtcc ttttccttat tttaccatta 60 ctcacaaaca gcttcggcgc aaaaaaagtg tttgcagagg agacagcagc tcaagtcatc 120 cttcataaaa agaaaatgac tgatttaccc gatcctttaa tccaaaacag cgggaaagaa 180 atgagcgaat tcgatcaata ccaaggatta gccgatattt cattttcagt ttataacgtc 240 actcaagaat tttatgcgca acgagataaa ggagcgtccg tggatgcagc aaaacaagca 300 gtccagtctt tgactcctgg tacaccagtt gcttcaggaa cgacagatgc tgatggaaat 360 gtcactttat ctttacctaa aaaacaaaat gggaaagatg cagtctacac gatcaaagaa 420 gaaccaaaag acggagtgtc agctgccgca aacatggttt tagctttccc tgtatatgag 480 atgatcaaac aagcagatgg ctcttataaa tacgggacag aagaactaga tactatccat 540 ctctacccta aaaatacagt cggtaatgat ggaacgttga aagttacaaa aatcggtact 600 gccgaaaacg aagcactaaa tggagcagaa tttattattt ctaaagaaga aggaacacca 660 agcgtcaaaa aatacatcca aagtgtcaca gatggattgt acacttggac aactgatcaa 720 accaaagcca aacatttcat tactggtcat tcttatgaca tcggcaacaa tgactttgcc 780 gaggcatcta ttgaaaaagg ccagttgatc gttaatcatt tagaagttgg aaaatataat 840 ttagaagaag taaaagctcc tgataatgcg gaaatgattg aaaagcaaac aatcacgcct 900 tttgagatcc tggcaaatag ccaaacacca gtagaaaaga ccatcaaaaa tgatacgtct 960 aaagttgata aaacaacacc tcaattgaat ggaaaagatg tcgcaatcgg tgaaaaaatt 1020 caatatgaga tttctgtcaa tatcccatta ggtatcgctg ataaagaagg aacgcaaaac 1080 aagtacacaa cattcaaact tatcgatact catgacgctg ctttaacatt tgataatgat 1140 tcttcaggaa cgtatgctta tgccttatat gatggaaata aagaaatcga cccagtaaat 1200 tattctgtca ctgagcaaac agacggattc acggtttcag ttgatccgaa ttatattcct 1260 tcattaactc ctggcggtac attgaaattc gtttactata tgcatttgaa cgaaaaagca 1320 gatccaacca aaggattttc taaccaagca aatgtcgata acgggcatac aaatgatcaa 1380 acaccaccgt cagtcgatgt cgttactggg ggcaaacgat ttgttaaagt agatggtgac 1440 gttacatcag accaaacact tgctggagca gaattcgtcg ttcgtgatca agatagtgac 1500 acagcgaaat atttatcgat cgacccatcc acaaaagccg tcagctgggt atcggcgaaa 1560 gaatcagcaa cggtttttac aaccacaagt aacggtttaa tcgatgtgac aggtctaaaa 1620 tatggcacgt actatctgga agaaacgaaa gcgccagaaa aatatgttcc attaacaaac 1680 cgtgtagcat ttactatcga tgaacaatct tatgtaacag caggacagtt gatttctcct 1740 gaaaaaatac caaataaaca caaaggtaca cttccttcaa caggcggtaa gggaatctat 1800 gtgtatatcg gtgcaggagt agtccttcta ctgattgctg gactgtactt tgctagacgc 1860 aagcacagtc agatttag 1878 19 625 PRT Staphylococcus epidermidis 19 Met Lys Asn His Lys Lys Ile Asn Val Met Leu Gly Val Leu Phe Leu 1 5 10 15 Ile Leu Pro Leu Leu Thr Asn Ser Phe Gly Ala Lys Lys Val Phe Ala 20 25 30 Glu Glu Thr Ala Ala Gln Val Ile Leu His Lys Lys Lys Met Thr Asp 35 40 45 Leu Pro Asp Pro Leu Ile Gln Asn Ser Gly Lys Glu Met Ser Glu Phe 50 55 60 Asp Gln Tyr Gln Gly Leu Ala Asp Ile Ser Phe Ser Val Tyr Asn Val 65 70 75 80 Thr Gln Glu Phe Tyr Ala Gln Arg Asp Lys Gly Ala Ser Val Asp Ala 85 90 95 Ala Lys Gln Ala Val Gln Ser Leu Thr Pro Gly Thr Pro Val Ala Ser 100 105 110 Gly Thr Thr Asp Ala Asp Gly Asn Val Thr Leu Ser Leu Pro Lys Lys 115 120 125 Gln Asn Gly Lys Asp Ala Val Tyr Thr Ile Lys Glu Glu Pro Lys Asp 130 135 140 Gly Val Ser Ala Ala Ala Asn Met Val Leu Ala Phe Pro Val Tyr Glu 145 150 155 160 Met Ile Lys Gln Ala Asp Gly Ser Tyr Lys Tyr Gly Thr Glu Glu Leu 165 170 175 Asp Thr Ile His Leu Tyr Pro Lys Asn Thr Val Gly Asn Asp Gly Thr 180 185 190 Leu Lys Val Thr Lys Ile Gly Thr Ala Glu Asn Glu Ala Leu Asn Gly 195 200 205 Ala Glu Phe Ile Ile Ser Lys Glu Glu Gly Thr Pro Ser Val Lys Lys 210 215 220 Tyr Ile Gln Ser Val Thr Asp Gly Leu Tyr Thr Trp Thr Thr Asp Gln 225 230 235 240 Thr Lys Ala Lys His Phe Ile Thr Gly His Ser Tyr Asp Ile Gly Asn 245 250 255 Asn Asp Phe Ala Glu Ala Ser Ile Glu Lys Gly Gln Leu Ile Val Asn 260 265 270 His Leu Glu Val Gly Lys Tyr Asn Leu Glu Glu Val Lys Ala Pro Asp 275 280 285 Asn Ala Glu Met Ile Glu Lys Gln Thr Ile Thr Pro Phe Glu Ile Leu 290 295 300 Ala Asn Ser Gln Thr Pro Val Glu Lys Thr Ile Lys Asn Asp Thr Ser 305 310 315 320 Lys Val Asp Lys Thr Thr Pro Gln Leu Asn Gly Lys Asp Val Ala Ile 325 330 335 Gly Glu Lys Ile Gln Tyr Glu Ile Ser Val Asn Ile Pro Leu Gly Ile 340 345 350 Ala Asp Lys Glu Gly Thr Gln Asn Lys Tyr Thr Thr Phe Lys Leu Ile 355 360 365 Asp Thr His Asp Ala Ala Leu Thr Phe Asp Asn Asp Ser Ser Gly Thr 370 375 380 Tyr Ala Tyr Ala Leu Tyr Asp Gly Asn Lys Glu Ile Asp Pro Val Asn 385 390 395 400 Tyr Ser Val Thr Glu Gln Thr Asp Gly Phe Thr Val Ser Val Asp Pro 405 410 415 Asn Tyr Ile Pro Ser Leu Thr Pro Gly Gly Thr Leu Lys Phe Val Tyr 420 425 430 Tyr Met His Leu Asn Glu Lys Ala Asp Pro Thr Lys Gly Phe Ser Asn 435 440 445 Gln Ala Asn Val Asp Asn Gly His Thr Asn Asp Gln Thr Pro Pro Ser 450 455 460 Val Asp Val Val Thr Gly Gly Lys Arg Phe Val Lys Val Asp Gly Asp 465 470 475 480 Val Thr Ser Asp Gln Thr Leu Ala Gly Ala Glu Phe Val Val Arg Asp 485 490 495 Gln Asp Ser Asp Thr Ala Lys Tyr Leu Ser Ile Asp Pro Ser Thr Lys 500 505 510 Ala Val Ser Trp Val Ser Ala Lys Glu Ser Ala Thr Val Phe Thr Thr 515 520 525 Thr Ser Asn Gly Leu Ile Asp Val Thr Gly Leu Lys Tyr Gly Thr Tyr 530 535 540 Tyr Leu Glu Glu Thr Lys Ala Pro Glu Lys Tyr Val Pro Leu Thr Asn 545 550 555 560 Arg Val Ala Phe Thr Ile Asp Glu Gln Ser Tyr Val Thr Ala Gly Gln 565 570 575 Leu Ile Ser Pro Glu Lys Ile Pro Asn Lys His Lys Gly Thr Leu Pro 580 585 590 Ser Thr Gly Gly Lys Gly Ile Tyr Val Tyr Ile Gly Ala Gly Val Val 595 600 605 Leu Leu Leu Ile Ala Gly Leu Tyr Phe Ala Arg Arg Lys His Ser Gln 610 615 620 Ile 625 20 2402 PRT Staphylococcus epidermidis 20 Met Lys Asn Lys Gln Gly Phe Leu Pro Asn Leu Leu Asn Lys Tyr Gly 1 5 10 15 Ile Arg Lys Leu Ser Ala Gly Thr Ala Ser Leu Leu Ile Gly Ala Thr 20 25 30 Leu Val Phe Gly Ile Asn Gly Gln Val Lys Ala Ala Glu Thr Asp Asn 35 40 45 Ile Val Ser Gln Asn Gly Asp Asn Lys Thr Asn Asp Ser Glu Ser Ser 50 55 60 Asp Lys Glu Leu Val Lys Ser Glu Asp Asp Lys Thr Ser Ser Thr Ser 65 70 75 80 Thr Asp Thr Asn Leu Glu Ser Glu Phe Asp Gln Asn Asn Asn Pro Ser 85 90 95 Ser Ile Glu Glu Ser Thr Asn Arg Asn Asp Glu Asp Thr Leu Asn Gln 100 105 110 Arg Thr Ser Thr Glu Thr Glu Lys Asp Thr His Val Lys Ser Ala Asp 115 120 125 Thr Gln Thr Thr Asn Glu Thr Thr Asn Lys Asn Asp Asp Asn Ala Thr 130 135 140 Thr Asn His Thr Glu Ser Ile Ser Asp Glu Ser Thr Tyr Gln Ser Asp 145 150 155 160 Asp Ser Lys Thr Thr Gln His Asp Asn Ser Asn Thr Asn Gln Asp Thr 165 170 175 Gln Ser Thr Leu Asn Pro Thr Ser Lys Glu Ser Ser Asn Lys Asp Glu 180 185 190 Ala Thr Ser Pro Thr Pro Lys Glu Ser Thr Ser Ile Glu Lys Thr Asn 195 200 205 Leu Ser Asn Asp Ala Asn His Gln Thr Thr Asp Glu Val Asn His Ser 210 215 220 Asp Ser Asp Asn Met Thr Asn Ser Thr Pro Asn Asp Thr Glu Asn Glu 225 230 235 240 Leu Asp Thr Thr Gln Leu Thr Ser His Asp Glu Ser Pro Ser Pro Gln 245 250 255 Ser Asp Asn Phe Thr Gly Phe Thr Asn Leu Met Ala Thr Pro Leu Asn 260 265 270 Leu Arg Asn Asp Asn Pro Arg Ile Asn Leu Leu Ala Ala Thr Glu Asp 275 280 285 Thr Lys Pro Lys Thr Tyr Lys Lys Pro Asn Asn Ser Glu Tyr Ser Tyr 290 295 300 Leu Leu Asn Asp Leu Gly Tyr Asp Ala Thr Thr Val Lys Glu Asn Ser 305 310 315 320 Asp Leu Arg His Ala Gly Ile Ser Gln Ser Gln Asp Asn Thr Gly Ser 325 330 335 Val Ile Lys Leu Asn Leu Thr Lys Trp Leu Ser Leu Gln Ser Asp Phe 340 345 350 Val Asn Gly Gly Lys Val Asn Leu Ser Phe Ala Gln Ser Asp Phe Tyr 355 360 365 Thr Gln Ile Glu Ser Ile Thr Leu Asn Asp Val Lys Met Asp Thr Thr 370 375 380 Asn Asn Gly Gln Asn Trp Ser Ala Pro Ile Asn Gly Ser Thr Val Arg 385 390 395 400 Ser Gly Leu Ile Gly Ser Val Thr Asn His Asp Ile Val Ile Thr Leu 405 410 415 Lys Asn Ser Gln Thr Leu Ser Ser Leu Gly Tyr Ser Asn Asn Lys Pro 420 425 430 Val Tyr Leu Thr His Thr Trp Thr Thr Asn Asp Gly Ala Ile Ala Glu 435 440 445 Glu Ser Ile Gln Val Ala Ser Ile Thr Pro Thr Leu Asp Ser Lys Ala 450 455 460 Pro Asn Thr Ile Gln Lys Ser Asp Phe Thr Ala Gly Arg Met Thr Asn 465 470 475 480 Lys Ile Lys Tyr Asp Ser Ser Gln Asn Ser Ile Lys Ser Val His Thr 485 490 495 Phe Lys Pro Asn Glu Asn Phe Leu Gln Thr Asp Tyr Arg Ala Val Leu 500 505 510 Tyr Ile Lys Glu Gln Val Asn Lys Glu Leu Ile Pro Tyr Ile Asp Pro 515 520 525 Asn Ser Val Lys Leu Tyr Val Ser Asp Pro Asp Gly Asn Pro Ile Ser 530 535 540 Gln Asp Arg Tyr Val Asn Gly Ser Ile Asp Asn Asp Gly Leu Phe Asp 545 550 555 560 Ser Ser Lys Ile Asn Glu Ile Ser Ile Lys Asn Asn Asn Thr Ser Gly 565 570 575 Gln Leu Ser Asn Ala Arg Thr Ser Leu Asp Arg Asn Val Phe Phe Gly 580 585 590 Thr Leu Gly Gln Ser Arg Ser Tyr Thr Ile Ser Tyr Lys Leu Lys Asp 595 600 605 Gly Tyr Thr Leu Glu Ser Val Ala Ser Lys Val Ser Ala Arg Glu Thr 610 615 620 Phe Asp Ser Trp Met Glu Val Asp Tyr Leu Asp Ser Tyr Asp Ser Gly 625 630 635 640 Ala Pro Asn Lys Arg Leu Leu Gly Ser Tyr Ala Ser Ser Tyr Ile Asp 645 650 655 Met Ile Asp Arg Ile Pro Pro Val Ala Pro Lys Ala Asn Ser Ile Thr 660 665 670 Thr Glu Asp Thr Ser Ile Lys Gly Thr Ala Glu Val Asp Thr Asn Ile 675 680 685 Asn Leu Thr Phe Asn Asp Gly Arg Thr Leu Asn Gly Lys Val Asp Ser 690 695 700 Asn Gly Asn Phe Ser Ile Ala Ile Pro Ser Tyr Tyr Val Leu Thr Gly 705 710 715 720 Lys Glu Thr Ile Lys Ile Thr Ser Ile Asp Lys Gly Asp Asn Val Ser 725 730 735 Pro Ala Ile Thr Ile Ser Val Ile Asp Lys Thr Pro Pro Ala Val Lys 740 745 750 Ala Ile Ser Asn Lys Thr Gln Lys Val Asn Thr Glu Ile Glu Pro Ile 755 760 765 Lys Ile Glu Ala Thr Asp Asn Ser Gly Gln Ala Val Thr Asn Lys Val 770 775 780 Glu Gly Leu Pro Ala Gly Met Thr Phe Asp Glu Ala Thr Asn Thr Ile 785 790 795 800 Ser Gly Thr Pro Ser Glu Val Gly Ser Tyr Asp Ile Thr Val Thr Thr 805 810 815 Thr Asp Glu Asn Gly Asn Ser Glu Thr Thr Thr Phe Thr Ile Asp Val 820 825 830 Glu Asp Thr Thr Lys Pro Thr Val Glu Ser Val Ala Asp Gln Thr Gln 835 840 845 Glu Val Asn Thr Glu Ile Glu Pro Ile Lys Ile Glu Ala Thr Asp Asn 850 855 860 Ser Gly Arg Ala Val Thr Asn Lys Val Asp Gly Leu Pro Asp Gly Val 865 870 875 880 Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val 885 890 895 Gly Ser Tyr Asp Ile Thr Val Thr Thr Thr Asp Glu Ser Gly Asn Val 900 905 910 Thr Glu Thr Ile Phe Thr Ile Asp Val Glu Asp Thr Thr Lys Pro Thr 915 920 925 Val Glu Ser Ile Ala Gly Gln Thr Gln Glu Val Asn Thr Glu Ile Glu 930 935 940 Pro Ile Lys Ile Glu Ala Lys Asp Asn Ser Gly Gln Thr Val Thr Asn 945 950 955 960 Lys Val Asp Gly Leu Pro Asp Gly Val Thr Phe Asp Glu Ala Thr Asn 965 970 975 Thr Ile Ser Gly Thr Pro Ser Glu Val Gly Ser Tyr Asp Val Thr Val 980 985 990 Thr Thr Thr Asp Glu Ser Gly Asn Ser Glu Thr Thr Thr Phe Thr Ile 995 1000 1005 Glu Val Lys Asp Thr Thr Lys Pro Thr Val Glu Ser Val Ala Asp 1010 1015 1020 Gln Thr Gln Glu Val Asn Thr Glu Ile Glu Pro Ile Lys Ile Glu 1025 1030 1035 Ala Arg Asp Asn Ser Gly Gln Ala Val Thr Asn Lys Val Asp Gly 1040 1045 1050 Leu Pro Asp Gly Val Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser 1055 1060 1065 Gly Thr Pro Ser Glu Val Gly Ser Tyr Asp Ile Thr Val Thr Thr 1070 1075 1080 Thr Asp Glu Ser Gly Asn Val Thr Glu Thr Thr Phe Thr Ile Glu 1085 1090 1095 Val Glu Asp Thr Thr Lys Pro Thr Val Glu Asn Val Ala Asp Gln 1100 1105 1110 Thr Gln Glu Val Asn Thr Glu Ile Thr Pro Ile Thr Ile Glu Ser 1115 1120 1125 Glu Asp Asn Ser Gly Gln Thr Val Thr Asn Lys Val Asp Gly Leu 1130 1135 1140 Pro Asp Gly Val Thr Phe Asp Glu Thr Thr Asn Thr Ile Ser Gly 1145 1150 1155 Thr Pro Ser Lys Val Gly Ser Tyr Asp Ile Thr Val Thr Thr Thr 1160 1165 1170 Asp Glu Ser Gly Asn Ala Thr Glu Thr Thr Phe Thr Ile Glu Val 1175 1180 1185 Glu Asp Thr Thr Lys Pro Thr Val Glu Asn Val Ala Gly Gln Thr 1190 1195 1200 Gln Glu Ile Asn Thr Glu Ile Glu Pro Ile Lys Ile Glu Ala Thr 1205 1210 1215 Asp Asn Ser Gly Gln Ala Val Thr Asn Lys Val Glu Gly Leu Pro 1220 1225 1230 Ala Gly Val Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr 1235 1240 1245 Pro Ser Glu Val Gly Ser Tyr Thr Val Thr Val Thr Thr Met Asp 1250 1255 1260 Glu Ser Gly Asn Ala Thr Glu Thr Thr Phe Thr Ile Asp Val Glu 1265 1270 1275 Asp Thr Thr Lys Pro Thr Val Glu Ser Val Ala Asp Gln Thr Gln 1280 1285 1290 Glu Val Asn Thr Glu Ile Thr Pro Ile Thr Ile Glu Ser Glu Asp 1295 1300 1305 Asn Ser Asp Gln Ala Val Thr Asn Lys Val Asp Gly Leu Pro Asp 1310 1315 1320 Gly Val Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr Pro 1325 1330 1335 Ser Glu Val Gly Ser Tyr Thr Val Thr Val Thr Thr Thr Asp Glu 1340 1345 1350 Ser Gly Asn Ala Thr Glu Thr Thr Phe Thr Ile Asp Val Glu Asp 1355 1360 1365 Thr Thr Lys Pro Thr Val Lys Ser Val Ser Asp Gln Thr Gln Glu 1370 1375 1380 Val Asn Thr Glu Ile Thr Pro Ile Lys Ile Glu Ala Thr Asp Asn 1385 1390 1395 Ser Gly Gln Thr Val Thr Asn Lys Val Asp Gly Leu Pro Asp Gly 1400 1405 1410 Ile Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr Pro Ser 1415 1420 1425 Glu Val Gly Ser Tyr Asp Ile Thr Val Thr Thr Thr Asp Glu Ser 1430 1435 1440 Gly Asn Ala Thr Glu Thr Thr Phe Thr Ile Asn Val Glu Asp Thr 1445 1450 1455 Thr Lys Pro Thr Val Glu Asp Ile Ala Asp Gln Thr Gln Glu Val 1460 1465 1470 Asn Thr Glu Ile Glu Pro Ile Lys Ile Glu Ala Thr Asp Asn Gly 1475 1480 1485 Gly Gln Ala Val Thr Asn Lys Val Asp Gly Leu Pro Asp Gly Val 1490 1495 1500 Thr Phe Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu 1505 1510 1515 Val Gly Ser Tyr Asp Ile Ile Val Thr Thr Thr Asp Glu Asn Gly 1520 1525 1530 Asn Ser Glu Thr Thr Thr Phe Thr Ile Asp Val Glu Asp Thr Thr 1535 1540 1545 Lys Pro Thr Val Glu Ser Val Val Asp Gln Thr Gln Glu Val Asn 1550 1555 1560 Thr Glu Ile Thr Pro Ile Lys Ile Glu Ala Thr Asp Asn Ser Gly 1565 1570 1575 Gln Ala Val Ala Asn Lys Val Asp Gly Leu Pro Asn Gly Val Thr 1580 1585 1590 Phe Asp Glu Thr Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val 1595 1600 1605 Gly Ser Tyr Asp Ile Ile Val Thr Thr Thr Asp Glu Ser Gly Asn 1610 1615 1620 Val Thr Glu Thr Ile Phe Thr Ile Asp Val Glu Asp Thr Thr Lys 1625 1630 1635 Pro Thr Val Glu Ser Ile Ala Gly Gln Thr Gln Glu Val Asn Thr 1640 1645 1650 Glu Ile Glu Pro Ile Lys Ile Glu Ala Thr Asp Asn Ser Gly Gln 1655 1660 1665 Ala Val Thr Asn Lys Val Asp Gly Leu Pro Asn Gly Val Thr Phe 1670 1675 1680 Asp Glu Ala Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val Gly 1685 1690 1695 Ile Tyr Thr Val Thr Val Thr Thr Thr Asp Glu Ser Gly Asn Ala 1700 1705 1710 Thr Glu Thr Thr Phe Thr Ile Asp Val Glu Asp Thr Thr Lys Pro 1715 1720 1725 Thr Val Glu Ser Val Ala Asp Gln Thr Gln Glu Val Asn Thr Glu 1730 1735 1740 Ile Thr Pro Ile Thr Ile Glu Ser Glu Asp Asn Ser Gly Gln Ala 1745 1750 1755 Val Thr Asn Lys Val Glu Gly Leu Pro Ala Gly Met Thr Phe Asp 1760 1765 1770 Glu Thr Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val Gly Ser 1775 1780 1785 Tyr Thr Val Thr Val Thr Thr Thr Asp Glu Ser Gly Asn Glu Thr 1790 1795 1800 Glu Thr Thr Phe Thr Ile Asp Val Glu Asp Thr Thr Lys Pro Thr 1805 1810 1815 Val Glu Ser Ile Ala Asn Gln Thr Gln Glu Val Asn Thr Glu Ile 1820 1825 1830 Thr Pro Ile Lys Ile Glu Ala Thr Asp Asn Ser Gly Gln Ala Val 1835 1840 1845 Thr Asn Lys Val Asp Gly Leu Pro Asn Gly Val Thr Phe Asp Glu 1850 1855 1860 Thr Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val Gly Ser Tyr 1865 1870 1875 Asp Ile Lys Val Thr Thr Thr Asp Glu Ser Gly Asn Ala Thr Glu 1880 1885 1890 Thr Thr Phe Thr Ile Asn Val Glu Asp Thr Thr Lys Pro Thr Val 1895 1900 1905 Glu Ser Val Ala Asp Gln Thr Gln Glu Ile Asn Thr Glu Ile Glu 1910 1915 1920 Pro Ile Lys Ile Glu Ala Arg Asp Asn Ser Gly Gln Ala Val Thr 1925 1930 1935 Asn Lys Val Asp Gly Leu Pro Asp Gly Val Thr Phe Asp Glu Ala 1940 1945 1950 Thr Asn Thr Ile Ser Gly Thr Pro Ser Glu Val Gly Ser Tyr Asp 1955 1960 1965 Ile Thr Val Thr Thr Thr Asp Glu Ser Gly Asn Ala Thr Glu Thr 1970 1975 1980 Thr Phe Thr Ile Asp Val Glu Asp Thr Thr Lys Pro Thr Val Glu 1985 1990 1995 Asp Ile Thr Asp Gln Thr Gln Glu Ile Asn Thr Glu Met Thr Pro 2000 2005 2010 Ile Lys Ile Glu Ala Thr Asp Asn Ser Gly Gln Ala Val Thr Asn 2015 2020 2025 Lys Val Glu Gly Leu Pro Asp Gly Val Thr Phe Asp Glu Ala Thr 2030 2035 2040 Asn Thr Ile Ser Gly Thr Pro Ser Glu Val Gly Lys Tyr Leu Ile 2045 2050 2055 Thr Ile Thr Thr Ile Asp Lys Asp Gly Asn Thr Ala Thr Thr Thr 2060 2065 2070 Leu Thr Ile Asn Val Ile Asp Thr Thr Thr Pro Glu Gln Pro Thr 2075 2080 2085 Ile Asn Lys Val Thr Glu Asn Ser Thr Glu Val Asn Gly Arg Gly 2090 2095 2100 Glu Pro Gly Thr Val Val Glu Val Thr Phe Pro Asp Gly Asn Lys 2105 2110 2115 Val Glu Gly Lys Val Asp Ser Asp Gly Asn Tyr His Ile Gln Ile 2120 2125 2130 Pro Ser Glu Thr Thr Leu Lys Gly Gly Gln Pro Leu Gln Val Ile 2135 2140 2145 Ala Ile Asp Lys Ala Gly Asn Lys Ser Glu Ala Thr Thr Thr Asn 2150 2155 2160 Val Ile Asp Thr Thr Ala Pro Glu Gln Pro Thr Ile Asn Lys Val 2165 2170 2175 Thr Glu Asn Ser Thr Glu Val Ser Gly Arg Gly Glu Pro Gly Thr 2180 2185 2190 Val Val Glu Val Thr Phe Pro Asp Gly Asn Lys Val Glu Gly Lys 2195 2200 2205 Val Asp Ser Asp Gly Asn Tyr His Ile Gln Ile Pro Ser Asp Glu 2210 2215 2220 Arg Phe Lys Val Gly Gln Gln Leu Ile Val Lys Val Val Asp Glu 2225 2230 2235 Glu Gly Asn Val Ser Glu Pro Ser Ile Thr Met Val Gln Lys Glu 2240 2245 2250 Asp Lys Asn Ser Glu Lys Leu Ser Thr Val Thr Gly Thr Val Thr 2255 2260 2265 Lys Asn Asn Ser Lys Ser Leu Lys His Lys Ala Ser Glu Gln Gln 2270 2275 2280 Ser Tyr His Asn Lys Ser Glu Lys Ile Lys Asn Val Asn Lys Pro 2285 2290 2295 Thr Lys Ile Val Glu Lys Asp Met Ser Thr Tyr Asp Tyr Ser Arg 2300 2305 2310 Tyr Ser Lys Asp Ile Ser Asn Lys Asn Asn Lys Ser Ala Thr Phe 2315 2320 2325 Glu Gln Gln Asn Val Ser Asp Ile Asn Asn Asn Gln Tyr Ser Arg 2330 2335 2340 Asn Lys Val Asn Gln Pro Val Lys Lys Ser Arg Lys Asn Glu Ile 2345 2350 2355 Asn Lys Asp Leu Pro Gln Thr Gly Glu Glu Asn Phe Asn Lys Ser 2360 2365 2370 Thr Leu Phe Gly Thr Leu Val Ala Ser Leu Gly Ala Leu Leu Leu 2375 2380 2385 Phe Phe Lys Arg Arg Lys Lys Asp Glu Asn Asp Glu Lys Glu 2390 2395 2400 21 892 PRT Staphylococcus epidermidis 21 Leu Phe Gly Leu Gly His Asn Glu Ala Lys Ala Glu Glu Asn Thr Val 1 5 10 15 Gln Asp Val Lys Asp Ser Asn Met Asp Asp Glu Leu Ser Asp Ser Asn 20 25 30 Asp Gln Ser Ser Asn Glu Glu Lys Asn Asp Val Ile Asn Asn Ser Gln 35 40 45 Ser Ile Asn Thr Asp Asp Asp Asn Gln Ile Lys Lys Glu Glu Thr Asn 50 55 60 Ser Asn Asp Ala Ile Glu Asn Arg Ser Lys Asp Ile Thr Gln Ser Thr 65 70 75 80 Thr Asn Val Asp Glu Asn Glu Ala Thr Phe Leu Gln Lys Thr Pro Gln 85 90 95 Asp Asn Thr Gln Leu Lys Glu Glu Val Val Lys Glu Pro Ser Ser Val 100 105 110 Glu Ser Ser Asn Ser Ser Met Asp Thr Ala Gln Gln Pro Ser His Thr 115 120 125 Thr Ile Asn Ser Glu Ala Ser Ile Gln Thr Ser Asp Asn Glu Glu Asn 130 135 140 Ser Arg Val Ser Asp Phe Ala Asn Ser Lys Ile Ile Glu Ser Asn Thr 145 150 155 160 Glu Ser Asn Lys Glu Glu Asn Thr Ile Glu Gln Pro Asn Lys Val Arg 165 170 175 Glu Asp Ser Ile Thr Ser Gln Pro Ser Ser Tyr Lys Asn Ile Asp Glu 180 185 190 Lys Ile Ser Asn Gln Asp Glu Leu Leu Asn Leu Pro Ile Asn Glu Tyr 195 200 205 Glu Asn Lys Val Arg Pro Leu Ser Thr Thr Ser Ala Gln Pro Ser Ser 210 215 220 Lys Arg Val Thr Val Asn Gln Leu Ala Ala Glu Gln Gly Ser Asn Val 225 230 235 240 Asn His Leu Ile Lys Val Thr Asp Gln Ser Ile Thr Glu Gly Tyr Asp 245 250 255 Asp Ser Asp Gly Ile Ile Lys Ala His Asp Ala Glu Asn Leu Ile Tyr 260 265 270 Asp Val Thr Phe Glu Val Asp Asp Lys Val Lys Ser Gly Asp Thr Met 275 280 285 Thr Val Asn Ile Asp Lys Asn Thr Val Pro Ser Asp Leu Thr Asp Ser 290 295 300 Phe Ala Ile Pro Lys Ile Lys Asp Asn Ser Gly Glu Ile Ile Ala Thr 305 310 315 320 Gly Thr Tyr Asp Asn Thr Asn Lys Gln Ile Thr Tyr Thr Phe Thr Asp 325 330 335 Tyr Val Asp Lys Tyr Glu Asn Ile Lys Ala His Leu Lys Leu Thr Ser 340 345 350 Tyr Ile Asp Lys Ser Lys Val Pro Asn Asn Asn Thr Lys Leu Asp Val 355 360 365 Glu Tyr Lys Thr Ala Leu Ser Ser Val Asn Lys Thr Ile Thr Val Glu 370 375 380 Tyr Gln Lys Pro Asn Glu Asn Arg Thr Ala Asn Leu Gln Ser Met Phe 385 390 395 400 Thr Asn Ile Asp Thr Lys Asn His Thr Val Glu Gln Thr Ile Tyr Ile 405 410 415 Asn Pro Leu Arg Tyr Ser Ala Lys Glu Thr Asn Val Asn Ile Ser Gly 420 425 430 Asn Gly Asp Glu Gly Ser Thr Ile Ile Asp Asp Ser Thr Ile Ile Lys 435 440 445 Val Tyr Lys Val Gly Asp Asn Gln Asn Leu Pro Asp Ser Asn Arg Ile 450 455 460 Tyr Asp Tyr Ser Glu Tyr Glu Asp Val Thr Asn Asp Asp Tyr Ala Gln 465 470 475 480 Leu Gly Asn Asn Asn Asp Val Asn Ile Asn Phe Gly Asn Ile Asp Ser 485 490 495 Pro Tyr Ile Ile Lys Val Ile Ser Lys Tyr Asp Pro Asn Lys Asp Asp 500 505 510 Tyr Thr Thr Ile Gln Gln Thr Val Thr Met Gln Thr Thr Ile Asn Glu 515 520 525 Tyr Thr Gly Glu Phe Arg Thr Ala Ser Tyr Asp Asn Thr Ile Ala Phe 530 535 540 Ser Thr Ser Ser Gly Gln Gly Gln Gly Asp Leu Pro Pro Glu Lys Thr 545 550 555 560 Tyr Lys Ile Gly Asp Tyr Val Trp Glu Asp Val Asp Lys Asp Gly Ile 565 570 575 Gln Asn Thr Asn Asp Asn Glu Lys Pro Leu Ser Asn Val Leu Val Thr 580 585 590 Leu Thr Tyr Pro Asp Gly Thr Ser Lys Ser Val Arg Thr Asp Glu Glu 595 600 605 Gly Lys Tyr Gln Phe Asp Gly Leu Lys Asn Gly Leu Thr Tyr Lys Ile 610 615 620 Thr Phe Glu Thr Pro Glu Gly Tyr Thr Pro Thr Leu Lys His Ser Gly 625 630 635 640 Thr Asn Pro Ala Leu Asp Ser Glu Gly Asn Ser Val Trp Val Thr Ile 645 650 655 Asn Gly Gln Asp Asp Met Thr Ile Asp Ser Gly Phe Tyr Gln Thr Pro 660 665 670 Lys Tyr Ser Leu Gly Asn Tyr Val Trp Tyr Asp Thr Asn Lys Asp Gly 675 680 685 Ile Gln Gly Asp Asp Glu Lys Gly Ile Ser Gly Val Lys Val Thr Leu 690 695 700 Lys Asp Glu Asn Gly Asn Ile Ile Ser Thr Thr Thr Thr Asp Glu Asn 705 710 715 720 Gly Lys Tyr Gln Phe Asp Asn Leu Asn Ser Gly Asn Tyr Ile Val His 725 730 735 Phe Asp Lys Pro Ser Gly Met Thr Gln Thr Thr Thr Asp Ser Gly Asp 740 745 750 Asp Asp Glu Gln Asp Ala Asp Gly Glu Glu Val His Val Thr Ile Thr 755 760 765 Asp His Asp Asp Phe Ser Ile Asp Asn Gly Tyr Tyr Asp Asp Asp Ser 770 775 780 Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Asp Ser Asp Ser Asp 785 790 795 800 Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp 805 810 815 Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp Ser Asp 820 825 830 Ser Asp Ser Asp Ser Asp Ser Gly Leu Asp Asn Ser Ser Asp Lys Asn 835 840 845 Thr Lys Asp Lys Leu Pro Asp Thr Gly Ala Asn Glu Asp His Asp Ser 850 855 860 Lys Gly Thr Leu Leu Gly Ala Leu Phe Ala Gly Leu Gly Ala Leu Leu 865 870 875 880 Leu Gly Lys Arg Arg Lys Asn Arg Lys Asn Lys Asn 885 890 22 1973 PRT Staphylococcus epidermidis 22 Met Lys Glu Asn Lys Arg Lys Asn Asn Leu Asp Lys Asn Asn Thr Arg 1 5 10 15 Phe Ser Ile Arg Lys Tyr Gln Gly Tyr Gly Ala Thr Ser Val Ala Ile 20 25 30 Ile Gly Phe Ile Ile Ile Ser Cys Phe Ser Glu Ala Lys Ala Asp Ser 35 40 45 Asp Lys His Glu Ile Lys Ser His Gln Gln Ser Met Thr Asn His Leu 50 55 60 Thr Thr Leu Pro Ser Asp Asn Gln Glu Asn Thr Ser Asn Asn Glu Phe 65 70 75 80 Asn Asn Arg Asn His Asp Ile Ser His Leu Ser Leu Asn Lys Ser Ile 85 90 95 Gln Met Asp Glu Leu Lys Lys Leu Ile Lys Gln Tyr Lys Ala Ile Asn 100 105 110 Leu Asn Asp Lys Thr Glu Glu Ser Ile Lys Leu Phe Gln Ser Asp Leu 115 120 125 Val Gln Ala Glu Ser Leu Ile Asn Asn Pro Gln Ser Gln Gln His Val 130 135 140 Asp Ala Phe Tyr His Lys Phe Leu Asn Ser Ala Gly Lys Leu Arg Lys 145 150 155 160 Lys Glu Thr Val Ser Ile Lys His Glu Arg Ser Glu Ser Asn Thr Tyr 165 170 175 Arg Leu Gly Asp Glu Val Arg Ser Gln Thr Phe Ser His Ile Arg His 180 185 190 Lys Arg Asn Ala Val Ser Phe Arg Asn Ala Asp Gln Ser Asn Leu Ser 195 200 205 Thr Asp Pro Leu Lys Ala Asn Glu Ile Asn Pro Glu Ile Gln Asn Gly 210 215 220 Asn Phe Ser Gln Val Ser Gly Gly Pro Leu Pro Thr Ser Ser Lys Arg 225 230 235 240 Leu Thr Val Val Thr Asn Val Asp Asn Trp His Ser Tyr Ser Thr Asp 245 250 255 Pro Asn Pro Glu Tyr Pro Met Phe Tyr Thr Thr Thr Ala Val Asn Tyr 260 265 270 Pro Asn Phe Met Ser Asn Gly Asn Ala Pro Tyr Gly Val Ile Leu Gly 275 280 285 Arg Thr Thr Asp Gly Trp Asn Arg Asn Val Ile Asp Ser Lys Val Ala 290 295 300 Gly Ile Tyr Gln Asp Ile Asp Val Val Pro Gly Ser Glu Leu Asn Val 305 310 315 320 Asn Phe Ile Ser Thr Ser Pro Val Phe Ser Asp Gly Ala Ala Gly Ala 325 330 335 Lys Leu Lys Ile Ser Asn Val Glu Gln Asn Arg Val Leu Phe Asp Ser 340 345 350 Arg Leu Asn Gly Met Gly Pro Tyr Pro Thr Gly Lys Leu Ser Ala Met 355 360 365 Val Asn Ile Pro Asn Asp Ile Asn Arg Val Arg Ile Ser Phe Leu Pro 370 375 380 Val Ser Ser Thr Gly Arg Val Ser Val Gln Arg Ser Ser Arg Glu His 385 390 395 400 Gly Phe Gly Asp Asn Ser Ser Tyr Tyr His Gly Gly Ser Val Ser Asp 405 410 415 Val Arg Ile Asn Ser Gly Ser Tyr Val Val Ser Lys Val Thr Gln Arg 420 425 430 Glu Tyr Thr Thr Arg Pro Asn Ser Ser Asn Asp Thr Phe Ala Arg Ala 435 440 445 Thr Ile Asn Leu Ser Val Glu Asn Lys Gly His Asn Gln Ser Lys Asp 450 455 460 Thr Tyr Tyr Glu Val Ile Leu Pro Gln Asn Ser Arg Leu Ile Ser Thr 465 470 475 480 Arg Gly Gly Ser Gly Asn Tyr Asn Asn Ala Thr Asn Lys Leu Ser Ile 485 490 495 Arg Leu Asp Asn Leu Asn Pro Gly Asp Arg Arg Asp Ile Ser Tyr Thr 500 505 510 Val Asp Phe Glu Ser Ser Ser Pro Lys Leu Ile Asn Leu Asn Ala His 515 520 525 Leu Leu Tyr Lys Thr Asn Ala Thr Phe Arg Gly Asn Asp Gly Gln Arg 530 535 540 Thr Gly Asp Asn Ile Val Asp Leu Gln Ser Ile Ala Leu Leu Met Asn 545 550 555 560 Lys Asp Val Leu Glu Thr Glu Leu Asn Glu Ile Asp Lys Phe Ile Arg 565 570 575 Asp Leu Asn Glu Ala Asp Phe Thr Ile Asp Ser Trp Ser Ala Leu Gln 580 585 590 Glu Lys Met Thr Glu Gly Gly Asn Ile Leu Asn Glu Gln Gln Asn Gln 595 600 605 Val Ala Leu Glu Asn Gln Ala Ser Gln Glu Thr Ile Asn Asn Val Thr 610 615 620 Gln Ser Leu Glu Ile Leu Lys Asn Asn Leu Lys Tyr Lys Thr Pro Ser 625 630 635 640 Gln Pro Ile Ile Lys Ser Asn Asn Gln Ile Pro Asn Ile Thr Ile Ser 645 650 655 Pro Ala Asp Lys Ala Asp Lys Leu Thr Ile Thr Tyr Gln Asn Thr Asp 660 665 670 Asn Glu Ser Ala Ser Ile Ile Gly Asn Lys Leu Asn Asn Gln Trp Ser 675 680 685 Leu Asn Asn Asn Ile Pro Gly Ile Glu Ile Asp Met Gln Thr Gly Leu 690 695 700 Val Thr Ile Asp Tyr Lys Ala Val Tyr Pro Glu Ser Val Val Gly Ala 705 710 715 720 Asn Asp Lys Thr Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr 725 730 735 Met Pro Arg Lys Glu Ala Thr Pro Leu Ser Pro Ile Val Glu Ala Asn 740 745 750 Glu Glu Arg Val Asn Val Val Ile Ala Pro Asn Gly Glu Ala Thr Gln 755 760 765 Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr Leu Val 770 775 780 Ala Ser Lys Asn Gly Ser Ser Trp Thr Leu Asn Lys Gln Ile Asp Tyr 785 790 795 800 Val Asn Ile Glu Glu Asn Ser Gly Lys Val Thr Ile Gly Tyr Gln Ala 805 810 815 Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr Lys Gly Asn Ser 820 825 830 Asp Glu Ser Ala Glu Ser Arg Val Thr Met Pro Arg Lys Glu Ala Thr 835 840 845 Pro His Ser Pro Ile Val Glu Ala Asn Glu Glu His Val Asn Val Thr 850 855 860 Ile Ala Pro Asn Gly Glu Ala Thr Gln Ile Ala Ile Lys Tyr Arg Thr 865 870 875 880 Pro Asp Gly Gln Glu Thr Thr Leu Ile Ala Ser Lys Asn Gly Ser Ser 885 890 895 Trp Thr Leu Asn Lys Gln Ile Asp Tyr Val Asn Ile Glu Glu Asn Ser 900 905 910 Gly Lys Val Thr Ile Gly Tyr Gln Ala Val Gln Leu Glu Ser Glu Val 915 920 925 Ile Ala Thr Glu Thr Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg 930 935 940 Ile Thr Met Leu Arg Lys Glu Ala Thr Pro His Ser Pro Ile Val Glu 945 950 955 960 Ala Asn Glu Glu His Val Asn Val Thr Ile Ala Pro Asn Gly Glu Ala 965 970 975 Thr Gln Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr 980 985 990 Leu Val Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 995 1000 1005 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1010 1015 1020 Tyr Gln Ala Val Gln Pro Glu Ser Glu Ile Ile Ala Thr Glu Thr 1025 1030 1035 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1040 1045 1050 Arg Lys Glu Ala Thr Pro Ile Pro Pro Thr Leu Glu Ala Ser Val 1055 1060 1065 Gln Glu Ala Ser Val Thr Val Thr Pro Asn Glu Asn Ala Thr Lys 1070 1075 1080 Val Phe Ile Lys Tyr Leu Asp Ile Asn Asp Glu Ile Ser Thr Ile 1085 1090 1095 Ile Ala Ser Lys Ile Asn Gln Gln Trp Thr Leu Asn Lys Asp Asn 1100 1105 1110 Phe Gly Ile Lys Ile Asn Pro Leu Thr Gly Lys Val Ile Ile Ser 1115 1120 1125 Tyr Val Ala Val Gln Pro Glu Ser Asp Val Ile Ala Ile Glu Ser 1130 1135 1140 Gln Gly Asn Ser Asp Leu Ser Glu Glu Ser Arg Ile Ile Met Pro 1145 1150 1155 Thr Lys Glu Glu Pro Pro Glu Pro Pro Ile Leu Glu Ser Asp Ser 1160 1165 1170 Ile Glu Ala Lys Val Asn Ile Phe Pro Asn Asp Glu Ala Thr Arg 1175 1180 1185 Ile Val Ile Met Tyr Thr Ser Leu Glu Gly Gln Glu Ala Thr Leu 1190 1195 1200 Val Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 1205 1210 1215 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1220 1225 1230 Tyr Gln Ala Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr 1235 1240 1245 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Val Thr Met Pro 1250 1255 1260 Arg Lys Glu Ala Thr Pro His Ser Pro Ile Val Glu Thr Asn Glu 1265 1270 1275 Glu Arg Val Asn Val Val Ile Ala Pro Asn Gly Glu Ala Thr Gln 1280 1285 1290 Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Thr Thr Leu 1295 1300 1305 Ile Ala Ser Lys Asn Gly Ser Ser Trp Thr Leu Asn Lys Gln Ile 1310 1315 1320 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1325 1330 1335 Tyr Gln Ala Val Gln Pro Glu Ser Glu Ile Ile Ala Thr Glu Thr 1340 1345 1350 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1355 1360 1365 Arg Lys Glu Ala Ile Pro His Ser Pro Ile Val Glu Ala Asn Glu 1370 1375 1380 Glu His Val Asn Val Thr Ile Ala Pro Asn Gly Glu Thr Thr Gln 1385 1390 1395 Ile Ala Val Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr Leu 1400 1405 1410 Ile Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 1415 1420 1425 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1430 1435 1440 Tyr Gln Ala Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr 1445 1450 1455 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1460 1465 1470 Val Lys Glu Lys Thr Pro Ala Pro Pro Ile Ser Ile Ile Asn Glu 1475 1480 1485 Ser Asn Ala Ser Val Glu Ile Ile Pro Gln Val Asn Val Thr Gln 1490 1495 1500 Leu Ser Leu Gln Tyr Ile Asp Ala Lys Gly Gln Gln Gln Asn Leu 1505 1510 1515 Ile Ala Thr Leu Asn Gln Asn Gln Trp Thr Leu Asn Lys Asn Val 1520 1525 1530 Ser His Ile Thr Val Asp Lys Asn Thr Gly Lys Val Leu Ile Asn 1535 1540 1545 Tyr Gln Ala Val Tyr Pro Glu Ser Glu Val Ile Ala Arg Glu Ser 1550 1555 1560 Lys Gly Asn Ser Asp Ser Ser Asn Val Ser Met Val Ile Met Pro 1565 1570 1575 Arg Lys Thr Ala Thr Pro Lys Pro Pro Ile Ile Lys Val Asp Glu 1580 1585 1590 Met Asn Ala Ser Leu Ala Ile Ile Pro Tyr Lys Asn Asn Thr Ala 1595 1600 1605 Ile Asn Ile His Tyr Ile Asp Lys Lys Gly Ile Lys Ser Met Val 1610 1615 1620 Thr Ala Ile Lys Asn Asn Asp Gln Trp Gln Leu Asp Glu Lys Ile 1625 1630 1635 Lys Tyr Val Lys Ile Asp Ala Lys Thr Gly Thr Val Ile Ile Asn 1640 1645 1650 Tyr Gln Ile Val Gln Glu Asn Ser Glu Ile Ile Ala Thr Ala Ile 1655 1660 1665 Asn Gly Asn Ser Asp Lys Ser Glu Glu Val Lys Val Leu Met Pro 1670 1675 1680 Ile Lys Glu Phe Thr Pro Leu Ala Pro Leu Leu Glu Thr Asn Tyr 1685 1690 1695 Lys Lys Ala Thr Val Ser Ile Leu Pro Gln Ser Asn Ala Thr Lys 1700 1705 1710 Leu Asp Phe Lys Tyr Arg Asp Lys Lys Gly Asp Ser Lys Ile Ile 1715 1720 1725 Ile Val Lys Arg Phe Lys Asn Ile Trp Lys Ala Asn Glu Gln Ile 1730 1735 1740 Ser Gly Val Thr Ile Asn Pro Glu Phe Gly Gln Val Val Ile Asn 1745 1750 1755 Tyr Gln Ala Val Tyr Pro Glu Ser Asp Ile Leu Ala Ala Gln Tyr 1760 1765 1770 Val Gly Asn Ser Asp Ala Ser Glu Trp Ala Lys Val Lys Met Pro 1775 1780 1785 Lys Lys Glu Leu Ala Pro His Ser Pro Ser Leu Ile Tyr Asp Asn 1790 1795 1800 Arg Asn Asn Lys Ile Leu Ile Ala Pro Asn Ser Asn Ala Thr Glu 1805 1810 1815 Met Glu Leu Ser Tyr Val Asp Lys Asn Asn Gln Ser Leu Lys Val 1820 1825 1830 Lys Ala Leu Lys Ile Asn Asn Arg Trp Lys Phe Asp Ser Ser Val 1835 1840 1845 Ser Asn Ile Ser Ile Asn Pro Asn Thr Gly Lys Ile Val Leu Gln 1850 1855 1860 Pro Gln Phe Leu Leu Thr Asn Ser Lys Ile Ile Val Phe Ala Lys 1865 1870 1875 Lys Gly Asn Ser Asp Ala Ser Ile Ser Val Ser Leu Arg Val Pro 1880 1885 1890 Ala Val Lys Lys Ile Glu Leu Glu Pro Met Phe Asn Val Pro Val 1895 1900 1905 Leu Val Ser Leu Asn Lys Lys Arg Ile Gln Phe Asp Asp Cys Ser 1910 1915 1920 Gly Val Lys Asn Cys Leu Asn Lys Gln Ile Ser Lys Thr Gln Leu 1925 1930 1935 Pro Asp Thr Gly Tyr Ser Asp Lys Ala Ser Lys Ser Asn Ile Leu 1940 1945 1950 Ser Val Leu Leu Leu Gly Phe Gly Phe Leu Ser Tyr Ser Arg Lys 1955 1960 1965 Arg Lys Glu Lys Gln 1970 23 10203 PRT Staphylococcus epidermidis 23 Met Lys Ser Lys Pro Lys Leu Asn Gly Arg Asn Ile Cys Ser Phe Leu 1 5 10 15 Leu Ser Lys Cys Met Ser Tyr Ser Leu Ser Lys Leu Ser Thr Leu Lys 20 25 30 Thr Tyr Asn Phe Gln Ile Thr Ser Asn Asn Lys Glu Lys Thr Ser Arg 35 40 45 Ile Gly Val Ala Ile Ala Leu Asn Asn Arg Asp Lys Leu Gln Lys Phe 50 55 60 Ser Ile Arg Lys Tyr Ala Ile Gly Thr Phe Ser Thr Val Ile Ala Thr 65 70 75 80 Leu Val Phe Met Gly Ile Asn Thr Asn His Ala Ser Ala Asp Glu Leu 85 90 95 Asn Gln Asn Gln Lys Leu Ile Lys Gln Leu Asn Gln Thr Asp Asp Asp 100 105 110 Asp Ser Asn Thr His Ser Gln Glu Ile Glu Asn Asn Lys Gln Asn Ser 115 120 125 Ser Gly Lys Thr Glu Ser Leu Arg Ser Ser Thr Ser Gln Asn Gln Ala 130 135 140 Asn Ala Arg Leu Ser Asp Gln Phe Lys Asp Thr Asn Glu Thr Ser Gln 145 150 155 160 Gln Leu Pro Thr Asn Val Ser Asp Asp Ser Ile Asn Gln Ser His Ser 165 170 175 Glu Ala Asn Met Asn Asn Glu Pro Leu Lys Val Asp Asn Ser Thr Met 180 185 190 Gln Ala His Ser Lys Ile Val Ser Asp Ser Asp Gly Asn Ala Ser Glu 195 200 205 Asn Lys His His Lys Leu Thr Glu Asn Val Leu Ala Glu Ser Arg Ala 210 215 220 Ser Lys Asn Asp Lys Glu Lys Glu Asn Leu Gln Glu Lys Asp Lys Ser 225 230 235 240 Gln Gln Val His Pro Pro Leu Asp Lys Asn Ala Leu Gln Ala Phe Phe 245 250 255 Asp Ala Ser Tyr His Asn Tyr Arg Met Ile Asp Arg Asp Arg Ala Asp 260 265 270 Ala Thr Glu Tyr Gln Lys Val Lys Ser Thr Phe Asp Tyr Val Asn Asp 275 280 285 Leu Leu Gly Asn Asn Gln Asn Ile Pro Ser Glu Gln Leu Val Ser Ala 290 295 300 Tyr Gln Gln Leu Glu Lys Ala Leu Glu Leu Ala Arg Thr Leu Pro Gln 305 310 315 320 Gln Ser Thr Thr Glu Lys Arg Gly Arg Arg Ser Thr Arg Ser Val Val 325 330 335 Glu Asn Arg Ser Ser Arg Ser Asp Tyr Leu Asp Ala Arg Thr Glu Tyr 340 345 350 Tyr Val Ser Lys Asp Asp Asp Asp Ser Gly Phe Pro Pro Gly Thr Phe 355 360 365 Phe His Ala Ser Asn Arg Arg Trp Pro Tyr Asn Leu Pro Arg Ser Arg 370 375 380 Asn Ile Leu Arg Ala Ser Asp Val Gln Gly Asn Ala Tyr Ile Thr Thr 385 390 395 400 Lys Arg Leu Lys Asp Gly Tyr Gln Trp Asp Ile Leu Phe Asn Ser Asn 405 410 415 His Lys Gly His Glu Tyr Met Tyr Tyr Trp Phe Gly Leu Pro Ser Asp 420 425 430 Gln Thr Pro Thr Gly Pro Val Thr Phe Thr Ile Ile Asn Arg Asp Gly 435 440 445 Ser Ser Thr Ser Thr Gly Gly Val Gly Phe Gly Ser Gly Ala Pro Leu 450 455 460 Pro Gln Phe Trp Arg Ser Ala Gly Ala Ile Asn Ser Ser Val Ala Asn 465 470 475 480 Asp Phe Lys His Gly Ser Ala Thr Asn Tyr Ala Phe Tyr Asp Gly Val 485 490 495 Asn Asn Phe Ser Asp Phe Ala Arg Gly Gly Glu Leu Tyr Phe Asp Arg 500 505 510 Glu Gly Ala Thr Gln Thr Asn Lys Tyr Tyr Gly Asp Glu Asn Phe Ala 515 520 525 Leu Leu Asn Ser Glu Lys Pro Asp Gln Ile Arg Gly Leu Asp Thr Ile 530 535 540 Tyr Ser Phe Lys Gly Ser Gly Asp Val Ser Tyr Arg Ile Ser Phe Lys 545 550 555 560 Thr Gln Gly Ala Pro Thr Ala Arg Leu Tyr Tyr Ala Ala Gly Ala Arg 565 570 575 Ser Gly Glu Tyr Lys Gln Ala Thr Asn Tyr Asn Gln Leu Tyr Val Glu 580 585 590 Pro Tyr Lys Asn Tyr Arg Asn Arg Val Gln Ser Asn Val Gln Val Lys 595 600 605 Asn Arg Thr Leu His Leu Lys Arg Thr Ile Arg Gln Phe Asp Pro Thr 610 615 620 Leu Gln Arg Thr Thr Asp Val Pro Ile Leu Asp Ser Asp Gly Ser Gly 625 630 635 640 Ser Ile Asp Ser Val Tyr Asp Pro Leu Ser Tyr Val Lys Asn Val Thr 645 650 655 Gly Thr Val Leu Gly Ile Tyr Pro Ser Tyr Leu Pro Tyr Asn Gln Glu 660 665 670 Arg Trp Gln Gly Ala Asn Ala Met Asn Ala Tyr Gln Ile Glu Glu Leu 675 680 685 Phe Ser Gln Glu Asn Leu Gln Asn Ala Ala Arg Ser Gly Arg Pro Ile 690 695 700 Gln Phe Leu Val Gly Phe Asp Val Glu Asp Ser His His Asn Pro Glu 705 710 715 720 Thr Leu Leu Pro Val Asn Leu Tyr Val Lys Pro Glu Leu Lys His Thr 725 730 735 Ile Glu Leu Tyr His Asp Asn Glu Lys Gln Asn Arg Lys Glu Phe Ser 740 745 750 Val Ser Lys Arg Ala Gly His Gly Val Phe Gln Ile Met Ser Gly Thr 755 760 765 Leu His Asn Thr Val Gly Ser Gly Ile Leu Pro Tyr Gln Gln Glu Ile 770 775 780 Arg Ile Lys Leu Thr Ser Asn Glu Pro Ile Lys Asp Ser Glu Trp Ser 785 790 795 800 Ile Thr Gly Tyr Pro Asn Thr Leu Thr Leu Gln Asn Ala Val Gly Arg 805 810 815 Thr Asn Asn Ala Thr Glu Lys Asn Leu Ala Leu Val Gly His Ile Asp 820 825 830 Pro Gly Asn Tyr Phe Ile Thr Val Lys Phe Gly Asp Lys Val Glu Gln 835 840 845 Phe Glu Ile Arg Ser Lys Pro Thr Pro Pro Arg Ile Ile Thr Thr Ala 850 855 860 Asn Glu Leu Arg Gly Asn Ser Asn His Lys Pro Glu Ile Arg Val Thr 865 870 875 880 Asp Ile Pro Asn Asp Thr Thr Ala Lys Ile Lys Leu Val Met Gly Gly 885 890 895 Thr Asp Gly Asp His Asp Pro Glu Ile Asn Pro Tyr Thr Val Pro Glu 900 905 910 Asn Tyr Thr Val Val Ala Glu Ala Tyr His Asp Asn Asp Pro Ser Lys 915 920 925 Asn Gly Val Leu Thr Phe Arg Ser Ser Asp Tyr Leu Lys Asp Leu Pro 930 935 940 Leu Ser Gly Glu Leu Lys Ala Ile Val Tyr Tyr Asn Gln Tyr Val Gln 945 950 955 960 Ser Asn Phe Ser Asn Ser Val Pro Phe Ser Ser Asp Thr Thr Pro Pro 965 970 975 Thr Ile Asn Glu Pro Ala Gly Leu Val His Lys Tyr Tyr Arg Gly Asp 980 985 990 His Val Glu Ile Thr Leu Pro Val Thr Asp Asn Thr Gly Gly Ser Gly 995 1000 1005 Leu Arg Asp Val Asn Val Asn Leu Pro Gln Gly Trp Thr Lys Thr 1010 1015 1020 Phe Thr Ile Asn Pro Asn Asn Asn Thr Glu Gly Thr Leu Lys Leu 1025 1030 1035 Ile Gly Asn Ile Pro Ser Asn Glu Ala Tyr Asn Thr Thr Tyr His 1040 1045 1050 Phe Asn Ile Thr Ala Thr Asp Asn Ser Gly Asn Thr Thr Asn Pro 1055 1060 1065 Ala Lys Thr Phe Ile Leu Asn Val Gly Lys Leu Ala Asp Asp Leu 1070 1075 1080 Asn Pro Val Gly Leu Ser Arg Asp Gln Leu Gln Leu Val Thr Asp 1085 1090 1095 Pro Ser Ser Leu Ser Asn Ser Glu Arg Glu Glu Val Lys Arg Lys 1100 1105 1110 Ile Ser Glu Ala Asn Ala Asn Ile Arg Ser Tyr Leu Leu Gln Asn 1115 1120 1125 Asn Pro Ile Leu Ala Gly Val Asn Gly Asp Val Thr Phe Tyr Tyr 1130 1135 1140 Arg Asp Gly Ser Val Asp Val Ile Asp Ala Glu Asn Val Ile Thr 1145 1150 1155 Tyr Glu Pro Glu Arg Lys Ser Ile Phe Ser Glu Asn Gly Asn Thr 1160 1165 1170 Asn Lys Lys Glu Ala Val Ile Thr Ile Ala Arg Gly Gln Asn Tyr 1175 1180 1185 Thr Ile Gly Pro Asn Leu Arg Lys Tyr Phe Ser Leu Ser Asn Gly 1190 1195 1200 Ser Asp Leu Pro Asn Arg Asp Phe Thr Ser Ile Ser Ala Ile Gly 1205 1210 1215 Ser Leu Pro Ser Ser Ser Glu Ile Ser Arg Leu Asn Val Gly Asn 1220 1225 1230 Tyr Asn Tyr Arg Val Asn Ala Lys Asn Ala Tyr His Lys Thr Gln 1235 1240 1245 Gln Glu Leu Asn Leu Lys Leu Lys Ile Val Glu Val Asn Ala Pro 1250 1255 1260 Thr Gly Asn Asn Arg Val Tyr Arg Val Ser Thr Tyr Asn Leu Thr 1265 1270 1275 Asn Asp Glu Ile Asn Lys Ile Lys Gln Ala Phe Lys Ala Ala Asn 1280 1285 1290 Ser Gly Leu Asn Leu Asn Asp Asn Asp Ile Thr Val Ser Asn Asn 1295 1300 1305 Phe Asp His Arg Asn Val Ser Ser Val Thr Val Thr Ile Arg Lys 1310 1315 1320 Gly Asp Leu Ile Lys Glu Phe Ser Ser Asn Leu Asn Asn Met Asn 1325 1330 1335 Phe Leu Arg Trp Val Asn Ile Arg Asp Asp Tyr Thr Ile Ser Trp 1340 1345 1350 Thr Ser Ser Lys Ile Gln Gly Arg Asn Thr Asp Gly Gly Leu Glu 1355 1360 1365 Trp Ser Pro Asp His Lys Ser Leu Ile Tyr Lys Tyr Asp Ala Thr 1370 1375 1380 Leu Gly Arg Gln Ile Asn Thr Asn Asp Val Leu Thr Leu Leu Gln 1385 1390 1395 Ala Thr Ala Lys Asn Ser Asn Leu Arg Ser Asn Ile Asn Ser Asn 1400 1405 1410 Glu Lys Gln Leu Ala Glu Arg Gly Ser Asn Gly Tyr Ser Lys Ser 1415 1420 1425 Ile Ile Arg Asp Asp Gly Glu Lys Ser Tyr Leu Leu Asn Ser Asn 1430 1435 1440 Pro Ile Gln Val Leu Asp Leu Val Glu Pro Asp Asn Gly Tyr Gly 1445 1450 1455 Gly Arg Gln Val Ser His Ser Asn Val Ile Tyr Asn Glu Lys Asn 1460 1465 1470 Ser Ser Ile Val Asn Gly Gln Val Pro Glu Ala Asn Gly Ala Ser 1475 1480 1485 Ala Phe Asn Ile Asp Lys Val Val Lys Ala Asn Ala Ala Asn Asn 1490 1495 1500 Gly Ile Met Gly Val Ile Tyr Lys Ala Gln Leu Tyr Leu Ala Pro 1505 1510 1515 Tyr Ser Pro Lys Gly Tyr Ile Glu Lys Leu Gly Gln Asn Leu Ser 1520 1525 1530 Asn Thr Asn Asn Val Ile Asn Val Tyr Phe Val Pro Ser Asp Lys 1535 1540 1545 Val Asn Pro Ser Ile Thr Val Gly Asn Tyr Asp His His Thr Val 1550 1555 1560 Tyr Ser Gly Glu Thr Phe Lys Asn Thr Ile Asn Val Asn Asp Asn 1565 1570 1575 Tyr Gly Leu Asn Thr Val Ala Ser Thr Ser Asp Ser Ala Ile Thr 1580 1585 1590 Met Thr Arg Asn Asn Asn Glu Leu Val Gly Gln Ala Pro Asn Val 1595 1600 1605 Thr Asn Ser Thr Asn Lys Ile Val Lys Val Lys Ala Thr Asp Lys 1610 1615 1620 Ser Gly Asn Glu Ser Ile Val Ser Phe Thr Val Asn Ile Lys Pro 1625 1630 1635 Leu Asn Glu Lys Tyr Arg Ile Thr Thr Ser Ser Ser Asn Gln Thr 1640 1645 1650 Pro Val Arg Ile Ser Asn Ile Gln Asn Asn Ala Asn Leu Ser Ile 1655 1660 1665 Glu Asp Gln Asn Arg Val Lys Ser Ser Leu Ser Met Thr Lys Ile 1670 1675 1680 Leu Gly Thr Arg Asn Tyr Val Asn Glu Ser Asn Asn Asp Val Arg 1685 1690 1695 Ser Gln Val Val Ser Lys Val Asn Arg Ser Gly Asn Asn Ala Thr 1700 1705 1710 Val Asn Val Thr Thr Thr Phe Ser Asp Gly Thr Thr Asn Thr Ile 1715 1720 1725 Thr Val Pro Val Lys His Val Leu Leu Glu Val Val Pro Thr Thr 1730 1735 1740 Arg Thr Thr Val Arg Gly Gln Gln Phe Pro Thr Gly Lys Gly Thr 1745 1750 1755 Ser Pro Asn Asp Phe Phe Ser Leu Arg Thr Gly Gly Pro Val Asp 1760 1765 1770 Ala Arg Ile Val Trp Val Asn Asn Gln Gly Pro Asp Ile Asn Ser 1775 1780 1785 Asn Gln Ile Gly Arg Asp Leu Thr Leu His Ala Glu Ile Phe Phe 1790 1795 1800 Asp Gly Glu Thr Thr Pro Ile Arg Lys Asp Thr Thr Tyr Lys Leu 1805 1810 1815 Ser Gln Ser Ile Pro Lys Gln Ile Tyr Glu Thr Thr Ile Asn Gly 1820 1825 1830 Arg Phe Asn Ser Ser Gly Asp Ala Tyr Pro Gly Asn Phe Val Gln 1835 1840 1845 Ala Val Asn Gln Tyr Trp Pro Glu His Met Asp Phe Arg Trp Ala 1850 1855 1860 Gln Gly Ser Gly Thr Pro Ser Ser Arg Asn Ala Gly Ser Phe Thr 1865 1870 1875 Lys Thr Val Thr Val Val Tyr Gln Asn Gly Gln Thr Glu Asn Val 1880 1885 1890 Asn Val Leu Phe Lys Val Lys Pro Asn Lys Pro Val Ile Asp Ser 1895 1900 1905 Asn Ser Val Ile Ser Lys Gly Gln Leu Asn Gly Gln Gln Ile Leu 1910 1915 1920 Val Arg Asn Val Pro Gln Asn Ala Gln Val Thr Leu Tyr Gln Ser 1925 1930 1935 Asn Gly Thr Val Ile Pro Asn Thr Asn Thr Thr Ile Asp Ser Asn 1940 1945 1950 Gly Ile Ala Thr Val Thr Ile Gln Gly Thr Leu Pro Thr Gly Asn 1955 1960 1965 Ile Thr Ala Lys Thr Ser Met Thr Asn Asn Val Thr Tyr Thr Lys 1970 1975 1980 Gln Asn Ser Ser Gly Ile Ala Ser Asn Thr Thr Glu Asp Ile Ser 1985 1990 1995 Val Phe Ser Glu Asn Ser Asp Gln Val Asn Val Thr Ala Gly Met 2000 2005 2010 Gln Ala Lys Asn Asp Gly Ile Lys Ile Ile Lys Gly Thr Asn Tyr 2015 2020 2025 Asn Phe Asn Asp Phe Asn Ser Phe Ile Ser Asn Ile Pro Ala His 2030 2035 2040 Ser Thr Leu Thr Trp Asn Glu Glu Pro Asn Ser Trp Lys Asn Asn 2045 2050 2055 Ile Gly Thr Thr Thr Lys Thr Val Thr Val Thr Leu Pro Asn His 2060 2065 2070 Gln Gly Thr Arg Thr Val Asp Ile Pro Ile Thr Ile Tyr Pro Thr 2075 2080 2085 Val Thr Ala Lys Asn Pro Val Arg Asp Gln Lys Gly Arg Asn Leu 2090 2095 2100 Thr Asn Gly Thr Asp Val Tyr Asn Tyr Ile Ile Phe Glu Asn Asn 2105 2110 2115 Asn Arg Leu Gly Gly Thr Ala Ser Trp Lys Asp Asn Arg Gln Pro 2120 2125 2130 Asp Lys Asn Ile Ala Gly Val Gln Asn Leu Ile Ala Leu Val Asn 2135 2140 2145 Tyr Pro Gly Ile Ser Thr Pro Leu Glu Val Pro Val Lys Val Trp 2150 2155 2160 Val Tyr Asn Phe Asp Phe Thr Gln Pro Ile Tyr Lys Ile Gln Val 2165 2170 2175 Gly Asp Thr Phe Pro Lys Gly Thr Trp Ala Gly Tyr Tyr Lys His 2180 2185 2190 Leu Glu Asn Gly Glu Gly Leu Pro Ile Asp Gly Trp Lys Phe Tyr 2195 2200 2205 Trp Asn Gln Gln Ser Thr Gly Thr Thr Ser Asp Gln Trp Gln Ser 2210 2215 2220 Leu Ala Tyr Thr Arg Thr Pro Phe Val Lys Thr Gly Thr Tyr Asp 2225 2230 2235 Val Val Asn Pro Ser Asn Trp Gly Val Trp Gln Thr Ser Gln Ser 2240 2245 2250 Ala Lys Phe Ile Val Thr Asn Ala Lys Pro Asn Gln Pro Thr Ile 2255 2260 2265 Thr Gln Ser Lys Thr Gly Asp Val Thr Val Thr Pro Gly Ala Val 2270 2275 2280 Arg Asn Ile Leu Ile Ser Gly Thr Asn Asp Tyr Ile Gln Ala Ser 2285 2290 2295 Ala Asp Lys Ile Val Ile Asn Lys Asn Gly Asn Lys Leu Thr Thr 2300 2305 2310 Phe Val Lys Asn Asn Asp Gly Arg Trp Thr Val Glu Thr Gly Ser 2315 2320 2325 Pro Asp Ile Asn Gly Ile Gly Pro Thr Asn Asn Gly Thr Ala Ile 2330 2335 2340 Ser Leu Ser Arg Leu Ala Val Arg Pro Gly Asp Ser Ile Glu Ala 2345 2350 2355 Ile Ala Thr Glu Gly Ser Gly Glu Thr Ile Ser Thr Ser Ala Thr 2360 2365 2370 Ser Glu Ile Tyr Ile Val Lys Ala Pro Gln Pro Glu Gln Val Ala 2375 2380 2385 Thr His Thr Tyr Asp Asn Gly Thr Phe Asp Ile Leu Pro Asp Asn 2390 2395 2400 Ser Arg Asn Ser Leu Asn Pro Thr Glu Arg Val Glu Ile Asn Tyr 2405 2410 2415 Thr Glu Lys Leu Asn Gly Asn Glu Thr Gln Lys Ser Phe Thr Ile 2420 2425 2430 Thr Lys Asn Asn Asn Gly Lys Trp Thr Ile Asn Asn Lys Pro Asn 2435 2440 2445 Tyr Val Glu Phe Asn Gln Asp Asn Gly Lys Val Val Phe Ser Ala 2450 2455 2460 Asn Thr Ile Lys Pro Asn Ser Gln Ile Thr Ile Thr Pro Lys Ala 2465 2470 2475 Gly Gln Gly Asn Thr Glu Asn Thr Asn Pro Thr Val Ile Gln Ala 2480 2485 2490 Pro Ala Gln His Thr Leu Thr Ile Asn Glu Ile Val Lys Glu Gln 2495 2500 2505 Gly Gln Asn Val Thr Asn Asp Asp Ile Asn Asn Ala Val Gln Val 2510 2515 2520 Pro Asn Lys Asn Arg Val Ala Ile Lys Gln Gly Asn Ala Leu Pro 2525 2530 2535 Thr Asn Leu Ala Gly Gly Ser Thr Ser His Ile Pro Val Val Ile 2540 2545 2550 Tyr Tyr Ser Asp Gly Ser Ser Glu Glu Ala Thr Glu Thr Val Arg 2555 2560 2565 Thr Lys Val Asn Lys Thr Glu Leu Ile Asn Ala Arg Arg Arg Leu 2570 2575 2580 Asp Glu Glu Ile Ser Lys Glu Asn Lys Thr Pro Ser Ser Ile Arg 2585 2590 2595 Asn Phe Asp Gln Ala Met Asn Arg Ala Gln Ser Gln Ile Asn Thr 2600 2605 2610 Ala Lys Ser Asp Ala Asp Gln Val Ile Gly Thr Glu Phe Ala Thr 2615 2620 2625 Pro Gln Gln Val Asn Ser Ala Leu Ser Lys Val Gln Ala Ala Gln 2630 2635 2640 Asn Lys Ile Asn Glu Ala Lys Ala Leu Leu Gln Asn Lys Ala Asp 2645 2650 2655 Asn Ser Gln Leu Val Arg Ala Lys Glu Gln Leu Gln Gln Ser Ile 2660 2665 2670 Gln Pro Ala Ala Ser Thr Asp Gly Met Thr Gln Asp Ser Thr Arg 2675 2680 2685 Asn Tyr Lys Asn Lys Arg Gln Ala Ala Glu Gln Ala Ile Gln His 2690 2695 2700 Ala Asn Ser Val Ile Asn Asn Gly Asp Ala Thr Ser Gln Gln Ile 2705 2710 2715 Asn Asp Ala Lys Asn Thr Val Glu Gln Ala Gln Arg Asp Tyr Val 2720 2725 2730 Glu Ala Lys Ser Asn Leu Arg Ala Asp Lys Ser Gln Leu Gln Ser 2735 2740 2745 Ala Tyr Asp Thr Leu Asn Arg Asp Val Leu Thr Asn Asp Lys Lys 2750 2755 2760 Pro Ala Ser Val Arg Arg Tyr Asn Glu Ala Ile Ser Asn Ile Arg 2765 2770 2775 Lys Glu Leu Asp Thr Ala Lys Ala Asp Ala Ser Ser Thr Leu Arg 2780 2785 2790 Asn Thr Asn Pro Ser Val Glu Gln Val Arg Asp Ala Leu Asn Lys 2795 2800 2805 Ile Asn Thr Val Gln Pro Lys Val Asn Gln Ala Ile Ala Leu Leu 2810 2815 2820 Gln Pro Lys Glu Asn Asn Ser Glu Leu Val Gln Ala Lys Lys Arg 2825 2830 2835 Leu Gln Asp Ala Val Asn Asp Ile Pro Gln Thr Gln Gly Met Thr 2840 2845 2850 Gln Gln Thr Ile Asn Asn Tyr Asn Asp Lys Gln Arg Glu Ala Glu 2855 2860 2865 Arg Ala Leu Thr Ser Ala Gln Arg Val Ile Asp Asn Gly Asp Ala 2870 2875 2880 Thr Thr Gln Glu Ile Thr Ser Glu Lys Ser Lys Val Glu Gln Ala 2885 2890 2895 Met Gln Ala Leu Thr Asn Ala Lys Ser Asn Leu Arg Ala Asp Lys 2900 2905 2910 Asn Glu Leu Gln Thr Ala Tyr Asn Lys Leu Ile Glu Asn Val Ser 2915 2920 2925 Thr Asn Gly Lys Lys Pro Ala Ser Ile Arg Gln Tyr Glu Thr Ala 2930 2935 2940 Lys Ala Arg Ile Gln Asn Gln Ile Asn Asp Ala Lys Asn Glu Ala 2945 2950 2955 Glu Arg Ile Leu Gly Asn Asp Asn Pro Gln Val Ser Gln Val Thr 2960 2965 2970 Gln Ala Leu Asn Lys Ile Lys Ala Ile Gln Pro Lys Leu Thr Glu 2975 2980 2985 Ala Ile Asn Met Leu Gln Asn Lys Glu Asn Asn Thr Glu Leu Val 2990 2995 3000 Asn Ala Lys Asn Arg Leu Glu Asn Ala Val Asn Asp Thr Asp Pro 3005 3010 3015 Thr His Gly Met Thr Gln Glu Thr Ile Asn Asn Tyr Asn Ala Lys 3020 3025 3030 Lys Arg Glu Ala Gln Asn Glu Ile Gln Lys Ala Asn Met Ile Ile 3035 3040 3045 Asn Asn Gly Asp Ala Thr Ala Gln Asp Ile Ser Ser Glu Lys Ser 3050 3055 3060 Lys Val Glu Gln Val Leu Gln Ala Leu Gln Asn Ala Lys Asn Asp 3065 3070 3075 Leu Arg Ala Asp Lys Arg Glu Leu Gln Thr Ala Tyr Asn Lys Leu 3080 3085 3090 Ile Gln Asn Val Asn Thr Asn Gly Lys Lys Pro Ser Ser Ile Gln 3095 3100 3105 Asn Tyr Lys Ser Ala Arg Arg Asn Ile Glu Asn Gln Tyr Asn Thr 3110 3115 3120 Ala Lys Asn Glu Ala His Asn Val Leu Glu Asn Thr Asn Pro Thr 3125 3130 3135 Val Asn Ala Val Glu Asp Ala Leu Arg Lys Ile Asn Ala Ile Gln 3140 3145 3150 Pro Glu Val Thr Lys Ala Ile Asn Ile Leu Gln Asp Lys Glu Asp 3155 3160 3165 Asn Ser Glu Leu Val Arg Ala Lys Glu Lys Leu Asp Gln Ala Ile 3170 3175 3180 Asn Ser Gln Pro Ser Leu Asn Gly Met Thr Gln Glu Ser Ile Asn 3185 3190 3195 Asn Tyr Thr Thr Lys Arg Arg Glu Ala Gln Asn Ile Ala Ser Ser 3200 3205 3210 Ala Asp Thr Ile Ile Asn Asn Gly Asp Ala Ser Ile Glu Gln Ile 3215 3220 3225 Thr Glu Asn Lys Ile Arg Val Glu Glu Ala Thr Asn Ala Leu Asn 3230 3235 3240 Glu Ala Lys Gln His Leu Thr Ala Asp Thr Thr Ser Leu Lys Thr 3245 3250 3255 Glu Val Arg Lys Leu Ser Arg Arg Gly Asp Thr Asn Asn Lys Lys 3260 3265 3270 Pro Ser Ser Val Ser Ala Tyr Asn Asn Thr Ile His Ser Leu Gln 3275 3280 3285 Ser Glu Ile Thr Gln Thr Glu Asn Arg Ala Asn Thr Ile Ile Asn 3290 3295 3300 Lys Pro Ile Arg Ser Val Glu Glu Val Asn Asn Ala Leu His Glu 3305 3310 3315 Val Asn Gln Leu Asn Gln Arg Leu Thr Asp Thr Ile Asn Leu Leu 3320 3325 3330 Gln Pro Leu Ala Asn Lys Glu Ser Leu Lys Glu Ala Arg Asn Arg 3335 3340 3345 Leu Glu Ser Lys Ile Asn Glu Thr Val Gln Thr Asp Gly Met Thr 3350 3355 3360 Gln Gln Ser Val Glu Asn Tyr Lys Gln Ala Lys Ile Lys Ala Gln 3365 3370 3375 Asn Glu Ser Ser Ile Ala Gln Thr Leu Ile Asn Asn Gly Asp Ala 3380 3385 3390 Ser Asp Gln Glu Val Ser Thr Glu Ile Glu Lys Leu Asn Gln Lys 3395 3400 3405 Leu Ser Glu Leu Thr Asn Ser Ile Asn His Leu Thr Val Asn Lys 3410 3415 3420 Glu Pro Leu Glu Thr Ala Lys Asn Gln Leu Gln Ala Asn Ile Asp 3425 3430 3435 Gln Lys Pro Ser Thr Asp Gly Met Thr Gln Gln Ser Val Gln Ser 3440 3445 3450 Tyr Glu Arg Lys Leu Gln Glu Ala Lys Asp Lys Ile Asn Ser Ile 3455 3460 3465 Asn Asn Val Leu Ala Asn Asn Pro Asp Val Asn Ala Ile Arg Thr 3470 3475 3480 Asn Lys Val Glu Thr Glu Gln Ile Asn Asn Glu Leu Thr Gln Ala 3485 3490 3495 Lys Gln Gly Leu Thr Val Asp Lys Gln Pro Leu Ile Asn Ala Lys 3500 3505 3510 Thr Ala Leu Gln Gln Ser Leu Asp Asn Gln Pro Ser Thr Thr Gly 3515 3520 3525 Met Thr Glu Ala Thr Ile Gln Asn Tyr Asn Ala Lys Arg Gln Lys 3530 3535 3540 Ala Glu Gln Val Ile Gln Asn Ala Asn Lys Ile Ile Glu Asn Ala 3545 3550 3555 Gln Pro Ser Val Gln Gln Val Ser Asp Glu Lys Ser Lys Val Glu 3560 3565 3570 Gln Ala Leu Ser Glu Leu Asn Asn Ala Lys Ser Ala Leu Arg Ala 3575 3580 3585 Asp Lys Gln Glu Leu Gln Gln Ala Tyr Asn Gln Leu Ile Gln Pro 3590 3595 3600 Thr Asp Leu Asn Asn Lys Lys Pro Ala Ser Ile Thr Ala Tyr Asn 3605 3610 3615 Gln Arg Tyr Gln Gln Phe Ser Asn Glu Leu Asn Ser Thr Lys Thr 3620 3625 3630 Asn Thr Asp Arg Ile Leu Lys Glu Gln Asn Pro Ser Val Ala Asp 3635 3640 3645 Val Asn Asn Ala Leu Asn Lys Val Arg Glu Val Gln Gln Lys Leu 3650 3655 3660 Asn Glu Ala Arg Ala Leu Leu Gln Asn Lys Glu Asp Asn Ser Ala 3665 3670 3675 Leu Val Arg Ala Lys Glu Gln Leu Gln Gln Ala Val Asp Gln Val 3680 3685 3690 Pro Ser Thr Glu Gly Met Thr Gln Gln Thr Lys Asp Asp Tyr Asn 3695 3700 3705 Ser Lys Gln Gln Ala Ala Gln Gln Glu Ile Ser Lys Ala Gln Gln 3710 3715 3720 Val Ile Asp Asn Gly Asp Ala Thr Thr Gln Gln Ile Ser Asn Ala 3725 3730 3735 Lys Thr Asn Val Glu Arg Ala Leu Glu Ala Leu Asn Asn Ala Lys 3740 3745 3750 Thr Gly Leu Arg Ala Asp Lys Glu Glu Leu Gln Asn Ala Tyr Asn 3755 3760 3765 Gln Leu Thr Gln Asn Ile Asp Thr Ser Gly Lys Thr Pro Ala Ser 3770 3775 3780 Ile Arg Lys Tyr Asn Glu Ala Lys Ser Arg Ile Gln Thr Gln Ile 3785 3790 3795 Asp Ser Ala Lys Asn Glu Ala Asn Ser Ile Leu Thr Asn Asp Asn 3800 3805 3810 Pro Gln Val Ser Gln Val Thr Ala Ala Leu Asn Lys Ile Lys Ala 3815 3820 3825 Val Gln Pro Glu Leu Asp Lys Ala Ile Ala Met Leu Lys Asn Lys 3830 3835 3840 Glu Asn Asn Asn Ala Leu Val Gln Ala Lys Gln Gln Leu Gln Gln 3845 3850 3855 Ile Val Asn Glu Val Asp Pro Thr Gln Gly Met Thr Thr Asp Thr 3860 3865 3870 Ala Asn Asn Tyr Lys Ser Lys Lys Arg Glu Ala Glu Asp Glu Ile 3875 3880 3885 Gln Lys Ala Gln Gln Ile Ile Asn Asn Gly Asp Ala Thr Glu Gln 3890 3895 3900 Gln Ile Thr Asn Glu Thr Asn Arg Val Asn Gln Ala Ile Asn Ala 3905 3910 3915 Ile Asn Lys Ala Lys Asn Asp Leu Arg Ala Asp Lys Ser Gln Leu 3920 3925 3930 Glu Asn Ala Tyr Asn Gln Leu Ile Gln Asn Val Asp Thr Asn Gly 3935 3940 3945 Lys Lys Pro Ala Ser Ile Gln Gln Tyr Gln Ala Ala Arg Gln Ala 3950 3955 3960 Ile Glu Thr Gln Tyr Asn Asn Ala Lys Ser Glu Ala His Gln Ile 3965 3970 3975 Leu Glu Asn Ser Asn Pro Ser Val Asn Glu Val Ala Gln Ala Leu 3980 3985 3990 Gln Lys Val Glu Ala Val Gln Leu Lys Val Asn Asp Ala Ile His 3995 4000 4005 Ile Leu Gln Asn Lys Glu Asn Asn Ser Ala Leu Val Thr Ala Lys 4010 4015 4020 Asn Gln Leu Gln Gln Ser Val Asn Asp Gln Pro Leu Thr Thr Gly 4025 4030 4035 Met Thr Gln Asp Ser Ile Asn Asn Tyr Glu Ala Lys Arg Asn Glu 4040 4045 4050 Ala Gln Ser Ala Ile Arg Asn Ala Glu Ala Val Ile Asn Asn Gly 4055 4060 4065 Asp Ala Thr Ala Lys Gln Ile Ser Asp Glu Lys Ser Lys Val Glu 4070 4075 4080 Gln Ala Leu Ala His Leu Asn Asp Ala Lys Gln Gln Leu Thr Ala 4085 4090 4095 Asp Thr Thr Glu Leu Gln Thr Ala Val Gln Gln Leu Asn Arg Arg 4100 4105 4110 Gly Asp Thr Asn Asn Lys Lys Pro Arg Ser Ile Asn Ala Tyr Asn 4115 4120 4125 Lys Ala Ile Gln Ser Leu Glu Thr Gln Ile Thr Ser Ala Lys Asp 4130 4135 4140 Asn Ala Asn Ala Val Ile Gln Lys Pro Ile Arg Thr Val Gln Glu 4145 4150 4155 Val Asn Asn Ala Leu Gln Gln Val Asn Gln Leu Asn Gln Gln Leu 4160 4165 4170 Thr Glu Ala Ile Asn Gln Leu Gln Pro Leu Ser Asn Asn Asp Ala 4175 4180 4185 Leu Lys Ala Ala Arg Leu Asn Leu Glu Asn Lys Ile Asn Gln Thr 4190 4195 4200 Val Gln Thr Asp Gly Met Thr Gln Gln Ser Ile Glu Ala Tyr Gln 4205 4210 4215 Asn Ala Lys Arg Val Ala Gln Asn Glu Ser Asn Thr Ala Leu Ala 4220 4225 4230 Leu Ile Asn Asn Gly Asp Ala Asp Glu Gln Gln Ile Thr Thr Glu 4235 4240 4245 Thr Asp Arg Val Asn Gln Gln Thr Thr Asn Leu Thr Gln Ala Ile 4250 4255 4260 Asn Gly Leu Thr Val Asn Lys Glu Pro Leu Glu Thr Ala Lys Thr 4265 4270 4275 Ala Leu Gln Asn Asn Ile Asp Gln Val Pro Ser Thr Asp Gly Met 4280 4285 4290 Thr Gln Gln Ser Val Ala Asn Tyr Asn Gln Lys Leu Gln Ile Ala 4295 4300 4305 Lys Asn Glu Ile Asn Thr Ile Asn Asn Val Leu Ala Asn Asn Pro 4310 4315 4320 Asp Val Asn Ala Ile Lys Thr Asn Lys Ala Glu Ala Glu Arg Ile 4325 4330 4335 Ser Asn Asp Leu Thr Gln Ala Lys Asn Asn Leu Gln Val Asp Thr 4340 4345 4350 Gln Pro Leu Glu Lys Ile Lys Arg Gln Leu Gln Asp Glu Ile Asp 4355 4360 4365 Gln Gly Thr Asn Thr Asp Gly Met Thr Gln Asp Ser Val Asp Asn 4370 4375 4380 Tyr Asn Asp Ser Leu Ser Ala Ala Ile Ile Glu Lys Gly Lys Val 4385 4390 4395 Asn Lys Leu Leu Lys Arg Asn Pro Thr Val Glu Gln Val Lys Glu 4400 4405 4410 Ser Val Ala Asn Ala Gln Gln Val Ile Gln Asp Leu Gln Asn Ala 4415 4420 4425 Arg Thr Ser Leu Val Pro Asp Lys Thr Gln Leu Gln Glu Ala Lys 4430 4435 4440 Asn Arg Leu Glu Asn Ser Ile Asn Gln Gln Thr Asp Thr Asp Gly 4445 4450 4455 Met Thr Gln Asp Ser Leu Asn Asn Tyr Asn Asp Lys Leu Ala Lys 4460 4465 4470 Ala Arg Gln Asn Leu Glu Lys Ile Ser Lys Val Leu Gly Gly Gln 4475 4480 4485 Pro Thr Val Ala Glu Ile Arg Gln Asn Thr Asp Glu Ala Asn Ala 4490 4495 4500 His Lys Gln Ala Leu Asp Thr Ala Arg Ser Gln Leu Thr Leu Asn 4505 4510 4515 Arg Glu Pro Tyr Ile Asn His Ile Asn Asn Glu Ser His Leu Asn 4520 4525 4530 Asn Ala Gln Lys Asp Asn Phe Lys Ala Gln Val Asn Ser Ala Pro 4535 4540 4545 Asn His Asn Thr Leu Glu Thr Ile Lys Asn Lys Ala Asp Thr Leu 4550 4555 4560 Asn Gln Ser Met Thr Ala Leu Ser Glu Ser Ile Ala Asp Tyr Glu 4565 4570 4575 Asn Gln Lys Gln Gln Glu Asn Tyr Leu Asp Ala Ser Asn Asn Lys 4580 4585 4590 Arg Gln Asp Tyr Asp Asn Ala Val Asn Ala Ala Lys Gly Ile Leu 4595 4600 4605 Asn Gln Thr Gln Ser Pro Thr Met Ser Ala Asp Val Ile Asp Gln 4610 4615 4620 Lys Ala Glu Asp Val Lys Arg Thr Lys Thr Ala Leu Asp Gly Asn 4625 4630 4635 Gln Arg Leu Glu Val Ala Lys Gln Gln Ala Leu Asn His Leu Asn 4640 4645 4650 Thr Leu Asn Asp Leu Asn Asp Ala Gln Arg Gln Thr Leu Thr Asp 4655 4660 4665 Thr Ile Asn His Ser Pro Asn Ile Asn Ser Val Asn Gln Ala Lys 4670 4675 4680 Glu Lys Ala Asn Thr Val Asn Thr Ala Met Thr Gln Leu Lys Gln 4685 4690 4695 Thr Ile Ala Asn Tyr Asp Asp Glu Leu His Asp Gly Asn Tyr Ile 4700 4705 4710 Asn Ala Asp Lys Asp Lys Lys Asp Ala Tyr Asn Asn Ala Val Asn 4715 4720 4725 Asn Ala Lys Gln Leu Ile Asn Gln Ser Asp Ala Asn Gln Ala Gln 4730 4735 4740 Leu Asp Pro Ala Glu Ile Asn Lys Val Thr Gln Arg Val Asn Thr 4745 4750 4755 Thr Lys Asn Asp Leu Asn Gly Asn Asp Lys Leu Ala Glu Ala Lys 4760 4765 4770 Arg Asp Ala Asn Thr Thr Ile Asp Gly Leu Thr Tyr Leu Asn Glu 4775 4780 4785 Ala Gln Arg Asn Lys Ala Lys Glu Asn Val Gly Lys Ala Ser Thr 4790 4795 4800 Lys Thr Asn Ile Thr Ser Gln Leu Gln Asp Tyr Asn Gln Leu Asn 4805 4810 4815 Ile Ala Met Gln Ala Leu Arg Asn Ser Val Asn Asp Val Asn Asn 4820 4825 4830 Val Lys Ala Asn Ser Asn Tyr Ile Asn Glu Asp Asn Gly Pro Lys 4835 4840 4845 Glu Ala Tyr Asn Gln Ala Val Thr His Ala Gln Thr Leu Ile Asn 4850 4855 4860 Ala Gln Ser Asn Pro Glu Met Ser Arg Asp Val Val Asn Gln Lys 4865 4870 4875 Thr Gln Ala Val Asn Thr Ala His Gln Asn Leu His Gly Gln Gln 4880 4885 4890 Lys Leu Glu Gln Ala Gln Ser Ser Ala Asn Thr Glu Ile Gly Asn 4895 4900 4905 Leu Pro Asn Leu Thr Asn Thr Gln Lys Ala Lys Glu Lys Glu Leu 4910 4915 4920 Val Asn Ser Lys Gln Thr Arg Thr Glu Val Gln Glu Gln Leu Asn 4925 4930 4935 Gln Ala Lys Ser Leu Asp Ser Ser Met Gly Thr Leu Lys Ser Leu 4940 4945 4950 Val Ala Lys Gln Pro Thr Val Gln Lys Thr Ser Val Tyr Ile Asn 4955 4960 4965 Glu Asp Gln Pro Glu Gln Ser Ala Tyr Asn Asp Ser Ile Thr Met 4970 4975 4980 Gly Gln Thr Ile Ile Asn Lys Thr Ala Asp Pro Val Leu Asp Lys 4985 4990 4995 Thr Leu Val Asp Asn Ala Ile Ser Asn Ile Ser Thr Lys Glu Asn 5000 5005 5010 Ala Leu His Gly Glu Gln Lys Leu Thr Thr Ala Lys Thr Glu Ala 5015 5020 5025 Ile Asn Ala Leu Asn Thr Leu Ala Asp Leu Asn Thr Pro Gln Lys 5030 5035 5040 Glu Ala Ile Lys Thr Ala Ile Asn Thr Ala His Thr Arg Thr Asp 5045 5050 5055 Val Thr Ala Glu Gln Ser Lys Ala Asn Gln Ile Asn Ser Ala Met 5060 5065 5070 His Thr Leu Arg Gln Asn Ile Ser Asp Asn Glu Ser Val Thr Asn 5075 5080 5085 Glu Ser Asn Tyr Ile Asn Ala Glu Pro Glu Lys Gln His Ala Phe 5090 5095 5100 Thr Glu Ala Leu Asn Asn Ala Lys Glu Ile Val Asn Glu Gln Gln 5105 5110 5115 Ala Thr Leu Asp Ala Asn Ser Ile Asn Gln Lys Ala Gln Ala Ile 5120 5125 5130 Leu Thr Thr Lys Asn Ala Leu Asp Gly Glu Glu Gln Leu Arg Arg 5135 5140 5145 Ala Lys Glu Asn Ala Asp Gln Glu Ile Asn Thr Leu Asn Gln Leu 5150 5155 5160 Thr Asp Ala Gln Arg Asn Ser Glu Lys Gly Leu Val Asn Ser Ser 5165 5170 5175 Gln Thr Arg Thr Glu Val Ala Ser Gln Leu Ala Lys Ala Lys Glu 5180 5185 5190 Leu Asn Lys Val Met Glu Gln Leu Asn His Leu Ile Asn Gly Lys 5195 5200 5205 Asn Gln Met Ile Asn Ser Ser Lys Phe Ile Asn Glu Asp Ala Asn 5210 5215 5220 Gln Gln Gln Ala Tyr Ser Asn Ala Ile Ala Ser Ala Glu Ala Leu 5225 5230 5235 Lys Asn Lys Ser Gln Asn Pro Glu Leu Asp Lys Val Thr Ile Glu 5240 5245 5250 Gln Ala Ile Asn Asn Ile Asn Ser Ala Ile Asn Asn Leu Asn Gly 5255 5260 5265 Glu Ala Lys Leu Thr Lys Ala Lys Glu Asp Ala Val Ala Ser Ile 5270 5275 5280 Asn Asn Leu Ser Gly Leu Thr Asn Glu Gln Lys Pro Lys Glu Asn 5285 5290 5295 Gln Ala Val Asn Gly Ala Gln Thr Arg Asp Gln Val Ala Asn Lys 5300 5305 5310 Leu Arg Asp Ala Glu Ala Leu Asp Gln Ser Met Gln Thr Leu Arg 5315 5320 5325 Asp Leu Val Asn Asn Gln Asn Ala Ile His Ser Thr Ser Asn Tyr 5330 5335 5340 Phe Asn Glu Asp Ser Thr Gln Lys Asn Thr Tyr Asp Asn Ala Ile 5345 5350 5355 Asp Asn Gly Ser Thr Tyr Ile Thr Gly Gln His Asn Pro Glu Leu 5360 5365 5370 Asn Lys Ser Thr Ile Asp Gln Thr Ile Ser Arg Ile Asn Thr Ala 5375 5380 5385 Lys Asn Asp Leu His Gly Val Glu Lys Leu Gln Arg Asp Lys Gly 5390 5395 5400 Thr Ala Asn Gln Glu Ile Gly Gln Leu Gly Tyr Leu Asn Asp Pro 5405 5410 5415 Gln Lys Ser Gly Glu Glu Ser Leu Val Asn Gly Ser Asn Thr Arg 5420 5425 5430 Ser Glu Val Glu Glu His Leu Asn Glu Ala Lys Ser Leu Asn Asn 5435 5440 5445 Ala Met Lys Gln Leu Arg Asp Lys Val Ala Glu Lys Thr Asn Val 5450 5455 5460 Lys Gln Ser Ser Asp Tyr Ile Asn Asp Ser Thr Glu His Gln Arg 5465 5470 5475 Gly Tyr Asp Gln Ala Leu Gln Glu Ala Glu Asn Ile Ile Asn Glu 5480 5485 5490 Ile Gly Asn Pro Thr Leu Asn Lys Ser Glu Ile Glu Gln Lys Leu 5495 5500 5505 Gln Gln Leu Thr Asp Ala Gln Asn Ala Leu Gln Gly Ser His Leu 5510 5515 5520 Leu Glu Glu Ala Lys Asn Asn Ala Ile Thr Gly Ile Asn Lys Leu 5525 5530 5535 Thr Ala Leu Asn Asp Ala Gln Arg Gln Lys Ala Ile Glu Asn Val 5540 5545 5550 Gln Ala Gln Gln Thr Ile Pro Ala Val Asn Gln Gln Leu Thr Leu 5555 5560 5565 Asp Arg Glu Ile Asn Thr Ala Met Gln Ala Leu Arg Asp Lys Val 5570 5575 5580 Gly Gln Gln Asn Asn Val His Gln Gln Ser Asn Tyr Phe Asn Glu 5585 5590 5595 Asp Glu Gln Pro Lys His Asn Tyr Asp Asn Ser Val Gln Ala Gly 5600 5605 5610 Gln Thr Ile Ile Asp Lys Leu Gln Asp Pro Ile Met Asn Lys Asn 5615 5620 5625 Glu Ile Glu Gln Ala Ile Asn Gln Ile Asn Thr Thr Gln Thr Ala 5630 5635 5640 Leu Ser Gly Glu Asn Lys Leu His Thr Asp Gln Glu Ser Thr Asn 5645 5650 5655 Arg Gln Ile Glu Gly Leu Ser Ser Leu Asn Thr Ala Gln Ile Asn 5660 5665 5670 Ala Glu Lys Asp Leu Val Asn Gln Ala Lys Thr Arg Thr Asp Val 5675 5680 5685 Ala Gln Lys Leu Ala Ala Ala Lys Glu Ile Asn Ser Ala Met Ser 5690 5695 5700 Asn Leu Arg Asp Gly Ile Gln Asn Lys Glu Asp Ile Lys Arg Ser 5705 5710 5715 Ser Ala Tyr Ile Asn Ala Asp Pro Thr Lys Val Thr Ala Tyr Asp 5720 5725 5730 Gln Ala Leu Gln Asn Ala Glu Asn Ile Ile Asn Ala Thr Pro Asn 5735 5740 5745 Val Glu Leu Asn Lys Ala Thr Ile Glu Gln Ala Leu Ser Arg Val 5750 5755 5760 Gln Gln Ala Gln Gln Asp Leu Asp Gly Val Gln Gln Leu Ala Asn 5765 5770 5775 Ala Lys Gln Gln Ala Thr Gln Thr Val Asn Gly Leu Asn Ser Leu 5780 5785 5790 Asn Asp Gly Gln Lys Arg Glu Leu Asn Leu Leu Ile Asn Ser Ala 5795 5800 5805 Asn Thr Arg Thr Lys Val Gln Glu Glu Leu Asn Lys Ala Thr Glu 5810 5815 5820 Leu Asn His Ala Met Glu Ala Leu Arg Asn Ser Val Gln Asn Val 5825 5830 5835 Asp Gln Val Lys Gln Ser Ser Asn Tyr Val Asn Glu Asp Gln Pro 5840 5845 5850 Glu Gln His Asn Tyr Asp Asn Ala Val Asn Glu Ala Gln Ala Thr 5855 5860 5865 Ile Asn Asn Asn Ala Gln Pro Val Leu Asp Lys Leu Ala Ile Glu 5870 5875 5880 Arg Leu Thr Gln Thr Val Asn Thr Thr Lys Asp Ala Leu His Gly 5885 5890 5895 Ala Gln Lys Leu Thr Gln Asp Gln Gln Ala Ala Glu Thr Gly Ile 5900 5905 5910 Arg Gly Leu Thr Ser Leu Asn Glu Pro Gln Lys Asn Ala Glu Val 5915 5920 5925 Ala Lys Val Thr Ala Ala Thr Thr Arg Asp Glu Val Arg Asn Ile 5930 5935 5940 Arg Gln Glu Ala Thr Thr Leu Asp Thr Ala Met Leu Gly Leu Arg 5945 5950 5955 Lys Ser Ile Lys Asp Lys Asn Asp Thr Lys Asn Ser Ser Lys Tyr 5960 5965 5970 Ile Asn Glu Asp His Asp Gln Gln Gln Ala Tyr Asp Asn Ala Val 5975 5980 5985 Asn Asn Ala Gln Gln Val Ile Asp Glu Thr Gln Ala Thr Leu Ser 5990 5995 6000 Ser Asp Thr Ile Asn Gln Leu Ala Asn Ala Val Thr Gln Ala Lys 6005 6010 6015 Ser Asn Leu His Gly Asp Thr Lys Leu Gln His Asp Lys Asp Ser 6020 6025 6030 Ala Lys Gln Thr Ile Ala Gln Leu Gln Asn Leu Asn Ser Ala Gln 6035 6040 6045 Lys His Met Glu Asp Ser Leu Ile Asp Asn Glu Ser Thr Arg Thr 6050 6055 6060 Gln Val Gln His Asp Leu Thr Glu Ala Gln Ala Leu Asp Gly Leu 6065 6070 6075 Met Gly Ala Leu Lys Glu Ser Ile Lys Asp Tyr Thr Asn Ile Val 6080 6085 6090 Ser Asn Gly Asn Tyr Ile Asn Ala Glu Pro Ser Lys Lys Gln Ala 6095 6100 6105 Tyr Asp Ala Ala Val Gln Asn Ala Gln Asn Ile Ile Asn Gly Thr 6110 6115 6120 Asn Gln Pro Thr Ile Asn Lys Gly Asn Val Thr Thr Ala Thr Gln 6125 6130 6135 Thr Val Lys Asn Thr Lys Asp Ala Leu Asp Gly Asp His Arg Leu 6140 6145 6150 Glu Glu Ala Lys Asn Asn Ala Asn Gln Thr Ile Arg Asn Leu Ser 6155 6160 6165 Asn Leu Asn Asn Ala Gln Lys Asp Ala Glu Lys Asn Leu Val Asn 6170 6175 6180 Ser Ala Ser Thr Leu Glu Gln Val Gln Gln Asn Leu Gln Thr Ala 6185 6190 6195 Gln Gln Leu Asp Asn Ala Met Gly Glu Leu Arg Gln Ser Ile Ala 6200 6205 6210 Lys Lys Asp Gln Val Lys Ala Asp Ser Lys Tyr Leu Asn Glu Asp 6215 6220 6225 Pro Gln Ile Lys Gln Asn Tyr Asp Asp Ala Val Gln Arg Val Glu 6230 6235 6240 Thr Ile Ile Asn Glu Thr Gln Asn Pro Glu Leu Leu Lys Ala Asn 6245 6250 6255 Ile Asp Gln Ala Thr Gln Ser Val Gln Asn Ala Glu Gln Ala Leu 6260 6265 6270 His Gly Ala Glu Lys Leu Asn Gln Asp Lys Gln Thr Ser Ser Thr 6275 6280 6285 Glu Leu Asp Gly Leu Thr Asp Leu Thr Asp Ala Gln Arg Glu Lys 6290 6295 6300 Leu Arg Glu Gln Ile Asn Thr Ser Asn Ser Arg Asp Asp Ile Lys 6305 6310 6315 Gln Lys Ile Glu Gln Ala Lys Ala Leu Asn Asp Ala Met Lys Lys 6320 6325 6330 Leu Lys Glu Gln Val Ala Gln Lys Asp Gly Val His Ala Asn Ser 6335 6340 6345 Asp Tyr Thr Asn Glu Asp Ser Ala Gln Lys Asp Ala Tyr Asn Asn 6350 6355 6360 Ala Leu Lys Gln Ala Glu Asp Ile Ile Asn Asn Ser Ser Asn Pro 6365 6370 6375 Asn Leu Asn Ala Gln Asp Ile Thr Asn Ala Leu Asn Asn Ile Lys 6380 6385 6390 Gln Ala Gln Asp Asn Leu His Gly Ala Gln Lys Leu Gln Gln Asp 6395 6400 6405 Lys Asn Thr Thr Asn Gln Ala Ile Gly Asn Leu Asn His Leu Asn 6410 6415 6420 Gln Pro Gln Lys Asp Ala Leu Ile Gln Ala Ile Asn Gly Ala Thr 6425 6430 6435 Ser Arg Asp Gln Val Ala Glu Lys Leu Lys Glu Ala Glu Ala Leu 6440 6445 6450 Asp Glu Ala Met Lys Gln Leu Glu Asp Gln Val Asn Gln Asp Asp 6455 6460 6465 Gln Ile Ser Asn Ser Ser Pro Phe Ile Asn Glu Asp Ser Asp Lys 6470 6475 6480 Gln Lys Thr Tyr Asn Asp Lys Ile Gln Ala Ala Lys Glu Ile Ile 6485 6490 6495 Asn Gln Thr Ser Asn Pro Thr Leu Asp Lys Gln Lys Ile Ala Asp 6500 6505 6510 Thr Leu Gln Asn Ile Lys Asp Ala Val Asn Asn Leu His Gly Asp 6515 6520 6525 Gln Lys Leu Ala Gln Ser Lys Gln Asp Ala Asn Asn Gln Leu Asn 6530 6535 6540 His Leu Asp Asp Leu Thr Glu Glu Gln Lys Asn His Phe Lys Pro 6545 6550 6555 Leu Ile Asn Asn Ala Asp Thr Arg Asp Glu Val Asn Lys Gln Leu 6560 6565 6570 Glu Ile Ala Lys Gln Leu Asn Gly Asp Met Ser Thr Leu His Lys 6575 6580 6585 Val Ile Asn Asp Lys Asp Gln Ile Gln His Leu Ser Asn Tyr Ile 6590 6595 6600 Asn Ala Asp Asn Asp Lys Lys Gln Asn Tyr Asp Asn Ala Ile Lys 6605 6610 6615 Glu Ala Glu Asp Leu Ile His Asn His Pro Asp Thr Leu Asp His 6620 6625 6630 Lys Ala Leu Gln Asp Leu Leu Asn Lys Ile Asp Gln Ala His Asn 6635 6640 6645 Glu Leu Asn Gly Glu Ser Arg Phe Lys Gln Ala Leu Asp Asn Ala 6650 6655 6660 Leu Asn Asp Ile Asp Ser Leu Asn Ser Leu Asn Val Pro Gln Arg 6665 6670 6675 Gln Thr Val Lys Asp Asn Ile Asn His Val Thr Thr Leu Glu Ser 6680 6685 6690 Leu Ala Gln Glu Leu Gln Lys Ala Lys Glu Leu Asn Asp Ala Met 6695 6700 6705 Lys Ala Met Arg Asp Ser Ile Met Asn Gln Glu Gln Ile Arg Lys 6710 6715 6720 Asn Ser Asn Tyr Thr Asn Glu Asp Leu Ala Gln Gln Asn Ala Tyr 6725 6730 6735 Asn His Ala Val Asp Lys Ile Asn Asn Ile Ile Gly Glu Asp Asn 6740 6745 6750 Ala Thr Met Asp Pro Gln Ile Ile Lys Gln Ala Thr Gln Asp Ile 6755 6760 6765 Asn Thr Ala Ile Asn Gly Leu Asn Gly Asp Gln Lys Leu Gln Asp 6770 6775 6780 Ala Lys Thr Asp Ala Lys Gln Gln Ile Thr Asn Phe Thr Gly Leu 6785 6790 6795 Thr Glu Pro Gln Lys Gln Ala Leu Glu Asn Ile Ile Asn Gln Gln 6800 6805 6810 Thr Ser Arg Ala Asn Val Ala Lys Gln Leu Ser His Ala Lys Phe 6815 6820 6825 Leu Asn Gly Lys Met Glu Glu Leu Lys Val Ala Val Ala Lys Ala 6830 6835 6840 Ser Leu Val Arg Gln Asn Ser Asn Tyr Ile Asn Glu Asp Val Ser 6845 6850 6855 Glu Lys Glu Ala Tyr Glu Gln Ala Ile Ala Lys Gly Gln Glu Ile 6860 6865 6870 Ile Asn Ser Glu Asn Asn Pro Thr Ile Ser Ser Thr Asp Ile Asn 6875 6880 6885 Arg Thr Ile Gln Glu Ile Asn Asp Ala Glu Gln Asn Leu His Gly 6890 6895 6900 Asp Asn Lys Leu Arg Gln Ala Gln Glu Ile Ala Lys Asn Glu Ile 6905 6910 6915 Gln Asn Leu Asp Gly Leu Asn Ser Ala Gln Ile Thr Lys Leu Ile 6920 6925 6930 Gln Asp Ile Gly Arg Thr Thr Thr Lys Pro Ala Val Thr Gln Lys 6935 6940 6945 Leu Glu Glu Ala Lys Ala Ile Asn Gln Ala Met Gln Gln Leu Lys 6950 6955 6960 Gln Ser Ile Ala Asp Lys Asp Ala Thr Leu Asn Ser Ser Asn Tyr 6965 6970 6975 Leu Asn Glu Asp Ser Glu Lys Lys Leu Ala Tyr Asp Asn Ala Val 6980 6985 6990 Ser Gln Ala Glu Gln Leu Ile Asn Gln Leu Asn Asp Pro Thr Met 6995 7000 7005 Asp Ile Ser Asn Ile Gln Ala Ile Thr Gln Lys Val Ile Gln Ala 7010 7015 7020 Lys Asp Ser Leu His Gly Ala Asn Lys Leu Ala Gln Asn Gln Ala 7025 7030 7035 Asp Ser Asn Leu Ile Ile Asn Gln Ser Thr Asn Leu Asn Asp Lys 7040 7045 7050 Gln Lys Gln Ala Leu Asn Asp Leu Ile Asn His Ala Gln Thr Lys 7055 7060 7065 Gln Gln Val Ala Glu Ile Ile Ala Gln Ala Asn Lys Leu Asn Asn 7070 7075 7080 Glu Met Gly Thr Leu Lys Thr Leu Val Glu Glu Gln Ser Asn Val 7085 7090 7095 His Gln Gln Ser Lys Tyr Ile Asn Glu Asp Pro Gln Val Gln Asn 7100 7105 7110 Ile Tyr Asn Asp Ser Ile Gln Lys Gly Arg Glu Ile Leu Asn Gly 7115 7120 7125 Thr Thr Asp Asp Val Leu Asn Asn Asn Lys Ile Ala Asp Ala Ile 7130 7135 7140 Gln Asn Ile His Leu Thr Lys Asn Asp Leu His Gly Asp Gln Lys 7145 7150 7155 Leu Gln Lys Ala Gln Gln Asp Ala Thr Asn Glu Leu Asn Tyr Leu 7160 7165 7170 Thr Asn Leu Asn Asn Ser Gln Arg Gln Ser Glu His Asp Glu Ile 7175 7180 7185 Asn Ser Ala Pro Ser Arg Thr Glu Val Ser Asn Asp Leu Asn His 7190 7195 7200 Ala Lys Ala Leu Asn Glu Ala Met Arg Gln Leu Glu Asn Glu Val 7205 7210 7215 Ala Leu Glu Asn Ser Val Lys Lys Leu Ser Asp Phe Ile Asn Glu 7220 7225 7230 Asp Glu Ala Ala Gln Asn Glu Tyr Ser Asn Ala Leu Gln Lys Ala 7235 7240 7245 Lys Asp Ile Ile Asn Gly Val Pro Ser Ser Thr Leu Asp Lys Ala 7250 7255 7260 Thr Ile Glu Asp Ala Leu Leu Glu Leu Gln Asn Ala Arg Glu Ser 7265 7270 7275 Leu His Gly Glu Gln Lys Leu Gln Glu Ala Lys Asn Gln Ala Val 7280 7285 7290 Ala Glu Ile Asp Asn Leu Gln Ala Leu Asn Pro Gly Gln Val Leu 7295 7300 7305 Ala Glu Lys Thr Leu Val Asn Gln Ala Ser Thr Lys Pro Glu Val 7310 7315 7320 Gln Glu Ala Leu Gln Lys Ala Lys Glu Leu Asn Glu Ala Met Lys 7325 7330 7335 Ala Leu Lys Thr Glu Ile Asn Lys Lys Glu Gln Ile Lys Ala Asp 7340 7345 7350 Ser Arg Tyr Val Asn Ala Asp Ser Gly Leu Gln Ala Asn Tyr Asn 7355 7360 7365 Ser Ala Leu Asn Tyr Gly Ser Gln Ile Ile Ala Thr Thr Gln Pro 7370 7375 7380 Pro Glu Leu Asn Lys Asp Val Ile Asn Arg Ala Thr Gln Thr Ile 7385 7390 7395 Lys Thr Ala Glu Asn Asn Leu Asn Gly Gln Ser Lys Leu Ala Glu 7400 7405 7410 Ala Lys Ser Asp Gly Asn Gln Ser Ile Glu His Leu Gln Gly Leu 7415 7420 7425 Thr Gln Ser Gln Lys Asp Lys Gln His Asp Leu Ile Asn Gln Ala 7430 7435 7440 Gln Thr Lys Gln Gln Val Asp Asp Ile Val Asn Asn Ser Lys Gln 7445 7450 7455 Leu Asp Asn Ser Met Asn Gln Leu Gln Gln Ile Val Asn Asn Asp 7460 7465 7470 Asn Thr Val Lys Gln Asn Ser Asp Phe Ile Asn Glu Asp Ser Ser 7475 7480 7485 Gln Gln Asp Ala Tyr Asn His Ala Ile Gln Ala Ala Lys Asp Leu 7490 7495 7500 Ile Thr Ala His Pro Thr Ile Met Asp Lys Asn Gln Ile Asp Gln 7505 7510 7515 Ala Ile Glu Asn Ile Lys Gln Ala Leu Asn Asp Leu His Gly Ser 7520 7525 7530 Asn Lys Leu Ser Glu Asp Lys Lys Glu Ala Ser Glu Gln Leu Gln 7535 7540 7545 Asn Leu Asn Ser Leu Thr Asn Gly Gln Lys Asp Thr Ile Leu Asn 7550 7555 7560 His Ile Phe Ser Ala Pro Thr Arg Ser Gln Val Gly Glu Lys Ile 7565 7570 7575 Ala Ser Ala Lys Gln Leu Asn Asn Thr Met Lys Ala Leu Arg Asp 7580 7585 7590 Ser Ile Ala Asp Asn Asn Glu Ile Leu Gln Ser Ser Lys Tyr Phe 7595 7600 7605 Asn Glu Asp Ser Glu Gln Gln Asn Ala Tyr Asn Gln Ala Val Asn 7610 7615 7620 Lys Ala Lys Asn Ile Ile Asn Asp Gln Pro Thr Pro Val Met Ala 7625 7630 7635 Asn Asp Glu Ile Gln Ser Val Leu Asn Glu Val Lys Gln Thr Lys 7640 7645 7650 Asp Asn Leu His Gly Asp Gln Lys Leu Ala Asn Asp Lys Thr Asp 7655 7660 7665 Ala Gln Ala Thr Leu Asn Ala Leu Asn Tyr Leu Asn Gln Ala Gln 7670 7675 7680 Arg Gly Asn Leu Glu Thr Lys Val Gln Asn Ser Asn Ser Arg Pro 7685 7690 7695 Glu Val Gln Lys Val Val Gln Leu Ala Asn Gln Leu Asn Asp Ala 7700 7705 7710 Met Lys Lys Leu Asp Asp Ala Leu Thr Gly Asn Asp Ala Ile Lys 7715 7720 7725 Gln Thr Ser Asn Tyr Ile Asn Glu Asp Thr Ser Gln Gln Val Asn 7730 7735 7740 Phe Asp Glu Tyr Thr Asp Arg Gly Lys Asn Ile Val Ala Glu Gln 7745 7750 7755 Thr Asn Pro Asn Met Ser Pro Thr Asn Ile Asn Thr Ile Ala Asp 7760 7765 7770 Lys Ile Thr Glu Ala Lys Asn Asp Leu His Gly Val Gln Lys Leu 7775 7780 7785 Lys Gln Ala Gln Gln Gln Ser Ile Asn Thr Ile Asn Gln Met Thr 7790 7795 7800 Gly Leu Asn Gln Ala Gln Lys Glu Gln Leu Asn Gln Glu Ile Gln 7805 7810 7815 Gln Thr Gln Thr Arg Ser Glu Val His Gln Val Ile Asn Lys Ala 7820 7825 7830 Gln Ala Leu Asn Asp Ser Met Asn Thr Leu Arg Gln Ser Ile Thr 7835 7840 7845 Asp Glu His Glu Val Lys Gln Thr Ser Asn Tyr Ile Asn Glu Thr 7850 7855 7860 Val Gly Asn Gln Thr Ala Tyr Asn Asn Ala Val Asp Arg Val Lys 7865 7870 7875 Gln Ile Ile Asn Gln Thr Ser Asn Pro Thr Met Asn Pro Leu Glu 7880 7885 7890 Val Glu Arg Ala Thr Ser Asn Val Lys Ile Ser Lys Asp Ala Leu 7895 7900 7905 His Gly Glu Arg Glu Leu Asn Asp Asn Lys Asn Ser Lys Thr Phe 7910 7915 7920 Ala Val Asn His Leu Asp Asn Leu Asn Gln Ala Gln Lys Glu Ala 7925 7930 7935 Leu Thr His Glu Ile Glu Gln Ala Thr Ile Val Ser Gln Val Asn 7940 7945 7950 Asn Ile Tyr Asn Lys Ala Lys Ala Leu Asn Asn Asp Met Lys Lys 7955 7960 7965 Leu Lys Asp Ile Val Ala Gln Gln Asp Asn Val Arg Gln Ser Asn 7970 7975 7980 Asn Tyr Ile Asn Glu Asp Ser Thr Pro Gln Asn Met Tyr Asn Asp 7985 7990 7995 Thr Ile Asn His Ala Gln Ser Ile Ile Asp Gln Val Ala Asn Pro 8000 8005 8010 Thr Met Ser His Asp Glu Ile Glu Asn Ala Ile Asn Asn Ile Lys 8015 8020 8025 His Ala Ile Asn Ala Leu Asp Gly Glu His Lys Leu Gln Gln Ala 8030 8035 8040 Lys Glu Asn Ala Asn Leu Leu Ile Asn Ser Leu Asn Asp Leu Asn 8045 8050 8055 Ala Pro Gln Arg Asp Ala Ile Asn Arg Leu Val Asn Glu Ala Gln 8060 8065 8070 Thr Arg Glu Lys Val Ala Glu Gln Leu Gln Ser Ala Gln Ala Leu 8075 8080 8085 Asn Asp Ala Met Lys His Leu Arg Asn Ser Ile Gln Asn Gln Ser 8090 8095 8100 Ser Val Arg Gln Glu Ser Lys Tyr Ile Asn Ala Ser Asp Ala Lys 8105 8110 8115 Lys Glu Gln Tyr Asn His Ala Val Arg Glu Val Glu Asn Ile Ile 8120 8125 8130 Asn Glu Gln His Pro Thr Leu Asp Lys Glu Ile Ile Lys Gln Leu 8135 8140 8145 Thr Asp Gly Val Asn Gln Ala Asn Asn Asp Leu Asn Gly Val Glu 8150 8155 8160 Leu Leu Asp Ala Asp Lys Gln Asn Ala His Gln Ser Ile Pro Thr 8165 8170 8175 Leu Met His Leu Asn Gln Ala Gln Gln Asn Ala Leu Asn Glu Lys 8180 8185 8190 Ile Asn Asn Ala Val Thr Arg Thr Glu Val Ala Ala Ile Ile Gly 8195 8200 8205 Gln Ala Lys Leu Leu Asp His Ala Met Glu Asn Leu Glu Glu Ser 8210 8215 8220 Ile Lys Asp Lys Glu Gln Val Lys Gln Ser Ser Asn Tyr Ile Asn 8225 8230 8235 Glu Asp Ser Asp Val Gln Glu Thr Tyr Asp Asn Ala Val Asp His 8240 8245 8250 Val Thr Glu Ile Leu Asn Gln Thr Val Asn Pro Thr Leu Ser Ile 8255 8260 8265 Glu Asp Ile Glu His Ala Ile Asn Glu Val Asn Gln Ala Lys Lys 8270 8275 8280 Gln Leu Arg Gly Lys Gln Lys Leu Tyr Gln Thr Ile Asp Leu Ala 8285 8290 8295 Asp Lys Glu Leu Ser Lys Leu Asp Asp Leu Thr Ser Gln Gln Ser 8300 8305 8310 Ser Ser Ile Ser Asn Gln Ile Tyr Thr Ala Lys Thr Arg Thr Glu 8315 8320 8325 Val Ala Gln Ala Ile Glu Lys Ala Lys Ser Leu Asn His Ala Met 8330 8335 8340 Lys Ala Leu Asn Lys Val Tyr Lys Asn Ala Asp Lys Val Leu Asp 8345 8350 8355 Ser Ser Arg Phe Ile Asn Glu Asp Gln Pro Glu Lys Lys Ala Tyr 8360 8365 8370 Gln Gln Ala Ile Asn His Val Asp Ser Ile Ile His Arg Gln Thr 8375 8380 8385 Asn Pro Glu Met Asp Pro Thr Val Ile Asn Ser Ile Thr His Glu 8390 8395 8400 Leu Glu Thr Ala Gln Asn Asn Leu His Gly Asp Gln Lys Leu Ala 8405 8410 8415 His Ala Gln Gln Asp Ala Ala Asn Val Ile Asn Gly Leu Ile His 8420 8425 8430 Leu Asn Val Ala Gln Arg Glu Val Met Ile Asn Thr Asn Thr Asn 8435 8440 8445 Ala Thr Thr Arg Glu Lys Val Ala Lys Asn Leu Asp Asn Ala Gln 8450 8455 8460 Ala Leu Asp Lys Ala Met Glu Thr Leu Gln Gln Val Val Ala His 8465 8470 8475 Lys Asn Asn Ile Leu Asn Asp Ser Lys Tyr Leu Asn Glu Asp Ser 8480 8485 8490 Lys Tyr Gln Gln Gln Tyr Asp Arg Val Ile Ala Asp Ala Glu Gln 8495 8500 8505 Leu Leu Asn Gln Thr Thr Asn Pro Thr Leu Glu Pro Tyr Lys Val 8510 8515 8520 Asp Ile Val Lys Asp Asn Val Leu Ala Asn Glu Lys Ile Leu Phe 8525 8530 8535 Gly Ala Glu Lys Leu Ser Tyr Asp Lys Ser Asn Ala Asn Asp Glu 8540 8545 8550 Ile Lys His Met Asn Tyr Leu Asn Asn Ala Gln Lys Gln Ser Ile 8555 8560 8565 Lys Asp Met Ile Ser His Ala Ala Leu Arg Thr Glu Val Lys Gln 8570 8575 8580 Leu Leu Gln Gln Ala Lys Ile Leu Asp Glu Ala Met Lys Ser Leu 8585 8590 8595 Glu Asp Lys Thr Gln Val Val Ile Thr Asp Thr Thr Leu Pro Asn 8600 8605 8610 Tyr Thr Glu Ala Ser Glu Asp Lys Lys Glu Lys Val Asp Gln Thr 8615 8620 8625 Val Ser His Ala Gln Ala Ile Ile Asp Lys Ile Asn Gly Ser Asn 8630 8635 8640 Val Ser Leu Asp Gln Val Arg Gln Ala Leu Glu Gln Leu Thr Gln 8645 8650 8655 Ala Ser Glu Asn Leu Asp Gly Asp Gln Arg Val Glu Glu Ala Lys 8660 8665 8670 Val His Ala Asn Gln Thr Ile Asp Gln Leu Thr His Leu Asn Ser 8675 8680 8685 Leu Gln Gln Gln Thr Ala Lys Glu Ser Val Lys Asn Ala Thr Lys 8690 8695 8700 Leu Glu Glu Ile Ala Thr Val Ser Asn Asn Ala Gln Ala Leu Asn 8705 8710 8715 Lys Val Met Gly Lys Leu Glu Gln Phe Ile Asn His Ala Asp Ser 8720 8725 8730 Val Glu Asn Ser Asp Asn Tyr Arg Gln Ala Asp Asp Asp Lys Ile 8735 8740 8745 Ile Ala Tyr Asp Glu Ala Leu Glu His Gly Gln Asp Ile Gln Lys 8750 8755 8760 Thr Asn Ala Thr Gln Asn Glu Thr Lys Gln Ala Leu Gln Gln Leu 8765 8770 8775 Ile Tyr Ala Glu Thr Ser Leu Asn Gly Phe Glu Arg Leu Asn His 8780 8785 8790 Ala Arg Pro Arg Ala Leu Glu Tyr Ile Lys Ser Leu Glu Lys Ile 8795 8800 8805 Asn Asn Ala Gln Lys Ser Ala Leu Glu Asp Lys Val Thr Gln Ser 8810 8815 8820 His Asp Leu Leu Glu Leu Glu His Ile Val Asn Glu Gly Thr Asn 8825 8830 8835 Leu Asn Asp Ile Met Gly Glu Leu Ala Asn Ala Ile Val Asn Asn 8840 8845 8850 Tyr Ala Pro Thr Lys Ala Ser Ile Asn Tyr Ile Asn Ala Asp Asn 8855 8860 8865 Leu Arg Lys Asp Asn Phe Thr Gln Ala Ile Asn Asn Ala Arg Asp 8870 8875 8880 Ala Leu Asn Lys Thr Gln Gly Gln Asn Leu Asp Phe Asn Ala Ile 8885 8890 8895 Asp Thr Phe Lys Asp Asp Ile Phe Lys Thr Lys Asp Ala Leu Asn 8900 8905 8910 Gly Ile Glu Arg Leu Thr Ala Ala Lys Ser Lys Ala Glu Lys Leu 8915 8920 8925 Ile Asp Ser Leu Lys Phe Ile Asn Lys Ala Gln Phe Thr His Ala 8930 8935 8940 Asn Asp Glu Ile Ile Asn Thr Asn Ser Ile Ala Gln Leu Ser Arg 8945 8950 8955 Ile Val Asn Gln Ala Phe Asp Leu Asn Asp Ala Met Lys Ser Leu 8960 8965 8970 Arg Asp Glu Leu Asn Asn Gln Ala Phe Pro Val Gln Ala Ser Ser 8975 8980 8985 Asn Tyr Ile Asn Ser Asp Glu Asp Leu Lys Gln Gln Phe Asp His 8990 8995 9000 Ala Leu Ser Asn Ala Arg Lys Val Leu Ala Lys Glu Asn Gly Lys 9005 9010 9015 Asn Leu Asp Glu Lys Gln Ile Gln Gly Leu Lys Gln Val Ile Glu 9020 9025 9030 Asp Thr Lys Asp Ala Leu Asn Gly Ile Gln Arg Leu Ser Lys Ala 9035 9040 9045 Lys Ala Lys Ala Ile Gln Tyr Val Gln Ser Leu Ser Tyr Ile Asn 9050 9055 9060 Asp Ala Gln Arg His Ile Ala Glu Asn Asn Ile His Asn Ser Asp 9065 9070 9075 Asp Leu Ser Ser Leu Ala Asn Thr Leu Ser Lys Ala Ser Asp Leu 9080 9085 9090 Asp Asn Ala Met Lys Asp Leu Arg Asp Thr Ile Glu Ser Asn Ser 9095 9100 9105 Thr Ser Val Pro Asn Ser Val Asn Tyr Ile Asn Ala Asp Lys Asn 9110 9115 9120 Leu Gln Ile Glu Phe Asp Glu Ala Leu Gln Gln Ala Ser Ala Thr 9125 9130 9135 Ser Ser Lys Thr Ser Glu Asn Pro Ala Thr Ile Glu Glu Val Leu 9140 9145 9150 Gly Leu Ser Gln Ala Ile Tyr Asp Thr Lys Asn Ala Leu Asn Gly 9155 9160 9165 Glu Gln Arg Leu Ala Thr Glu Lys Ser Lys Asp Leu Lys Leu Ile 9170 9175 9180 Lys Gly Leu Lys Asp Leu Asn Lys Ala Gln Leu Glu Asp Val Thr 9185 9190 9195 Asn Lys Val Asn Ser Ala Asn Thr Leu Thr Glu Leu Ser Gln Leu 9200 9205 9210 Thr Gln Ser Thr Leu Glu Leu Asn Asp Lys Met Lys Leu Leu Arg 9215 9220 9225 Asp Lys Leu Lys Thr Leu Val Asn Pro Val Lys Ala Ser Leu Asn 9230 9235 9240 Tyr Arg Asn Ala Asp Tyr Asn Leu Lys Arg Gln Phe Asn Lys Ala 9245 9250 9255 Leu Lys Glu Ala Lys Gly Val Leu Asn Lys Asn Ser Gly Thr Asn 9260 9265 9270 Val Asn Ile Asn Asp Ile Gln His Leu Leu Thr Gln Ile Asp Asn 9275 9280 9285 Ala Lys Asp Gln Leu Asn Gly Glu Arg Arg Leu Lys Glu His Gln 9290 9295 9300 Gln Lys Ser Glu Val Phe Ile Ile Lys Glu Leu Asp Ile Leu Asn 9305 9310 9315 Asn Ala Gln Lys Ala Ala Ile Ile Asn Gln Ile Arg Ala Ser Lys 9320 9325 9330 Asp Ile Lys Ile Ile Asn Gln Ile Val Asp Asn Ala Ile Glu Leu 9335 9340 9345 Asn Asp Ala Met Gln Gly Leu Lys Glu His Val Ala Gln Leu Thr 9350 9355 9360 Ala Thr Thr Lys Asp Asn Ile Glu Tyr Leu Asn Ala Asp Glu Asp 9365 9370 9375 His Lys Leu Gln Tyr Asp Tyr Ala Ile Asn Leu Ala Asn Asn Val 9380 9385 9390 Leu Asp Lys Glu Asn Gly Thr Asn Lys Asp Ala Asn Ile Ile Ile 9395 9400 9405 Gly Met Ile Gln Asn Met Asp Asp Ala Arg Ala Leu Leu Asn Gly 9410 9415 9420 Ile Glu Arg Leu Lys Asp Ala Gln Thr Lys Ala His Asn Asp Ile 9425 9430 9435 Lys Asp Thr Leu Lys Arg Gln Leu Asp Glu Ile Glu His Ala Asn 9440 9445 9450 Ala Thr Ser Asn Ser Lys Ala Gln Ala Lys Gln Met Val Asn Glu 9455 9460 9465 Glu Ala Arg Lys Ala Leu Ser Asn Ile Asn Asp Ala Thr Ser Asn 9470 9475 9480 Asp Leu Val Asn Gln Ala Lys Asp Glu Gly Gln Ser Ala Ile Glu 9485 9490 9495 His Ile His Ala Asp Glu Leu Pro Lys Ala Lys Leu Asp Ala Asn 9500 9505 9510 Gln Met Ile Asp Gln Lys Val Glu Asp Ile Asn His Leu Ile Ser 9515 9520 9525 Gln Asn Pro Asn Leu Ser Asn Glu Glu Lys Asn Lys Leu Ile Ser 9530 9535 9540 Gln Ile Asn Lys Leu Val Asn Gly Ile Lys Asn Glu Ile Gln Gln 9545 9550 9555 Ala Ile Asn Lys Gln Gln Ile Glu Asn Ala Thr Thr Lys Leu Asp 9560 9565 9570 Glu Val Ile Glu Thr Thr Lys Lys Leu Ile Ile Ala Lys Ala Glu 9575 9580 9585 Ala Lys Gln Met Ile Lys Glu Leu Ser Gln Lys Lys Arg Asp Ala 9590 9595 9600 Ile Asn Asn Asn Thr Asp Leu Thr Pro Ser Gln Lys Ala His Ala 9605 9610 9615 Leu Ala Asp Ile Asp Lys Thr Glu Lys Asp Ala Leu Gln His Ile 9620 9625 9630 Glu Asn Ser Asn Ser Ile Asp Asp Ile Asn Asn Asn Lys Glu His 9635 9640 9645 Ala Phe Asn Thr Leu Ala His Ile Ile Ile Trp Asp Thr Asp Gln 9650 9655 9660 Gln Pro Leu Val Phe Glu Leu Pro Glu Leu Ser Leu Gln Asn Ala 9665 9670 9675 Leu Val Thr Ser Glu Val Val Val His Arg Asp Glu Thr Ile Ser 9680 9685 9690 Leu Glu Ser Ile Ile Gly Ala Met Thr Leu Thr Asp Glu Leu Lys 9695 9700 9705 Val Asn Ile Val Ser Leu Pro Asn Thr Asp Lys Val Ala Asp His 9710 9715 9720 Leu Thr Ala Lys Val Lys Val Ile Leu Ala Asp Gly Ser Tyr Val 9725 9730 9735 Thr Val Asn Val Pro Val Lys Val Val Glu Lys Glu Leu Gln Ile 9740 9745 9750 Ala Lys Lys Asp Ala Ile Lys Thr Ile Asp Val Leu Val Lys Gln 9755 9760 9765 Lys Ile Lys Asp Ile Asp Ser Asn Asn Glu Leu Thr Ser Thr Gln 9770 9775 9780 Arg Glu Asp Ala Lys Ala Glu Ile Glu Arg Leu Lys Lys Gln Ala 9785 9790 9795 Ile Asp Lys Val Asn His Ser Lys Ser Ile Lys Asp Ile Glu Thr 9800 9805 9810 Val Lys Arg Thr Asp Phe Glu Glu Ile Asp Gln Phe Asp Pro Lys 9815 9820 9825 Arg Phe Thr Leu Asn Lys Ala Lys Lys Asp Ile Ile Thr Asp Val 9830 9835 9840 Asn Thr Gln Ile Gln Asn Gly Phe Lys Glu Ile Glu Thr Ile Lys 9845 9850 9855 Gly Leu Thr Ser Asn Glu Lys Thr Gln Phe Asp Lys Gln Leu Thr 9860 9865 9870 Ala Leu Gln Lys Glu Phe Leu Glu Lys Val Glu His Ala His Asn 9875 9880 9885 Leu Val Glu Leu Asn Gln Leu Gln Gln Glu Phe Asn Asn Arg Tyr 9890 9895 9900 Lys His Ile Leu Asn Gln Ala His Leu Leu Gly Glu Lys His Ile 9905 9910 9915 Ala Glu His Lys Leu Gly Tyr Val Val Val Asn Lys Thr Gln Gln 9920 9925 9930 Ile Leu Asn Asn Gln Ser Ala Ser Tyr Phe Ile Lys Gln Trp Ala 9935 9940 9945 Leu Asp Arg Ile Lys Gln Ile Gln Leu Glu Thr Met Asn Ser Ile 9950 9955 9960 Arg Gly Ala His Thr Val Gln Asp Val His Lys Ala Leu Leu Gln 9965 9970 9975 Gly Ile Glu Gln Ile Leu Lys Val Asn Val Ser Ile Ile Asn Gln 9980 9985 9990 Ser Phe Asn Asp Ser Leu His Asn Phe Asn Tyr Leu His Ser Lys 9995 10000 10005 Phe Asp Ala Arg Leu Arg Glu Lys Asp Val Ala Asn His Ile Val 10010 10015 10020 Gln Thr Glu Thr Phe Lys Glu Val Leu Lys Gly Thr Gly Val Glu 10025 10030 10035 Pro Gly Lys Ile Asn Lys Glu Thr Gln Gln Pro Lys Leu His Lys 10040 10045 10050 Asn Asp Asn Asp Ser Leu Phe Lys His Leu Val Asp Asn Phe Gly 10055 10060 10065 Lys Thr Val Gly Val Ile Thr Leu Thr Gly Leu Leu Ser Ser Phe 10070 10075 10080 Trp Leu Val Leu Ala Lys Arg Arg Lys Lys Glu Glu Glu Glu Lys 10085 10090 10095 Gln Ser Ile Lys Asn His His Lys Asp Ile Arg Leu Ser Asp Thr 10100 10105 10110 Asp Lys Ile Asp Pro Ile Val Ile Thr Lys Arg Lys Ile Asp Lys 10115 10120 10125 Glu Glu Gln Ile Gln Asn Asp Asp Lys His Ser Ile Pro Val Ala 10130 10135 10140 Lys His Lys Lys Ser Lys Glu Lys Gln Leu Ser Glu Glu Asp Ile 10145 10150 10155 His Ser Ile Pro Val Val Lys Arg Lys Gln Asn Ser Asp Asn Lys 10160 10165 10170 Asp Thr Lys Gln Lys Lys Val Thr Ser Lys Lys Lys Lys Thr Pro 10175 10180 10185 Gln Ser Thr Lys Lys Val Val Lys Thr Lys Lys Arg Ser Lys Lys 10190 10195 10200 24 1973 PRT Staphylococcus epidermidis 24 Met Lys Glu Asn Lys Arg Lys Asn Asn Leu Asp Lys Asn Asn Thr Arg 1 5 10 15 Phe Ser Ile Arg Lys Tyr Gln Gly Tyr Gly Ala Thr Ser Val Ala Ile 20 25 30 Ile Gly Phe Ile Ile Ile Ser Cys Phe Ser Glu Ala Lys Ala Asp Ser 35 40 45 Asp Lys His Glu Ile Lys Ser His Gln Gln Ser Met Thr Asn His Leu 50 55 60 Thr Thr Leu Pro Ser Asp Asn Gln Glu Asn Thr Ser Asn Asn Glu Phe 65 70 75 80 Asn Asn Arg Asn His Asp Ile Ser His Leu Ser Leu Asn Lys Ser Ile 85 90 95 Gln Met Asp Glu Leu Lys Lys Leu Ile Lys Gln Tyr Lys Ala Ile Asn 100 105 110 Leu Asn Asp Lys Thr Glu Glu Ser Ile Lys Leu Phe Gln Ser Asp Leu 115 120 125 Val Gln Ala Glu Ser Leu Ile Asn Asn Pro Gln Ser Gln Gln His Val 130 135 140 Asp Ala Phe Tyr His Lys Phe Leu Asn Ser Ala Gly Lys Leu Arg Lys 145 150 155 160 Lys Glu Thr Val Ser Ile Lys His Glu Arg Ser Glu Ser Asn Thr Tyr 165 170 175 Arg Leu Gly Asp Glu Val Arg Ser Gln Thr Phe Ser His Ile Arg His 180 185 190 Lys Arg Asn Ala Val Ser Phe Arg Asn Ala Asp Gln Ser Asn Leu Ser 195 200 205 Thr Asp Pro Leu Lys Ala Asn Glu Ile Asn Pro Glu Ile Gln Asn Gly 210 215 220 Asn Phe Ser Gln Val Ser Gly Gly Pro Leu Pro Thr Ser Ser Lys Arg 225 230 235 240 Leu Thr Val Val Thr Asn Val Asp Asn Trp His Ser Tyr Ser Thr Asp 245 250 255 Pro Asn Pro Glu Tyr Pro Met Phe Tyr Thr Thr Thr Ala Val Asn Tyr 260 265 270 Pro Asn Phe Met Ser Asn Gly Asn Ala Pro Tyr Gly Val Ile Leu Gly 275 280 285 Arg Thr Thr Asp Gly Trp Asn Arg Asn Val Ile Asp Ser Lys Val Ala 290 295 300 Gly Ile Tyr Gln Asp Ile Asp Val Val Pro Gly Ser Glu Leu Asn Val 305 310 315 320 Asn Phe Ile Ser Thr Ser Pro Val Phe Ser Asp Gly Ala Ala Gly Ala 325 330 335 Lys Leu Lys Ile Ser Asn Val Glu Gln Asn Arg Val Leu Phe Asp Ser 340 345 350 Arg Leu Asn Gly Met Gly Pro Tyr Pro Thr Gly Lys Leu Ser Ala Met 355 360 365 Val Asn Ile Pro Asn Asp Ile Asn Arg Val Arg Ile Ser Phe Leu Pro 370 375 380 Val Ser Ser Thr Gly Arg Val Ser Val Gln Arg Ser Ser Arg Glu His 385 390 395 400 Gly Phe Gly Asp Asn Ser Ser Tyr Tyr His Gly Gly Ser Val Ser Asp 405 410 415 Val Arg Ile Asn Ser Gly Ser Tyr Val Val Ser Lys Val Thr Gln Arg 420 425 430 Glu Tyr Thr Thr Arg Pro Asn Ser Ser Asn Asp Thr Phe Ala Arg Ala 435 440 445 Thr Ile Asn Leu Ser Val Glu Asn Lys Gly His Asn Gln Ser Lys Asp 450 455 460 Thr Tyr Tyr Glu Val Ile Leu Pro Gln Asn Ser Arg Leu Ile Ser Thr 465 470 475 480 Arg Gly Gly Ser Gly Asn Tyr Asn Asn Ala Thr Asn Lys Leu Ser Ile 485 490 495 Arg Leu Asp Asn Leu Asn Pro Gly Asp Arg Arg Asp Ile Ser Tyr Thr 500 505 510 Val Asp Phe Glu Ser Ser Ser Pro Lys Leu Ile Asn Leu Asn Ala His 515 520 525 Leu Leu Tyr Lys Thr Asn Ala Thr Phe Arg Gly Asn Asp Gly Gln Arg 530 535 540 Thr Gly Asp Asn Ile Val Asp Leu Gln Ser Ile Ala Leu Leu Met Asn 545 550 555 560 Lys Asp Val Leu Glu Thr Glu Leu Asn Glu Ile Asp Lys Phe Ile Arg 565 570 575 Asp Leu Asn Glu Ala Asp Phe Thr Ile Asp Ser Trp Ser Ala Leu Gln 580 585 590 Glu Lys Met Thr Glu Gly Gly Asn Ile Leu Asn Glu Gln Gln Asn Gln 595 600 605 Val Ala Leu Glu Asn Gln Ala Ser Gln Glu Thr Ile Asn Asn Val Thr 610 615 620 Gln Ser Leu Glu Ile Leu Lys Asn Asn Leu Lys Tyr Lys Thr Pro Ser 625 630 635 640 Gln Pro Ile Ile Lys Ser Asn Asn Gln Ile Pro Asn Ile Thr Ile Ser 645 650 655 Pro Ala Asp Lys Ala Asp Lys Leu Thr Ile Thr Tyr Gln Asn Thr Asp 660 665 670 Asn Glu Ser Ala Ser Ile Ile Gly Asn Lys Leu Asn Asn Gln Trp Ser 675 680 685 Leu Asn Asn Asn Ile Pro Gly Ile Glu Ile Asp Met Gln Thr Gly Leu 690 695 700 Val Thr Ile Asp Tyr Lys Ala Val Tyr Pro Glu Ser Val Val Gly Ala 705 710 715 720 Asn Asp Lys Thr Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr 725 730 735 Met Pro Arg Lys Glu Ala Thr Pro Leu Ser Pro Ile Val Glu Ala Asn 740 745 750 Glu Glu Arg Val Asn Val Val Ile Ala Pro Asn Gly Glu Ala Thr Gln 755 760 765 Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr Leu Val 770 775 780 Ala Ser Lys Asn Gly Ser Ser Trp Thr Leu Asn Lys Gln Ile Asp Tyr 785 790 795 800 Val Asn Ile Glu Glu Asn Ser Gly Lys Val Thr Ile Gly Tyr Gln Ala 805 810 815 Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr Lys Gly Asn Ser 820 825 830 Asp Glu Ser Ala Glu Ser Arg Val Thr Met Pro Arg Lys Glu Ala Thr 835 840 845 Pro His Ser Pro Ile Val Glu Ala Asn Glu Glu His Val Asn Val Thr 850 855 860 Ile Ala Pro Asn Gly Glu Ala Thr Gln Ile Ala Ile Lys Tyr Arg Thr 865 870 875 880 Pro Asp Gly Gln Glu Thr Thr Leu Ile Ala Ser Lys Asn Gly Ser Ser 885 890 895 Trp Thr Leu Asn Lys Gln Ile Asp Tyr Val Asn Ile Glu Glu Asn Ser 900 905 910 Gly Lys Val Thr Ile Gly Tyr Gln Ala Val Gln Leu Glu Ser Glu Val 915 920 925 Ile Ala Thr Glu Thr Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg 930 935 940 Ile Thr Met Leu Arg Lys Glu Ala Thr Pro His Ser Pro Ile Val Glu 945 950 955 960 Ala Asn Glu Glu His Val Asn Val Thr Ile Ala Pro Asn Gly Glu Ala 965 970 975 Thr Gln Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr 980 985 990 Leu Val Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 995 1000 1005 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1010 1015 1020 Tyr Gln Ala Val Gln Pro Glu Ser Glu Ile Ile Ala Thr Glu Thr 1025 1030 1035 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1040 1045 1050 Arg Lys Glu Ala Thr Pro Ile Pro Pro Thr Leu Glu Ala Ser Val 1055 1060 1065 Gln Glu Ala Ser Val Thr Val Thr Pro Asn Glu Asn Ala Thr Lys 1070 1075 1080 Val Phe Ile Lys Tyr Leu Asp Ile Asn Asp Glu Ile Ser Thr Ile 1085 1090 1095 Ile Ala Ser Lys Ile Asn Gln Gln Trp Thr Leu Asn Lys Asp Asn 1100 1105 1110 Phe Gly Ile Lys Ile Asn Pro Leu Thr Gly Lys Val Ile Ile Ser 1115 1120 1125 Tyr Val Ala Val Gln Pro Glu Ser Asp Val Ile Ala Ile Glu Ser 1130 1135 1140 Gln Gly Asn Ser Asp Leu Ser Glu Glu Ser Arg Ile Ile Met Pro 1145 1150 1155 Thr Lys Glu Glu Pro Pro Glu Pro Pro Ile Leu Glu Ser Asp Ser 1160 1165 1170 Ile Glu Ala Lys Val Asn Ile Phe Pro Asn Asp Glu Ala Thr Arg 1175 1180 1185 Ile Val Ile Met Tyr Thr Ser Leu Glu Gly Gln Glu Ala Thr Leu 1190 1195 1200 Val Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 1205 1210 1215 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1220 1225 1230 Tyr Gln Ala Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr 1235 1240 1245 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Val Thr Met Pro 1250 1255 1260 Arg Lys Glu Ala Thr Pro His Ser Pro Ile Val Glu Thr Asn Glu 1265 1270 1275 Glu Arg Val Asn Val Val Ile Ala Pro Asn Gly Glu Ala Thr Gln 1280 1285 1290 Ile Ala Ile Lys Tyr Arg Thr Pro Asp Gly Gln Glu Thr Thr Leu 1295 1300 1305 Ile Ala Ser Lys Asn Gly Ser Ser Trp Thr Leu Asn Lys Gln Ile 1310 1315 1320 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1325 1330 1335 Tyr Gln Ala Val Gln Pro Glu Ser Glu Ile Ile Ala Thr Glu Thr 1340 1345 1350 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1355 1360 1365 Arg Lys Glu Ala Ile Pro His Ser Pro Ile Val Glu Ala Asn Glu 1370 1375 1380 Glu His Val Asn Val Thr Ile Ala Pro Asn Gly Glu Thr Thr Gln 1385 1390 1395 Ile Ala Val Lys Tyr Arg Thr Pro Asp Gly Gln Glu Ala Thr Leu 1400 1405 1410 Ile Ala Ser Lys Asn Glu Ser Ser Trp Thr Leu Asn Lys Gln Ile 1415 1420 1425 Asp His Val Asn Ile Asp Glu Asn Ser Gly Lys Val Thr Ile Gly 1430 1435 1440 Tyr Gln Ala Val Gln Pro Glu Ser Glu Val Ile Ala Thr Glu Thr 1445 1450 1455 Lys Gly Asn Ser Asp Ala Ser Ala Glu Ser Arg Ile Thr Met Pro 1460 1465 1470 Val Lys Glu Lys Thr Pro Ala Pro Pro Ile Ser Ile Ile Asn Glu 1475 1480 1485 Ser Asn Ala Ser Val Glu Ile Ile Pro Gln Val Asn Val Thr Gln 1490 1495 1500 Leu Ser Leu Gln Tyr Ile Asp Ala Lys Gly Gln Gln Gln Asn Leu 1505 1510 1515 Ile Ala Thr Leu Asn Gln Asn Gln Trp Thr Leu Asn Lys Asn Val 1520 1525 1530 Ser His Ile Thr Val Asp Lys Asn Thr Gly Lys Val Leu Ile Asn 1535 1540 1545 Tyr Gln Ala Val Tyr Pro Glu Ser Glu Val Ile Ala Arg Glu Ser 1550 1555 1560 Lys Gly Asn Ser Asp Ser Ser Asn Val Ser Met Val Ile Met Pro 1565 1570 1575 Arg Lys Thr Ala Thr Pro Lys Pro Pro Ile Ile Lys Val Asp Glu 1580 1585 1590 Met Asn Ala Ser Leu Ala Ile Ile Pro Tyr Lys Asn Asn Thr Ala 1595 1600 1605 Ile Asn Ile His Tyr Ile Asp Lys Lys Gly Ile Lys Ser Met Val 1610 1615 1620 Thr Ala Ile Lys Asn Asn Asp Gln Trp Gln Leu Asp Glu Lys Ile 1625 1630 1635 Lys Tyr Val Lys Ile Asp Ala Lys Thr Gly Thr Val Ile Ile Asn 1640 1645 1650 Tyr Gln Ile Val Gln Glu Asn Ser Glu Ile Ile Ala Thr Ala Ile 1655 1660 1665 Asn Gly Asn Ser Asp Lys Ser Glu Glu Val Lys Val Leu Met Pro 1670 1675 1680 Ile Lys Glu Phe Thr Pro Leu Ala Pro Leu Leu Glu Thr Asn Tyr 1685 1690 1695 Lys Lys Ala Thr Val Ser Ile Leu Pro Gln Ser Asn Ala Thr Lys 1700 1705 1710 Leu Asp Phe Lys Tyr Arg Asp Lys Lys Gly Asp Ser Lys Ile Ile 1715 1720 1725 Ile Val Lys Arg Phe Lys Asn Ile Trp Lys Ala Asn Glu Gln Ile 1730 1735 1740 Ser Gly Val Thr Ile Asn Pro Glu Phe Gly Gln Val Val Ile Asn 1745 1750 1755 Tyr Gln Ala Val Tyr Pro Glu Ser Asp Ile Leu Ala Ala Gln Tyr 1760 1765 1770 Val Gly Asn Ser Asp Ala Ser Glu Trp Ala Lys Val Lys Met Pro 1775 1780 1785 Lys Lys Glu Leu Ala Pro His Ser Pro Ser Leu Ile Tyr Asp Asn 1790 1795 1800 Arg Asn Asn Lys Ile Leu Ile Ala Pro Asn Ser Asn Ala Thr Glu 1805 1810 1815 Met Glu Leu Ser Tyr Val Asp Lys Asn Asn Gln Ser Leu Lys Val 1820 1825 1830 Lys Ala Leu Lys Ile Asn Asn Arg Trp Lys Phe Asp Ser Ser Val 1835 1840 1845 Ser Asn Ile Ser Ile Asn Pro Asn Thr Gly Lys Ile Val Leu Gln 1850 1855 1860 Pro Gln Phe Leu Leu Thr Asn Ser Lys Ile Ile Val Phe Ala Lys 1865 1870 1875 Lys Gly Asn Ser Asp Ala Ser Ile Ser Val Ser Leu Arg Val Pro 1880 1885 1890 Ala Val Lys Lys Ile Glu Leu Glu Pro Met Phe Asn Val Pro Val 1895 1900 1905 Leu Val Ser Leu Asn Lys Lys Arg Ile Gln Phe Asp Asp Cys Ser 1910 1915 1920 Gly Val Lys Asn Cys Leu Asn Lys Gln Ile Ser Lys Thr Gln Leu 1925 1930 1935 Pro Asp Thr Gly Tyr Ser Asp Lys Ala Ser Lys Ser Asn Ile Leu 1940 1945 1950 Ser Val Leu Leu Leu Gly Phe Gly Phe Leu Ser Tyr Ser Arg Lys 1955 1960 1965 Arg Lys Glu Lys Gln 1970 

What is claimed is:
 1. A method of identifying LPXTG-containing cell wall-anchored surface proteins from Gram positive bacteria that bind to an extracellular matrix molecule comprising searching a database of sequence information to identify a putative protein sequence from Gram positive bacteria having an LPXTG-motif in its C-terminal region, analyzing the identified sequence to determine the presence of one or more IG-like fold regions, and positively identifying said putative protein sequence as an LPXTG-containing cell wall-anchored surface protein that binds to an extracellular matrix molecule if that sequence has one or more IG-like fold regions of an LPXTG-containing cell wall-anchored surface protein that binds to an extracellular matrix molecule.
 2. The method according to claim 1 wherein the Gram positive bacteria is from a genus selected from the group consisting of Enterococcus, Streptococcus, Staphylococcus and Bacillus.
 3. The method according to claim 1 wherein the Gram positive bacteria is from a species selected from the group consisting of Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pneumoniae, Streptococcus mutans, Staphylococcus aureus, Staphylococcus epidermidis, and Bacillus anthracis.
 4. The method according to claim 1 wherein the Ig-like folds of the putative LPXTG-containing protein sequence are determined by comparing the sequence of that protein with the sequence of Ig-like folds in a known LPXTG-containing cell wall-anchored surface protein that binds to an extracellular matrix molecule
 5. The method according to claim 4 wherein the putative LPXTG-containing protein is compared to a known LPXTG-containing protein using a probability value based on the comparison of the sequences, and wherein a putative LPXTG-containing protein is identified as an LPXTG-containing cell wall-anchored surface protein that binds to an extracellular matrix molecule when the probability value is <0.25.
 6. An isolated protein identified by the method of claim
 1. 7. The isolated protein according to claim 6 wherein the protein is selected from the group consisting of Gram positive bacterial proteins identified as SP0368, SP0462, SP0463, SP0464; EF2224, EF1091, EF1092, EF1093, EF3023, EF1269, EF0089, EF1824, EF1075, EF1074, EF1651, SMU.610, SMU.987, SMU.63c, SA2447, SA2290, SA2291, SA2423, SA0742, SA0519, SA0520, SA0521, BA0871, BA5258, SERP_GSE_(—)14_(—)6.M, SERP_GRE_(—)2_(—)50.AA, SERP_GSE_(—)9_(—)28.M, SEPN_(—)5_(—)124.M, and SEPN_(—)8_(—)63.M.
 8. An isolated A domain of the protein according to claim
 6. 9. An isolated antibody that can bind to a protein according to claim
 6. 10. An isolated nucleic acid sequence encoding the protein according to claim
 6. 11. A method of identifying LPXTG-containing cell wall-anchored surface proteins from Gram positive bacteria that bind to an extracellular matrix molecule comprising searching a database of sequence information to identify a putative protein sequence from Gram positive bacteria having an LPXTG-motif in its C-terminal region, analyzing the identified sequence to determine if said sequence has a signal peptide at the N-terminus, the LPXTG-motif close to the C-terminus followed by a hydrophobic transmembrane segment, and several positively charged residues at the C-terminus, and positively identifying said putative protein sequence as an LPXTG-containing cell wall-anchored surface protein that binds to an extracellular matrix molecule if that sequence has a signal peptide at the N-terminus, the LPXTG-motif close to the C-terminus followed by a hydrophobic transmembrane segment, and several positively charged residues at the C-terminus.
 12. An isolated protein identified by the method of claim
 11. 13. An isolated A domain of the protein according to claim
 12. 14. An isolated antibody that can bind to a protein according to claim
 12. 15. An isolated nucleic acid sequence encoding the protein according to claim
 11. 16. An isolated LPXTG-containing cell wall-anchored surface protein from Gram positive bacteria or A domain from said protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NOS:20-24 and the A domains of said sequences.
 17. An isolated nucleic acid sequence encoding the protein according to claim
 16. 18. An isolated nucleic acid encoding an PXTG-containing cell wall-anchored surface protein from Gram positive bacteria or A domain from said protein having a nucleic acid sequence selected from the group consisting of SEQ ID NO: 8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, and SEQ ID NO:18, or degenerates thereof.
 19. An isolated antibody that can bind to a protein according to claim
 16. 20. The antibody according to claim 19 wherein the antibody is a monoclonal antibody.
 21. The antibody according to claim 19 selected from the group consisting of single chain, chimeric, murine, humanized and human monoclonal antibodies.
 22. The antibody according to claim 19, wherein said antibody treats or prevents a Gram positive bacterial infection in a human or animal.
 23. The antibody according to claim 19, wherein said antibody is suitable for parenteral, oral, intranasal, subcutaneous, aerosolized or intravenous administration in a human or animal.
 24. Isolated antisera containing an antibody according to claim
 19. 25. A diagnostic kit comprising an antibody according to claim 19 and means for detecting binding by that antibody.
 26. A diagnostic kit according to claim 25 wherein said means for detecting binding comprises a detectable label that is linked to said antibody.
 27. A method of treating or preventing a infection of a Gram positive bacteria comprising administering to a human or animal patient an effective amount of an antibody according to claim
 19. 28. A pharmaceutical composition comprising an effective amount of the antibody of claim 19 and a pharmaceutically acceptable vehicle, carrier or excipient.
 29. A pharmaceutical composition comprising an immunogenic amount of the protein or peptide of claim 8 and a pharmaceutically acceptable vehicle, carrier or excipient.
 30. A pharmaceutical composition comprising an immunogenic amount of the protein or peptide of claim 16 and a pharmaceutically acceptable vehicle, carrier or excipient.
 31. A method of treating or preventing a infection of a Gram positive bacteria comprising administering to a human or animal patient an effective amount of an antibody according to claim
 19. 32. A method of diagnosing an infection caused by a Gram positive bacteria comprising introducing the antibody according to claim 19 into a sample of biological material suspected of having such an infection and determining if said antibody binds with antigens in said sample.
 33. A method of eliciting an immunogenic reaction in a human or animal comprising administering to said human or animal an immunologically effective amount of the protein according to claim
 8. 34. A vaccine comprising an immunogenic amount of the protein according to claim 8 and a pharmaceutically acceptable vehicle, carrier or excipient.
 35. A method of assaying for the presence of antigens from Gram positive bacteria in a biological sample suspected of containing said antigens comprising (a) simultaneously forming a mixture comprising the sample, together with an antibody according to claim 19 in the form of either a solid phase immobilized antibody bound to a solid phase immunoadsorbent or a soluble labeled antibody; (b) incubating the mixture formed in step (a) for a time and under conditions sufficient to allow antigen in the sample to bind to either said immobilized or said labeled antibody; and (c) detecting either labeled antibody bound to the solid phase immunoadsorbent or detecting the labeled soluble antibody.
 36. A method according to claim 35 further including a step of washing, stirring, shaking or filtering.
 37. A method of monitoring the level of Gram positive bacteria antigens in a human or animal patient suspected of containing said antigens comprising (a) obtaining a biological sample from said human or animal patient; (b) introducing into said sample either a determinable level of an antibody according to claim 19, (c) incubating the sample when combined with the antibodies for a time and under conditions sufficient to allow the antigens and antibodies to bind; and (d) monitoring the level of antigens in the sample by determining the level of antigen-antibody binding which will reflect the level of Gram positive bacterial antigens which are in the sample.
 38. A pharmaceutical composition comprising an immunogenic amount of the protein according to claim 16 and a pharmaceutically acceptable vehicle, carrier or excipient.
 39. A method of diagnosing an infection caused by a Gram positive bacteria comprising introducing the protein according to claim 16 into a sample of biological material suspected of having such an infection and determining if said protein binds to antibodies in said sample.
 40. A method of eliciting an immunogenic reaction in a human or animal comprising administering to said human or animal an immunologically effective amount of the protein according to claim
 16. 